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Summary 
 
DNA double-strand breaks are the most deleterious type of DNA damage that cells experience, 
which makes the study of double-strand break repair extremely important. Unrepaired or 
aberrantly repaired DNA can result in changes to core genes with critical function and thus 
lead to multiple diseases. Two main repair pathways for double-strand breaks exist: 
homologous recombination (HR) and non-homologous end-joining (NHEJ). Whilst the 
regulation of HR has been heavily investigated, the regulation of NHEJ remains to be fully 
explored. The aim of this thesis is to investigate the regulation of DNA NHEJ through 
interacting factors of the core NHEJ protein heterodimer, Ku70/80 (Ku).  
 
This thesis consists of three main research projects. The first, explores the potential role of 
the CUL4 substrate adaptor, WDR76, in the removal of Ku from sites of DNA damage. Data 
presented here highlight a role of WDR76 in the DNA damage response (DDR), and through 
effects on Ku removal kinetics, suggest a role for WDR76 in the regulating NHEJ. 
 
The second research project investigates a potential cyclin-dependent kinase 
phosphorylation site on the protein paralog of XRCC4 and XLF (PAXX). As PAXX is a Ku 
interactor with a role in NHEJ, the effect of PAXX phosphorylation is investigated as a potential 
NHEJ regulatory system. 
 
Lastly, I investigate the role of the RecQ helicase WRN, whose precise roles in the DDR are 
unclear. As an interactor of both HR and NHEJ proteins, WRN may affect the regulation of 
both pathways. WRN knockout cells were generated and a CRISPR-Cas9 screen performed to 
identify suppressors of WRN sensitivity to DNA damage. The targets identified offer insights 
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1. Introduction 
1.1. The integrity of DNA 
DNA is the code of life, the important data-store that encodes all the necessary components 
that maintain the function and progression of organisms. From the development in early life, 
right through to ageing, maintenance of these data is important to prevent loss of vital 
information that could compromise life.  
 
The DNA in our cells is under constant threat throughout our daily lives, as we are exposed to 
a number of different factors that cause DNA damage. These can be exogenous, 
environmental factors, such as ultraviolet (UV) light from the sun or ionising radiation (IR) 
from radioactive materials that can both be natural or manmade. Exposure to other 
carcinogens, for example those found in tobacco products or everyday consumables including 
food can also lead to DNA damage1,2. Cells in our bodies are also susceptible to DNA damage 
caused by endogenous factors; these include DNA damage caused by reactive oxygen species 
(ROS), a natural product generated through normal cell metabolism, or damage that occurs 
through errors in DNA replication and repair during the cell cycle3,4. Constant DNA damage 
can lead to loss of DNA integrity through changes such as mutations, deletions, insertions and 
chromosomal rearrangements. This can be disastrous to cells and can compromise the life of 
organisms. 
 
Despite this constant onslaught of DNA damage, organisms have a plethora of proteins 
involved in maintaining the integrity of the genome; these proteins are those involved in the 
DNA damage response (DDR). The activity of these proteins ultimately repair the DNA damage 
or target cells for destruction if the level of damage is beyond the threshold of repair5. 
 
DNA damage can occur in a variety of forms that can be broadly categorised into the following 
groups: single strand breaks (SSBs), crosslinks and bulky lesions, mismatches and base lesions, 
and double strand breaks (DSBs)6 (Figure 1). Proteins involved in the DDR have evolved specific 
functions to combat these various forms of DNA damage and act through distinct cascades 
and mechanisms to ultimately aid in the repair of the damage.  
 




1.2. DNA repair pathways 
 
1.2.1. Base excision repair and single-strand break repair 
Single strand break repair (SSBR) refers to repair of DNA damage that occurs in one strand of 
the DNA backbone; specifically, in the sugar-phosphate bond form between adjacent DNA 
bases (Figure 1). SSBs are thought to be the most common type of DNA insult and occur more 
frequently than DSBs7,8. SSBs can occur directly or indirectly as a result of DNA base-excision 
repair (BER) intermediates9. As a result of the crossover between the two pathways SSBR is 
generally considered to be a sub-pathway of BER.   
 
BER is the repair pathway which removes and replaces damaged bases that do not distort the 
DNA helix10,11 (Figure 1). The process involves DNA glycosylases to recognise and remove the 
damaged base, creating an abasic site which is removed by endonucleases. This is a single 
strand nick, which is subsequently repaired by the proteins: DNA polymerase b (DNA polb), 
x-ray cross complementing 1 (XRCC1) and DNA ligase III. If more than one base in a tract length 
is needed to be replaced DNA ligase I acts instead of DNA ligase III11. These downstream 
Figure 1 Types of DNA damage 
Diagram showing the many types of DNA damage. The DNA backbone is in grey with the nucleotide 
bases indicated by the various colours. Types of DNA damage include DNA mismatches, damaged 
bases, DSBs, SSBs, pyrimidine dimers and inter-strand crosslinks. Pink circles mark bulkier DNA lesions 
which can cause distortion of the DNA double helix.   
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proteins and mechanisms are common to BER and SSBR, however the recognition step in SSBR 
is different.  
 
SSBs are primarily recognised by poly(ADP-ribose) polymerase 1 (PARP1),  although activity 
of PARP1 can also be found at other types of DNA lesions12,13. Upon DNA-damage detection, 
PARP1 catalyses the synthesis of poly(ADP-ribose) (PAR) chains on itself and other proteins. 
This promotes the recruitment of XRCC1 and DNA ligase III which together repair the SSB8,12,13.  
 
 
1.2.2. Mismatch repair  
The mismatch repair (MMR) pathway involves the recognition and resolving of base to base 
mismatches (Figure 1). MMR can repair both single base mismatches as well as larger stretches 
of base mismatch loops. The process of repairing these two types of mismatches are largely 
similar, although the initial recognition steps differ slightly. MMR recognition is performed by 
mutS homolog 2 (MSH2), which forms a heterodimer with MSH6 for the recognition of single 
base mismatches, and with MSH3 for the recognition of larger loop mismatches14,15. These 
heterodimer complexes form a ternary complex with mutL homolog 1 (MLH1) and 
postmeiotic segregation homolog 2 (PMS2). Endonuclease activity of PMS2 and recruitment 
and activity of exonucleases, such as exonuclease I (EXO1), results in degradation of bases 
and the associated phosphodiester DNA backbone, leading to a stretch of single stranded 
DNA. DNA polymerase d, proliferating cell nuclear antigen (PCNA), replication factor C (RFC) 
and DNA ligase I subsequently synthesise the missing bases and maintain DNA integrity16.  
 
1.2.3. Nucleotide excision repair and inter-strand crosslink repair 
Certain types of DNA damage can lead to bulkier base damage which causes distortion of the 
DNA helix. These include typical photoproducts such as cyclopyrimidine dimers produced by 
UV light (Figure 1). This type of DNA damage is repaired by a process called nucleotide excision 
repair (NER). NER is facilitated by the recognition of unstable duplex DNA through the protein 
xeroderma pigmentosum complementation group C (XPC) which binds the non-damaged 
strand opposite the lesion17. XPC then recruits a range of downstream proteins including 
transcription factor II human (TFIIH) and excision repair cross complementing 1 (ERCC1) to 
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facilitate the removal of damaged bases. Repair is then accomplished by DNA polymerases, 
XRCC1 and DNA ligases17.   
 
Inter-strand crosslinks (ICLs) can arise between opposite DNA strands usually as a result of 
mutagen exposure within the environment. This type of DNA damage can be particularly toxic 
as it creates a stable bond between complementary strands of DNA and thus inhibits DNA 
strand separation (Figure 1). This prevents the progression of processes like transcription and 
replication18. ICLs are repaired by proteins involved in the Fanconi anaemia (FA) pathway, 
named after the genetic disorder FA which is associated with increased sensitivity to ICLs18. 
Recognition of ICLs is performed by the protein FANCM and the rest of the FA complex 
(FANCA, B, C, E, F, G and L) 18. This leads to the repair of ICLs through concerted efforts of 
nucleases and polymerases18.   
 
 
1.2.4. Double strand breaks and their repair 
Double strand breaks (DSBs) (Figure 1) are the most toxic of DNA lesions as they require more 
coordination to repair since an undamaged intact strand is not immediately available19. DSBs 
can therefore result in the loss of genetic information if repaired incorrectly. DSBs can arise 
from the effects of ionising radiation (IR), which, amongst other types of DNA damage, can 
generate blunt ended DSBs. Additionally, two single strand breaks can be generated in close 
proximity also resulting in DSBs20. Naturally occurring developmental processes such as V(D)J 
(variable diversity joining) recombination and meiosis can also generate DSBs that require 
appropriate processing21. DSBs can also occur when there are blocks to the progression of the 
processes like replication and transcription and often single strand breaks can become 
converted into double strand breaks during these processes22. Cells overloaded with SSBs 
often carry over unrepaired SSBs into replication, thus resulting in DSBs. DNA damaging 
agents like camptothecin (CPT) work by causing double strand breaks specifically in S-phase. 
This happens as CPT inhibits the ligase activity, but not the initial cleavage activity, of 
topoisomerase 1 (TOP1). CPT thus causes a single strand break in DNA which is bound by TOP1. 
This complex creates collisions with the replication machinery in S-phase, causing replication 
forks to collapse and generating double strand breaks23.  
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Two primary pathways exist to repair DSBs, these are homologous recombination (HR) and 
non-homologous end-joining (NHEJ). NHEJ is a process which directly ligates DSB ends 
together and is active throughout the cell cycle. HR on the other hand uses template DNA to 
restore information that is potentially lost during a DSB; this restricts repair by HR to S/G2 
phases of the cell cycle when a sister chromatid is available. These two processes are 
described in more detail in sections 1.5 and 1.6.    
 
1.3. Initial double strand break response 
The initial response to DSBs and the chromatin signalling to mediate repair is coordinated by 
the phosphatidylinositol 3-kinase related kinases (PIKKs). These are ataxia telangiectasia 
mutated (ATM), ataxia telangiectasia and RAD3-related (ATR) and DNA-dependent protein 
kinase (DNA-PK). The main PIKK which mediates DNA-damage signalling in response to DSBs 
is ATM. ATM is recruited to DSBs through the meiotic recombination 11(MRE11)-RAD50-
Nijmegen breakage syndrome 1 (NBS1) (MRN) complex which acts as a sensor of DSBs24. ATM 
phosphorylates histone H2AX on serine 139 which is referred to as gH2AX25. Production of 
gH2AX is one of the first things to occur in response to DNA damage and is thus used widely 
as a marker of DNA damage. Generation of gH2AX leads to the recruitment of mediator of 
DNA damage checkpoint protein 1 (MDC1) which is constitutively phosphorylated by casein 
kinase 2 (CK2), this results in the recruitment of more MRN and ATM26. This potentiates the 
DNA damage signalling pathway. MDC1 is also phosphorylated by ATM, which results in the 
recruitment and activation of the ubiquitin E3 ligases RING finger 8 (RNF8) and RING finger 
168 (RNF168). RNF8/168 ubiquitylation of histones further potentiates the DNA damage 
signal on chromatin at and surrounding the site of DNA damage27,28. This recruits other 
proteins involved in the DDR including p53 binding protein 1 (53BP1) and breast and ovarian 
cancer susceptibility protein 1 (BRCA1); two proteins which are involved in the choice 
between double strand break repair (DSBR) through either HR or NHEJ (See section 1.8 for 
more) (Figure 2)25,26.  
 






1.4. Roles of ATM/ATR in checkpoint signalling 
The PIKKs, ATM and ATR are also responsible for checkpoint signalling through downstream 
kinases known as checkpoint kinase 2 (CHK2) and checkpoint kinase 1 (CHK1). These kinases 
phosphorylate further downstream factors and thus expands the number and diversity of 
factors affected by ATM and ATR29. The major functions of the checkpoint kinases are to cause 
cell cycle arrest and promote DNA repair, or in the presence of excessive DNA damage drive 
apoptosis or senescence30. The two main checkpoint pathways are the ATM-CHK2 and ATR-
CHK1 responses.  
 
ATM phosphorylates CHK2 on multiple sites, including on T6829,31,32. Activated CHK2 has a 
range of downstream targets which include DDR factors, cell cycle regulators as well as 
proteins involved in p53 signalling and apoptosis33. CHK2 can initiate both G1/S and G2/M 
Figure 2 Initial double strand break response signalling 
DSBs are recognised by the MRN complex which interacts with ATM mainly through the NBS1 subunit. 
Detection of DSBs results in auto-phosphorylation of ATM which promotes the phosphorylation of 
H2AX on ser139 (gH2AX). Blue cyclinders show nucleosomes with H2AX indicated. gH2AX recruits 
constitutively phosphorylated MDC1 which recruits more ATM, thus potentiating the signal further via 
gH2AX production. ATM phosphorylates MDC1 to promote the recruitment of the RNF8 E3 ligase. RNF8 
ubiquitylates histones to promote the recruitment of RNF168. RNF8/168 together further ubiquitylate 
histones to expand the DNA damage signal resulting in recruitment of DNA damage proteins including 
53BP1 and BRCA1. (Figure adapted from Panier and Boulton, 2014. Nature reviews26). 
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phase checkpoints by the phosphorylation of cell division cycle 25A (CDC25A) and cell division 
cycle 25C (CDC25C) respectively34,35. Phosphorylation of CDC25A leads to its degradation, 
which subsequently prevents the activation of cyclin dependent kinase 2 (CDK2), a step 
required for progression into S-phase35. In the case of the G2/M phase checkpoint, CHK2 
mediated phosphorylation of CDC25C causes its translocation to the cytoplasm and thus 
CDC25C cannot activate cyclin dependent kinase 1 (CDK1) to allow for progression into 
mitosis36,37. CHK2 has also been linked to the activation of p53, although it has a potentially 
redundant role here with other p53 activators30. CHK2 has also been shown to be a driver of 
senescence and apoptosis as CHK2-/- mice were shown to be resistant to apoptosis after DNA 
damage exposure38. Furthermore, CHK2-/- mice also been shown to be cancer prone due to 
accumulation of DNA damage and apoptotic evasion39. 
 
The ATR-CHK1 checkpoint has overlapping functions with the ATM-CHK2 response30 however 
the activation of the ATR-CHK1 pathway is predominantly due to replication stress40,41. ATR 
phosphorylates CHK1 on sites that include S345 to activate CHK142,43. CHK1 promotes arrest 
of the cell cycle predominantly at the intra-S and G2/M checkpoint through similar 
mechanisms by which CHK2 prevents cell cycle progression29. CHK2 has been shown to 
phosphorylate CDC25A and CDC25C as well as the WEE1 kinase44. Phosphorylation activates 
WEE1 kinase activity, which results in the inhibitory phosphorylation of CDK1, and thus 
inhibits entry into mitosis44–46.  
 
1.5. Homologous recombination (HR) 
HR involves the repair of DSBs through the use of a template DNA strand. This process is 
characterised by 5’ to 3’ DNA resection, which exposes single-stranded DNA (ssDNA), to allow 
for strand invasion into template DNA and subsequent repair (Figure 3). HR is mainly initiated 
by the MRN complex which recognises and binds DSBs47. Through interaction with NBS1, the 
C-terminal binding protein interacting protein (CtIP) protein is recruited to sites of DNA 
damage and is involved in the initiation of 5’ to 3’ resection to expose ssDNA. Whilst short 
range resection is promoted by CtIP, extensive long-range resection is promoted by EXO15. 
This ssDNA is immediately coated by replication protein A (RPA), a heterotrimeric protein 
complex consisting of RPA1, RPA2 and RPA3. RPA binding to ssDNA stabilises it and prevents 
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its degradation. RPA is hyperphosphorylated in response to DNA damage by the PIKKs which 
is necessary for subsequent steps in HR48. RPA2 phosphorylation at serine 4/8 sites is often 
used as a readout of resection. ATR is recruited to RPA-coated ssDNA through ATR interacting 
protein (ATRIP), and is activated49.  
 
BRCA1 is a main coordinator of homologous recombination acting at multiple stages 
throughout the HR process50. BRCA1 together with BRCA1 associated RING domain 1 (BARD1) 
forms a complex to mediate ubiquitylation of substrates including BRCA1 itself, to promote 
complex assembly and protein stabilisation of proteins involved in HR50. BRCA1 also interacts 
breast and ovarian cancer susceptibility protein 2 (BRCA2) via the protein partner and 
localiser of BRCA2 (PALB2), to mediate downstream events in HR50. BRCA2 coordinates the 
unloading of RPA from ssDNA and replaces it with RAD51, resulting in RAD51 nucleofilament 
coated ssDNA51.  This RAD51 coated ssDNA is key to homology search and strand invasion 
into template DNA which may require the RAD51 paralogs52. Strand invasion allows for 
replication of the resected DNA, which can create complex structures of intercalated DNA 
which include D-loops and double Holliday junctions. These are ultimately resolved by various 
helicases and nucleases which can result in either a crossover or a non-crossover event 
between the sister chromatids (Figure 3)52.  
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1.6. Non-homologous end-joining (NHEJ) 
Unlike HR, NHEJ is not restricted to S and G2 phases of the cell cycle as it does not require 
template DNA to initiate repair53. As a result, NHEJ is active throughout the cell cycle and is 
thought to be the main pathway of DSBR. NHEJ repairs DSBs that are generated by exogenous 
sources such as irradiation but is also important in repairing DSBs generated by the processes 
of (V(D)J) recombination and class-switch recombination (CSR). These recombination 
processes allow for the diverse production of antibodies in B-cells and the antigen binding 
domains of T-cells and is thus crucial to health54,55.  
 
DSB detection in the NHEJ pathway is performed by the Ku70/80 heterodimer (Ku), which is 
composed of a 70kDa and 80kDa protein respectively. Ku is able to bind a variety of DNA 
structures but has the highest affinity for DSB ends56. Two separate Ku molecules bind on 
both ends of a DNA DSB. This binding of Ku serves as a platform to recruit other downstream 
factors of the NHEJ pathway56,57. After initial detection and binding, Ku recruits DNA-PK 
catalytic subunit (DNA-PKcs), which together form the DNA-PK holoenzyme58.  
 
Depending on the nature of the DSB, DNA ends may need to be processed prior to final 
ligation step. Ku interacts with a number of proteins which may be involved in the processing 
Figure 3 Homologous recombination pathway for double strand break repair (DSBR) 
Homologous recombination pathway for DSBR. Double strand breaks are recognised by the MRN 
complex. CtIP is recruited by the MRN complex through direct interaction with NBS1. This promotes 
initiation of resection with EXO1 promoting long range resection. This generates ssDNA which is 
immediately coated by the multimeric RPA complex proteins (shown in red). Exchange of RPA coated 
ssDNA to RAD51 coated ssDNA is then mediated by the BRCA1 and BRCA2 proteins. RAD51 coated 
ssDNA drives homology search and strand invasion to form a D-loop structure and DNA synthesis. D-
loop structures can be resolved by a process called synthesis dependent strand annealing where only 
one strand is used as a template before being resolved. Alternatively, double Holliday junctions are 
formed which can be subsequently resolved in a number of ways resulting in either crossovers or non-
crossovers. The RecQ helicase BLM promotes Holliday junction dissolution to prevent crossovers. 
(Figure adapted from Panier and Boulton, 2014. Nature reviews26)   
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of DNA ends57. This includes the polynucleotide kinase/phosphatase, PNKP, which has 3’ DNA 
phosphatase activity and 5’ DNA kinase activity which can process incompatible DNA ends 
into compatible ends for ligation59. 
 
Aprataxin and PNKP-like factor (APLF) is another factor which interacts directly with Ku80 and 
has been reported to have nuclease activity60–62. In addition, APLF, through its interaction 
with Ku, promotes the recruitment of downstream factors and thus promotes NHEJ60,61.  
 
Artemis is another protein that forms a complex with DNA-PKcs and is involved in the 
processing of DNA termini prior to ligation63,64. The Artermis-DNA-PKcs complex is able to 
process DNA ends in a number of ways as it has 5’ and 3’ endonuclease activity, hairpin 
opening activity and Artermis alone has 5’ exonuclease activity64. Ku can bind a number of 
duplex DNA end substrates, one of which is hairpin DNA ends65,66.  
 
NHEJ is said to be the more error prone of the two DSBR pathways. This is because insertions 
and deletions can occur at sites of DNA damage, largely as a result of DNA end processing 
activities67. Ku interacts with multiple other factors that may have a role in DNA end 
processing; this includes DNA polymerase µ and l as well as the Werner’s syndrome helicase 
(WRN) which will be discussed in more detail in chapter 5. DNA polymerase µ can add 
nucleotides in a template independent manner and DNA polymerase l has also been shown 
to add nucleotides in a template independent manner in the presence of manganese68–70. 
Both DNA polymerase µ and l also have a greater flexibility when using template DNA, with 
the ability to fold ssDNA back onto itself to prime DNA synthesis68,69. This results in short 
repeats, which are often seen at sites of DNA damage70–72. 
 
When DSBs have undergone DNA end processing, the DNA ends are ligated together in the 
final step of NHEJ. This happens through the recruitment of X-ray repair cross-complementing 
4 (XRCC4) and XRCC4-like factor (XLF). Paralog of XRCC4 and XLF (PAXX) also promotes NHEJ 
and its function is discussed in more detail in chapter 4. These proteins aid in the recruitment 
of DNA ligase IV to the DSB which ultimately ligates the DNA ends together57.   
 





Figure 4 Non-homologous end-joining pathway 
Non-homologous end-joining pathway for DSBR. DSBs are detected by the Ku heterodimer which has 
a high affinity for duplex DNA ends. Once bound, Ku recruits DNA-PKcs to form the DNA-PK 
holoenzyme. Depending on the nature of the break, DNA ends may need processing prior to ligation. 
Artemis has 5’ exonuclease activity and when in complex with DNA-PKcs, 5’ and 3’ endonuclease 
activity, which process DNA ends. PNKP phosphatase and kinase activities ensure compatibility of DNA 
ends. PAXX, XRCC4, XLF and DNA LIG4 are recruited in a complex to finally ligate the DNA ends and 
repair the DSB.   
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1.7. Consequences of improper repair 
The importance of DNA repair mechanisms is highlighted by the implication of DNA repair 
proteins in a variety of diseases such as immunodeficiency, infertility, cancer, premature 
ageing and neurodegeneration.  
 
Ataxia-telangiectasia (AT) is an autosomal recessive disorder caused by mutations in ATM. 
Classical AT patients have frameshift mutations in ATM which result in loss of the protein, 
some patients exhibit a milder form of the disease which is usually associated with missense 
mutations resulting in partial ATM function73–75. The main characteristic of AT is progressive 
diffuse cerebellar atrophy, but about two thirds of patients also display abnormalities of the 
immune system76,77. This is at least partly due to the involvement of ATM in stabilising DSBs 
in V(D)J recombination78. AT is also associated with an increased sensitivity to radiation and 
an increased predisposition to a range of cancers77.  
 
Mutations in genes involved in NHEJ have also been linked to V(D)J recombination defects79,80. 
This has mainly been shown in mice containing mutations in DNA-PKcs which show 
developmental defects in B and T cells. DNA-PKcs null mice also display severe combined 
immunodeficiency (SCID)81–83. In addition, Lig4 syndrome is a rare human genetic disorder 
caused by hypomorphic mutations in LIG4, and is characterised by immunodeficiency84.  
 
Defects in DNA repair genes have been linked to male infertility85. Some men presenting with 
non-obstructive azoospermia have been shown to have defects in the MMR repair genes 
MLH1 and MSH2. Cells from these patients also display microsatellite instability85.  
 
Defects in DNA repair genes have also been linked to neurodegenerative disorders such as 
Parkinson’s disease and Alzheimer’s disease86. Reduced levels of DNA-PKcs and the MRN 
complex as well as an increased level of DNA damage have also been shown in patients with 
Alzheimer’s disease87–89. Similarly, an increased level of DNA damage, in particular oxidative 
DNA damage has been linked to the degeneration of dopaminergic neurons in Parkinson’s 
disease90,91. 
 
Chapter 1: Introduction 
 35 
Parkinson’s disease is also connected to mitochondrial dysfunction, a process which can occur 
as a result of DNA damage to the mitochondrial DNA92. Mitochondrial DNA was thought to be 
maintained mainly by the BER pathway, however an increasing amount of evidence suggests 
that other DNA damage repair pathways are also active in mitochondria93. The importance of 
mitochondrial DNA maintenance can be exemplified by diseases such as Kearns-Sayre 
syndrome, which occurs as a result of deletions in mitochondrial DNA and results in drooping 
eyelids and lethargy. Furthermore, mice deficient in POLG, the mitochondrial DNA 
polymerase with proof-reading ability, show signs of premature ageing and a significantly 
reduced lifespan94. Other DNA repair proteins associated with premature ageing syndromes 
include the RecQ helicases; these will be discussed further in chapter 5.  
 
Perhaps the most obvious connection DNA repair proteins have to disease is that with cancer. 
p53 is the most commonly mutated gene in all cancers, these mutations can arise via the 
erroneous repair of DNA damage within the gene. Often there are underlying mutations in 
DNA repair genes which present prior to cancer inducing mutations. An example of this is in 
the mutations in the genes BRCA1 and BRCA2 which are particularly associated with breast 
and ovarian cancers95. BRCA1/2 have roles in DSBR by HR; defects in these proteins therefore 
can lead to error prone repair and are therefore drivers of cancer. Mutations in the mismatch 
repair genes MSH2 and MLH1 also have strong correlation with colorectal cancers14.  
 
The link between DNA damage/repair and cancer is also evident in the treatment of cancers 
as radiotherapy and many chemotherapies function by generating DNA damage in the quest 
to overload fast replicating cells with enough DNA damage to kill the cells96. The newly 
approved treatment of BRCA1 and BRCA2 mutant tumours using PARP inhibitors such as 
olaparib (LynparzaTM- Astra Zeneca), exploits an HR deficiency in these tumours. Olaparib and 
other PARP inhibitors work by slowing down BER/SSBR and also by trapping PARP when it 
binds to SSBs; these structures are converted into DSBs when replication machinery 
encounters them. The HR deficiency in these tumour cells results in repair by NHEJ which 
leads to genetic instability and eventually death in these cells97.  
 
Due to the range of biological and medical impacts that DNA repair proteins have, it is 
extremely important to understand the mechanisms by which they mediate repair and also 
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the consequences of loss of DNA repair proteins in disease. Research further into these areas 
is extremely important to enhance the basic understanding of a multitude of diseases as well 
as offering potential therapeutic avenues for their treatment. This is particularly meaningful 
in the treatment of cancers which become resistant to chemotherapy, as understanding the 
mechanisms of resistance can offer new therapeutic targets to exploit the underlying genetics.  
 
1.8. Regulation of HR vs. NHEJ 
The type of DSB and the phase of the cell cycle it occurs in strongly influences the preferred 
method of repair98. HR requires template sister chromatid DNA and thus must be restricted 
to S and G2 phases of the cell cycle98. Initiation of HR without template DNA could result in 
loss of genetic information. NHEJ on the other hand is active throughout the cell cycle but is 
the more error prone of the two pathways53. Initiation of NHEJ in S and G2 phases during 
replication poses a threat to genome integrity as it may result in gross chromosomal 
rearrangements. As a result, there are mechanisms to control the type of DSBR initiated.  
 
One of the major factors contributing to DSBR pathway choice is in the decision for cells to 
resect DNA99. Once extensive resection occurs at DSBs, cells become committed to repairing 
the DNA via HR. One of the ways of regulating this is through cyclin dependent kinases (CDKs) 
which can specifically promote HR in S and G2 phases100. A good example of this is in the 
phosphorylation at the threonine-847 CDK consensus site of CtIP. The phosphorylation of CtIP 
at this residue was specifically shown to enhance the ability of CtIP to promote DNA 
resection101. Interestingly cells expressing a phosphomimetic T847E mutant version of CtIP 
showed a decreased level of NHEJ, most likely as a result of resection occurring in G1. 
Additionally, other CDK phosphorylation sites on CtIP also promote HR by promoting 
interactions with other proteins involved in the same pathway; an example is the CDK 
mediated S347 phosphorylation that increases the interaction with BRCA1102. CDKs have also 
been implicated further downstream in the regulation of HR as CDK mediated BRCA2 
phosphorylation promotes its interaction with RAD51 during S and G2 phases103.  
 
BRCA1 and 53BP1 promote HR and NHEJ respectively, and have antagonistic roles in the early 
DDR104. Both 53BP1 and BRCA1 are recruited to sites of DNA damage in an RNF8/168 
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dependent manner105. BRCA1 has been shown to promote HR, and importantly cells lacking 
BRCA1 show increased sensitivity to S-phase specific DNA damage. This sensitivity is partially 
suppressed by the 53BP1 depletion which shows the relevance of the interplay between the 
two proteins106,107. 53BP1 depletion alone results in hypersensitivity to IR in mouse cells, and 
B-cells from 53BP1 null mice exhibit CSR and V(D)J recombination defects108–111, which is 
symptomatic of impaired NHEJ. 53BP1 has been shown to negatively regulate resection in the 
G1-phase of the cell cycle112, as does yeast Rad9, which shares domain similarity with 
53BP1113. 
 
BRCA1 together with BARD1 ubiquitylates CtIP which promotes its interaction with chromatin 
at sites of DNA damage; however CtIP driven resection does not require BRCA199. 
Interestingly, super resolution microscopy showed that 53BP1 is enriched in foci in G0 and G1 
cells, however BRCA1 pushes 53BP1 to the periphery of DNA damage foci in S-phase114. It is 
clear that BRCA1 and 53BP1 influence repair pathway choice however the exact mechanism 
by which BRCA1 and 53BP1 achieve this is still unclear. 
    
The initial recognition of a DSB can also influence the repair pathway choice and therefore Ku 
and the MRN complex may compete for recognition and promotion of NHEJ and HR 
respectively. In line with this, Ku depletion can suppress the hypersensitivity of MRN/CtIP 
(mrx/sae2) null yeast mutants115,116 and Ku loss increases the level of HR in mice cells117,118. 
Although the MRN and CtIP interaction seems to be positively regulated to promote HR during 
S and G2, DSBs formed during these phases would still be substrates for Ku binding. The MRN 
complex is far less abundant than Ku, and Ku binds DSB ends with high affinity; this suggests 
that Ku is first to bind DSBs and may therefore initiate NHEJ119. This raises the question of 
how NHEJ may be negatively regulated in these instances. Despite insights into the positive 
regulation of HR, the regulation mechanisms behind NHEJ are largely unexplored.  
 
 
1.9. The DSB repair protein, Ku 
Ku is the main protein involved in the NHEJ pathway, as it is the first responder to a DSB. 
Crystal structures of Ku alone and bound to DNA revealed that both Ku70 and Ku80 
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components are held together in a doughnut like shape66. The hole in the middle allows Ku 
to slide onto duplex DNA ends66. The structure of Ku and its nuclear abundance make it a 
great sensor of DNA DSBs120. This is because Ku has an extremely high affinity for double-
stranded DNA ends121. Although Ku can bind a variety of DNA structures including double 
stranded DNA with short single stranded overhangs, its highest affinity is for blunt ended 
duplex DNA120. Ku has also been shown to bind RNA, although the significance of this is largely 
unexplored122,123. Ku outcompetes PARP1 in binding to DSB ends, although PARP1 dependent 
ribosylation of Ku can reduce its affinity for DNA124. DNA-PKcs itself does have some affinity 
for DNA, however this is greatly enhanced upon interaction with Ku and therefore makes Ku 
important in the assembly of the DNA-PK complex and subsequent recruitment of 
downstream proteins in the NHEJ pathway125,126.     
 
Ku has also been implicated in the maintenance of telomeres; this has been shown by the 
observation of shorter telomeres in S. cerevisiae strains containing a deletion in either of the 
Ku subunits compared to wildtype (WT)127,128. Ku deficient mice have also shown telomeric 
abnormalities, showing an increased level of telomere end to end fusions compared to 
WT129,130. Human cells with a Ku80 deletion have also been shown to have abnormal telomere 
structure and telomere loss ultimately resulting in cell death after a few cell divisions131.  
 
Ku interacts with the telomeric proteins including telomeric repeat binding factor 2 (TRF2) 
and it has been proposed that its role in telomere maintenance may be through these 
proteins132. Ku presence at telomeres serves to prevent loss of telomeric loops and prevent 
the generation of disjointed extrachromosomal telomere circles131,133. This happens by 
preventing recombination at telomeres and either happens through a direct action of Ku or 
an interactor of Ku. Some have proposed Ku’s essentiality in humans may be as a result of its 
role in telomere maintenance rather than its role in NHEJ133. Clearly from phenotypes seen 
across a range of species Ku does have a role in telomere maintenance although the precise 
mechanism by which this is achieved is still unknown131,133.   
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1.10. Regulation and Removal of Ku 
The pivotal role Ku has in NHEJ makes it a likely target of regulation. Ku has been shown to be 
phosphorylated on various residues on both parts of the heterodimer however the 
significance of this is largely undetermined. Phosphorylation sites have been identified at S6 
of Ku70 and S557, S580 and T715 of Ku80134. These phosphorylation sites were originally 
identified as DNA-PK phosphorylation sites in vitro but were shown to not be dependent on 
DNA-PK or ATM in vivo134. Furthermore, mutation of these residues to non-phosphorylatable 
alanine residues did not have an effect on NHEJ, as mutants were able to complement the IR 
sensitivity of Ku null mammalian cells134. Mutation of phosphorylation sites to alanine on 
Ku80 do not have obvious effects on Ku dynamics at laser line induced sites of DNA damage, 
however mutation of Ku70 phosphorylation sites resulted in significant retention of Ku at DNA 
damage sites98. The Ku70 phosphorylation sites at T305, S306, T307, S314 and T316 were 
shown to be necessary for retention of Ku and DSBs135. Conserved CDK phosphorylation sites 
have also been identified at T401 and T428 on Ku70136. Phosphorylation at these sites was 
shown to inhibit the interaction of Ku70 with Ku80 and inhibit the interaction of Ku with 
replication origin sites137. This modification of Ku was linked to its role in the initiation and 
stabilisation of replication but may also be significant to its roles in DNA damage. 
 
The removal of Ku from DNA DSBs after completion of NHEJ has not been extensively studied, 
however a number of studies have implicated that ubiquitylation facilitates the removal of 
Ku. Work carried out in Xenopus laevis egg extracts showed that ubiquitylation of Ku80 
promotes its removal from DNA138. In addition, multiple ubiquitin ligases have also been 
shown to be linked the removal of Ku138–140 and the ubiquitin interacting protein valosin-
containing protein (VCP)/p97 has also been linked to Ku removal141. The importance of Ku 
removal will be discussed in more detail in chapter 3.   
 
1.11. Aims of projects in thesis 
The overall aim of the work described in this thesis was to investigate the relatively 
unexplored mechanisms behind the regulation of NHEJ. This was carried out through 
investigating factors which interact with the core NHEJ heterodimer, Ku, and assessing how 
they influence DNA repair processes.  
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My thesis is broken down in to three projects. The first involves investigating the Ku 
interacting factor WDR76 for its potential involvement in the removal of Ku following DSBR.  
 
The second involves investigating a potential CDK phosphorylation site on the NHEJ protein 
PAXX and its involvement in DSB repair pathway choice.  
 
Lastly, I investigated the RecQ helicase linked to Werner syndrome (WS), WRN, and describe 
the results of a CRISPR-Cas9 screen that I performed to gain insights into its precise function(s) 
within the DDR.  
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2. Methods 
2.1. Mammalian cell culture techniques 
 
2.1.1. Cell culture maintenance 
All mammalian cell lines were grown in a 5% CO2 humidified incubator at 37°C. HEK293, HeLa 
and U2OS cell lines were grown in Dulbecco’s Modified Eagles Medium (DMEM) (Sigma-
Aldrich) supplemented with 10% foetal bovine serum (FBS), 100U/ml penicillin, 100µg/ml 
streptomycin and 2mM L-glutamine. hTERT RPE-1 cells (RPE-1) were grown in DMEM/nutrient 
mixture F-12 Ham (Sigma-Aldrich) supplemented with 10% FBS, 100U/ml penicillin, 100µg/ml 
streptomycin and 2mM L-glutamine. Cells were split using trypsin (Thermo Fischer Scientific). 
The following cell lines were maintained in antibiotic selection as indicated:  
HeLa green fluorescent protein (GFP)-WDR76 in 0.4mg/ml G418 (Sigma Aldrich).  
RPE-1 WDR76-/- clones: 1G6,4B1,5B1,3H11 in 0.75mg/ml G418. 
RPE-1 cell lines expressing WT, S148A and S148E mRuby2-PAXX in 0.6mg/ml Zeocin. 
RPE-1 stable CRISPR associated protein 9 (Cas9) expressing clones: WT #28, WRN-/- E5-C6 and 
WRN-/- G7-C5 in 0.25mg/ml blasticidin.  
 
2.1.2. Mammalian cell stock freezing and revival 
Cells were washed in phosphate-buffered saline (PBS) and incubated at 37°C in trypsin (Life 
Technologies) to detach cells. Once detached, cells were resuspended in media and pelleted 
using a centrifuge at 300 RCF (relative centrifugal force) for 5 minutes. The supernatant was 
discarded. Cells were resuspended in freezing media (FBS containing 10% dimethyl sulfoxide 
(DMSO)) and aliquoted into cryovials (NuncÒ); 1-2x106 cells in 1.5ml freezing media per 
cryovial. Cells were stored for 2 days at -80°C in an isopropanol chamber (Thermo Fischer 
Scientific) before being transferred into dewars containing liquid nitrogen.  
 
Frozen cell stocks were revived by removing the cryovials from liquid nitrogen and thawing in 
a water bath at 37°C. Once defrosted, cells were quickly pipetted in a dropwise manner into 
a falcon tube containing 5ml of prewarmed media. Cells were then pelleted in a centrifuge 
(300 RCF for 5 minutes). The supernatant was discarded, cells resuspended in the relevant 
fresh medium and transferred to cell culture flasks.   
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2.1.3. siRNA transfections 
siRNA transfections were performed using LipofectamineÒ RNAiMAX reagent (Invitrogen) 
according to the manufacturer’s protocol. Briefly, the siRNA and lipofectamine reagent were 
incubated in Opti-MEMTM (Gibcoâ) before being dosed dropwise onto cells in penicillin and 
streptomycin free media. The siRNA was incubated with cells for 6 hours and media was 
replaced with fresh media. Strong knockdown of protein levels was typically seen at 48/72 
hours post transfection, as measured by Western blot. Typically, 20nM of siRNA was used 
unless stated otherwise in the figures (see figure details). siRNAs used: siWDR76-ORF 5’-GUA 
GAA GGU CAA CAA UGC GAU GAU UTT-3’, siWDR76-UTR 5’- CCG CUA AGA AGC CGA AAG ATT-
3’, siWRN-ORF 5’-GGA UGA AUG UGC AGA AUA ATT-3’, siATM 5’-GAC UUU GGC UGU CAA 
CUU UCG UU-3’, siControl – 5’-CGU ACG CGG AAU ACU UCG AUU-3’. 
 
2.1.4. Plasmid transfections 
Plasmid transfections were performed using either LipofectamineÒ 2000 transfection 
reagent (Thermo Fischer Scientific) or TransIT-LT1 transfection reagent (Mirus) according to 




Plasmids used for generation of stable cell lines were introduced into cells via electroporation 
using a Neon transfection system (Invitrogen). Plasmids and cells were prepared according to 
the manufacturer’s specifications and electroporated using the following protocol: 1 pulse at 
1400V for 30ms. 
 
2.1.6. Stable cell line generation 
RPE-1 WDR76-/- and WRN-/- cell lines were made using clustered regularly interspaced short 
palindromic repeats (CRISPR) and CRISPR associated protein 9 (Cas9) (CRISPR/Cas9) 
technology derived from the bacteria Streptococcus pyogenes. Cas9 is a nuclease which can 
be targeted to genomic regions via a guide RNA (gRNA). Cas9 must be directed by the gRNA 
to a region of DNA which is 5’ to a protospacer adjacent motif (PAM) sequence containing the 
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nucleotides NGG. Cas9 can then cut the DNA at these directed sites, thus generating a DSB142. 
Editing can occur at these sites as a result of natural erroneous repair mechanisms or can be 
specifically manipulated using exogenous constructs. Reduction of off target cutting can be 
achieved by directing a mutant nickase version of the Cas9 nuclease which only generates a 
SSB, this is Cas9 D10A142. 
 
RPE-1 WDR76-/- cells were generated using two gRNAs (gRNA25 and 26 in Appendix Table 1), 
Cas9D10A and a plasmid targeting construct (detailed in sections 2.6.3 and 3.2.7). RPE-1 
WRN-/- cells were generated using two gRNAs, Cas9D10A and a plasmid targeting construct 
(5.2.1 and Appendix Table 2). Plasmids were electroporated in as described earlier.     
 
RPE-1 cells stably expressing mRuby2 tagged WT and S148A/E mutant PAXX were generated 
by electroporation of plasmids into RPE-1 PAXX -/- cells generated by Ochi et al.143. Clones 
expressing mRuby2 PAXX versions were picked using zeocin antibiotic resistance selection 
and visually inspecting clones for nuclear mRuby2 using a fluorescent microscope.  
 
2.1.7. Cell cycle synchronisation 
Cell cycle synchronisation was performed using two different methods: double thymidine 
blocking and nocodazole treatment. For double thymidine blocking, cells were incubated in 
media containing 2.5mM thymidine (Sigma-Aldrich) for 18 hours followed by three PBS 
washes and fresh media added. Cells were left to recover for 10 hours and a second treatment 
of thymidine was added for a further 16 hours. Cells were washed with PBS and media 
replaced as before. Cells were harvested at relevant time points as indicated (see figures). For 
the non-released samples, cells were harvested immediately after washes. For nocodazole 
synchronisation, 100ng/ml of nocodazole was added for 18 hours to T175 flasks containing 
~70% confluent cells. Mitotic cells were detached from the flasks by harsh tapping of the flask 
on a bench top. Cells were re-plated for subsequent recovery and time points taken (as 
indicated in the figures). For the non-released samples, cells were harvested immediately 
after the washes. 
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2.2. Survival Assays 
 
2.2.1. Clonogenic cell survival assay 
Cells were seeded onto plates/dishes at concentrations which allowed for good colony 
spacing and thus reliable counting after colony staining. Where indicated cells may have 
received siRNA mediated protein depletion prior to seeding and further treatment. For IR 
survivals, cells were irradiated at concentrations ranging from 1-4Gy using a CellRadÒ 
machine (FaxitronÒ). Cells were then incubated as normal for around 10 days to obtain ideal 
colony densities for counting. Cells were washed with PBS and stained using a 20% ethanol 
solution containing 0.1% crystal violet. Colonies were counted manually, and a percentage of 
survival was calculated based on initial seeding densities and relative to untreated cells.  
 
2.2.2. IncuCyteÒ cell growth assays 
Cells were seeded onto 24 well plates at 1500 cells per well (triplicate wells per treatment). 
Treatments were added 24 hours after seeding and plates were placed inside the IncuCyteÒ 
ZOOM machine (Essen Biosciences) which captures images over time and calculates cell 
confluency. Cells were monitored over time and percentage confluence was measured using 
a confluence mask. Chronic treatments of camptothecin (CPT) were performed ranging from 
1 – 10nM CPT. Cells were left inside the IncuCyteÒ machine for 6 -10 days to allow for 
untreated controls to become fully confluent. In some instances, at the end of the IncuCyteÒ 
incubation period, cells were stained with Hoechst as detailed below. 
 
 
2.2.3. Hoechst 33342 staining cell survival assay 
Cells were seeded into 24 well plates in triplicate at 1500 cells per well and drug treatments 
were added 24 hours later (as indicated in the figure legends). Cells were grown for 6 -10 days 
without letting cells become overconfluent. Cells were fixed and stained with Hoechst 33342 
(Hoechst) (Thermo Fischer Scientific). Images were taken on a fluorescent microscope and 
number of nuclei counted using ImageJ.  
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2.2.4. Crystal violet staining 
Crystal violet staining was used to visualise colony survival for cells exposed to a range of DNA 
damaging agents including UV, CPT and heat-shock. Cells were washed with PBS and stained 
using a 20% ethanol solution containing 0.1% crystal violet. Colonies were counted manually, 




2.3. Yeast work 
 
2.3.1. Yeast culture 
Yeast cells were grown on 2% agar plates containing yeast extract, peptone and glucose 
(prepared by the media kitchen at the Gurdon Institute) at 30°C. Cells were temporarily 
stored on plates at 4°C. Yeast strains were frozen in glycerol for long term storage at -80°C.   
 
2.3.2. Yeast knockout generation 
A stable S. cerevisiae cmr1D strain was generated by first PCR amplifying a kanamycin 
resistance gene with primers containing overhangs that were homologous to the flanking 
regions of the Cmr1 gene (see Figure 11 and primers RS040 and RS041 in Appendix Table 1). This 
product was transformed into a K699 haploid strain of S. cerevisiae. Knockouts were identified 
by selecting single colonies grown on agar plates containing kanamycin resistance. Knockouts 
were confirmed for deletion of Cmr1 by PCR.  
 
2.3.3. Yeast DNA damage sensitivity assays  
Yeast, peptone, adenine (YPA) agar plates containing 20% glucose and different 
concentrations of either hydroxyurea (HU), camptothecin (CPT), phleomycin or methyl-
methanesulfonate (MMS) were used to measure the sensitivity of a cmr1 deletion strain 
(cmr1D) compared to a wildtype strain (K699 wildtype) and a DNA damage sensitive strain 
(mec1Dsml1D). 10µl drops of yeast strain culture were spotted onto plates at concentrations 
starting from 106 cells/ml and then descending 1:10 serial dilutions. Plates were incubated at 
30°C and left for 2-3 days. Plates were then scanned using a scanner (Epson). For ultraviolet 
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(UV) sensitivity assays normal agar plates were used, and plates were exposed to 5-100 J/m2 





2.4.1. Persistence of Ku Foci by immunofluorescent staining 
Detection of Ku foci by immunofluorescence (IF) staining was performed as previously 
described by Britton et al144. Briefly, cells were treated with siRNA (as described earlier) and 
then reseeded onto cover slips. Cells were then irradiated at 10Gy using the CellRad 
(FaxitronÒ). 3µM MLN4924 was used 1 hour prior to irradiation of relevant samples. Cells 
were then pre-extracted in cytoskeleton (CSK) buffer (100mM NaCl, 300mM sucrose, 3mM 
MgCl2, 0.7% Triton X-100, 10mM PIPES pH7.0 with 0.3mg/ml RNase A) and cells were fixed, 
permeabilised and stained for Ku80, gH2AX and DAPI. Cover slips were mounted onto 
microscope slides and widefield images were taken using a DeltaVision (GE Healthcare) 
microscope. Quantification of Ku foci was performed using the program Volocity (PerkinElmer) 
and counting the number of foci per DAPI stained area.  
 
2.4.2. Laser line micro-irradiation 
Cells were seeded onto glass-bottomed dishes (Wilco Wells) and incubated with 10µM 
bromodeoxyuridine (BrdU) for 48 hours prior to laser micro-irradiation. Cells had their media 
changed into phenol-red free medium on the day of laser line micro-irradiation. Laser line 
micro-irradiation was performed on an Olympus Inverted FV1000 confocal microscope with a 
405nm laser. Images were taken before and after micro-irradiation and recruitment of 
proteins to sites of DNA damage visualised via GFP/RFP recruitment through either GFP-
tagged proteins or by fixing, staining and IF afterwards.  
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2.4.3. ClickiT EU – RNA imaging – transcription inhibition at sites of 
laser lines 
Cells were seeded and treated as described above for laser micro-irradiation. After laser 
micro-irradiation cells were allowed to recover for 10 minutes and then cells were incubated 
with 1mM 5-ethynyl uridine (EU) (Invitrogen) for 30 minutes. This was followed by fixation in 
4% paraformaldehyde (PFA) in PBS for 15 minutes at room temperature followed by PBS 
washes. Permeabilisation was performed with 0.1% Triton X-100 in PBS for 15 minutes at 
room temperature. EU incorporation was detected using the Click-iT RNA Alexa Fluor 594 
imaging kit (Invitrogen) according to the manufacturer’s guidelines. Subsequent antibody 
labelling of gH2AX and DNA staining with Hoechst was performed. Cells were visualised on an 
Olympus Inverted FV-1000 confocal microscope and images taken.  
 
 
2.5. Molecular biology techniques 
 
2.5.1. Polymerase chain reaction (PCR) 
Crude lysate, genomic DNA (gDNA) or plasmid DNA were used as templates for PCR reactions. 
Crude lysate was extracted from cells using Direct PCR lysis buffer (Viagen Biotech) containing 
0.1mg/ml proteinase K (Sigma-Aldrich). 5-10µl of trypsinised cells were taken into 30µl lysis 
mix. Lysis/cell mix was incubated at 55°C for 1 hour followed by 95°C for 30 minutes. 1-2µl of 
crude lysate was used as template for PCRs. gDNA extractions were performed using a DNeasy 
blood and tissue kit (Qiagen) according to the manufacturer’s guidelines. 25-200ng of 
template gDNA were used for PCR reactions. 10-50ng of plasmid DNA was used as template 
for PCR reactions. PCRs were set up using Phusion high fidelity DNA polymerase (New England 
Biolabs (NEB)) according to the manufacturer’s protocol. See Appendix Table 1 for list of 
primers used. PCRs were set up in tubes/96W plates and performed in a VeritiTM 96-well fast 
thermal cycler (Thermo Fischer Scientific) to the following protocol: 30 seconds at 98°C 
followed by 30 cycles of 10 seconds at 98°C, 30 seconds at 45-72°C (melting temperature) 
and 30 seconds per kilobase (kb) at 72°C then a final extension for 10 minutes at 72°C. Melting 
temperatures were adjusted based on the primers being used. 
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2.5.2. Agarose gel electrophoresis 
Amplified PCR products had gel loading dye added and subsequently run on 1-2% agarose 
gels at 100-150 Volts in 1x Tris/acetic acid/EDTA (TAE) buffer. Samples were run with either a 
100 base-pair (bp) or 1kb ladder (NEB). DNA bands were visualised with a UV imager (Biorad 
GelDoc). 
 
2.5.3. PCR purification 
PCR purifications were performed either directly on amplified products in solution or on 
bands excised from agarose gels. In both cases products were purified using a GeneJet PCR 
purification kit according to the manufacturer’s guidelines (Thermo Fischer Scientific).   
 
2.5.4. Immunoprecipitation 
Cell lines expressing GFP tagged versions of proteins were cultured, expanded and harvested 
by washing cells twice in PBS and scraping cells into 1.5ml micro-centrifuge tubes. Cells were 
pelleted by centrifugation at 300 RCF for 5 minutes at 4°C and the supernatant removed. 
Pellets were resuspended and rotated for 30 minutes at 4°C in the following lysis buffer: 
50mM Tris-HCl pH7.4, 100mM NaCl, 1mM MgCl2, 10% glycerol, 5mM NaF, 0.2% Igepal CA-
630, 1x EDTA-free protease inhibitor tablet (Roche) and 25U/ml Benzonase. NaCl and EDTA 
were then added to final concentrations of 200mM and 2mM respectively and vortexed 
briefly. Samples were rotated at 4°C for a further 10 minutes before being spun down at 3000 
RCF for 5 minutes at 4°C. The supernatant was then transferred to fresh micro-centrifuge 
tubes. Samples were then spun hard at 20,000 RCF for 30 minutes at 4°C and the supernatant 
kept. A fraction of sample was kept for loading as inputs and the rest were incubated with 
GFP-trap beads (ChromoTek) for 3 hours on a rolling rotator at 4°C. Beads were then spun 
down, the supernatant discarded, and the beads washed with lysis buffer. Finally samples 
were eluted in Laemmli buffer (62.5mM Tris-HCl pH6.8, 2% SDS, 10% glycerol, 25mM tris(2-
carboxyethyl)phosphine (TCEP)) and heated at 100°C for 5 minutes. Protein samples were 
subsequently used for Western blotting.  
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2.5.5. Protein extractions 
Cell pellets were resuspended in 50-200µl of lysis buffer (50mM Tris-HCl pH7.4, 400mM NaCl, 
10% glycerol, 1mM EDTA, 5mM NaF, 0.2% IGEPAL CA-630 and 1 protease inhibitor tablet 
(Roche)), put into micro-centrifuge tubes and vortexed briefly. Samples were then rotated at 
4°C for 30 minutes followed by centrifugation at >20,000x g at 4°C for 30 minutes. 
Supernatants were transferred to fresh micro-centrifuge tubes.  
 
In some cases, a sodium dodecyl sulphate (SDS) lysis buffer (4% SDS, 20% glycerol and 120mM 
Tris-HCl pH6.8) was used to prepare protein samples. Cell pellets were resuspended in 50-
200µl of SDS lysis buffer, boiled for 5 minutes at 95°C and syringed 10 times with a 25-gauge 
needle.  
 
2.5.6. Western blotting 
Protein concentrations were determined by measuring the absorbance at a 280nm 
wavelength on a NanoDrop (Thermo Fischer Scientific). Samples of equal concentration were 
made up by diluting in the same buffer as the protein extractions were performed. Gel loading 
dye containing 10% b-mercaptoethanol and 0.005% bromophenol blue was added, and 
samples were boiled for 5 minutes at 95°C. Samples were run on NuPAGE 4-12% Bis-Tris 
protein gels (Invitrogen) with a PageRuler (Thermo Fischer Scientific) Plus protein ladder in 
Novex gel running tanks (Thermo Fischer Scientific) with MOPS buffer. Protein was wet-
transferred at 100V for 1 hour onto nitrocellulose membranes (GE Healthcare) in transfer 
buffer (1x protein running buffer (15g Tris, 72g glycine in 5L dH20) and 20% methanol). 
Membranes were then stained with Ponceau solution (1% acetic acid, 0.1% Ponceau S) to 
check for correct transfer. Membranes were washed in distilled water to remove any 
remaining Ponceau and then membranes were blocked in tris-buffered saline and Tween20 
(TBS-T) containing either 5% milk (Marvel) or 5% bovine serum albumin (BSA) (Sigma-Aldrich), 
dependent on the downstream antibodies used. Membranes were blocked for 1-2 hours at 
room temperature on a shaker. Membranes were then incubated with primary antibody 
overnight at 4°C on a shaker. Membranes were washed 5 times in TBS-T and then incubated 
with the relevant horseradish peroxidase conjugated secondary antibodies. Protein bands 
were visualised using ECL reagent and Amersham Hyperfilm (GE Healthcare). 
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2.5.7. Chromatin fractionation 
Cells were either left untreated or treated as detailed in the figures. Cells were harvested by 
first washing with PBS and subsequently pre-extracted twice (with PBS washes between each 
pre-extraction) for 3 minutes at 4°C with the following CSK buffer: 100mM NaCl, 300mM 
sucrose, 3mM MgCl2, 0.7% Triton X-100, 10mM PIPES pH7.0 with 0.3mg/ml RNase A. Cells 
were scraped into microcentrifuge tubes and protein extracted using Laemmli lysis buffer as 
described before. Western blotting was then performed as described earlier.  
 
2.5.8. Sample preparation for mass spectrometry 
HEK293 FT cells were transfected with either 10µg of a GFP-tagged WDR76 containing 
plasmid (Genscript-WDR76cDNA pEGFP-C1) or a GFP-only containing plasmid (pEGFP-C1), 48 
hours prior to further treatment. Samples which received treatment had either 3µM of the 
neddylation inhibitor MLN4924 or 10µM of the proteasomal inhibitor MG132 added for 2 
hours. Cells were then harvested and immunoprecipitation with GFP-trap beads performed 
as described earlier. A subset of eluted immunoprecipitated sample was run on a gel and 
stained with Coomassie to visualise banding patterns. Samples were sent to the Professor 
Benedikt Kessler lab (Target Discovery Institute, University of Oxford) for mass spectrometry 
analysis. 
 
2.5.9. DNA Sequencing 
Sequencing of DNA PCR fragments and plasmids was performed by the Department of 
Biochemistry Sequencing Facility, University of Cambridge. Relevant primers were provided. 
Alignments were carried out using either DNAdynamo DNA sequence analysis software (Blue 
Tractor Software) or SnapGene. 
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2.6. Cloning techniques 
 
2.6.1. Site directed mutagenesis 
Site directed mutagenesis was performed on a plasmid expressing mRuby2 tagged WT PAXX 
using a QuikChange site-directed mutagenesis kit (Agilent) according to the manufacturer’s 
guidelines. Briefly, plasmids were amplified by PCR using forward and reverse primers which 
were designed to incorporate the coding sequences for the desired S148A, and S148E 
mutations (RS121, RS122, RS125, RS126 primers were used – see Appendix Table 1). The PCR 
product was DpnI digested, purified and transformed into chemically competent XL1-Blue 
bacteria (Agilent).   
 
2.6.2. Guide RNA plasmid cloning 
Guide RNA (gRNA) sequences were designed against exon 2 of human WDR76 using the Broad 
Institute gRNA design tool. Two gRNAs were used: a forward gRNA – 
TGTTGATGTGGAAAGTAGTC (gRNA25) and a reverse gRNA – CATCGCATCTGCCGTTCTCT 
(gRNA26).  These were made by first annealing two oligos for each gRNA, RS095 and RS096 
for the forward gRNA and RS097 and RS098 for the reverse gRNA. Annealing was 
accomplished by mixing equal volumes (1µl) of 100µM oligos with 98µl of annealing buffer 
(20mM Tris pH8.0 and 50mM NaCl) and heating to 96°C for 5 minutes followed by cooling 
down to 4°C at a rate of -1.5°C per minute. Heating and cooling were performed in a VeritiTM 
96-well fast thermal cycler (Thermo Fischer Scientific). Once annealed, gRNAs were cloned 
into an all-in-one Cas9D10A plasmid (this was performed by Matylda Sczaniecka-Clift and 
Siyue Wang in the Steve Jackson Lab). This was achieved by sequential restriction enzyme 
cutting of the plasmid and insertion of gRNAs through the restriction sites BsaI and BbsI. 
 
2.6.3. WDR76 targeting plasmid construction 
The targeting construct was made by cloning three fragments into a pUC19 plasmid backbone: 
a 5’ left homology arm (LHA), a 3’ right homology arm (RHA) and a positive selection cassette. 
Homology arms were designed to flank either side of the gRNA cut sites and generated via 
PCR. Due to the complexity of the overhangs on the primers needed for the cloning steps, the 
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fragments were amplified off of a template PCR product which was generated with less 
complex primers. These templates were generated by PCR amplification of RPE-1 (genomic 
DNA) gDNA using the primers RS051 and RS060 for the LHA template and RS058 and RS055 
for the RHA template. The LHA fragment was generated using the primers RS083 and RS118, 
and the RHA fragment was generated using the primers RS140 and RS088. The positive 
selection cassette containing a neomycin resistance gene driven by a PGK promoter was 
amplified from plasmid pAAV0323 (Horizon Discovery) using the primers RS085 and RS119. 
 
DNA fragments were cloned into a pUC19 vector backbone (NEB) between the XbaI and 
HindIII restriction sites using In-FusionÒ cloning methods. The pUC19 vector backbone was 
linearised using XbaI and HindIII restriction enzymes and treated with Antarctic phosphatase 
(NEB) to prevent re-ligation of the backbone. Fragments and backbone were mixed at an 
equal ratio using 10-200ng of fragments in a 10µl reaction containing 2µl of 5X In-Fusion HD 
enzyme premix (Takara-Clontech). Ligations were performed by incubating the sample at 
50°C for 15 minutes and then placing on ice. The ligated plasmid was then transformed into 
bacteria (see below).   
 
2.6.4. Bacterial transformation 
Ligated DNA fragments were transformed into chemically competent StellarTM competent 
bacterial cells (Takara-Clontech). StellarTM cells were thawed on ice and 50µl of cells aliquoted 
into pre-chilled Eppendorf tubes. 1µl (1-5ng) of DNA was added to the cells and left on ice for 
30 minutes. Heat-shock was then performed by submerging the bottom half of the Eppendorf 
tubes into a water bath at 42°C for 45 seconds. Tubes were then placed back onto ice for 2 
minutes. 500µl of super optimal broth with catabolite repression (SOC) medium (pre-warmed 
to 37°C) was then added and tubes incubated for 1 hour at 37°C with shaking (160-225rpm). 
Between 50 – 200µl of culture was then spread onto agar plates containing relevant antibiotic 
selection. Plates were incubated overnight at 37°C and then inspected for colonies. Colonies 
were picked for mini-prepping and confirmed for the correct constructs by restriction enzyme 
digestion and sequencing. Correct colonies were then maxiprepped to yield higher 
concentrations of plasmid DNA.  
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2.6.5. Plasmid Maxiprep      
Bacterial colonies were picked and cultured in 200ml of LB medium in a conical flask. Cells 
were incubated overnight at 37°C with shaking. Cells were pelleted in a centrifuge (3000rpm 
for 20 minutes) and maxipreps were performed using a QIAGENÒ plasmid maxi kit (Qiagen) 
according to the manufacturer’s protocol.  
 
 
2.7. Virus work 
 
2.7.1. Lentivirus generation 
Lentivirus carrying a CRISPR gRNA encoding library was produced by transfection of HEK293 
Lenti-X cells with the human DDR (hDDR) plasmid library (made by Ramsay Bowden, Dr Yaron 
Galanty in the Prof Steve Jackson laboratory and Emmanouil Metzakopian at the Wellcome 
Trust Sanger Institute) and two packaging plasmids: psPAX2 (Addgene ID12260) and pMD2.G 
(Addgene ID12259). 3x106 HEK-293 Lenti-X cells were seeded per 15cm dishes (4x dishes) in 
25ml of penicillin and streptomycin free media. Plasmid transfections were performed the 
following day by mixing 7.5µg, 4µg and 18.5µg of the hDDR library, pMD2.G and psPAX2 
plasmids respectively, in 1.6ml of Opti-MEM (GibcoÒ). Separately, 90µl of Lipofectamine LTX 
(Thermo Fischer Scientific) was mixed with 1.6ml Opti-MEM. Both Opti-MEM-plasmid and 
Opti-MEM-lipofectamine mixes were then pooled together and incubated at room 
temperature for 30 minutes. The mixture was then added to a 15cm dish containing cells in a 
dropwise manner, ensuring equal coverage across the dish (this was performed for each dish). 
Transfected cells were left for 54 hours before the supernatant media containing the virus 
was collected into 50ml falcon tubes. Tubes were spun at 300 RCF for 5 minutes and the 
supernatant passed through a 0.45µm filter using a syringe and collected. Virus was aliquoted 
into 5ml and 1ml volumes, snap frozen in an ethanol and dry-ice ice bath and stored at -80°C.  
 
2.7.2. Virus titre determination 
To determine the concentration of the hDDR library containing virus cells were infected with 
various dilutions of virus and fluorescence activated cell sorting (FACS) analysed for 
percentage of blue fluorescent protein (BFP) positive cells as follows. Two cell lines were used 
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for infection: an RPE-1 clone expressing Cas9 and an RPE-1 WRN-/- clone expressing Cas9 
(which were used in the actual CRISPR screen). Measuring the titre in these cell lines most 
closely replicated screen conditions and thus gave the best determination of virus titre. Cells 
were seeded in 6cm dishes at 0.6x106 cells per dish with a dish for each dilution of virus to be 
added as well as extra non-infected dishes: 1:250, 1:500, 1:2500, 1:5000, 1:25000 and 
1:50000. 24 hours after seeding a dish from each cell line was used to count the number of 
cells at the time of infection using a Coulter counter. Virus was diluted, and relevant dishes 
infected. Cells were left for 5 days following infection and then harvested, fixed with 4% PFA 
and resuspended in PBS containing 1% BSA. Cells were measured for BFP expression by FACS, 
using a MoFlo Astrios (Beckman Coulter) cell sorter (excitation at 402nm, emission at 457nm). 
Virus titre was calculated using number of cells infected, dilution of virus used and percentage 
BFP expressed to give a final virus titre.       
 
 
2.8. CRISPR-Cas9 genetic screen 
 
2.8.1. Principle of the screen 
The basic principle of a CRISPR-Cas9 screen is to identify genes, which when inactivated, alter 
an observed cellular phenotype. This is achieved by infecting cells expressing Cas9 with a 
library which contains gRNAs targeting Cas9 to different genes. The number of genes targeted 
depends on the design and size of the library. A population of cells where only one gRNA is 
expressed per cell can be achieved by controlling the multiplicity of infection (MOI). Once 
infected, gRNA mediated CRISPR-Cas9 generates genetic knockouts in a population of cells 
that represents the gRNA library. A given phenotype can be observed and changes to the 
phenotype can be traced back to the gRNA infected.  
 
In this thesis, a CRISPR screen was set up to look for genes which when inactivate alter the 
hypersensitivity of WRN-/- cells to camptothecin (CPT). RPE-1 WT and WRN-/- clones 
expressing Cas9 were infected with a human DDR library and subject to CPT treatment at 
concentrations which kills the majority of cells. Genes which when inactivated give a growth 
advantage to cells can be identified at the end of the experiment by sequencing the 
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population and looking for gRNAs that are enriched compared to samples sequenced prior to 
treatment. In addition, genes which when inactivated, increase the sensitivity of cells to the 
treatment can be identified by looking at gRNAs which are reduced/dropout in the 
sequencing from samples after treatment compared to before.  
 
The screen was performed with a focused human DDR library targeting 737 genes associated 
with the DDR. The library contained 11,281 gRNAs with an average number of 13 gRNAs 
targeting each gene to increase confidence in the data. In addition, the human DDR library 
also contained 1200 non-targeting gRNAs as negative controls. (See Appendix Table 4-
Appendix Table 8 for list of genes). 
 
2.8.2. Performing the CRISPR-Cas9 screen 
The screen was performed in three separate Cas9 expressing cell lines: RPE-1 WT clone 28, 
RPE-1 WRN-/- E5-C6 and RPE-1 WRN-/- G7-C5. 28x106 cells were seeded per T300 flasks (4x 
T300 flasks). 24 hours later cells were infected with the human DDR library containing virus 
at an MOI of 0.2. Cells were then bulk-sorted by FACS for blue fluorescent protein (BFP) 
positive cells ~72 hours after post infection to sort for positively infected cells. The number 
of cells sorted was enough to maintain a 500x library representation, meaning there are 500 
cells for each gRNA. These cells were plated into fresh T300 flasks and cultured for 14 days 
maintaining sufficient cell numbers for 500x library representation of subsequent treatments. 
A fraction of the cell population was frozen down at this stage for subsequent gDNA 
extractions to be used as controls before the drug treatments.  
 
6x106 cells were seeded into 2x T300 flasks per treatment; these were DMSO, 2nM CPT and 
5nM CPT treatments for the RPE-1 WT cell line and a DMSO and 2nM CPT treatments for the 
WRN-/- clones. Treatments were performed by administering the CPT/DMSO 24 hours after 
seeding. Cells were left in the presence of the CPT/DMSO for 5 days, counted and reseeded.  
For the RPE-1 WT cells, 2nM CPT gave around an inhibitory constant 40 (IC40) and 5nM CPT 
gave around an IC70. For both WRN-/- clones 2nM CPT gave an IC60. Cells were grown to 
recover from the drug treatment for a further 6 days and samples frozen for subsequent gDNA 
extractions.  
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2.8.3. gDNA extractions and library preparation  
6x106 cells per sample were used for gDNA extraction to ensure the 500x library 
representation was maintained. Cell were pelleted by centrifugation and washed twice in PBS. 
Cells were pelleted again, resuspended in 5ml of lysis buffer (17mM Tris pH7.5, 17mM EDTA, 
170mM NaCl, 0.85% SDS and 1mg/ml proteinase K), and incubated overnight at 55°C with 
shaking. DNA was precipitated by adding 5ml isopropanol and inverting multiple times until 
a DNA precipitate was visible. DNA was pelleted in a centrifuge at full speed for 5 minutes. 
Pelleted DNA was washed three times in 70% ethanol before being resuspended in distilled 
water to a final DNA concentration of 200ng/µl as measured on a NanoDropTM.  
 
For each sample, 48 initial PCR reactions were set up using 1µg of template DNA to ensure 
full representation of the experiment. This was to specifically amplify the gRNAs in the 
samples. PCRs were performed in 50µl in a 96 well plate using Q5 DNA polymerase (NEB) 
(10µl Q5 buffer, 2µl 10mM dNTPs, 0.5µl Q5 DNA polymerase, 2.5µl of 100µM primer (RS204 
and RS208), 27.5µl H2O and 5µl (1µg) template DNA). PCRs were performed in a VeritiTM 
thermocycler at the following conditions: 1 minute at 95°C followed by 30 cycles of 30 
seconds at 95°C, 30 seconds at 53°C and 30 seconds at 72°C then a final extension for 10 
minutes at 72°C.  
 
PCR reactions were pooled, and samples run on an agarose gel and bands gel purified. DNA 
concentrations were all around 200ng/µl. Purified products were then used for a second PCR 
to add IlluminaÒ (Nextera with Truseq adaptors) sequencing specific overhangs, so that DNA 
samples could be sequenced, and gRNAs identified. 8x 50µl PCR reactions were set up using 
1µg of template PCR product from the gel purified RS204/RS208 products. Primer RS217 was 
used as a forward primer and one of primers RS218 – RS227 was used as a reverse primer for 
each sample (Table 1). PCRs were performed in the same setup as before and products pooled 
and gel purified separately for each sample.    
  






Sample detail 1st PCR primers 2nd PCR primers 
SIV1 RPE-1 WT DMSO treated RS204 – RS208 RS217 – RS218 
SIV2 RPE-1 WT 2nM CPT treated RS204 – RS208 RS217 – RS219 
SIV3 RPE-1 WT 5nM CPT treated RS204 – RS208 RS217 – RS220 
SIV4 WRN-/- G7-C5 DMSO treated RS204 – RS208 RS217 – RS221 
SIV5 WRN-/- G7-C5 2nM CPT treated RS204 – RS208 RS217 – RS222 
SIV6 WRN-/- E5-C6 DMSO treated RS204 – RS208 RS217 – RS223 
SIV7 WRN-/- E5-C6 2nM CPT treated RS204 – RS208 RS217 – RS224 
SIV8 RPE-1 WT day 14 control RS204 – RS208 RS217 – RS225 
SIV9 WRN-/- G7-C5 day 14 control RS204 – RS208 RS217 – RS226 
SIV10 WRN-/- E5-C6 day 14 control RS204 – RS208 RS217 – RS227 
 
 
Gel purified products were run on a Tapestation2200 (Agilent) to verify product size. Purified 
PCR products were quantified using a QubitTM double stranded DNA (dsDNA) high sensitivity 
assay kit (Thermo Fischer Scientific) and by quantitative PCR (qPCR) using an NEBNextÒ library 
quantification kit for IlluminaÒ (NEB). Once quantified, 15nM of each PCR product was pooled 
together (multiplexed) and re-run by qPCR to verify concentration. The multiplexed sample 
was then submitted for IlluminaÒ sequencing.  
 
2.8.4. Sequencing 
Sequencing was performed by Kay Harnish at the Gurdon Institute using an IlluminaÒ Hi-Seq 
1500. An IlluminaÒ single read 22bp sequencing protocol was performed using RS228 as a 
sequencing primer. An average of 38x106 reads matching gRNAs per sample was achieved.  
 
Table 1 Details of samples in screen and primers used for generating library for sequencing 
Table shows the primers used for first and second PCRs for each sample sent for sequencing from 
the screen. Samples were given tracking IDs.  
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2.8.5. Bioinformatics analysis 
Sequence files were processed by Fabio Puddu in the Steve Jackson lab. Sequences were 
traced to original samples and matched to gRNAs and genes in the library. Joint analysis of 
CRISPR/Cas9 knockout screens (JACKS) was performed on the datasets from the screen by 
Iñigo Ayestaran in the Steve Jackson lab.   
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3.1.1. Ubiquitylation in the DNA damage response 
Post translational modifications (PTMs) are a key method of regulating multiple biological 
processes145 that involves the covalent attachment of molecules onto an existing protein. 
PTMs include processes like phosphorylation which covalently attaches a phosphate group 
onto amino acid residues within a protein; this can modify the structure or interaction 
capabilities of a protein thereby altering the role of that protein. Acetylation is another type 
of PTM which is often associated with modifying histones to regulate gene transcription146. 
Another common PTM is ubiquitylation. This involves the covalent attachment of a small, 76 
amino acid protein called ubiquitin onto target proteins147. The attachment of ubiquitin 
happens in a three-step process that firstly involves the activation of ubiquitin through an E1 
ubiquitin-activating enzyme. This first step is an adenosine triphosphate (ATP) dependent 
process and results in a covalent attachment between ubiquitin and the E1 enzyme. This now 
primed ubiquitin is then transferred onto an E2 ubiquitin-conjugating enzyme. Finally, 
through an interaction between the E2 enzyme and an E3 ubiquitin-ligase, the ubiquitin 
molecule is transferred onto a target substrate, usually with a bond forming between the C-
terminus of ubiquitin and a lysine residue on the target protein147,148 (Figure 5A).  
 
Ubiquitylation of target proteins exists in multiple forms whereby ubiquitin can be attached 
to a substrate in different ways. Monoubiquitylation is when a single ubiquitin molecule is 
attached to an amino acid residue on a substrate. Substrates can also be multi-ubiquitylated, 
whereby multiple residues on a single protein are monoubiquitylated149. Substrates can also 
be polyubiquitylated; this involves the attachment of additional ubiquitin molecules onto 
existing ubiquitin, either through an N-terminal methionine (M1) or one of seven lysine 
residues (K6, K11, K27, K29, K33, K48, K63) on a ubiquitin moiety. This variety of ubiquitin 
conjugation creates a range of ubiquitin chain topologies, including ubiquitin branchings that 
have been linked to different types of protein regulation148 (Figure 5B). The best described 
ubiquitylation process is K48 linked ubiquitylation which has been shown to be a major signal 
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driving degradation of proteins via the proteasome150. Additional research in the field has 
linked other types of ubiquitylation to distinct biological roles, such as K63 linked ubiquitin 
chains playing important roles in DNA damage signalling cascades. An example of this is in the 
initial DNA damage response to DSBs, where K63 ubiquitylation occurs on histones H1 and 
H2A by the RNF8 and RNF168 ubiquitin ligases respectively. This K63 ubiquitylation serves as 
a signal/platform for the downstream recruitment of DNA repair factors to sites of DNA 
damage151. 
 
Ubiquitylation is a dynamic process that is negatively regulated by enzymes which catalyse 
the removal of ubiquitin from substrates. These enzymes are known as deubiquitylating 
enzymes (DUBs)152. Since DNA damage is such a threat to organisms, the DNA repair 
machinery needs to be tightly coordinated and regulated. One of the ways in doing this is 
through the constant ubiquitylation and deubiquitylation of proteins involved in the DDR, 
which can affect their activity and recruitment/retention at sites of DNA damage153. 
 





3.1.2. Cullin-RING ligases in the DNA damage response 
The Cullin-RING ligases (CRLs) are a family of multi-subunit E3 ubiquitin ligases that comprise 
of a RING protein and a core scaffold Cullin protein, of which there are seven in humans: Cullin 
1, 2, 3, 4A, 4A, 5 and 7 (CUL1, 2, 3, 4A, 4B, 5 and 7)154. The core Cullin scaffold protein has an 
elongated shape which allows for docking of an E2 conjugating enzyme through the RING 
protein at the C-terminal end of the Cullin. Binding of substrate adaptors and receptors is 
Figure 5 The ubiquitylation cascade and consequences of substrate ubiquitylation 
(A) Simplified diagram of the activation and transfer of ubiquitin via E1, E2 and E3 enzymes onto 
substrates. (B) Ubiquitin can be conjugated in many forms which are linked to many different 
functions. Figure adapted from Rape. Nature Reviews 2018148. 
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mediated by the N-terminal end of the Cullin. CRLs are activated through a process called 
neddylation, which involves the attachment of the ubiquitin like protein NEDD8 (Neural 
Precursor Cell Expressed Down-Regulated 8) onto the Cullin. Neddylation is a multistep 
process which is very similar to the ubiquitin attachment cascade described earlier155. Only 
when CRLs are in their neddylated form, are they able to effectively facilitate the ligation of 
ubiquitin onto substrates156. 
 
As with ubiquitylation, neddylation is also a dynamic process and the CRLs are negatively 
regulated by the removal of NEDD8; a process referred to as de-neddylation. This is 
performed by the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a multi-
subunit protein complex that directly interacts with CRLs and through isopeptidase activity, 
removes NEDD8 and thereby shifts CRLs into an inactive state154,156.  
 
Due to their ability to bind multiple substrate receptors, CRLs have multiple targets and 
therefore multiple functions. Additionally, CRL substrates are usually proteins that have 
already undergone PTMs and therefore the diversity and complexity of their functions are 
further increased154. The CRL with the strongest connection to DNA damage is the Cullin 4 
(CUL4) complex157.        
 
 
3.1.3. The CUL4 complex and the DNA damage response 
The CUL4 complex exists in two forms in mammals defined by the central backbone to the 
complex, either with CUL4A or CUL4B158. Despite high sequence similarity between the two 
paralogs, evidence suggests the two paralogs are not functionally redundant with each other. 
CUL4B plays an important role in embryonic development as indicated by the embryonic 
lethality of CUL4B knockout mice; CUL4A knockout mice in contrast, develop with no apparent 
defects159–161.   
 
The CUL4 complex is capable of the ubiquitylation of multiple target proteins. This is achieved 
through its binding of an adaptor protein, DNA damage binding protein 1 (DDB1) through the 
N-terminal end of CUL4. DDB1 subsequently has the ability to bind multiple different 
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substrate receptors; each substrate receptor binds specific substrates (Figure 6A)162. The 
substrate receptors bring potential substrates into close proximity to an E2 ligase which forms 
part of the complex by binding through a RING finger protein, RING box protein 1 (RBX1), 
located at the C-terminal region of CUL4.  This then allows for transfer of ubiquitin onto a 
substrate. The substrate receptors are often referred to as DDB1-CUL4 associated factors 
(DCAFs). Many of these substrate receptor proteins are WD40 domain containing proteins. 
WD40 repeat domain containing proteins are able to fold into b-propeller structures allowing 
for large surfaces of interaction with potential substrates163. Many of the DCAFs have been 
identified through immunopurification techniques however a large proportion of them still 
have unknown functions and undefined substrates162. 
 
Due to its ability to bind multiple substrates, the CUL4 complex is involved in a number of 
biological processes including cell cycle regulation, transcription regulation, ribosome 
biogenesis, RNA splicing and histone modification 157,162. In addition to these processes 
evidence suggests that the complex is involved in the DDR; this has been shown via its 
involvement in the nucleotide excision repair (NER) pathway and the response to UV 
damaged DNA. Two of the best characterised substrate receptors demonstrating the 
involvement of CUL4 in DNA repair are DNA damage binding 2 (DDB2) and Cockayne 
syndrome A (CSA)164. DDB1 and DDB2 are important components in the global genome NER 
(GG-NER) sub-pathway, which repairs bulky DNA adducts throughout the genome. Mutations 
in DDB1 or DDB2 result in xeroderma pigmentosum (XP), an autosomal recessive rare disease 
characterised by extreme sensitivity to sunlight165,166. One of the most common causes of 
death in XP patients is skin cancer167. CSA is involved in the transcription-coupled NER (TC-
NER) sub-pathway, which acts solely on DNA damage that inhibits transcription168. Mutations 
in CSA result in Cockayne syndrome, a rare disease characterised by microcephaly and growth 
failure. This syndrome is also associated with increased sensitivity to sunlight164.  
 
Data published within the Steve Jackson laboratory clearly shows that neddylation occurs at 
sites of DNA damage as seen by recruitment of GFP-NEDD8 to sites of laser line induced DNA 
damage169. Furthermore, the level of GFP-NEDD8 recruitment was reduced upon siRNA 
mediated depletion of CUL4A/B, and both CUL4A and B themselves localise to sites of DNA 
damage. Inhibition of neddylation using MLN4924, an inhibitor of the NEDD8 activating 
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enzyme E1 (NAE1), resulted in an increased persistence of Ku foci after IR induced DNA 
damage169. One of the unanswered questions in the DNA damage field is how the Ku 
heterodimer is removed from the DNA after repair has taken place. The doughnut shaped 
structure of the heterodimer allows it to slide onto DNA ends; however when the break has 
been fixed by NHEJ, Ku could remain trapped on the DNA with the ability only to slide66,170. 
This would create potential problems by creating a barrier to transcription or replication and 
could lead to toxicity by creating more DNA damage. It is therefore likely that a method(s) 
exists for the removal of Ku from DNA. Postow et al.138 showed that Ku80 can be removed 
from DNA via a K48-linked ubiquitin dependent pathway138. In addition, Brown et al169 
highlighted a role of Cullin mediated ubiquitylation in the removal of Ku after DNA damage 
and indicates the likely role of CUL4 specifically in the regulation of NHEJ. This raises the 
question: which substrate adaptor of the CUL4 complex is responsible for the ubiquitylation 
and subsequent removal of Ku?  
 
 
3.1.4. Investigating the role of WDR76 in the regulation of NHEJ 
WDR76 is a substrate receptor of the CUL4 complex but currently its substrate(s) is (are) 
unknown162. The implications of CUL4 in the regulation of Ku DNA binding make WDR76 an 
interesting protein to study, as it potentially has a role in the regulation of NHEJ.  
 
WDR76 is a conserved protein from yeast to mammals and shows a high sequence similarity 
(18.97% sequence identity) between the human and S. cerevisiae orthologs (Figure 6B). This 
likely indicates that it has an important biological function(s). The S. cerevisiae ortholog of 
WDR76 is Cmr1. A number of groups have implicated Cmr1 in the DNA damage response171–
173. Cmr1 has been shown to interact with several proteins involved in DDR processes, 
including the yeast orthologs of Ku70 and Ku80 as well as the yeast orthologs of the RPA 
complex174,175. Cmr1 has also been shown to directly bind both single-stranded DNA (ssDNA) 
and double-stranded DNA (dsDNA), with a slightly higher affinity for dsDNA over ssDNA172.  In 
addition, Cmr1 showed preferential binding to UV damaged DNA which again suggests an 
involvement of WDR76 in the DNA repair process172. Studies in yeast have also identified 
Rtt101 as being the closest homolog to CUL4176. Interestingly Rtt101 knockout strains are 
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hypersensitive to a range of DNA damaging agents including methyl methanesulfonate (MMS) 
and camptothecin176,177.  
 
More recently, two different groups showed via endogenous GFP-tagging that Cmr1 
relocalises to form sub-nuclear foci under DNA damaging conditions173,178. In yeast, this is 
symptomatic of proteins involved in DDR processes. Gallina et al. also showed that human 
WDR76 interacts with Ku70/80 and alluded to a role in the cellular repair and recovery after 
DNA damage173.   
 
Despite these findings the precise role(s) of WDR76 within the DDR remains to be defined. 
This makes WDR76 an interesting target for investigation, as it has a potential role in the 
removal of Ku as well as in the regulation of NHEJ. 
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Figure 6 WDR76 is a conserved substrate receptor of the CUL4 ubiquitin ligase 
(A) Simplified diagram of the CUL4 ubiquitin ligase in its active, NEDD8 bound, form. The substrate 
adaptor DDB1 allows binding of the substrate receptor WDR76 to facilitate the ubiquitylation of a 
substrate. (B) Representative protein alignment comparing a section of WDR76 across a range of 
species. WD40 domains 4,5 and 6 of human WDR76 are highlighted and in orange text. Table 
shows sequence identity compared to human WDR76. * = single fully conserved residue, : = 
conservation between groups of strongly similar properties, . = conservation between groups of 
weakly similar properties. 





3.2.1. WDR76 interacts with Ku70/Ku80 
If WDR76 is responsible in mediating the ubiquitylation of Ku, one would expect the two 
proteins to interact with each other. To first identify whether WDR76 interacts with the 
Ku70/80 heterodimer, immunoprecipitation assays (IPs) were set up. A plasmid construct 
expressing a GFP-tagged version of WDR76 in a pEGFP-C1 background was transfected into 
either human RPE-1 or HEK-293 cells and GFP-WDR76 captured using GFP trap beads. In both 
cell lines, WDR76 showed an interaction with Ku70 and Ku80 which was not seen in the GFP 
only transfected controls (Figure 7A/B). WDR76 also exhibited interactions with the substrate 
adaptor protein DDB1 and the CUL4A E3 ligase in both cell lines. As all IPs were performed in 
the presence of ethidium bromide (EtBr) and were benzonase treated, the likelihood of 
indirect interactions through DNA bridging was low.  
 





3.2.2. WDR76 localises to sites of DNA damage 
As WDR76 appeared to interact with Ku, I next tested to see if WDR76 is recruited to sites of 
DNA damage. Live HeLa cells stably expressing a GFP tagged mouse version of WDR76 were 
used to visualise recruitment of the protein to sites of laser line induced DNA damage. Cells 
that had not undergone pre-treatment with BrdU showed no recruitment to UV lasered areas, 
Figure 7 WDR76 interacts with Ku70, Ku80 and the CUL4 complex 
Immunoprecipitation assays (IPs) showing pulldown of CUL4A, DDB1, Ku70 and Ku80 in RPE-1 cells (A) 
and HEK293 cells (B) expressing GFP-tagged WDR76 (WDR76-GFP). A plasmid expressing GFP only was 
used as a control. IPs were performed in the presence of EtBr (which intercalates with DNA) and 
benzonase (an endonuclease which digests DNA and RNA) to reduce the likelihood of DNA/RNA 
bridged interactions. 
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whereas cells pre-sensitised with BrdU did show obvious recruitment as seen by an enriched 
line of GFP in the lasered areas (Figure 8). This suggests that the recruitment of WDR76 is 
specific to DNA damage and not as a result of the laser itself. Recruitment of WDR76 to laser 
induced DNA damage appeared rapid, with clear GFP induction seen within a minute after 
damage. Recruitment appeared to fade around the 12-15 minute time points.  
 
  
Figure 8 WDR76 is recruited to sites of laser line induced DNA damage 
HeLa GFP-WDR76 expressing cells were either untreated (top panel) or pre-treated with BrdU (middle 
and bottom panels) prior to laser micro-irradiation and imaging to visualise recruitment of WDR76 to 
sites of DNA damage. Bottom panel shows zoomed in images of nuclei. White arrows indicate the 
positions of the start and end of lines.  
After laser irradiation 
No 
BrdU 
1min 3min 6min 
12min 3min 1min No laser 
+BrdU 
No laser 
15min 3min 1min No laser 
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3.2.3. WDR76 depletion does not increase persistence of NHEJ factors 
at sites of DNA damage 
As explained earlier, neddylation, the process that activates Cullins, occurs at sites of DNA 
damage containing DSBs. Inhibition of this neddylation, using the small molecule drug 
MLN4924179, results in an increase in persistence of the core NHEJ component Ku169. In light 
of this, investigations were carried out to see if siRNA mediated depletion of WDR76 resulted 
in persistence of Ku at sites of DNA damage. Chromatin fractionation was performed on 
WDR76 siRNA depleted and control cells before and after phleomycin treatment to see if 
NHEJ proteins were retained on chromatin after DNA damage. An siRNA against luciferase 
was used as a negative control (siControl). In undamaged control cells (siControl -0) there is 
a low level of the NHEJ factors Ku70, Ku80, XLF and XRCC4 on chromatin (Figure 9A). This level 
of these proteins on chromatin is induced upon DNA damage with phleomycin which can be 
seen strongly 1.5 hours after phleomycin treatment. The level of Ku80 on chromatin subsides 
5.5 hours after phleomycin treatment. Two siRNAs against WDR76 were used, one against 
the open reading frame (ORF) (siWDR76 ORF) and one against the untranslated region (UTR) 
(siWDR76 UTR). Cells treated with siRNA against WDR76 show similar levels of NHEJ proteins 
on chromatin to the control cells; no obvious persistence of NHEJ factors on chromatin was 
detected relative to the control cells. Cells treated with MLN4924 did show an increased 
persistence of Ku80 compared to control siRNA treated cells, which is particularly evident in 
the 3.5 and 5.5 hours post phleomycin treatment samples (Figure 9B).  
 




Figure 9 siRNA depletion of WDR76 does not increase persistence of NHEJ factors after DNA damage in 
the chromatin fraction 
(A) U2OS cells were depleted with 20nM of either a negative control siRNA (siControl) or siRNA 
against either the ORF (siWDR76ORF) or UTR (siWDR76UTR) of WDR76. Cells were treated with 
0.75mg/ml phleomycin and samples taken at 1.5, 3.5 and 5.5 hours of recovery. This was followed by 
chromatin fractionation and Western blotting. (B) Negative control siRNA treated cells were dosed 
with 3µM MLN4924 before chromatin fractionation and Western blot.  
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3.2.4. siRNA mediated knockdown of WDR76 leads to persistence of Ku 
foci after irradiation 
Although an effect of WDR76 on persistence of Ku on chromatin after DNA damage was not 
detected by chromatin fractionation approaches, if WDR76 is involved in the ubiquitylation 
and subsequent removal of Ku from sites of DNA damage one would expect that WDR76 
depletion might result in persistence of Ku foci after DNA damage. To test this, an established 
method to detect Ku foci by immunofluorescent (IF) staining was used (as described in the 
Methods section 2.4.1). U2OS cells were either transfected with a control siRNA or siRNA 
against WDR76. Cells treated with the control siRNA only have a relatively low number of Ku 
foci in undamaged cells (Figure 10A). This number increases sharply after irradiation with a 
peak in number of foci per nucleus 8 minutes after DNA damage. The number of foci then 
begin to drop with recovery time after irradiation, returning back to baseline level around 2 
hours after the initial irradiation. Cells pre-treated with the neddylation inhibitor MLN4924 
(MLNi), behave similarly to the control in non-irradiated cells and at the 8-minute after 
irradiation time-point. However, in these cells there is an increased persistence of Ku foci at 
the 1 hour and 2 hour after irradiation time-points compared to cells not treated with 
MLN4924 (Figure 10A/B). Cells treated with siRNA against WDR76 (si76ORF/si76UTR) show an 
increase in persistence of Ku foci at the 2-hour time-point compared to control siRNA treated 
cells at the same timepoint (Figure 10A/B).  
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Figure 10 WDR76 knockdown results in an increased persistence of Ku foci 
Non-treated (NT) and irradiated U2OS cells were pre-extracted with CSK buffer and stained by IF 
for Ku80 (A) Graph showing number of Ku foci before and after 10 Grays of irradiation. Negative 
control siRNA (siControl) or siRNA against either the ORF (siWDR76ORF) or UTR (siWDR76UTR) of 
WDR76 were used. MLNi = siControl cells pre-treated with 3µM MLN4924. N=3, error bars show 
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3.2.5. Yeast CMR1 knockout does not show sensitivity to DNA 
damaging agents 
As shown previously, WDR76 is conserved across a range of species (Figure 6B). In order to 
investigate its function in another model organism, a knockout in S. cerevisiae was generated 
in parallel to carrying out studies on mammalian cells. A knockout was made by first 
generating a PCR fragment containing a kanamycin resistance gene flanked by the genomic 
regions either side of the CMR1 gene (Figure 11A). The CMR1 deleted strain (cmr1D)  was then 
tested for sensitivity to a range of different DNA damaging agents in comparison to a wildtype 
strain and a mec1Dsml1D strain that is hypersensitive to DNA damage. The cmr1D strain 
showed no detectable increase in sensitivity to HU, CPT, MMS, phleomycin or UV compared 
to the wildtype strain as can be seen from the similar growth in colonies across all drug doses. 
The mec1Dsml1D strain, as expected, showed increased sensitivity to all DNA damaging 
agents compared to the WT, thus showing that the drugs were working (Figure 11B). 




Figure 11 S. cerevisiae cmr1 knockout does not show hypersensitivity to DNA damaging agents 
(A) Strategy used for the generation of cmr1 knockout in S. cerevisiae. (B) Sensitivity profile to 
indicated DNA damaging agents in WT = wildtype, mec1Dsml1D and cmr1D backgrounds.  
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3.2.6.  siRNA mediated depletion of WDR76 does not increase 
sensitivity of cells to irradiation 
As WDR76 was shown to be recruited to sites of DNA damage and may be influencing the 
ubiquitylation of Ku, I tested to see if siRNA mediated depletion of WDR76 renders cells more 
sensitive to DNA damage. To do this, clonogenic survival assays were performed in U2OS cells 
treated with increasing doses of irradiation. Control siRNA treated cells (siControl) showed a 
typical decline in percentage survival with increasing doses of irradiation (Figure 12). Cells 
treated with an siRNA against ATM (siATM), a central component of the DNA damage 
response, showed increased sensitivity to DNA damage by irradiation compared to the 
control. This is particularly evident at the 3 and 4 Gy doses. Cells treated with siRNA against 
WDR76 (siWDR76 ORF/UTR) did not show any significant difference in its DNA damage 
sensitivity profile from that of the control (Figure 12).  
  






3.2.7. Human cell WDR76 gene knockouts exhibit IR hypersensitivity 
My investigations into WDR76 thus far showed a link to the DDR via its interaction with Ku, 
effect on Ku foci after DNA damage and obvious localisation to sites of DNA damage. In order 
to further investigate the role of WDR76 within the DDR, isogenic knockouts were generated 
in human RPE-1 cells. It was expected that any phenotypes associated with WDR76 loss would 
be more apparent in a knockout background rather than by depletion with siRNA.  
 
In order to generate knockouts, two CRISPR-Cas9 guide RNA (gRNA) targeting sites in exon 2 
of the human WDR76 gene were determined using the Broad Institute gRNA design tool. 
These sequences were then cloned into an all-in-one plasmid backbone containing U6 
Figure 12 siRNA mediated depletion of WDR76 does not increase sensitivity to irradiation 
U2OS clonogenic survival assay showing sensitivities of siRNA depleted cells to increasing doses of 
irradiation. N=3, error bars show SEM. Blots show depletion of relevant proteins in cells used in the 
assay. 
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promoters driving expression of each gRNA and a separate promoter driving Cas9D10A 
nickase expression. Using the Cas9D10A nickase causes ssDNA incisions at the gRNA targeted 
regions and thus reduces the potential of off-target editing. An enhanced GFP (EGFP) marker 
after a T2A linker from the nickase was also utilised to ensure plasmid entry upon targeting 
(Figure 13A). A targeting construct was also generated to make downstream validation of 
WDR76 knockouts easier. This was made by first generating PCR products of homology arms 
flanking the gRNA cut sites, and a PCR product of a positive selection cassette containing a 
neomycin resistance gene driven by a PGK promoter (Figure 13A). These PCR products were 
then cloned into a pUC19 backbone using InFusionÒ cloning techniques. Both plasmids were 
sequence validated to check for correct cloning.  
 
Plasmids were electroporated into RPE-1 cells using a Neon nucleofector. 48 hours after 
electroporation, cells were single cell sorted by FACS into 96 well plates containing 0.75mg/ml 
G418. Colonies were grown and expanded whilst PCR validation was performed on potential 
knockout candidates (Figure 13B). An initial PCR screen was performed using a primer pair that 
allowed detection of insertions or deletions at the WDR76 exon 2 genomic locus as well as 
being able to visualise stable insertion of the targeting construct into cells. Colonies were 
picked where a PCR electrophoresis band showed an obvious variant to the WT control (Figure 
14A). These colonies were then taken forward for further analysis to check for on target 
integration of the targeting construct by using primer pairs that contained one primer within 
the targeting construct itself and the second primer in the surrounding genomic locus. 
Products run by gel electrophoresis showed on-target integration of the targeting construct 
in multiple targeted colonies but not in untargeted WT cells (Figure 14B). Colonies were 
checked for insertions/deletions (indels) which put WDR76 out of frame by reducing the 
extension time of PCR cycles to specifically amplify the smaller of the two products. Sequence 
analysis revealed that clone 1G6 had a 142bp insertion and clone 3H11 had a 196bp insertion 
(Figure 15A). Both these insertions put WDR76 out of frame. Lastly, clones were confirmed for 
a WDR76 knockout on a protein level by Western blotting, once a reliable antibody was 
identified (Figure 15B). 
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Figure 13 WDR76 knockout generation in RPE-1 cells  
(A) Schematic of constructs used and design of gRNAs for the knockout strategy. Two gRNAs targeting 
exon2 of WDR76 were designed and cloned into an all-in-one plasmid containing a promoter driven 
Cas9D10A nickase. EGFP was also included via a T2A linker. A positive selection targeting plasmid 
containing a neomycin resistance gene (Neo) and homology arms flanking the gRNA cut-sites (LHA/RHA) 
was constructed. (B) Diagram showing overall knockout process from transfection through to validation. 
5µg of targeting construct and all-in-one plasmid were transfected into RPE-1 cells and single cell sorted 
into 96W plates by FACS 48 hours after transfection. Single colonies were identified, and crude lysates 
taken for PCR validation. Potential knockout clones were expanded and validated by PCRs and Western 
blotting.  
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Figure 14 PCR screening of potential RPE-1 WDR76 knockouts 
(A) Top shows the PCR screening strategy used to check for the introduction of the targeting cassette 
and indel incorporation using primer pair RS058/060. Bottom shows PCR gel; red dotted lines 
indicate size expected for product of targeting cassette incorporation and an unedited WT band. 
Bold annotations indicate clones taken forward for further validation. (B) PCR screen for the 
validation of on-target integration of the targeting cassette using two primer pair combinations. 






Figure 15 Validation of WDR76 knockouts 
(A) Specific amplification of lower PCR product shown in Figure 14A for two potential WDR76 
knockouts (1G6 & 3H11). Sequencing of gel purified bands shows insertions occurring in WDR76 exon 
2 locus. An 142bp insertion was seen in clone 1G6 and a 196bp insertion was seen in clone 3H11. (B) 
Western blot showing confirmation of WDR76 knockouts, verified with an siRNA against WDR76.   
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Clonogenic survivals with four Western-blot confirmed WDR76 knockout cell lines were 
performed with wildtype RPE-1 cells as a control (Figure 16A/B). Three out of the four clones 
(1G6, 4G1 and 5B1) showed a lower percentage survival compared to the WT with increasing 
doses of IR (Figure 16A). This is particularly evident at the 3 and 4 Gy doses which show 
increased sensitivity to IR compared to the WT. Clones 1G6 and 4G1 showed a very similar 
profile of sensitivity to each other, while clone 5B1 showed a slightly milder sensitivity. 






Figure 16 RPE-1 WDR76 knockouts show increased sensitivity to IR 
(A) Clonogenic cell survival assays showing percentage survival to increasing doses of IR. N=3, error 
bars show SEM. (B) Western blot showing validation of knockout clones used. 
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3.2.8. Mass spectrometry identifies interacting partners of WDR76 
Mass spectrometry was performed on immunoprecipitations in human HEK293-FT cells 
transfected with GFP-tagged WDR76 to identify proteins that WDR76 interacts with. This was 
in order to try to gain insight in to the function of WDR76 by looking at the functions and 
pathways of its binding partners. Four samples derived from cells that had been transfected 
with as plasmid directing the expression of GFP only or WDR76-GFP were sent for analysis. 
These were: a GFP only expressing sample, a WDR76-GFP only expressing sample, a WDR76-
GFP expressing sample treated with the proteasomal inhibitor MG132 and a WDR76-GFP 
expressing sample treated with the neddylation inhibitor MLN4924 (Figure 17A). Gel staining 
showed the transfections worked efficiently, as there appears to be distinct bands present in 
WDR76-GFP transfected cells which correspond to the tagged protein, while the GFP-only 
transfected cells showed a strong band corresponding to GFP (Figure 17A). The 
immunoprecipitations also worked well as multiple other bands, corresponding to its binding 
partners, were present in WDR76-GFP transfected cells.  GFP-only transfected cells did not 
produce many other bands and the banding pattern is distinctly different from the WDR76-
GFP transfected cells. Samples were sent to Prof. Benedikt Kessler’s lab (Target Discovery 
Institute, University of Oxford) for mass spectrometry analysis. Figure 17B displays the 
number of hits identified in each of the samples with everything that was present in the GFP 
only transfected sample removed, thus showing only protein interactors specific to WDR76 
(Figure 17B). Comparing the three lists identified 32 proteins which were present in all three 
WDR76-GFP transfected samples but not GFP controls (Figure 17C).  
 
Several DNA damage proteins appear in the list including DNA-PKcs (PRKDC), Ku70 (XRCC6) 
and Ku80 (XRCC5); all of which are components of the NHEJ machinery. PARP1, an enzyme 
involved in single strand break repair12, also appears in the list. In addition to DNA damage 
repair proteins, WDR76 also seems to interact with several proteins involved in protein 
folding. This includes all components of the chaperonin complex containing T-complex 
protein 1 (TCP1) (CCT complex)180: CCT2, 3, 4, 5, 6A, 7, 8 and TCP1. Other chaperone 
proteins/proteins involved in protein folding that were identified from the mass spectrometry 
as WDR76 interactors include HSP90AA1, DNAJC7, DNAJA1 and STUB1. Other interactors 
identified by mass spectrometry include; HELLS, H3F3B and CBX3, which have roles in 
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chromatin regulation as well as a number of ribosomal protein subunits (RPS4X, RPL7, RPL3, 
RPS14, RPL18, RPL23, RPLP2, RPS21, RPL9, RPL24, RPL27A and RPL19)181. 
 
It was clear that there are a lower number of significant hits in the MG132 treated sample 
compared to the others. This may have been due to depletion of the ubiquitin pool as a result 
of the inability to recycle ubiquitin in MG132 treated cells182. To expand my search into other 
interactors of WDR76, I compared overlapping proteins across the NT and MLN4924 treated 
samples only (Figure 17D). This yielded a greater list of proteins which have roles in multiple 
processes including protein folding, ribosomal biogenesis, DNA repair, chromatin regulation, 
transcriptional regulation and RNA processing (See Discussion section 3.3 for more).  
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Figure 17 WDR76 interacting partners identified by mass spectrometry 
(A) IPs were performed on extracts from HEK293-FT transfected samples, run by SDS-PAGE and 
stained with Coomassie Blue. Samples transfected with 10µg of plasmids expressing either GFP only 
or WDR76-GFP containing plasmids. NT= non-treated, +MG132 = sample pre-treated with 10µM 
MG132 for 2 hours prior to IP, +MLN4924 = sample pre-treated with 3µM MLN4924 for 2 hours prior 
to IP. (B) Venn diagram showing overlapping proteins from mass spectrometry significant hits. Any 
hits present in GFP only sample were removed, and subsequent lists compared. (C) List of 32 proteins 
identified in all three samples. 




Figure 17 (continued) WDR76 interacting partners identified by mass spectrometry 
(D) List of 212 significant hits overlapping between NT and +MLN4924 samples. 
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3.2.9. WDR76 knockout cells do not show increased sensitivity to heat 
shock 
Mass spectrometry analysis identified all components of the CCT complex as well as other 
chaperone proteins.  Chaperone proteins are not only involved in promoting the correct 
folding of proteins but also the degradation of misfolded proteins183. One potential role of 
WDR76 could be the ubiquitylation and therefore targeting of misfolded proteins for 
proteasomal degradation. In order to see if accumulation of potential damaged/misfolded 
WDR76 substrates gives an increase in cell sensitivity to protein damage, WDR76 knockout 
clones were tested for sensitivity to heat shock. WT and two WDR76 knockout clones were 
subjected to short periods of time at higher temperatures before being placed back into 37°C 
incubators and left to recover. Crystal violet staining showed that all cells were sensitive to 
exposure at higher temperatures for extended periods of time. However, there was no 
dramatic differences between the WT and knockout clones with respect to survival (Figure 18).  
  






3.2.10. WDR76 knockout cells do not show increased sensitivity to UV 
Chaperones and heat shock proteins have roles in protecting against UV induced DNA damage, 
and UV has also been shown to cause protein misfolding and protein damage184. In addition 
to assessing their ability to withstand heat shock, the WDR76 knockout clones were tested 
for sensitivity to UV. This was to investigate if WDR76 knockout clones were more sensitive 
to UV through either protein damage or DNA damage. The yeast homolog of WDR76, Cmr1, 
has previously been shown to bind UV damaged DNA172 so one might expect the human 
protein to be involved in the DNA repair mechanism specific to UV damage. In addition, the 
CUL4 complex in association with different substrate receptors has also been shown to be 
implicated in the response to UV damaged DNA185–187. Crystal violet staining of cells exposed 
Figure 18 WDR76 knockouts are not sensitive to heat shock 
Crystal violet staining of RPE-1 cell survival assays. Cells were seeded on day 1, heat shock performed 
on day 2 (at indicated temperature and time) and stained with crystal violet 6-10 days later. LSD refers 
to low seeding density used, HSD refers to a high seeding density used.  
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to UV showed no discernible differences between WT and WDR76 knockout clones when 
considering seeding densities (Figure 19A). Survival assays analysed by Hoechst staining also 
showed no detectable differences between the WT and knockout clones (Figure 19A). 
Therefore it was concluded that WDR76 knockout clones did not show any increase in 
sensitivity to UV damage compared to the WT control (Figure 19A,B).  
  






Figure 19 WDR76 knockouts do not show increased sensitivity to UV 
(A) Crystal violet staining of cell survival from cells exposed to indicated doses of UV. Cells were 
seeded on day 1, UV dosed on day 2 and stained with crystal violet 6-10 days later. (B) Graph showing 
percentage survival relative to non-treated as measured by Hoechst staining and counting of nuclei. 
Clone numbers are indicated. Error bars show SEM.  
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3.2.11. Assessing WDR76 protein levels throughout the cell cycle 
To investigate which DNA repair pathway WDR76 might be part of I looked to see if WDR76 
itself is cell cycle regulated. For example, if WDR76 has a specific role in HR, one might expect 
the protein levels to be higher in the S/G2 phases of the cell cycle compared to rest of the cell 
cycle. U2OS cells were synchronised by double thymidine blocking to arrest cells in the G1 to 
S transition. Cells were then released from thymidine exposure and allowed to progress 
throughout the cell cycle. Protein samples were taken at various timepoints to achieve S and 
G2 populations. In addition, a separate population of cells were exposed to nocodazole to 
arrest cells in mitosis. Mitotic cells were recovered via shake off and then removed from the 
drug and allowed to progress through the cell cycle. This achieved samples from M phase and 
from the subsequent G1 phase.  
 
In U2OS cells WDR76 levels seem to be highest in S and G2 phases of the cell cycle as seen by 
WDR76 protein levels correlating with that of Cyclin A (CycA) (Figure 20A). Conversely, WDR76 
levels are reduced in mitotic cells (as indicated by sample with high phosphorylation of 
histone H3 at serine 10). WDR76 levels seem to decrease following release from nocodazole, 
suggesting lower levels of the protein in the G1 phase of the cell cycle (Figure 20A). 
 
Despite the variations in WDR76 level in U2OS cells, the same trend is not seen in RPE-1 cells. 
WDR76 levels seem to be relatively stable in RPE-1 cells in both CycA positive and negative 
cells (Figure 20B).  
 




Figure 20 WDR76 protein levels throughout the cell cycle 
Cells were synchronised by either double thymidine block or nocodazole treatment and released to 
allow progression through cell cycle. Samples were taken at time points to cover the cell cycle and 
Western blotting performed in (A) U2OS cells and (B) RPE-1 cells. NT = non-treated, NR = non-
released from drug treatment, numbers indicate hours after drug release. 
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3.2.12. WDR76 knockout cells do not show enhanced sensitivity to 
camptothecin 
Cell survival assays were set up to investigate if WDR76 knockouts were sensitive to S phase 
specific damage. Cells were seeded and exposed to chronic treatment of camptothecin (CPT). 
Cells were then stained with crystal violet 6 – 10 days after dosing. All cell lines showed 
sensitivity at 2nM CPT as seen by a decrease in observable colonies. There does not, however, 
appear to be increased sensitivity in the knockouts compared to the WT as when comparing 
differences in initial seeding densities the level of sensitivity to CPT looks the same across all 
cell lines (Figure 21A). To confirm sensitivity results, the same experiment was set up but 
instead of crystal violet staining, cell nuclei were stained with Hoechst and cell numbers 
counted from images taken under a fluorescent microscope. WDR76-/- cells do not differ 
drastically from WT cells. Perhaps a slight resistance is seen, as knockout clones show a higher 




Chapter 3: Investigating the role of WDR76 in the removal of Ku from DNA ends 
 96 
  
Figure 21 WDR76 knockouts do not show increased sensitivity to camptothecin 
(A) Crystal violet staining of cell survival from cells exposed to indicated doses of camptothecin (CPT). 
Cells were seeded on day 1, drug administered on day 2 and stained with crystal violet 6-10 days later. 
Two different seeding densities were plated, a low/high seeding density (LSD/HSD). (B) Graph 
showing percentage survival as measured by Hoechst staining and counting nuclei relative to non-
treated cells. Clone numbers indicated. N=2, error bars show SEM. 
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3.2.13. Transcription inhibition causes loss of WDR76 nucleolar 
localisation 
One possibility of proteins localising to sites of DNA damage is to shutdown transcription and 
prevent further damage or impairment of DNA repair as a result of transcription machinery 
colliding with DNA damage sites188. Notably, CUL4 has been linked to transcriptional 
regulation162,189 which raises the possibility of the substrate receptor WDR76 taking part in 
this process. To test if WDR76 is involved in inhibiting transcription at sites of DNA damage, I 
pre-treated cells with actinomycin D and then visualised recruitment of GFP-WDR76 to sites 
of laser line induced DNA damage as before. A low dose of actinomycin D was used to 
primarily inhibit RNA polymerase I mediated ribosomal DNA (rDNA) transcription. A higher 
dose was used to inhibit all transcription190. Recruitment of GFP-WDR76 was still seen in cells 
pre-treated with actinomycin-D at two different concentrations of the inhibitor (Figure 22A).  
 
To subsequently test if WDR76 had an effect on transcription at sites of DNA damage, a Click-
iT RNA imaging kit was used to visualise nascent RNA. WDR76-GFP expressing HeLa cells were 
subjected to laser induced DNA damage and allowed to recover whilst being incubated with 
EU. The EU incorporated with nascent RNA and could then be visualised by Click chemistry 
reactions. Under wildtype conditions transcription is inhibited in the vicinity of sites of 
damaged DNA, as seen from an exclusion of EU signal in areas with obvious gH2AX production. 
In both knockout clones the exclusion of EU can also be seen in areas with gH2AX staining, 
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Figure 22 Transcription inhibition at sites of DNA damage is intact in WDR76 knockout clones 
(A) Images in HeLa GFP-WDR76 cells showing recruitment of WDR76 to sites of laser line induced 
DNA damage. Indicated cells were pre-treated with actinomycin D for 1 hour prior to laser line 
micro-irradiation. (B) IF images after laser line micro-irradiation. Nascent RNA was visualised by a 
clickable reaction on EU incorporated after DNA damage as lines of damage can be seen from 
gH2AX staining as indicated by the white arrow-heads.  
B 
A 
BrdU only 2ug/ml actinomycin D  40ng/ml actinomycin D  
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3.2.14. Assessing whether WDR76 affects Ku ubiquitylation 
 
If Ku is a potential substrate of WDR76 and becomes ubiquitylated after DNA damage, one 
would expect to see a reduction of Ku ubiquitylation after DNA damage in WDR76-/- cell lines. 
IPs were set up initially on extracts derived from RPE-1 wildtype and knockout clones 
transfected with a GFP-Ku80 expressing plasmid. Cells were harvested immediately after IR 
induced DNA damage. Despite good detection of GFP-tagged Ku80, detection of 
ubiquitylation via the FK2 antibody was not strong, with it detecting no obvious higher 
molecular weight bands; however, suggestive of Ku80 ubiquitylation, the smear detected 
with the FK2 antibody does appear to be stronger in damaged versus undamaged cells. No 
clear differences can be seen between WT and knockout clones (Figure 23A). In an attempt to 
ensure detection of ubiquitin a subset of samples were also transfected with a plasmid 
expressing human influenza hemagglutinin (HA-tagged) ubiquitin. A corresponding shift can 
be seen in the FK2 smear compared to samples transfected with the plasmid expressing GFP-
Ku80 only, but again the poor level of detection and lack of sensitivity by this method made 
it difficult to conclude any effects on Ku ubiquitylation.  
 
IPs were also performed on samples transfected with a plasmid expressing GFP-Ku70. Levels 
of ubiquitylation detected by FK2 antibody appear to be higher in all samples from damaged 
cells compared to undamaged cells, although no obvious differences between the WT and 
knockouts can be detected when compared to the loading controls (Figure 23B). RPE-1 cells 
proved to be challenging to work with when performing transfections and thus made this 
type of assay difficult.  
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Figure 23 Detection of Ku ubiquitylation in wildtype vs. WDR76 knockout cells 
IPs performed in RPE-1 wildtype vs. WDR76 knockout cells transfected with plasmids expressing (A) 
GFP-Ku80 and HA-tagged ubiquitin (HA-Ub) and (B) GFP-Ku70. Cells were irradiated with 10Gy IR 
and samples taken either 1min (1’) or 1hr after irradiation as indicated.   
Chapter 3: Investigating the role of WDR76 in the removal of Ku from DNA ends 
 101 
3.2.15. Persistence of Ku on chromatin could not be detected in 
knockout cells  
siRNA mediated depletion of WDR76 in U2OS cells did not show and increased persistence of 
NHEJ factors on chromatin (Figure 9A). In an attempt to detect retention of NHEJ factors on 
chromatin, similar experiments were performed but in the RPE-1 WDR76-/- cells. Ku80 levels 
were stable across all cell lines and treatment conditions. This was unexpected as one would 
normally expect there to be an increase in Ku accumulation on chromatin following DNA 
damage169. This indicated a problem with the assay. The same issue was apparent when 
blotting for Ku70 and the other NHEJ factors (XLF and XRCC4) as no radiation-induced 
recruitment on chromatin was detected. As expected an increase in gH2AX was seen in all cell 
lines after DNA damage with no increased persistence of gH2AX in the WDR76-/- clones. One 
noticeable difference was the increased levels of phosphorylated ATM at S1981 (pATM) in 
the WDR76 knockouts compared to the wildtype. This was apparent in all timepoints after 
DNA damage. A higher amount of pATM in undamaged WDR76 knockout cells compared to 
wildtype cells was also observed in a higher exposure (Figure 24). Neither chromatin 
fractionation nor Ku foci experiments were technically possible in RPE-1 cells. This issue was 
also experienced by other members in the lab and meant performing these experiments to 
detect persistence of Ku was unfortunately not technically achievable.  
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Figure 24 Chromatin fractionation in RPE-1 wildtype and WDR76-/- cells 
Chromatin fractionation on wildtype (RPE-1-WT) and two WDR76-/- clones (1G6 & 4G1) before and 
after DNA damage by 10 Gy of irradiation. Western blotting was performed and probed for 
indicated proteins. Duplicate probes show different exposures as labelled. Dotted line indicates 
blots performed on separate gel. 




3.3.1. WDR76 is involved in DNA repair 
Overall the data presented here does implicate WDR76 within the DDR. Initial IPs performed 
on cells expressing GFP-WDR76 show that WDR76 interacts directly with CUL4A and DDB1 
which corroborates with existing literature (Figure 7)162,191; this suggests WDR76 is a DCAF and 
thus confirms that it is a component of the CUL4A E3 ligase. Both CUL4A and DDB1 are known 
to have roles within the DDR192,193. IPs also confirmed an interaction with the DNA damage 
specific Ku70/80 heterodimer (Ku) (Figure 7), and therefore suggests Ku as a potential 
substrate of WDR76. The fact that WDR76 localises to sites of DNA damage also implicate it 
within the DDR. Recruitment was seen very rapidly after DNA damage induction (Figure 8), 
which might suggest that WDR76 plays a role in the early response to DNA damage. Ku itself 
is also known to be recruited quickly and with high affinity to double-strand breaks which 
encourages the possibility of functional interactions occurring between WDR76 and Ku56,121. 
The dependency of WDR76 to be recruited to sites of DNA damage in the absence of Ku could 
not be tested due to the essentiality of Ku in human cells.  
 
Persistence of NHEJ factors was not detected by Western blot in the chromatin fraction of 
WDR76 siRNA depleted U2OS cells as compared to controls (Figure 9), however a persistence 
of Ku foci was seen by IF after DNA damage in WDR76 siRNA depleted cells compared to 
control siRNA treated cells (Figure 10). This may be because subtle changes in overall protein 
levels are harder to detect by the chromatin fractionation approach; even cells treated with 
MLN4924, which cause a dramatic increase in persistence of Ku foci after DNA damage, only 
led to a moderate increase in chromatin persistence on a Western blot level (Figure 9 & Figure 
10). Furthermore, WDR76 depletion caused increased persistence of Ku80 foci relative to the 
wildtype 2 hours after DNA damage, which is further evidence highlighting a link between 
WDR76 and the DDR through regulation of Ku (Figure 10). The level of persistence in WDR76 
depleted cells was not as great as the level of persistence seen in MLN4924 treated cells. This 
could be due to inefficient depletion of the protein by siRNA but could also suggest that there 
are other neddylation dependent mechanisms regulating Ku after DNA damage. This might 
be in the form of other substrate adaptors of CUL4 but could also be other members of the 
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Cullin E3 ligase family or even unknown targets of the MLN4924 inhibitor. The fact that 
WDR76 depletion did increase persistence of Ku foci might imply that it is responsible for the 
removal of Ku after DNA damage, although the possibility of Ku ubiquitylation being a method 
for positively regulating NHEJ cannot be ruled out. While the CRL family of E3 ligases are 
normally associated with ubiquitylation of targets for proteasomal degradation, there are 
examples of CRL dependent ubiquitylation that regulates substrates in a non-proteolysis 
driven manner194.   
 
Proteins involved in promoting NHEJ often show an increase in sensitivity to IR when depleted 
or deleted in cell lines195. Although siRNA mediated depletion of WDR76 in U2OS cells did not 
lead to an increase in sensitivity to IR (Figure 12), RPE-1 WDR76-/- cells did show an increase 
in sensitivity to IR in clonogenic survival assays (Figure 16). Three out of four clones tested 
showed an increase in IR sensitivity while knockout clone 3H11 did not show an increased 
sensitivity, potentially due to clonal variation/selection and perhaps an unintended off-target 
effect of the knockout process in that particular clone. The increased sensitivity to IR in 
knockout clones again suggests that WDR76 has a role that affects the DDR. In addition, 
chromatin fractionation experiments showed an increase in pATM in WDR76-/- cells 
compared to WT cells in both damaged and undamaged conditions (Figure 24). This may be 
due to increased DNA damage as a result of inefficient repair occurring in a WDR76-/- 
background.  
 
S. cerevisiae cells with a Cmr1 deletion did not show sensitivity to a broad range of DNA 
damaging agents (Figure 11B), a phenotype which is also stated in other publications172,173. 
Although at first these findings might argue against a role of the protein in the DDR, it may 
also be because yeast cells replicate and divide quickly and do not spend much time in G1; a 
phase when cells are more reliant on NHEJ as a means of double strand break repair. 
Furthermore, yeast cells predominantly repair via HR and therefore proteins affecting NHEJ 
may not show a clear phenotype in this background. Even S. cerevisiae cells with a yeast Ku70 
(yKu70) deletion, do not show increased sensitivity to IR196. Yeast cells with mutations in both 
yKu70 and rad52 do enhance the IR and MMS sensitivity of rad52 mutants alone, and so 
generating triple mutants with a Cmr1 deletion could be a means of investigating this 
further127,196. This could further support a role of WDR76 specifically in the NHEJ pathway of 
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DNA repair, or could also imply an evolutionarily distinct development of WDR76 (over other 
CUL4 substrate receptors) from the yeast ortholog. Additionally, when testing my human 
WDR76 knockout cells for sensitivity to camptothecin, a drug which causes S-phase specific 
damage, I did not see a change in sensitivity compared to WT cells (Figure 21).  
 
Mass spectrometry analysis identified Ku70, Ku80 and DNA-PKcs as potential interactors of 
WDR76 (Figure 17), which again points to a role of WDR76 in the NHEJ pathway. Interactions 
between the proteins were present in undamaged cells, so it would be interesting to see if 
there is enhancement in these interactions when DNA damage is administered, or whether 
WDR76 interacts with additional DNA damage related proteins in this scenario. In the future, 
performing a SILAC based mass spectrometry analysis in damaged versus undamaged cells 
would be a good way of doing this.  
 
 
3.3.2. Other potential roles of WDR76 
Mass spectrometry revealed a diverse range of proteins with which WDR76 interacts. These 
interactors could explain the potential mechanisms through which WDR76 affects DNA repair 
or alternatively may reveal additional, diverse functions of WDR76. 
 
 
3.3.2.1. Involvement of WDR76 in protein folding 
The interaction of WDR76 with Ku was also seen by Gallina et al.173, as was the interaction 
between WDR76 and the CCT complex that I also identified through mass spectrometry (Figure 
17). The CCT complex is a chaperone complex that is involved in the folding of around 10% of 
the proteome180. Many of the proteins that associate with the CCT complex do so upon 
translation197 which might suggest a role of WDR76 in the folding of newly translated proteins. 
WDR76 also interacts with ribosomal proteins and RNA modifiers and is enriched in the 
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The CCT complex has also been linked to the folding and assembly of oligomeric protein 
structures197. This raises the possibility that WDR76 through its association with multiple 
proteins by means of its WD40 domains, is capable of creating protein complexes. It is 
tempting to speculate whether WDR76 aids in the coordination of the NHEJ proteins to 
promote a stable complex to initiate DNA repair. This could be through the coordinated 
binding of the Ku heterodimer and CCT complex to then promote the stable assembly of the 
downstream NHEJ machinery. In this regard, binding Ku may be particularly important as, due 
to its high affinity for dsDNA ends, it is the first protein recruited to double strand breaks.  
 
Alternatively, the interaction between WDR76 and the CCT complex could purely be for the 
folding of WDR76 itself. Proteomic approaches have identified WD proteins that form b-
propeller domains as CCT complex substrates198. One example of this is in the activation of 
the anaphase-promoting complex (APC/C) through the correct folding of the WD40 domain 
containing protein CDC20.199   
 
 
3.3.2.2. WDR76 and ribosome biogenesis 
From localisation studies, WDR76 is a nuclear protein but a large accumulation of WDR76 
appears to be nucleolar (Figure 8 & Figure 22). The nucleolus is the centre of ribosome subunit 
biogenesis200, which might suggest that WDR76 plays a part in this process. Indeed, a large 
number of ribosomal proteins were also identified as interactors of WDR76 (Figure 17). 
Additionally, a loss of WDR76 from nucleoli was seen upon transcription inhibition suggesting 
its role in nucleoli is transcription dependent. This could mean it is involved in the correct 
folding of the ribosome through its interaction with ribosomal proteins and newly transcribed 
ribosomal DNA (rDNA).   
 
The CUL4 complex has also been associated in ribosome biogenesis, as an RNAi based screen 
performed by Badertscher et al201 showed that CUL4 and DDB1 are required for ribosome 
maturation. Interestingly the publication revealed 302 proteins required for 40S subunit 
production, which included the CCT complex, as well as other proteins identified as 
interactors of WDR76. Although WDR76 itself was not identified in this screen, the 
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involvement of its interactors in addition to the data presented here might suggest its 
involvement in ribosome biogenesis.  
 
 
3.3.2.3. WDR76 and transcription 
Data presented here points to a potential link between WDR76 and transcription regulation 
however it is difficult to specify its exact role within this process. Due to the density of WDR76 
in the nucleolus one might speculate its involvement in the transcription of rDNA. When 
transcription was inhibited, WDR76 was no longer concentrated in nucleoli (Figure 22). WDR76 
could either be a positive regulator of transcription, or an inhibitor of transcription and thus 
is no longer concentrated in the nucleolus when transcription is inhibited.  
 
Despite the interaction with multiple proteins that could be linked to transcriptional 
regulation, transcription inhibition at sites of DNA damage was still seen in WDR76-/- cells. 
This suggests that local inhibition of transcription at sites of DNA damage is still intact and not 
affected by WDR76 loss.  
 
Recruitment of GFP-WDR76 to laser induced DNA damage was also seen in the presence of 
transcription inhibition. This does not necessarily mean that WDR76 is not involved in 
transcription inhibition, as it could be redundant over other proteins or could be that its 
recruitment is specific to DNA damage and/or recruitment of Ku regardless of downstream 
function.   
 
In the future, performing RNA-seq in WT versus WDR76-/- cells might enable identification of 




3.3.2.4. WDR76 and chromatin regulation 
When comparing the non-treated and MLN4924 treated samples only and looking at a larger 
list of interacting partners, a number of proteins involved in chromatin remodelling are 
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present. These include: SMARCA5, SIRT1, HIST1H2BJ, H3F3B, HP1BP3, RBBP7, CBX1, CBX3, 
and CBX5. This might suggest an involvement of WDR76 in nucleosome remodelling. Again, 
this could be linked to transcriptional regulation as all of the aforementioned proteins have 
roles modulating gene expression through mechanism connected to histone modifications. 
The increased pATM levels in WDR76-/- cells previously mentioned could also be linked to the 
chromatin state in these cells as hyperacetylated DNA, commonly associated with increased 
transcription, causes an increase in ATM activation202,203. The interactions with chromatin 
regulators could also be directly linked to the early DNA repair process, and the potentiation 
of DNA damage signalling and opening of chromatin to allow DNA repair factors access to 
DNA lesions. Despite efforts to detect changes in histone modifications by Western blotting, 
I was unable to interrogate variance in histone modifications between WT and WDR76-/- cells.  
 
 
3.3.2.5. WDR76 and RNA processing 
The WDR76 interactome also identified a number of proteins involved in RNA related 
processes including splicing, folding and resolution of RNA secondary structure. Whilst this 
could again point to roles of WDR76 in transcriptional and translational regulation it also 
raises the possibility of a role connecting RNA and the DDR. An increasing field of investigation 
in the DDR points to roles of RNAs in the maintenance of genome stability204,205. Notably, 
WDR76 interacts with both DNA repair factors and RNA processing factors. Some of these 
include RNA helicases such as DHX9 and DDX17. This could implicate WDR76 in the resolution 
of dsRNA or even in the resolution of DNA-RNA hybrids. These DNA-RNA hybrids naturally 
arise as a result of transcription, creating R-loops which can pose a threat to an efficient DNA 
repair if left unresolved.  
 
Another possibility is that WDR76 is involved in the generation of DNA damage-induced small 
RNAs (diRNAs). These diRNAs are produced at sites of DSBs and although not involved in the 
initial recognition of DSBs seem to be required for proficient DNA repair206. This could fit data 
generated here, in that Ku loading and recruitment of gH2AX to sites of DNA damage seems 
to be unaffected, although there is an increased persistence of Ku foci which might suggest a 
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delay in the completion of NHEJ (potentially through reduced recruitment of downstream 
NHEJ factors).  
 
The endoribonuclease DICER, which was identified as an interactor of WDR76 (Figure 17D), has 
also been implicated in the generation of small non-coding RNAs to mediate the DDR207,208. 
The exact mechanisms by which RNA and associated proteins coordinate DNA repair is still 
largely unexplored. One theory is the utilisation of RNA as a template for DNA repair which 
has been demonstrated in both yeast and human cells209–211.   
 
 
3.3.3. WDR76 concluding remarks 
Overall, I have shown that WDR76 does appear to have a role(s) in the DDR but have been 
unable to identify the exact substrate(s) and mechanism(s) by which it affects DNA repair and 
perhaps other DDR processes. Given the range of interactors of WDR76, its fast localisation 
to sites of DNA damage and IR sensitivity seen in WDR76 knockouts one might speculate that 
its role is in the initial stages of the DDR and may influence repair through chromatin 
regulation and processing of RNA. The depletion of WDR76 results in a persistence of Ku foci 
but not a delay in Ku loading to DNA-damage sites, suggesting it may be involved in the 
removal of Ku or completion of NHEJ through the recruitment of downstream factors. In 
summary my data has revealed interesting insights into the largely unknown role(s) of WDR76 
in the DDR. 
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4. Investigation of a potential CDK phosphorylation site on 




4.1.1. PAXX and the DDR 
A new player involved in NHEJ was identified relatively recently by several groups through 
both bioinformatic and proteomic approaches143,212,213. This originally undefined protein, 
C9orf142, was shown to be a paralog of XRCC4 and XLF and was hence named PAXX (also 
known as XLS). PAXX was shown to contain a ‘present in SAS6’ (PISA) motif, a motif that is 
conserved throughout the XRCC4 superfamily 143,214. Similarly to XLF and XRCC4, PAXX 
contains a head domain (within which lies the PISA motif), followed by an a helical domain214 
(Figure 25A). This helical domain is required for the formation of a coiled-coil with another PAXX 
monomer to form a homodimer. PAXX and XLF differ from XRCC4 in that they have a relatively 
short coiled-coil region which is unable to bind LIG4 directly 215,216. The C-terminal section of 
PAXX contains a highly conserved unstructured region, with the extreme C-terminus 
containing a region required for Ku binding (Figure 25A). PAXX itself cannot bind DNA but is 
recruited swiftly to sites of laser line induced DNA damage and co-localises with Ku. This 
interaction with Ku is extremely important to PAXX function; mutation of residues within this 
region, result in loss of Ku binding and an increased cellular sensitivity to DNA damage. Total 
PAXX loss results in the same phenotype. This suggests PAXX’s involvement in NHEJ is directly 
linked to its interaction with Ku. 
 





Figure 25 PAXX contains a conserved phosphorylation site 
(A) PAXX contains a structured N terminal section required for dimerisation and an unstructured C-
terminal section required for Ku binding. (B) PAXX contains a conserved CDK phosphorylation site as 
shown by the pS/T-P-X-R/K motif highlighted in yellow. Danio rerio (zebrafish), Xenopus laevis (frog), 
Anolis (anole lizard), Homo sapiens (human), Mus musculus (mouse) (C) PAXX phosphorylation at S148 
can be detected in WT PAXX expressing cells but not in cells expressing a S148A mutant (performed by 
Dr. Andrew Blackford) 
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Since my studies began, PAXX has been deemed as an accessory canonical NHEJ factor as it 
has many similarities to XLF217. Both proteins have some overlapping functions and evidence 
exists suggesting largely redundant functions. PAXX-/- cells and XLF-/- cells both show 
increased sensitivity to IR (compared to WT cells) to a fairly similar level; double knockout 
cells show an even greater level of sensitivity to IR218,219 and double knockout mice were 
embryonic lethal218,220. Neither PAXX loss or XLF loss individually result in impaired V(D)J 
recombination, however a double XLF/PAXX knockout does result in V(D)J recombination 
defects. This suggests functional redundancy between the two proteins. Despite this, ATM-/- 
XLF-/- cells show significantly greater defects in end-joining compared to ATM-/- PAXX-/- 
cells219. Importantly, overexpression of PAXX did not rescue end-ligation defects in ATM-/- 
XLF-/- cells219. These findings suggest PAXX and XLF do seem to have some distinct functions. 
Furthermore, loss of PAXX results in reduced Ku recruitment to laser induced DSBs; a 
phenotype not seen with XLF loss218. PAXX therefore seems to mediate its role in NHEJ 
through direct association with Ku and may be involved in the stabilisation of Ku at DSBs. XLF 
on the other hand seems to have a role in NHEJ that is mainly mediated by its interaction with 
XRCC4, allowing for efficient DNA-damage recruitment of LIG4221. Another possibility could 
be that PAXX and XLF have cell cycle specific differences and roles. More research is needed 




4.1.2. CDKs in the regulation of the DDR 
CDKs have influential roles in the DDR, and their inhibition is important in the arrest of the 
cell cycle which facilitates repair of damaged DNA. In addition to this important function, CDKs 
are also thought to act further upstream in the choice of DNA repair pathways 222. This has 
been shown through their roles in controlling the initiation of resection; for example, in the 
CDK mediated phosphorylation of CtIP  and NBS1101,223,224. In addition, multiple other proteins 
involved in HR such as RPA and BRCA1 have been documented to contain CDK 
phosphorylation sites that influence their activity during repair 223,225,226. Despite the positive 
regulation of HR by CDKs, there is a lack of information on how they may influence NHEJ. One 
theory is that CDKs may act to dampen NHEJ during the S-phase of the cell cycle; a time when 
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replication fork problems occur and HR is the favoured DNA repair choice 227. NHEJ occurring 
at these types of DNA insults could lead to error-prone repair and unwanted translocations 
of DNA, which could be toxic to cells.  
 
 
4.1.3. PAXX contains a potential CDK phosphorylation site 
Within the highly conserved C-terminal tail of PAXX, there is a potential CDK phosphorylation 
site, just upstream of the region necessary for Ku binding. This is at serine 148 (position in 
human) which fits the consensus pS/T-P-X-R/K. The serine, proline and lysine residues are all 
conserved amongst vertebrates (Figure 25B). This conservation and the close proximity of the 
site relative to the Ku binding region raises the possibility of a regulatory mechanism of PAXX 
which may be performed by CDKs. Unpublished data by a previous postdoc in the lab, Dr. 
Andrew Blackford showed via immunoprecipitation and a phospho-specific antibody that 
PAXX phosphorylation is detected at S148 in cells expressing WT PAXX but not in cells 
containing a S148A mutation (Figure 25C). 
 
Since PAXX is involved at the very early stages of NHEJ and contains a CDK phosphorylation 
site, one might speculate that PAXX is a potential candidate for CDK regulation and thus a way 
of regulating NHEJ. A hypothesis that was explored in this project was that CDK mediated 
phosphorylation of PAXX is a mechanism of down-regulating NHEJ in order to promote HR.   




4.2.1. PAXX levels remain constant throughout the cell cycle 
One possibility regarding CDK regulation of PAXX is that phosphorylation of PAXX results in 
loss of PAXX protein. This could occur by phosphorylation targeting the protein for 
ubiquitylation and proteasomal degradation. This principle is found in other regulatory 
systems, and multiple proteins have been identified as being more likely to be ubiquitylated 
after phosphorylation 228. In the human form of PAXX, there appears to be a potential CDK-
targeted F-box and WD repeat domain containing 7 (FBXW7) degron229,230 at the same site. 
This is a site recognised by an F-box protein of the SCF (SKP1-CUL1-FBox) complex which 
ubiquitylates and targets proteins for proteasomal degradation. Often these substrates are 
phosphorylated, which promotes FBXW7 binding and subsequent degradation 230. To test 
whether PAXX is targeted for degradation in a cell cycle dependent manner, cell cycle 
synchronisation and release was performed, and samples were taken throughout various 
stages for Western blotting. PAXX levels did not vary discernibly throughout the cell cycle and 
there were no time points that showed a loss of PAXX (Figure 26). PAXX levels were relatively 
constant throughout S and G2 phases, as indicated by CycA levels, and remained essentially 
constant through M phase as indicated by increased levels of phosphorylated histone 3 at 
serine 10 (pH3 ser10). PAXX levels remained similar in G1 phase as indicated by a lack of CycA 









Figure 26 Total PAXX levels throughout the cell cycle 
Cell synchronisation with thymidine block and nocodazole treatment was performed in human RPE-
1 cells. Cells were treated with either thymidine or nocodazole to synchronise cell cycle timings and 
then released. Samples were taken at different timepoints and Western blotting performed. 
NT=non-treated (asynchronous cells), NR=non-released from drug, hr=time sample collected after 
release and recovery from drug in hours. pH3 ser10=phosphorylated histone 3 at serine 10. 
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4.2.2. PAXX phosphorylation throughout cell cycle 
Although total PAXX levels did not vary throughout the cell cycle, it is important to assess if 
PAXX phosphorylation at S148 varies. To test this, U2OS cells were transfected with a GFP-
PAXX construct and protein levels were monitored throughout cell cycle via Western blot. 
PAXX phosphorylation, as detected with an antibody generated against the S148 phospho-
site, did not show any detectable changes throughout the cell cycle (Figure 27A).  
 
In order to test PAXX phosphorylation levels throughout the cell cycle in a different way, IPs 
were performed in cells overexpressing GFP-PAXX and probed with an MPM2 antibody; an 
antibody shown to specifically recognise phospho-serine/threonine-proline sites. This 
revealed a slight variation in phospho-PAXX levels with a detectable increase at the 6-hour 
and 9-hour time-points after thymidine release (Figure 27B). This seems to correlate with CycA 
levels, and importantly total PAXX levels appear to be relatively constant.  
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Figure 27 PAXX phosphorylation throughout the cell cycle 
(A) U2OS cells were transfected with GFP-PAXX and synchronised using thymidine or nocodazole. 
Cells were released, and samples taken throughout the cell cycle. Western blotting was performed to 
look at phosphorylation of PAXX S148. (B) U2OS cells were transfected with GFP-PAXX and 
immunoprecipitation performed using GFP-trap beads. Blots were stained with an MPM2 antibody to 
look at phosphorylation of PAXX throughout the cell cycle (left). Inputs are shown on right. WT = 
wildtype, NT=non-treated (asynchronous cells), NR=non-released from drug, hr=time sample collected 
after release and recovery from drug in hours. pH3 ser10=phosphorylated histone 3 at serine 10. 
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4.2.3. Generation of PAXX point mutants 
To investigate the potential roles of the phosphorylation site at serine 148 in PAXX, PAXX 
mutant cell lines were generated. This was achieved by site directed mutagenesis of a plasmid 
construct expressing mRuby2 tagged PAXX and subsequent stable integration in RPE-1 PAXX-
/- cells. Clones were selected based on zeocin resistance and cells expressing nuclear mRuby2, 
since PAXX is a nuclear protein (Figure 28A). Two types of PAXX mutants were made; S148A 
and S148E mutants. Mutating a serine residue to an alanine removes the hydroxyl (OH) group 
on the side chain of serine and thus leaves a residue that is unable to be phosphorylated. 
Conversely mutating the serine to a glutamic acid adds a carboxyl group creating a negatively 
charged side chain, which can mimic phosphorylation.  
 
Cell lines were verified via Western blotting to visualise expression of mRuby2 tagged PAXX. 
Blotting with an antibody against PAXX revealed a higher molecular weight band 
corresponding to the mRuby2 tagged version (Figure 28B). Blotting with an antibody specific to 
the S148 phosphorylation site on PAXX showed a band present just below a non-specific band 
in WT mRuby2-PAXX samples only. This band is not seen in the S148A/E mutants as the 
antibody binding site is disrupted (Figure 28B). Although the antibody did not work particularly 
well (because of the non-specific band) it does show the expected trend with regard to the 
WT and mutant clones.  
 
  






Figure 28 PAXX mutant generation in RPE-1 cells 
(A) Microscope images of cell lines generated by random plasmid integration of mRuby2 expressing 
PAXX mutants. Mutant clones show nuclear expression of mRuby2-PAXX (B) Western blot showing 
detection of tagged PAXX. Endogenous PAXX can be seen in WT cells only whereas a mRuby2-tagged 
PAXX is seen in stable cell lines generated.  Detection of phosphorylation at S148 can be seen in cells 
complemented with WT PAXX only (As indicated just below non-specific band). Clone numbers are 
indicated. 
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4.2.4. Testing IR sensitivity in cells expressing PAXX mutants 
PAXX-/- cells have already been shown to have an increased sensitivity to IR compared to WT 
cells143,213. If PAXX phosphorylation at serine 148 has a significant impact on PAXX function, 
changes in sensitivity to IR may be detectable when this site is mutated. Clonogenic survivals 
reproduced the increased sensitivity to IR seen in PAXX-/- cells as compared to WT cells (Figure 
29). Complementation of PAXX-/- cells by expressing WT PAXX (+PAXX WT), however, did not 
rescue sensitivity back to the same level as the WT cells. The clone expressing the PAXX S148A 
mutant (+PAXX S148A) showed similar levels of sensitivity to the PAXX knockout (PAXX-/-). 
The clone expressing PAXX S148E (+PAXX S148E) showed a similar trend to the WT PAXX 
complement cells (+PAXX WT). None of the complemented clones showed much variation 
from each other and none of them rescued sensitivity of the knockout clone (PAXX-/-) to 
levels seen in WT cells (PAXX +/+) (Figure 29).  
 
  
Figure 29 Clonogenic cell survival assays in RPE-1 PAXX mutant cell lines 
Clonogenic cell survival assays of RPE-1 PAXX mutant cell lines to increasing doses or irradiation. RPE-
1 WT cells = PAXX +/+, RPE-1 PAXX knockout = PAXX -/-. + PAXX WT/S148E/S148A = RPE-1 PAXX -/- 
cells complemented with stable WT/S148E/S148A mRuby2 tagged PAXX, respectively. Error bars show 
SEM, n=4. 
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4.2.5. CDK inhibition and PAXX phosphorylation 
Since no obvious differences in IR sensitivity phenotypes were detectable between PAXX-/- 
cells containing WT of S148 mutated PAXX derivatives, I wanted to check phospho-PAXX S148 
levels when inhibiting CDKs, in order to test if a reduction could be seen. Cells expressing GFP-
tagged PAXX were subjected to three different CDK inhibitors (CDK1/2 inhibitor III, 
Flavopiridol and RO-3306) and blotted using an anti pPAXX-S148 antibody. Although CDK 
inhibition was observed, as seen by a reduction in many bands detected by with the MPM2 




Figure 30 Testing effects of CDK inhibitors on PAXX S148 phosphorylation 
U2OS cells were transfected with GFP PAXX and treated with various CDK inhibitors. CDKi 1/2 III was 
dosed for 2 hours at 300nM. Flavopiridol was dosed for 2 hours at 3µM. RO-3306 was dosed for 8 
hours at 10µM. DMSO treatment was used as a control. Samples were harvested without recovery 
and blots were performed to detect PAXX S148 phosphorylation. 
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4.3. Discussion 
Results presented here suggest PAXX is not a target for cell cycle dependent degradation, as 
total PAXX levels remained essentially constant throughout the cell cycle (Figure 26). This 
makes the possibility of PAXX phosphorylation targeting the protein for proteasomal 
degradation through a FBXW7 degron highly unlikely. PAXX seems to be phosphorylated at 
serine/threonine sites, as a noticeable band was detected via MPM2 probing in IPs that 
correlate with GFP-tagged PAXX (Figure 27B). This is not specific to S148 however and could be 
detecting other potential phosphorylation sites on PAXX. From my data PAXX does seem to 
be phosphorylated on S148 which was detectable with a specific antibody against that residue 
in U2OS cells over expressing GFP PAXX (Figure 27A). Although the antibody used did not seem 
to work brilliantly in RPE-1 cells, there does appear to be a band present in cells expressing 
mRuby2 tagged WT PAXX compared to cells expressing S148A/E variant of PAXX (Figure 28B). 
This suggests that mutating these residues results in loss of phosphorylation at this site. The 
online tool, PhosphoSitePlusâ231, also indicates that PAXX is indeed phosphorylated at S148.    
 
By creating point mutants of PAXX S148, I explored potential effects that this site and its 
phosphorylation may have on PAXX function. Point mutants did not show much variation 
from each other in terms of sensitivity to IR. Unexpectedly, mRuby2 tagged WT PAXX 
complemented cells did not rescue the sensitivity seen in PAXX-/- cells back to the level of WT 
cells (Figure 29). This may indicate problems with the cells to tolerate overexpression of PAXX 
or potentially problems with the tagging of the protein. PAXX is a relatively small protein and 
both the N-terminal and C-terminal regions of the protein are highly important for PAXX 
function. mRuby2 was tagged at the N-terminal side of PAXX to prevent any disruption to the 
C-terminal interaction with Ku. The N-terminal head domain of PAXX is required for PAXX 
dimerization143 and it is possible that fluorescent N-terminal tagging may have interfered with 
this.  
 
In the interest of time, cell lines were generated by stable random plasmid integration which 
overexpressed variants of mRuby2 tagged PAXX in an already established RPE-1 PAXX-/- 
background. A better, more reliable model to use, would have been by generating point 
mutants of S148 at the endogenous PAXX locus by CRISPR-Cas9 mediated mutagenesis. 
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Nevertheless, this approach would have also had its limitations as a reliable antibody to 
detect phosphorylation at S148, especially in the context of endogenous PAXX protein levels 
was not available. The antibody used here gave mixed results in the two different cell lines 
chosen for experiments. When the antibody was tested to see if the band detected by it was 
depleted upon CDK inhibition, a reduction was not observed (Figure 30). CDK inhibition was 
occurring as validated by a loss of bands detected by the MPM2 antibody (Figure 30). This 
either suggests that the phospho-PAXX S148 antibody is not specific to that site, or the 
phosphorylation is not CDK dependent. This raises the intriguing possibility that PAXX S148 
phosphorylation may be mediated via a distinct kinase whose identity remains to be 
determined. 
 
Clonogenic survival assays performed with the PAXX mutants generated did not show obvious 
differences compared to PAXX-/- cells, furthermore WT PAXX complemented PAXX-/- cells did 
not rescue IR hypersensitivity to the same level as WT cells. This might suggest that the level 
of PAXX expression in these cells was not at the level needed to rescue sensitivity and perhaps 
overexpression in these cell lines is almost as toxic as total loss of the protein.  
 
The difficulties encountered, and lack of appropriate tools to study PAXX S148 
phosphorylation, coupled with the fact that there were no detectable changes in IR sensitivity 
phenotype between mutants meant that the project was put on hold.     
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5. Performing a CRISPR-Cas9 screen to investigate the role 
of WRN in the DDR 
5.1. Introduction 
 
5.1.1. Werner syndrome 
Otto Werner, a medical student, first identified patients presenting with bilateral cataracts 
and scleroderma-like skin in 1904232. The disease has since been referred to as ‘Werner 
Syndrome’ (WS).     
 
WS is a progeroid syndrome as it is mainly characterised by accelerated ageing. Symptoms 
that WS patients express are signs of premature ageing which include greying and loss of hair, 
bilateral cataracts, skin atrophy and loss of muscle and fat233,234. Unlike classical progeria 
syndromes such as Hutchinson-Gilford progeria syndrome (HGPS), WS patients seem to 
develop normally with no obvious abnormalities throughout childhood; however, they often 
miss their pubertal growth spurt during their teenage years235,236. WS syndrome patients only 
begin to show obvious premature ageing symptoms in their 20s-30s, typically showing an 
early onset of cataracts, osteoporosis, hypergonadism, diabetes mellitus, neoplasms and 
atherosclerosis236,237. The life span of WS patients is severely reduced with an average life 
expectancy of around 45-47 years238. The most common forms of death in WS patients are 
myocardial infarction and death from malignant cancers. Despite the link to cancer and 
neoplasms there are variations in the type of cancers that develop and ultimately, WS 
patients present with a diverse range of tumours. One study of literature case-reports found 
there to be a 1:1 ratio of epithelial to non-epithelial cancers in WS patients compared to a 
normal ratio of 10:1239. Others have reported an increased incidence of cancers of 
mesenchymal origin including an increased incidence of osteosarcoma240.  
 
WS is a rare autosomal recessive disorder which has an estimated incidence of 1:380,000 – 
1:1,000,000; however the Japanese population has a greater incidence of around 1:20,000 – 
1:40,000241–243.  
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WS is solely caused by mutations at the WRN locus on chromosome 8. The gene spreads 
across ~140kb of genomic DNA and contains 35 exons (34 coding exons) which code for the 
WRN protein. A range of mutations have been identified in WS patients, with mutations 
occurring throughout the gene with no particular clustering in any one domain. Whilst some 
mutations appear to generate a truncated protein, all mutations result in loss of functional 




5.1.2. RecQ helicases 
Escherichia coli (E. coli) contains a single RecQ helicase, RecQ, which has been shown to be 
involved in plasmid recombination and in the recovery of replication fork stalling at sites of 
UV-induced DNA damage245–247. Mutations in E. coli RecQ result in increased illegitimate 
recombination in both untreated and UV damaged backgrounds248. S. cerevisiae and S. pombe 
also contain a single RecQ helicase; Sgs1 and Rqh1 respectively, which are homologous to E. 
coli RecQ. Sgs1 and Rqh1 are also involved in the responses to DNA damage. Despite knockout 
strains being viable, both Sgs1 and Rqh1 deficiency show a hypersensitivity to DNA damaging 
agents and an increase in chromosomal abnormalities249,250. Sgs1 deletion also results in a 
decreased number of total cell divisions251,252. Sgs1 has been shown to be particularly involved 
in HR, as levels of the protein are increased in S-phase and deletion of Sgs1 results in a 
reduced rate of DNA resection at double strand break ends253. The RecQ helicases have 
therefore been shown to be involved in DNA repair and the maintenance of genome stability, 
in both bacteria and fungi. 
 
In humans, there are five known RecQ helicases: RECQ1, BLM, WRN, RECQ4 and RECQ5 which 
have evolved from a single ancestral gene to have specialised functions254. The RecQ helicases 
all contain a highly conserved helicase domain and are known to be involved in maintenance 
of genome stability. Three of the five human helicases are associated with rare genetic 
diseases; these are RECQ4, BLM and WRN. Mutations in RECQ4 have been linked to three 
disorders: RAPADILINO syndrome, Rothmund-Thomson syndrome (RTS) and Baller-Gerold 
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syndrome (BGS). These three disorders are distinct disorders although they have some 
similarities in their symptoms which include skeletal malformation.  
 
RAPADILINO is an acronym for the pathological features presented in patients with this 
syndrome; RA (radial ray malformation), PA (patella and palate abnormalities), DI (diarrhoea 
and dislocated joints), LI (limb abnormalities and little size) and NO (slender nose and normal 
intelligence)255. RAPADILINO has a higher incidence in Finland and characterisation of Finnish 
patients shows that they all carry at least one allele with a splice site mutation in intron 7 
which results in an in-frame deletion of exon 7254.  
 
RTS is mainly characterised by poikiloderma, a skin condition featuring hypo/hyper 
pigmentation and atrophy which usually presents on the face and neck. Juvenile cataracts are 
also evident in patients with RTS in addition to some overlapping features described earlier. 
RTS is associated with an increased risk of developing osteosarcomas256.  
 
BGS is the least well studied of the three disorders due to the low incidence, predicted to be 
rarer than 1:1,000,000. Less than 40 cases of BGS have been reported in medical 
literature255,257. It has overlapping clinical features with RAPADILINO but also is characterised 
by poikiloderma which usually occurs within the first few months of life 254. 
 
Mutations in BLM give rise to the rare genetic disorder Bloom syndrome (BS). BS patients 
typically have a significantly smaller body size than average which is evident in both young 
and adult patients258,259. Again, BS shares many of the symptoms of RTS, however the most 
striking and distinct phenotype of BS is an extreme sensitivity to sunlight which manifests in 
children between 1 and 2 years old. This usually presents on the faces of patients. The most 
common cause of death in BS is as a result of cancer which occurs at a much earlier average 
age than normal; 23, relative to 66 respectively. The average age of death in BS is below 
30260,261. Despite similarities between BLM and WRN, BS is not a premature ageing syndrome 
and patients do not exhibit the typical accelerated ageing phenotypes associated with WS260.  
 
Of the RecQ helicases, BLM is the most well studied. The most distinct phenotype in cells 
lacking BLM is a large increase in sister chromatid exchanges254,260,262. These can be visualised 
Chapter 5: Performing a CRISPR-Cas9 screen to investigate the role of WRN in the DDR 
 130 
in chromosome spreads by labelling with BrdU, Hoechst and Giemsa. Chromosomes from 
wildtype cells usually show chromatid arms in one colour. Cells from BS show alternating 
colours within chromatid arms as a result of sister chromatid exchanges262. This occurs as a 
result of crossovers between nascent DNA and template DNA during DNA damage at 
replication forks, when strand invasion of the damaged DNA uses the sister chromatid as a 
template for repair260. BLM has specifically been implicated in preventing crossovers and has 
been shown to bind Holliday junctions263–265. BLM forms a complex with DNA topoisomerase 
III 𝛼 (TOP3A), RecQ mediated genome instability 1 (RMI1), and RecQ mediated genome 
instability 2 (RMI2), which together resolve Holliday junctions266,267. BLM is specifically 
important in the HR pathway of DSBR and has a role in the promotion of long-range resection 
through its interaction with the exonucleases DNA replication helicase/nuclease 2 (DNA2) and 
EXO1268–270. BLM has some functional redundancies with WRN but also has non-redundant 
functions, this can be evidenced by differences in cell sensitivities between single and double 
knockouts to DNA damaging agents and differences in chromosome aberrations271.  
 




5.1.3. WRN structure 
WRN possesses a conserved helicase domain just like the other RecQ helicases and, like BLM, 
contains a RecQ C-terminal (RQC) domain and a helicase-and-ribonuclease D-C-terminal 
(HRDC) domain (Figure 31). 
 
The helicase domain is essential for ATP binding and hydrolysis and serves as an ATP-
dependent mode of DNA translocation to allow for the subsequent DNA helicase activity of 
the protein272. Despite the name the helicase domain alone cannot unwind DNA and requires 
a concerted effort with the RQC domain to have helicase activity273. 
 
The RQC domain folds into a winged-helix motif, which is a motif that is known to bind double 
stranded DNA273. Structural insights into the WRN RQC domain showed binding of the RQC 
domain onto duplex DNA, and specifically with blunt ended DNA273,274.  
Figure 31 The RecQ helicases 
Diagram showing RecQ helicases in bacteria, fungi and humans. E. coli, S. cerevisiae and S. pombe 
contain a single RecQ helicase whereas humans have 5 RecQ helicases: BLM, WRN, RECQ4, RECQ1 
and RECQ5. All proteins contain a conserved helicase domain (yellow) and RecQ C-terminal (RQC) 
domain (blue). Helicase-and-ribonuclease D-C-terminal (HRDC) domains have also been highlighted 
(green). RECQ4 contains a Sld-2 like domain (orange) and WRN contains an exonuclease domain 
(pink). Domain sizes are not to scale. Figure adapted from W. Chu & I. Hickson, Nature Reviews 
Cancer, 2009254. 
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The HRDC domain is unique to WRN and BLM amongst the other RecQ helicases. HRDC 
domains have typically been associated with structure specific DNA binding activity and the 
HRDC domain present in Sgs1 has been shown to have DNA binding activity for both ssDNA 
and partial duplex DNA275,276. The WRN HRDC domain has controversial reports on its activity; 
some suggest it has no DNA binding activity whilst others suggest it binds Holliday junctions 
and forked DNA but not ssDNA273,277. The HRDC domain function in WRN therefore remains 
unclear but is potentially involved in the binding of DNA and in particular, in the binding of 
DNA secondary structures. Another possibility is that it is involved in protein-protein 
interactions. The HRDC domain is connected to the RQC domain via a linker; this linker is 
longer in WRN than in BLM and likely to be unstructured. One proposed theory is that this 
distance between the two may be beneficial to aid interactions with other proteins; this could 
be with other DNA damage related proteins273,278.  
 
Although the BLM and WRN proteins contain many of the same domains the sequence 
identity between them varies; the helicase domain shares ~30%, the RQC shares around ~10% 
and the HRDC ~20% identity273. This may explain some of the functional differences in the 
two proteins and the clinical differences between the two syndromes. One unique feature of 
WRN compared to other RecQ helicases is its N-terminal exonuclease domain, which, like its 
helicase activity, acts in a 3’ to 5’ direction. WRN exonuclease activity is stimulated by Ku and 
LIG4/XRCC4279. Interestingly Ku, LIG4 and XRCC4 do not stimulate WRN helicase activity and 
thus suggests that WRN exonuclease activity is perhaps specific to NHEJ (discussed further in 
section 5.1.8). Recently, WRN was identified to contain two Ku binding motifs, one at the N-
terminus next to the exonuclease domain and another at the C-terminus. Both the Ku binding 
motifs and the exonuclease domain are required for efficient DSBR in irradiated cells280.  
 
 
5.1.4. WRN binding partners 
WRN interacts with a diverse range of proteins and has thus been implicated in a range of 
biological processes including replication, base excision repair (BER), DSBR, transcription and 
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telomere maintenance. The binding partners and relevant pathways WRN has a potential role 
in are discussed below. 
 
 
5.1.5. WRN in base excision repair 
WRN has been linked to BER through its interaction with other proteins involved in the same 
pathway. These include flap endonuclease 1 (FEN1), DNA polymerase b (DNAPolb) and the 
DNA glycosylase, Nei like DNA glycosylase 1 (NEIL1)281.  
 
BER is a DNA repair process that results in the removal and replacement of damaged bases. 
BER exists in two forms: short patch BER (SP-BER) and long patch BER (LP-BER). SP-BER 
involves the removal and replacement of a single nucleotide base of DNA and is the more 
frequently used of the two processes. LP-BER involves the removal and replacement of more 
than one nucleotide282.  
 
BER begins by the recognition of damaged bases through damage-specific DNA glycosylases. 
These glycosylases cleave the N-glycosylic bond and thus detach the base from the sugar 
phosphate backbone. There are several DNA glycosylases, each of which recognises a specific 
type of base damage282. NEIL1 is a DNA glycosylase that recognises a number of base lesions 
including formamido-pyrimidine (fapy) lesions283. WRN interacts with NEIL1 both in vivo and 
in vitro and the binding between the two is enhanced upon oxidative stress284,285. WRN has 
been shown to stimulate the ability of NEIL1 to excise oxidative lesions from DNA 
substrates284. Consistent with this, WRN depleted cells accumulate oxidative damage284. 
 
The abasic site created after excision via the glycosylase in BER is processed to create a single 
strand break (SSB). DNAPolb then catalyses the addition of nucleotide bases and the DNA is 
ligated via the XRCC1-DNA ligase IIIa complex286,287. WRN also interacts with DNAPolb and 
stimulates its activity thus confirming its role in BER288. 
 
WRN has also been implicated in LP-BER through its interaction with FEN1. FEN1 has 5’ 
exonuclease activity and is thought to bind DNA containing 5’ ssDNA flaps289. This activity of 
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FEN1 is involved in LP-BER but it also functions at replication forks, particularly in the 
processing of Okazaki fragments289. WRN has been shown to stimulate FEN1 cleavage of 5’ 
flap DNA. This functional interaction between the two also applies to the processing of DNA 
replication and repair intermediates290.   
 
 
5.1.6. WRN at replication forks 
WRN has been linked to DNA replication through a number of interactors; these include RPA, 
DNAPold, PCNA and, as previously mentioned, FEN1291,292. The Xenopus ortholog of WRN, Ffa-
1, was originally identified in the replication initiation complex and has been shown to be 
required for replication foci formation293 which suggests a role for WRN in the DNA replication 
process. WRN promotes the activity of DNAPold, however WRN helicase and exonuclease 
activities are not enhanced by this interaction292. This might suggest that the role of WRN 
during replication is non-enzymatic. Interestingly, WRN also enables DNAPold to overcome 
DNA secondary structures, to perform DNA replication294. This may indicate that one of the 
main roles of WRN at replication forks is to resolve DNA secondary structures that create a 
potential block to replication fork progression. In concordance with this, WRN binds a range 
of DNA secondary structures, particularly those which are likely to form at replication forks277. 
Specific domains within WRN have been shown to have preferred secondary structure 
specificity; for example, the exonuclease domain preferentially binds forked DNA structures 
and 5’ overhang duplex DNA whereas the HRDC domain shows a greater preference for 
Holliday junctions295,296.   
 
WRN has been implicated in promoting replication fork restart after fork stalling and fork 
collapse. Multiple groups have demonstrated this link by showing an increased sensitivity of 
WS cells to drugs that induce replication fork stalling297–299. This includes an increased 
sensitivity of WRN deficient cells to HU, a drug that induces replication fork stalling by 
depleting the dNTP pool. WRN depleted cells showed a delay in cell cycle progression when 
treated with HU and also showed an impaired ability in replication fork elongation, as 
measured by DNA fibre analysis298. Furthermore, WRN depleted cells showed an increased S-
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phase arrest in cells treated with the TOP1 inhibitor topotecan300. This suggests an inability 
of replication fork restart after collapse in WRN depleted cells.  
 
Despite extensive research in this area, the precise mechanisms by which WRN functions to 
prevent replication fork collapse is still debated.  
 
 
5.1.7. WRN involvement in HR 
There is strong evidence to suggest WRN is involved in DSBR as it accumulates at sites of laser 
induced DNA damage and interacts with proteins from both the HR and NHEJ pathways281,301. 
This consequently makes WRN an interesting protein with regards to regulation of DSBR 
pathway choice. 
 
WRN interacts with some of the key components of the HR pathway and importantly has been 
shown to colocalise with RPA and RAD51, both of which are essential for HR302. The physical 
interaction of RPA and WRN has been shown to promote WRN helicase activity and therefore 
a potential role of WRN is in promoting DNA resection. Consistent with this WRN inhibition 
results in a decrease in pRPA following DNA damage which may be due to impaired 
resection303. Furthermore, WRN and DNA2 interact and together promote 5’-3’ DNA resection 
as stimulated by RPA. The significance of this function of WRN may be redundant as BLM also 
performs this function and can perhaps compensate for any lack of WRN, with BLM being the 
more important RecQ helicase in this process in humans304. 
 
The involvement of WRN in HR is also apparent from the kinetics downstream of DNA 
resection. Cells from WS patients show increased levels of RAD51 foci compared to control 
cells, suggesting defects at the strand invasion stage of HR305,306. Consistent with this, WRN 
also interacts with RAD52 and RAD54 which both have roles in promoting recombination307,308. 
The hypersensitivity that WRN depleted cells show to DNA damaging agents that induce HR 
is further evidence of WRN functioning in HR271,305.   
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5.1.8. WRN involvement in NHEJ 
WRN is also implicated in NHEJ and has been shown to interact with DNA-PKcs, Ku, XRCC4 
and DNA ligase IV. Similarly to Ku, XRCC4 and DNA ligase IV stimulate the exonuclease activity 
of WRN279,309,310. This suggests that WRN may have a role in processing DNA ends for NHEJ to 
take place. DNA-PKcs on the other hand is reported to have an inhibitory effect on WRN 
exonuclease activity in the presence of Ku311. The opposing effects of the NHEJ components 
on WRN suggest that the WRN activity in NHEJ is tightly controlled. WS cells only show a mild 
increase in sensitivity to IR compared to the core NHEJ factors, but this sensitivity is rescued 
by overexpression of WRN312.  
 
Recently, WRN has been linked to NHEJ pathway choice through promotion of canonical NHEJ 
versus alternative NHEJ. WRN appears to specifically inhibit alternative NHEJ by inhibiting 
resection, this was shown to occur via a mechanism which results in reduced recruitment of 
MRE11 and CtIP in G1 cells313. This reported inhibition of resection perhaps contradicts the 
functions of WRN proposed in promoting HR but may imply that WRN function is regulated 
throughout the cell cycle.      
 
 
5.1.9. WRN at telomeres 
WRN interacts with several components of the Shelterin complex including telomere repeat-
binding factor 1 (TRF1), telomere repeat-binding factor 2 (TRF2) and protection of telomeres 
1 (POT1). All of these factors are responsible for the recognition of TTAGGG repeats found at 
telomeric DNA314,315. The Shelterin complex acts to shape telomere secondary structures and 
protect the DNA ends from aberrant processing by DNA repair316–318. WRN might be involved 
in the resolution of DNA secondary structures at telomeres to enable efficient and successful 
telomere elongation. T-loops and D-loops are both substrates of WRN and both occur at 
Shelterin bound telomeres. In vitro experiments implicate WRN exonuclease activity in the 
resolution of telomeric D-loops by removing the homologous region of the 3’ invading strand 
that forms the D-loop319. Several DNA damage proteins, which are also interactors of WRN, 
associate with telomeres320. These aid in the repair and maintenance of telomeres and 
perhaps achieve this through their interaction with WRN. Repetitive sequences of triple 
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guanines in telomeric DNA make it prone to oxidative DNA damage and telomere shortening. 
This type of DNA damage is repaired by the BER pathway, which, as described earlier, WRN 
has been implicated in. 
 
 
5.1.10. WRN, G4 quadruplexes and transcription 
Telomeric TTAGGG sequences can also form G4 quadruplexes, a DNA secondary structure 
that is a preferential substrate of WRN319,321,322. Whilst telomeric G4 quadruplexes exist, the 
vast majority of G4 forming DNA regions are non-telomeric. G4 quadruplexes can be formed 
in both DNA and RNA. A large number of G4 quadruplexes are found in promoter regions and 
have been linked in regulating transcription in addition to their roles in regulating replication 
and telomere maintenance323. WRN has also been linked to transcription and has been shown 
to be a highly nucleolar protein. Nucleolar intensity of WRN is lost upon actinomycin-D 
treatment suggesting an involvement in rDNA transcription324. WRN helicase activity is also 
functional on RNA-DNA heteroduplexes. Cells from patients with WS also show a 40-60% 
reduction in the level of transcription compared to cells from normal individuals325. These 
results suggest WRN is involved in transcription and might suggest that the overall decrease 




5.1.11. Insights into WRN function from WRN knockout mice 
Studies in patient cells and human cells depleted for WRN have offered insights into WRN 
function but its precise roles are still to be identified. Mouse models have been generated as 
a means to explore WRN function but unfortunately have not been able to establish any exact 
mechanisms. Neither WRN null mice nor mice containing an in-frame deletion of the helicase 
domain present the same clinical premature ageing phenotypes associated with WS326,327. 
Cells taken from WRN null mice did not show an increased sensitivity to CPT or 4-
nitroquinoline 1-oxide (4NQO) contrary to cells taken from WS patients and contrary to 
embryonic stem (ES) cells derived from the helicase deleted mouse326. Despite the lack of 
physical clinical manifestations of mice harbouring only WRN defects, late generation mice 
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that are WRN and telomerase RNA component (TERC) null do show signs of premature ageing. 
WRN-/- TERC-/- mice were smaller in size compared to controls and showed a reduced 
lifespan. These mice also presented kyphotic stature, greying of hair and alopecia as well as 
cataracts, all of which can be linked to WS328. This might suggest that WRN function and the 
phenotypes presented in WS are a result of improper telomere maintenance and telomere 
shortening.    
 
 
5.1.12. WRN investigations herein 
Literature on WRN suggest it has a variety of possible functions, and publications convey a 
number of conflicting and contradictory results (as described above). The fact that WRN is 
involved in DNA repair and seems to have functions in both HR and NHEJ mechanisms of DSBR 
make it an interesting protein that may influence and regulate DSBR pathway choice. In order 
to further investigate WRN and interrogate its function, two main areas of research were 
pursued.  
 
The main area of research involved using a generated isogenic WRN knockout cell line as a 
tool, to perform a CRISPR-Cas9 gene inactivation screen to look for suppressors of WRN 
specific DNA damage sensitivity. This was performed with the aim of identifying genetic 
interactors that could offer mechanistic insights into the functions of WRN within the DDR.  
 
The second aspect of my research was to utilise the knockout cell line to investigate 
mutational signatures that accumulate over time. WS is a premature ageing syndrome which 
gives an increased predisposition to cancers. Little is known about why this might be the case. 
Performing mutational signatures analysis might give insights into multiple questions 
regarding the involvement of WRN in maintaining genome stability. This includes information 
like the number and types of indels and single nucleotide polymorphisms, as well as the 
location of any mutations. This will reveal which genetic areas are prone to mutations and 
may allow us to link it to other features such as DNA secondary structure or highly transcribed 
areas. Unfortunately, the sequencing data is still in a pipeline for bioinformatic analysis and 
therefore has not been fully interrogated. As a result, it will not be presented in this thesis.  
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5.2.1. Generation of RPE-1 WRN knockout 
In order to better study the functions and roles of WRN, I first generated a WRN gene 
knockout in RPE-1 cells. This gave me a novel system to study WRN, as previously published 
reports on WRN have typically been focused using patient derived fibroblasts taken from 
patients towards the later stages of their lives, or mouse and chicken cell lines. Knockouts 
were generated by the process detailed in Figure 32A, which began with the electroporation 
of RPE-1 cells with four separate plasmids. This included two encoding gRNAs targeting Exon 
12 of WRN (Figure 32B), one encoding a Cas9 nickase and one carrying a targeting cassette 
containing a puromycin resistance gene and GFP (targeting cassette and gRNA plasmids were 
obtained from Sasa Svikovic in the Julian Sale lab, Laboratory of Molecular Biology, 
Cambridge). The RPE-1 cells used already contained a puromycin resistance gene and thus 
the knockouts were generated using GFP as a selection marker; cells were FACS bulk sorted 
initially in order to select for positively transfected cells. These cells were split into two 
populations and plated back onto dishes and left to recover. Cells were then FACS single cell 
sorted into 96 well plates for cells still expressing GFP. This enabled selection of stable 
integration of the targeting cassette. Plates were monitored over the next 10 days and 
inspected under a microscope to ensure only wells which contained single colonies were 
taken forward. Crude lysate was extracted from potential positive clones and PCR screened 
for bands shifts. Bands shifts differing from the WT product correspond to insertions or 
deletions at the locus. Clones were expanded and then verified for loss of WRN by Western 
blot. Four clones tested showed complete loss of WRN with no evidence of truncated 
products (Figure 32C). For the duration of my studies I used these four clones (E5, F11, G7 & 
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Figure 32 WRN knockout generation 
(A) Schematic showing the WRN knockout generation process. RPE-1 cells were transfected with 
gRNAs, Cas9nickase and a targeting construct (3µg each plasmid). Positively transfected cells were 
selected by FACS bulk sorting for GFP and split into two populations. Subsequent populations were 
single cell GFP sorted by FACS for stable integration of the targeting construct. Clones were then 
screened by PCR and Western blotting to confirm knockout (B) Diagram of targeting construct 
designed against Exon12 of WRN. (C) Western Blot validation of knockout clones generated.   
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5.2.2. WRN knockout clones are hypersensitive to CPT 
Previous literature has shown that WRN deficient cells exhibit an increased sensitivity to drugs 
that interfere with DNA replication, such as hydroxyurea (HU) and camptothecin (CPT)271,305. 
I tested this in my knockout cell lines to see if they showed the same phenotype to allow for 
direct comparison and were a reliable cellular model of the disease. Growth assays were set 
up with chronic treatment of CPT at 2nM, and growth monitored by percentage confluence 
using an IncuCyteÒ ZOOM system. There was a slower increase in percentage confluence 
over time when comparing 2nM CPT treated to the non-treated (NT) in the WRN-/- clones 
(NT) (Figure 33A). Importantly the WT clone does not show the same level of increased CPT 
sensitivity (as measured by percentage confluence) at this concentration. Knockout clones G7, 
E5 and 1A6 all showed an increased sensitivity to CPT compared to WT cells. Clone F11, by 
contrast, did not show the same increase in sensitivity at this concentration of CPT.  
 
I next tested to see if an increase in CPT sensitivity could be seen in WRN siRNA depleted cells. 
This was to verify if depletion of WRN showed the same hypersensitivity to CPT phenotype as 
the majority of the WRN-/- clones tested. Depletion of WRN protein with siRNA was seen at 
both 24 hours and 96 hours after transfection (Figure 33B). This meant that protein levels were 
efficiently depleted at the time the CPT was administered (48 hours after transfection). WRN 
depleted cells did show an increased sensitivity to 2nM CPT compared to cells transfected 
with the control siRNA (Figure 33C).  
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Upon performing the survival assays, I noticed a tendency for the RPE-1 cells to senesce when 
exposed to high levels of DNA damage. This was particularly noticeable in the RPE-1 WRN-/- 
knockout clones used. Senescent cells, although not continuing to divide, maintain adherence 
to cell culture plates and expand in size. Both the nucleus size and the cytoplasmic size 
increase in senescent cells. The confluence mask used in the IncuCyteÒ assays does take this 
into account, however at higher levels of senescence, the software struggles to distinguish 
alive, proliferative confluent cells from large expanding senescent cells. This could have 
therefore led to overestimates of the level of survival following CPT treatment seen in the 
WRN-/- compared to WT cells, thereby underestimating the CPT hypersensitivity of WRN-/- 
cells. 
 
To overcome this potential issue, plates were stained with the DNA stain Hoechst, at the end 
point of experiments and images taken under a fluorescent microscope. NT WT cells and NT 
WRN-/- cells grow normally and cells become compact and highly confluent. In WT cells 
treated with 2nM CPT, there is a mixture of cells which correspond to both proliferative and 
senescent cells. This can be seen by the mixture of densely packed smaller nuclei (proliferative 
cells) as well as swollen nuclei with few nuclei surrounding them (senescent cells) (Figure 34A). 
WRN-/- cells treated with 2nM CPT show an almost complete loss of proliferative cells, with 
the majority of cells showing swollen nuclei. The number of nuclei in a given field therefore 
correlate to the level of cell survival. Multiple images were taken from triplicate wells and 
nuclei numbers counted using ImageJ software. The three WRN knockout clones showed an 
increase in sensitivity to 2nM CPT giving 4-7.5% survival. WT cells in contrast were much less 
affected at this concentration of CPT, showing around 30% survival (Figure 34B).   
Figure 33 WRN knockout clones show sensitivity to camptothecin 
(A) Graphs of IncucyteÒ growth assays performed in RPE-1 WT and WRN knockout clones 
(G7,E5,F11,1A6), showing percentage confluence in untreated and 2nM CPT treated samples. Each 
graph shows a different WRN knockout clone tested as indicated in the key. Error bars show SEM, 
n³2.  (B) Western blot showing validation of siRNA mediated WRN depletion relevant to (C) Graph of 
IncucyteÒ growth assay shown in performed in WT and WRN siRNA depleted cells. (siRNA against 
WDR76 was used as a control in (B)). 







Figure 34 WRN knockout cells show increased sensitivity to camptothecin 
(A) Cell survival assays were performed in non-treated (NT) or chronic 2nM CPT treated (2nM CPT) 
WT or WRN-/- RPE-1 cells. Cells were stained 6-10days after dosing and stained with Hoechst. Images 
of Hoechst staining from cell survival assays can be seen. (B) Images of Hoechst stained cells were 
quantified using ImageJ and percentage survival measured relative to non-treated. Error bars show 
SEM, n=4. 
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5.2.3. Generating stable Cas9 expressing cells for CRISPR genetic 
screen 
Having established a defined window of sensitivity between WT and WRN-/- cells to CPT, I set 
out to explore functional mechanisms behind the sensitivity. To do this, a CRISPR-Cas9 screen 
to look for potential suppressors was performed. In order to setup a screen, I first had to 
generate WRN-/- cells stably expressing Cas9. This was done by lentiviral infection of the 
already validated WRN-/- clones (E5,G7,F11 & 1A6) with a plasmid containing WT Cas9 and a 
blasticidin resistance gene. Once infected, cells were selected using blasticidin and resistant 
clones picked (Figure 35A). Clones then had to be tested to ensure that Cas9 was active in these 
cells. This was performed using a lentiviral vector expressing both blue fluorescent protein 
(BFP) and GFP as well as a gRNA targeting GFP (Figure 35B). The principle behind this system is 
that cells infected with the lentivirus that do not express Cas9 would express both BFP and 
GFP; conversely lentiviral infection in cells expressing Cas9 would result in largely BFP only as 
the GFP sequence would be cut and mutated by Cas9/gRNA complex. This is the case that can 
be seen in RPE-1 WT cells (Figure 35C top panel); non-treated cells are non-fluorescent, lentiviral 
infected cells without Cas9 show both BFP and GFP, and lentiviral infected cells containing 
Cas9 show mostly BFP only cells.  
 
The WRN-/- cells that were generated already contained GFP in them as a result of the 
targeting construct used to make them, and thus gating had to be adjusted accordingly (Figure 
35C bottom panel). An obvious shift can still be seen when comparing lentiviral infected cells 
with and without Cas9 (Figure 35C bottom panel, middle and right). Efficiency of the Cas9 cutting 
was quantified by FACS and measured by percentage of GFP remaining (Figure 35D). All Cas9 
expressing clones exhibited a dramatic reduction in GFP to below or around 10% GFP 
remaining therefore showing good Cas9 efficiency. This is probably an underestimate of Cas9 
efficiency in WRN-/- Cas9 clones as they contained two copies of GFP (one from the original 
knockout generation).  
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Figure 35 Testing Cas9 efficiency in cell lines for screen 
(A) Diagram showing generation of WRN-/- cells stably expressing Cas9. Knockout clones were 
infected with lentivirus carrying Cas9 and placed under blasticidin selection. Resistant clonal 
colonies were picked. (B) Map of lentiviral Cas9 test plasmid which contains BFP and GFP driven by 
a PGK promoter and a U6 promoter driving a gRNA targeting the GFP. (C) FACS plots of Cas9 testing. 
Top row shows WT cells and bottom row shows WRN knockout clone G7. Left column shows cells 
expressing Cas9 but without infection with test plasmid. Middle column shows cells not expressing 
Cas9 but infected with the test plasmid. Right column shows cells expressing Cas9 and infected with 
test plasmid. Column titles denote presence of Cas9/test plasmid as denoted by Cas9+/- and 
Plasmid+/-. (D) Graph showing quantification of Cas9 gene mutation efficiency testing as measured 
by percentage GFP. Clones are indicated below bars with indication of Cas9 status. Two non-
infected clones as controls are plotted on the far right.    
Chapter 5: Performing a CRISPR-Cas9 screen to investigate the role of WRN in the DDR 
 149 
5.2.4. CRISPR-Cas9 screen to identify suppressors of WRN-/- sensitivity 
to CPT    
A CRISPR-Cas9 screen was performed in three cell lines: the RPE-1 WT background and two 
knockout clones (all expressing Cas9). WRN-/- clones G7-C6 and E5-C5 were chosen as they 
showed good Cas9 cutting efficiency and both showed an increased sensitivity to CPT 
compared to WT cells (Figure 33A, Figure 34B, Figure 35D). The screen was performed with a 
focused human DDR CRISPR library targeting a total of 737 genes (Table 2). 
 
Total number of guides 11281 
Number of DDR target genes 737 
Number of targeting guides 10081 
Number of non-targeting guides 1200 
Average number of guides per gene 13.68 
 
 
All cell lines were infected with a 0.2 multiplicity of infection (MOI) with enough cells to get a 
500x cells per guide library representation (Figure 36A). Infecting at this MOI reduced the 
likelihood of single cells being targeted with more than one guide. Positively targeted cells 
were selected for BFP expression by FACS, as again the resistance in the hDDR library was 
puromycin (a resistance gene already present in the clones used) (Figure 36B). Cells were then 
cultured for 14 days to allow for removal of cells mutated in essential genes. Cells were 
treated with 2nM CPT and left in the drug for 5 days before being washed and allowed 6 days 
recovery. At all stages throughout the screen, cell numbers were maintained to give 500 times 
representation for each guide in the starting library (Figure 36A).   
 
Table 2 Human DDR CRISPR library 
Information on the content of the human DDR CRISPR (hDDR) library. Non-targeting guides contained 
sequences which do not match human genomic DNA and thus do not target the genome. The human 
DDR CRISPR library contained multiple gRNAs targeting each gene with an average of ~13 gRNAs per 
gene. For full list of genes in the library see Appendix Table 4. 
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PCR library preparation was performed in two stages with an initial PCR to generate a product 
which includes the gRNA ‘barcode’ for the guide present in the cell (Figure 36B). This PCR 
product was then purified and used as templates to generate PCR products containing 
adaptors for Illumina sequencing (Figure 36C). These products were quantified by Qubit and 










Figure 36 Library Preparation for Illumina Sequencing 
(A) Schematic of the CRISPR-Cas9 screen process. Stably expressing Cas9 clones were infected with a 
0.2MOI to gain a 500x representation. Targeted cells were BFP sorted and cultured in flasks for 14 
days, splitting and maintaining cell numbers for 500x library representation. Cells were chronically 
treated with DMSO or CPT at either 2nM or 5nM for 5 days. Cells were allowed to recover, and 
samples taken for library preparation. (B) Map of gRNA lentivirus containing a gRNA driven by a U6 
promoter and a puromycin and BFP driven by a PGK promoter. Black arrows annotated RS204 and 
RS208 indicated the primers used for the first PCR which was used as a template for subsequent PCRs 
in library preparation (C) PCR products of second PCR to add Illumina sequencing specific adaptors. 
Sample labels SIV1-10 were used for the 10 samples and primers indicated (RS***) (see Table 1 and 
Appendix Table 1 for details). These samples were pooled and sequenced.   
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5.2.5. CRISPR-Cas9 screen results 
 
5.2.5.1. Suppressors in the WT background 
CRISPR screen analysis was performed by comparing DMSO treated and CPT treated endpoint 
samples (after treatment and recovery) to the day 14 control (prior to treatments) for each 
cell line included in the screen. This was done using joint analysis of CRISPR/Cas9 knock-out 
screens (JACKS)329 and performed by Iñigo Ayestaran in the Jackson Lab. This allowed a 
comparison of changes in gRNA sequence counts between CPT treated and DMSO treated 
cells, which allowed for identification of suppressors specific to the DNA damage treatment. 
By comparing the lists of genes between the cell lines used, suppressors specific to the WRN-
/- background could be identified. Figure 37A/B shows a comparison of the level of 
enrichment of DMSO treated and CPT treated cells compared to the day 14 control in WT 
RPE-1 cells. Two concentrations of CPT were used in the WT background: 2nM which gave an 
IC40 and 5nM which gave an IC70. The non-targeting guides present in the DDR library have 
been randomly clumped into groups of 15 and plotted in red on the graphs. They tend to 
localise close to the XY intersect which reflects little enrichment or loss from the day14 control. 
The blue dotted line is plotted where X=Y and thus reflects the position where enrichments 
are equal in the DMSO and CPT treated samples.  
 
gRNAs against TP53 showed the greatest enrichment in both samples but shows a 
comparatively greater enrichment of around 6-fold increase in the CPT treated sample 
compared to a 3.5-fold increase in the DMSO treated sample (Figure 37A/B). gRNAs against 
CDKN1A showed the next greatest enrichment in the CPT treated sample. Other gRNA targets 
that showed a greater enrichment in the CPT mediated DNA damage samples include: NEDD8, 
CHEK2, SOD1, and POLR2A (Figure 37A/B). 
 
A number of targets were identified which showed a greater enrichment in DMSO treated 
samples compared to CPT treated samples in the WT background. These can be seen by points 
that have a positive value for enrichment in DMSO treated samples but fall below the blue 
dotted line. These include RNF146, KEAP1, CAND1, UBE2F, PTEN, SCAF4 and CUL3 (Figure 
37A/B).  








5.2.5.2. Suppressors in WRN-/- background 
gRNAs enriched in both CPT and DMSO treated samples were also the same in both WRN-/- 
clones compared to WT RPE-1 cells and included gRNAs targeting RNF146, KEAP1, CAND1, 
PTEN, SCAF4 and CUL3 as before (Figure 38A/B). The two strongest suppressors of CPT 
sensitivity in both WRN-/- clones screened were also TP53 and CDKN1A, thus matching the 
strongest suppressors in the WT background (Figure 38A/B). 
 
When looking at the raw numbers from the JACKS analysis for the E5 WRN knockout clone, 
other suppressors which showed greater suppression in the CPT treated versus the DMSO 
treated were identified. These hits were picked by looking at the fold difference between the 
two samples and taking hits which showed a difference greater than 0.3 and a false discovery 
rate (FDR) less than 10% (Appendix Table 7 & Appendix Table 9). This identified the other targets 
CHEK2, SMARCC1, POLD3, EME2 and MAPK14 (highlighted in the plots) in addition to TP53 
and CDKN1A (Figure 38A).  
 
The same analysis was performed for the G7 WRN knockout clone which identified the 
following suppressors specific to CPT treatment: MAPK14, TP53, ENDOV, CDKN1A, CUL3, 
DNTT, SHFM1, DCLRE1A, CDC25A, APEX1, GADD45G, MLH3 and PBRM1 (Appendix Table 6 & 
Appendix Table 9) (Figure 38B).  
 
Figure 37 JACKS analysis plots of CRISPR screens performed in WT RPE-1 cells 
Plot of JACKS analysis showing fold enrichment of grouped gRNAs in DMSO treated samples versus 
CPT treated samples compared to the day 14 control in WT cells. Red dots indicate non-targeting 
guides. All black dots indicate the gene target of gRNAs, which have been grouped. Some have been 
indicated. The blue dotted line represents x=y where enrichments in DMSO and CPT treated samples 
are equal. The black dotted line shows enrichments at +/- 1. (A) Plot of DMSO treated vs. 2nM CPT 
treated (B) Plot of DMSO treated vs. 5nM CPT. (Raw data in Appendix Table 4 & Appendix Table 5) 









An advantage of performing the screen in two independent WRN knockout clones was that it 
allowed JACKS analysis to be performed by combining both biological replicates (Figure 39). 
gRNAs enriched in the CPT treated versus DMSO treated samples were identified as before. 
This revealed a selection of target genes which included TP53, CDKN1A, MAPK14, CHEK2, 
ZDHCC16, POLD3, SMARCC1, PBRM1, CHFR, EME2 and SETD2 (Figure 39).  
 
When comparing gRNAs enriched in the CPT treated samples between WT and WRN-/- clones, 
unique genes were identified which were specific to the WRN-/- background. These were: 
CHFR, EME2, MAPK14, PBRM1, SETD2, SMARCC1 and ZDHHC16.     
 
Figure 38 JACKS analysis plots of analysis performed on individual WRN knockout clones 
Plot of JACKS analysis showing fold enrichment of grouped gRNAs in DMSO treated samples versus 
CPT treated samples compared to the day 14 control in WRN-/- cells. Red dots indicate non-targeting 
guides. All black dots indicate the gene target of gRNAs, which have been grouped. Some have been 
indicated. The blue dotted line represents x=y where enrichments in DMSO and CPT treated samples 
are equal. The black dotted line shows enrichments at +/- 1. Plot of screen performed in WRN-/- clone 
(A) E5 and (B) G7. (Raw data in Appendix Table 6 & Appendix Table 7)  






5.2.5.3. Dropouts in a WRN-/- background  
In addition to suppressors, the screen can also identify factors that when lost, increase the 
sensitivity of cells either to CPT treatment or DMSO treatment alone. These can be seen by 
points that show a negative value for enrichment. The WT clone did not really show any genes 
which when lost conferred a greater sensitivity to CPT compared to DMSO. This can be seen 
by the lack of data points below the X axis and below the blue dotted line. One possible 
exception is NBN (aka NBS1) (Figure 37A/B). NBN appears as a dropout in the screens 
Figure 39 JACKS analysis plots of analysis performed on WRN knockout clones as biological replicates 
Plot of JACKS analysis showing fold enrichment of grouped gRNAs in DMSO treated samples versus 
CPT treated samples compared to the day 14 control in WRN-/- clones treated as biological replicates. 
Red dots indicate non-targeting guides. All black dots indicate the gene target of gRNAs, which have 
been grouped. Some have been indicated. The blue dotted line represents x=y where enrichments in 
DMSO and CPT treated samples are equal. The black dotted line shows enrichments at +/- 1. (Raw 
data in Appendix Table 8)  
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performed at both concentrations of CPT, however it does not have an FDR value of less than 
10% in both sets of analysis (Figure 37A/B and Appendix Table 4 & Appendix Table 5). From the plots 
of the analysis performed on individual WRN knockout clones, there is a noticeably greater 
number of genes which show a negative fold change compared to the WT clone (Figure 38A/B). 
WRN knockout clone G7 has more of these compared to the E5 clone (Figure 38A/B). When 
considering both sets of data as biological replicates, two target genes which show the 
greatest loss of gRNA representation compared to day 14 are SOD1 and NEDD8 (Figure 39). 
gRNAs against SOD1 and NEDD8 also show a slightly greater loss in the CPT treated sample 
over the DMSO treated sample. These two genes are enriched however in the WT screens as 
can be seen in the table of data (Appendix Table 4 & Appendix Table 5). gRNAs against RPS27L 
show a greater loss which is specific to CPT induced DNA damage in WRN-/- samples (Figure 
39). Again, when looking at the table of results, RPS27L is enriched in the WT cells in both 
treatments of CPT and in DMSO treated cells compared to the day 14 control (Appendix Table 
4 & Appendix Table 5).    
 
The results also show genes which are lost without the presence of DNA damage in a WRN-/- 
background. These can be seen by the points which drop down into the negative enrichment 
in DMSO treated but remain above the dotted blue line. The factors which dropout the most 
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5.3. WRN Discussion 
 
WRN function has been largely debated and its precise functions and roles within the DDR are 
still not clearly defined. Until now, most studies have been conducted in either WS patient 
cells, which may have already undergone significant genetic alteration, or in non-human 
mammalian knockout cells, which may not properly reflect the function of WRN and the 
human specific syndrome. Generating an isogenic WRN knockout in RPE-1 cells allowed the 
study of WRN in a novel way.  
 
WRN knockouts were generated using CRISPR-Cas9 nickase technology to ensure minimal off-
target effects of gRNA targeted cutting330,331. Western blotting showed that there was 
complete loss of WRN in the clones selected and that there was no detection of any truncated 
products (Figure 32C). This meant that WRN was completely absent and therefore there was 
no possibility of retained function through its exonuclease/helicase domains.  
 
Three of the four knockout clones tested showed an increased sensitivity to CPT when 
measured by two independent methods (Figure 33A & Figure 34B). Interestingly clone F11 did 
not show an increased sensitivity to CPT despite showing complete loss of WRN (Figure 33A). 
The growth rate of this clone does not vary from that of the WT and thus shows that the lack 
of sensitivity is not as a result of a slower cell cycle turnover (Figure 33A). The lack of sensitivity 
in this clone could be due to a genetic alteration occurring in the clone which has 
compensated for the loss of WRN. The sensitivity seen in the other three WRN knockout 
clones was also seen when depleting WT cells for WRN with siRNA (Figure 33C). Multiple 
independent groups have also shown that WRN deficient cells show an increase in sensitivity 
to CPT and thus the bulk of the results shown here corroborate this phenotype271,305. It would 
be interesting to test the sensitivity of WRN knockout clones to other types of DNA damage 
since the literature on WS cells has some conflicting reports of sensitivity.  
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5.3.1. p53 and p21 loss give growth advantage 
Testing both WT and WRN knockout clones in a CRISPR-Cas9 screen using a DDR focused 
library allowed me to search for DDR components whose loss might suppress CPT sensitivity 
in a WT background as well as in a WRN-/- specific background. The strongest suppressors of 
CPT sensitivity in all backgrounds were TP53 and CDKN1A (Figure 37, Figure 38 & Figure 39). 
Unsurprisingly TP53, the gene coding for p53, was the strongest hit, as it is a strong tumour 
suppressor involved in cell cycle arrest, cell senescence and apoptosis in response to cellular 
stresses332. TP53 is the most common gene mutated in cancer and loss of p53 function is 
common in progressive tumours332. Loss of TP53 in the screen therefore presumably offers a 
growth advantage to cells as it allows cells to survive even after sustaining high levels of DNA 
damage. This is evident as gRNAs targeting TP53 were enriched in both DMSO treated and 
CPT treated samples in both WT and WRN-/- backgrounds (Figure 37, Figure 38 & Figure 39). This 
also shows that p53 loss offers a growth advantage even in a WRN-/- background.  
 
CDKN1A is the gene responsible for the p21 protein. p21 is a direct target of p53 and is 
responsible for the inhibition of CDK1, CDK2 and CDK4/6 333,334. p21 acts downstream of p53 
as a cell cycle regulator to prevent cell cycle progression after a cell stress response and in 
particular in response to DNA damage333,334. Again, it is therefore not surprising that gRNAs 
targeting this gene were enriched in all cell backgrounds and conditions tested (Figure 37, Figure 
38 & Figure 39).    
 
Interestingly, in all cases, loss of p53 or loss of p21 resulted in a greater level of suppression 
to CPT compared to DMSO treated cells. This may have been due to a comparatively better 
growth advantage of these targets over others in CPT treated cells which might have 
dominated the total cell populations faster.  
 
 
5.3.2. CAND1, KEAP1, RNF146, PTEN, SCAF4, CUL3 loss offers growth 
advantage 
Other strong suppressors that were not specific to the cell background included the genes 
CAND1, KEAP1, RNF146, PTEN, CUL3 and SCAF4 (Figure 37, Figure 38 & Figure 39). gRNAs targeting 
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these genes were enriched in DMSO treated cells as well as CPT treated cells but showed a 
greater level of suppression in DMSO treated cells. This suggests that loss of these factors 
offers cells a growth advantage that is not changed by loss of WRN.  
 
KEAP1 (Kelch like ECH associated protein 1) is a substrate adaptor of the CUL3 (Cullin3) 
complex which is responsible for the degradation of nuclear factor erythroid 2-related factor 
(NRF2), a transcription factor that is responsible for the induction of cytoprotective proteins. 
NRF2 has been shown to enhance the survival of normal cells but also accumulates in and 
promotes survival of cancer cells335. It is possible that both gRNAs against CUL3 and KEAP1 
are enriched as a result of their effects on NRF2. CUL3 however, does bind other substrate 
adaptors and may therefore act through a different mechanism. Interestingly gRNAs targeting 
NRF2 (labelled as NFE2L2) are lost in all backgrounds and treatments compared to the day 14 
controls (Appendix Table 4 & Appendix Table 8). This fits the suggested mechanism by which 
KEAP1 and CUL3 loss, and subsequent stabilisation of NRF2 confers a growth advantage to 
cells. 
 
Cullin associated NEDD8 dissociated protein 1 (CAND1) is also linked to the regulation of 
Cullins, as it binds Cullins in their deneddylated state and promotes the assembly of the full 
complex which includes the substrate adaptors and receptors336. This has mainly been shown 
to be the case in the assembly of the SKP1-CUL1-FBox complex but CAND1 is thought to also 
promote the assembly of the other CRL complexes. This could mean that CAND1 loss 
functions in the same pathway as KEAP1 and CUL3 and results in increased NRF2 thus 
resulting in increased survival. Alternatively, CAND1 could also be involved through the 
regulation of a separate CRL complex and interestingly gRNAs targeting NEDD8 were also 
enriched in the WT samples. The lack of enrichment in other components of CRL complexes 
however, makes CUL3 the likely mode of function. 
 
PTEN gRNAs were also enriched in all samples and conditions compared to the day 14 control. 
PTEN is another well-known tumour suppressor gene that is involved in the regulation of a 
wide number of biological processes. PTEN inhibits AKT serine/threonine kinase 1 (AKT) 
through its phosphatase activity and thus inhibits the cell proliferative and anti-apoptotic 
functions of AKT337. PTEN, like p53, is one of the most frequently mutated or lost genes in 
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several cancers332,338. It is therefore not surprising that cells which lose PTEN are enriched in 
all endpoint samples compared to the earlier day 14 sample.    
 
RNF146 is a RING finger E3 ubiquitin ligase that can specifically bind PARP1 dependent poly 
ADP-ribosylated (PARsylated) proteins339. RNF146 ubiquitylates several PARsylated proteins 
involved in the DDR including XRCC1, PARP1, DNA Ligase III and Ku70339,340. RNF146 has also 
been shown to be a positive regulator of the Wnt signalling pathway and therefore may 
promote apoptosis341. Since RNF146 loss provides a growth advantage in both CTP and DMSO 
treated samples it is likely that the mechanism of resistance is through its effects on apoptosis 
rather than through regulation of DNA damage proteins.   
 
SCAF4 is an SR-like CTD-associated (splicing factor serine/arginine rich like carboxy terminal 
domain associated) factor with a largely undefined function, however it is structurally similar 
to SCAF8, and therefore is predicted to have a similar function181. SCAF8 binds to the CTD of 
the largest subunit of RNA polymerase II (RNA pol II), a region which is thought to act as the 
main regulatory site of RNA pol II mediated transcription. SCAF8 colocalises with sites of 
transcription and is predicted to have a role in splicing. The yeast paralog of SCAF4 and SCAF8 
is nrd1 which may be involved in RNA pol II termination and in the regulation of cryptic 
unstable transcripts (CUTs)342. CUTs are thought to play a role in the control of gene 
expression343. Based on the limited understanding of SCAF4’s function it is difficult to explain 
why SCAF4 loss might increase cell survival, but one hypothesis could be that it influences 
expression of genes involved in cell proliferation and apoptosis.    
 
 
5.3.3. Hits that suppress CPT sensitivity in a WT background 
Suppressors specific to the DNA damage treatment were identified by looking specifically at 
gRNAs enriched in the CPT treated samples. Interestingly guides against multiple subunits of 
RNA pol II were more enriched in the CPT treated samples compared to the DMSO treated 
samples. These included gRNAs targeting POLR2A, POLR2G, POLR2D and POLR2L. This 
suggests that loss of RNA pol II activity increased resistance of WT cells to CPT.  
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RNA pol II is responsible for the transcription of DNA into mRNA. CPT works by preventing the 
religation step of topoisomerase I (TOPI) activity, creating a ternary complex with TOP1 and 
nicked DNA. This primarily causes S-phase specific damage due to collisions of the replication 
machinery with DNA SSBs and subsequent generation of DSBs. Another cause of CPT toxicity 
is due to DSBs caused by the transcription machinery colliding with DNA nicks and ternary 
TOP1-DNA complexes23. RNA pol II loss resulted in a resistance to CPT which may most likely 
be due to a reduction in RNA pol II mediated transcription occurring and thus a reduction in 
the cytotoxic effects of the TOP1-DNA complexes. 
 
 
5.3.4. Suppressors of CPT sensitivity in WRN-/- background 
Multiple genes were identified as suppressors of CPT sensitivity in a WRN-/- specific 
background. These include: CHFR, EME2, MAPK14, PBRM1, SETD2, SMARCC1 and ZDHHC16. 
Of these, MAPK14 showed the greatest difference in enrichment in CPT treated compared to 
DMSO treated samples. The MAPK14 gene codes for one of four members of the p38 
mitogen-activated protein kinases (MAPKs), specifically p38a. The p38 MAPKs are collectively 
known as stress activated protein kinases344. p38a is involved in a variety of processes which 
perhaps most significantly include the regulation of apoptosis, cellular senescence and the 
cell cycle345,346. Interestingly, p38a seems to initiate the G2/M checkpoint after UV induced 
DNA damage as inhibition of p38a resulted in a loss of this checkpoint347. This however, does 
not explain the suppression of sensitivity to CPT, as one would expect that cells progressing 
into mitosis prematurely after suffering CPT induced DNA damage would die of mitotic 
catastrophe due to unrepaired DNA. Another role of p38a is in growth inhibition as a result 
of contact inhibition345. Conditions of the screen may have therefore given these cells a 
growth advantage as flasks may have been densely populated at certain times in the screen. 
Loss of contact inhibition would allow the cells to continue to grow whereas other cells in the 
population could not. Although p38a was identified as a suppressor specific to CPT treatment 
in a WRN-/- background, the diverse functions of the protein make it difficult to fully 
understand potential mechanisms behind it. Clearly, further research needs to be conducted 
to validate this target and identify its mechanism of suppression.      
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CHFR (Checkpoint with FHA and RING finger domains) is an E3 ubiquitin ligase whose targets 
include polo like kinase 1 (PLK1) and Aurora kinase A181. CHFR targets PLK1 and Aurora kinase 
A for degradation and thus prevents cells from entering into mitosis. CHFR therefore functions 
in the antephase checkpoint and delays entry into mitosis. Loss of CHFR should therefore 
promote mitotic entry of cells181,348. This seems counterintuitive to causing CPT resistance, as 
one would expect that delaying entry into mitosis and prolonging S and G2 phase, would 
enable cells more time to repair damaged DNA. One possible explanation is that these cells 
would initially divide faster and, if the level of DNA damage sustained is not significant enough 
to kill the cell, they would continue to grow at an accelerated rate. Another of CHFR’s targets 
is histone deacetylase 1 (HDAC1) which downregulates transcription349. CHFR ubiquitylates 
and downregulates HDAC1, and thus loss of CHFR would result in an increase in HDAC1 levels 
and subsequently a reduction in transcription. A reduction in transcription would increase 
resistance to CPT due to a reduction in DSBs caused by progression of the transcription 
machinery, as described earlier. 
 
SMARCC1 and PBRM1 both code for proteins which make up the SWI/SNF complex350. This 
complex is an ATP dependent chromatin remodelling complex351,352. Loss of ATP-dependent 
chromain remodeller SMARCA4 (BRG1), the main component of the SWI/SNF complex, has 
been linked to increased sensitivity to DSBs associated with replication fork collapse. The 
opposite effect was seen in a WRN-/- background which could suggest interplay between 
WRN and the SWI/SNF complex. WRN has been linked to heterochromatin organisation 
through its interaction with other heterochromatin proteins and the irregular nuclei often 
seen in WRN deficient cells. It is possible that WRN and the SWI/SNF complex together 
regulate chromatin remodelling in response to DNA damage and that loss of WRN destabilises 
this regulation. Loss of the SWI/SNF complex may therefore counterbalance the loss of WRN. 
 
Interestingly, the SWI-SNF complex has also been shown to be required for the recruitment 
of TOP1 to chromatin351,352. This could explain why loss of the complex increases resistance 
to CPT, as potentially less TOP1 becomes inhibited and bound to chromatin. This would ease 
the toxicity of CPT induced DNA damage from replication fork and transcription machinery 
collisions. This mechanism however should also apply to CPT sensitivity in a WT background; 
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whilst SMARCC1 and PBRM1 gRNAs are enriched in CPT treated samples, they are also 
enriched in DMSO treated samples to a similar extent (Appendix Table 4 & Appendix Table 5).       
 
EME2 (essential meiotic structure specific endonuclease subunit 2) forms a heterodimer with 
MUS81, a structure specific endonuclease that plays a role in DNA secondary structure 
resolution181. The MUS81-EME2 heterodimer seems to be important for replication fork 
restart and unlike the MUS81-EME1 heterodimer is not required for Holliday junction. MUS81 
depletion causes a decrease in the number of DSBs created after HU as does depletion of 
EME2. This is not the case for EME1 depletion 353. Potentially in a WRN-/- background, activity 
of MUS81-EME2 specifically, causes the generation of double strand breaks at sites of CPT 
induced replication stress and thus leads to cytotoxicity. This might suggest that WRN also 
acts to compete with and suppress inappropriate repair of collapsed replication forks by 
MUS81-EME2354. It would be interesting to investigate the potential interplay between 
MUS81 and WRN further and in particular tease out the differences in their roles in response 
to HU versus CPT. 
 
ZDHHC16 (zinc finger DHHC-type containing 16) is a palmitoyl acyltransferase that is involved 
in heart development and cardiac function as well as being linked to eye development181. 
Recently ZDHHC16 has been linked to the DDR as inhibition of palmitoylation, and specifically 
depletion of ZDHHC16, resulted in impaired activation of ATM355. The exact function and 
mechanisms of ZDHHC16 in the DDR are still unknown, but ZDHHC16 could potentially affect 
proteins that stimulate ATM activation or be involved in remodelling of chromatin. The 
interplay between ATM and ATR at sites of replication stress is an extremely important and 
tightly regulated process, timely ATM inactivation could potentially promote HR repair and 
an ATR dominant replication fork restart process29,40. Interestingly WS is associated with 
increased heart defects as well as premature cataracts; whether there is link between these 
phenotypes and the processes ZDHHC16 is involved in is unknown but could be an interesting 
area of research.     
 
SETD2 (SET domain containing 2) is a histone methyltransferase that is responsible for the 
trimethylation of Histone3 at K36 (H3K36me3)356. H3K36me3 is a marker of transcriptional 
activation but has also been linked to the promotion of HR via CtIP, RPA and RAD51 
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recruitment356. As discussed previously, inhibiting transcription reduces the effects of CPT due 
to a reduction in DSBs generated by collision with active transcription complexes and thus 
may explain the effect of SETD2 loss on CPT resistance. The link H3K36me3 has to HR however 
makes it is more complicated to explain a functional mechanism. One explanation could be 
that since loss of WRN results in the inability to restart collapsed replication forks efficiently 
or results in improper resolution of Holliday junctions; inhibiting HR and extensive resection 
therefore may allow cells to repair the damage by alternative methods such as 
microhomology-mediated end-joining (MMEJ).    
 
The next steps would be to validate these targets to see if they are indeed suppressors of CPT 
sensitivity and if they are indeed specific to a WRN-/- background. The best way to do this 
would be to perform survival assays in WT and WRN-/- cells with siRNA depletion of the 
potential suppressors. Once confirmed, experiments to investigate mechanisms can be 
pursued. This could be in the form of looking at kinetics at the replication fork by DNA fibre 
techniques or investigating recruitment of factors involved in HR such as RPA or RAD51.  
 
 
5.3.5. NBN1 as a dropout in WT cells 
The screen in WT cells did not reveal strong factors which dropout specifically in the CPT 
treated samples versus the DMSO treated. This may be due to the essentiality of genes 
involved in promoting HR357. gRNA read counts for these genes may therefore have already 
been low at the day 14 sample making identifying dropouts difficult. One potential dropout 
identified however, was NBN. NBN is the gene responsible for NBS1, a component of the MRN 
complex. Since the MRN complex is critical to the repair of DSBs by HR it is logical that loss of 
NBS1 and subsequently loss of the MRN complex causes increased sensitivity to a DNA 
damaging drug that induces S-phase specific damage which has to be repaired by HR. 
Interestingly NBN appears to be an essential gene and this might suggest that it somehow did 
not get eliminated after 14 days or could mean that the gRNAs targeting this gene did not 
efficiently eliminate the protein and led to a truncated protein or a protein with an in-frame 
indel with some retained functions.  
 
Chapter 5: Performing a CRISPR-Cas9 screen to investigate the role of WRN in the DDR 
 167 
 
5.3.6. Dropouts specific to WRN-/- background 
Screen results in WRN-/- cells showed a greater number of genes which were lost from the 
day 14 control in both CPT and DMSO treated samples. This might suggest WRN is synthetic 
lethal/sick with a number of genes or could suggest that the factors that gave WRN-/- cells a 
growth advantage took over sample populations and thus skewed results. The fact that a large 
number of factors were depleted from day 14 controls made it difficult to identify dropouts. 
Two genes which showed the greatest loss were NEDD8 and SOD1. Interestingly these genes 
were enriched in the WT cells and this therefore suggests that the loss of either of the two 
genes is particularly cytotoxic in a WRN knockout background. NEDD8 as previously discussed 
(3.1.2), is the protein which binds to and thus activates all Cullins. Due to the diversity of 
functions of Cullins it is difficult to speculate by which mechanism this synthetic 
lethality/sickness occurs. Out of the Cullins in the DDR library, only CUL1 and CUL9 showed a 
mild decrease from the day 14 control.  
 
SOD1 encodes for superoxide dismutase 1 (SOD1) whose main function is to convert 
superoxide radicals into less harmful substances. Most studies investigating SOD1 are based 
on its mutations which link it to amyotrophic lateral sclerosis, however there is some evidence 
that suggests it is linked to the DNA damage response and inhibition of apoptosis through 
p53358. Loss of SOD1 might therefore be as a result of induced apoptosis in response to a 
greater accumulation of DNA damage in WRN-/- cells compared to WT cells.   
 
gRNAs targeting the RAD51 paralogs XRCC2 and XRCC3, dropout in WRN-/- cells in both DMSO 
treated and CPT treated cells, although there seems to be a greater decrease in the DMSO 
treated samples. This suggest that there might be synthetic lethality/sickness between WRN 
and the RAD51 paralogs that occurs overtime in these cells. gRNAs against XRCC2 and XRCC3 
did not dropout to the same extent in WT cells, suggesting a specific lethality in WRN 
knockout cells only. Both these RAD51 paralogs form a complex with RAD51C, which is also a 
dropout in WRN-/- cells, but to a less significant extent. The RAD51 paralogs do not currently 
have robustly defined functions but are involved in the HR pathway and have been linked to 
the strand invasion process of RAD51 coated single stranded DNA into the sister chromatid52. 
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They have also been linked to DNA repair and maintenance of telomeres359. XRCC2 and XRCC3 
in particular have also been shown to prevent long tract gene conversions and WRN-/- XRCC3-
/- DT40 cells display an increased sensitivity to MMS compared to WRN-/- or XRCC3-/- DT40 
cells alone360,361. Since WRN has been shown to be involved in the resolution of D-loops one 
might hypothesise that the increased sensitivity in the double knockout is as a result of a 
greater length of D-loop at Holliday junction formed by HR. This enhanced length coupled 
with the inability to resolve the D loop may lead to cytotoxicity. Potentially BLM may help 
resolve these types of extended Holliday junctions in the absence of WRN as triple knockout 
(WRN-/-, XRCC3-/-, BLM-/-) DT40 cells show an even greater sensitivity to MMS361.  
 
This points to a function for WRN in the later stages of HR after resection in a manner 
dependent on RAD51 and RAD51 paralogs. Interestingly sensitivity of WRN cells to DNA 
damage has been shown to be suppressed by expression of a dominant negative form of 
RAD51362, which also implies a role for WRN in the later stages of HR. Again, further 
investigation of these genetic interactions will need to be carried out in order to validate the 
results of the screen.  
 
RPS27L was identified as a dropout in WRN-/- cells and showed a greater loss in CPT treated 
samples compared to DMSO treated samples. In addition, RPS27L did not show a loss in a WT 
background in either treatments. This suggests that the loss of RPS27L results in cell toxicity 
in WRN-/- cells which is enhanced by DNA damage with CPT. RPS27L encodes for a ribosomal 
protein with similarity to the ribosomal protein S27 (RPS27), hence the name ribosomal 
protein S27-like protein (RPS27L)181. RPS27L has been shown to be involved in the DDR 
through direct interaction with p53363,364. The exact function or RPS27L with respect to DNA 
damage is unclear, however one report suggests that RPS27L disruption leads to p53 
activation365. Loss of RPS27L may therefore result in cell death following DNA damage as a 
result of increased p53 activity. Having said this, loss of RPS27L did not seem to have the same 
effect in WT cells and therefore could suggest functional overlap/interactions with WRN. 
Interestingly, an interaction between WRN and p53 has also been shown to exist281,366,367. 
This could suggest that RPS27L and WRN both have functions that maintain genome stability 
by coordinating the DDR through interactions with p53. Loss of RPS27L in addition to loss of 
WRN may result in genome instability that may result in apoptosis or senescence of cells. The 
Chapter 5: Performing a CRISPR-Cas9 screen to investigate the role of WRN in the DDR 
 169 
interplay between senescence and apoptosis by p53 could be governed by RPS27L and WRN. 
It would be interesting to explore these potential functional interactions further in both p53 
proficient and p53 null backgrounds.  
 
 
5.3.7. Limitations in the screening process 
One of the main advantages of performing the CRISPR screen with a DDR focused library was 
that the number of cells required were much more manageable than if the screen had been 
performed with the same level of representation using a whole genome library. This did 
however create some complications when analysing the data as it is difficult to define cut-
offs of significance. Since all the guides apart from the non-targeting guides in the library 
targeted DDR genes, it makes it difficult to identify real hits from false positive hits as they 
can perhaps all be justified in some way or another as to why they might increase or decrease 
sensitivity. The DDR library could therefore be improved by incorporating some control gRNAs 
that still target genes, but simply genes which are not linked to the DDR and therefore are 
unlikely to influence cell survival after DNA damage. This would make it easier to set cut-offs 
and focus on the true hits. A new human DDR library incorporating these features has since 
recently been generated by the Steve Jackson Lab. 
 
The strongest hit in all screens was TP53. Although this is explainable and is evidence of the 
screen working properly, it does potentially mask the enrichment of other genes due to these 
cells dominating the total cell population. Performing the screen in a p53 null background 
therefore would enhance the detection of other factors that suppress CPT sensitivity.  
 
 
5.3.8. Concluding remarks 
Generating a WRN knockout in human primary cells has allowed me to research into WRN 
function in a novel way. Utilising the cell lines, sensitivity to the DNA damaging drug CPT was 
established and a screen set-up in the search for suppressors of sensitivity. This has identified 
potential suppressors of CPT sensitivity in WRN-/- cells and also suppressors of WRN-/- cell 
toxicity in undamaged cells. Continued investigation can be pursued by interrogating the data 
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further as well as validating potential targets by methods discussed earlier. This would allow 
insights into the specific function of WRN in response to DNA damage.  
 
Research can be continued by defining other sensitivities in the WRN knockout cells 
generated and performing further screens with different DNA damaging agents or even with 
drugs which stabilise DNA secondary structures that might be potential substrates of WRN.  
 
Serially passaging WRN knockout cells and looking for accumulation of mutational signatures 
over time may allow me to gain insights into why WS patients might show premature ageing 
phenotypes and why they have a higher predisposition to cancers. Again, interrogating this 
data by cross-referencing it with other data such as with replication origins, highly transcribed 
regions or regions of high DNA secondary structure might establish a greater understanding 
of WRN function.  
 
Altogether I believe that the work shown here offers a good foundation for further 
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6. Final Discussion 
 
The main aim of the work described in this thesis was to investigate the regulation of NHEJ 
through Ku interacting factors. This has been performed by looking at three factors which 
have been shown here or elsewhere to be interactors of Ku. 
 
The first part of this thesis investigated the protein WDR76. WDR76 was shown to be a Ku 
interacting factor and whilst its precise function was not identified, it clearly plays a part in 
the DDR. This was strongly evidenced by the increased sensitivity of WDR76 knockout cells to 
IR. Depletion of WDR76 resulted in an increased persistence of Ku on chromatin, suggesting 
a role of WDR76 in the removal of Ku following DNA damage. Whether this is due to WDR76 
mediated ubiquitylation of Ku itself or other proteins remains to be determined.  
 
Ubiquitylation of Ku has been implicated in its removal from DNA in a number of 
publications138–140,169,368. Most recently, the E3 ligase RNF126 was shown to be involved in the 
ubiquitylation of Ku80, and depletion of RNF126 resulted in persistence of Ku on chromatin368. 
In addition, RNF8 has also been shown to promote Ku80 ubiquitylation and removal with 
RNF8 depletion also resulting in a persistence of Ku at damage sites 139. Interestingly, Ismail 
et al.140 confirmed the ability of RNF8 to ubiquitylate Ku80, however they showed that this 
ability is restricted to G1. Ismail et al. also describe a mechanism whereby RNF138 
ubiquitylates Ku80 to facilitate its removal prior to NHEJ initiation to promote HR140. This work 
demonstrates that ubiquitylation of Ku is a complex process that can affect the regulation of 
NHEJ in many scenarios, likely depending on the location, timing, and type of ubiquitylation 
on Ku. WDR76 can therefore be another factor that regulates NHEJ through Ku. WDR76 may 
also be involved in the ubiquitylation of Ku70 specifically, as opposed to the majority of 
publications describing Ku80 ubiquitylation138–140,368.  
 
My continued research into WDR76 highlighted other potential roles of WDR76 in the DDR. 
Further investigation to identify the specific substrate(s) of WDR76 and the residues it 
ubiquitylates will help define its precise role in the DDR.   
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The second part of my work described in this thesis showed that PAXX is phosphorylated on 
S148 in human cell lines. Whilst S148 was initially identified as a potential CDK 
phosphorylation site through sequence analysis, my data raises the possibility of other 
kinases mediating this phosphorylation.  The proximity of this phosphorylation site to the Ku 
binding domain of PAXX raises the possibility of this site being involved in the regulation of 
NHEJ by modulating the PAXX-Ku interaction. Interestingly, the lysine residue at position 151 
(K151) is also conserved, encouraging the potential for an additional level of regulation at this 
site, perhaps by ubiquitylation. The functional relevance of S148 phosphorylation however 
remains to be defined, and further work is needed to explore the significance of this 
modification.  
 
In the last part of my research, WRN knockouts were generated by CRISPR-Cas9 in RPE-1 cells 
to use as tools for investigating WRN function. The sensitivity of the knockout to CPT was 
determined and the data I generated were consistent with previous reports of CPT sensitivity 
seen in WS cells. Despite the knowledge of CPT sensitivity, the mechanism by which WRN loss 
creates sensitivity is still unclear. A CRISPR-Cas9 based genetic screen was performed to look 
for suppressors and dropouts in order to gain insights into the function of WRN. 
 
WRN-/- hypersensitivity to CPT has been shown to be suppressed by loss of Ku70 in chicken 
DT40 cells369, which raised the possibility of gRNAs targeting factors promoting NHEJ being 
enriched in my screen. Ku is essential in humans cells in culture, so unsurprisingly it did not 
come out as a suppressor of WRN-/- CPT sensitivity in my screen; nevertheless, neither did 
any other factors that positively regulate NHEJ, despite them not being essential for cell 
viability in WT cells. This might suggest that WRN does not have a role in downregulating NHEJ 
during S-phase or is redundant with other mechanisms that downregulate NHEJ; perhaps its 
roles in NHEJ are not significant with respect to CPT induced damage. 
 
The increased CPT sensitivity of WRN-/- cells compared to WT cells reinforces the conclusion 
that WRN has a role(s) in HR. Many of the suppressors identified were targets that promote 
transcription, and therefore may be a reflection of the CPT induced DNA damage treatment 
rather than the genetic background. Despite this, the dropouts specific to a WRN-/- 
background, XRCC2 and XRCC3, may imply a role of WRN in the later processes of HR, 
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downstream of DNA resection and at the level of RAD51 loading/recombination. Suppressors 
and dropouts identified in the screen will need to be validated and further experiments 
pursued (as described in section 5.3) in order to help understand the exact mechanisms by 
which WRN promotes DNA repair. Once generated, sequence analysis data from the 
mutational signatures aspect of my research may also yield novel insights into the functions 
of WRN in the maintenance of genome stability.     
 
In summary this thesis has identified some potential regulatory mechanisms of NHEJ, and has 
offered insights into the functions and regulation of the Ku interactors: WDR76, PAXX and 
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Appendix Table 1 List of primers used 
 























































Appendix Table 2 Sequences of gRNAs used 
 
gRNA ID Description Sequence 
gRNA25 WDR76 knockout forward TGTTGATGTGGAAAGTAGTC 
gRNA26 WDR76 knockout reverse CATCGCATCTGCCGTTCTCT 
WRN gRNA1 WRN knockout forward GTTCTACCGTGCCACTATTG 
WRN gRNA2 WRN knockout reverse TTAAAAATGGAAAGAAATCT 
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Appendix Table 3 List of antibodies used  
All antibodies were diluted in 5% Milk in TBST. 
 
Antibody Dilution Species Supplier Catalog 
number 
GFP 1:2000 Mouse Roche 11814460001 
Ku80 1:2000 Mouse Fischer Scientific 
worldwide 
MS-285-P1 
Ku70 1:400 Mouse Abcam ab3114 
DDB1  Goat Abcam ab9194 
CUL4A 1:20000 Rabbit Abcam ab92554 
XRCC4 1:3000 Rabbit Abcam ab145 
XLF 1:500 Rabbit Abcam ab33499 𝛾H2AX 1:1000 Mouse Merck-Millipore 05-636 
GAPDH 1:30000 Mouse Millipore MAB374 
WDR76 1:250 Rabbit Atlas HPA039804 
ATM 1:5000 Rabbit Abcam ab32420 
Cyclin A 1:5000 Rabbit Santa Cruz Biotechnology sc-751 
Histone H3 1:500 Rabbit Abcam ab1791 
CDT1 1:1000 Rabbit Abcam ab70829 
pH3 ser10 1:5000 Mouse Abcam ab14955 
FK2 1:1000 Mouse Enzo Life Sciences BML-PW8810 
pATM S1981 1:1000 Rabbit Epitomics 2152-1 
H2AX 1:5000 Rabbit Abcam ab11175 
pPAXX S148 1:200 Rabbit Peptide1510021 1510021 
PAXX 1:100 Goat Abcam ab126353 
KAP1 1:5000 Rabbit Abcam ab10483 𝛽-actin 1:5000 Mouse Abcam ab8226 
MPM2 1:500 Mouse Millipore 05-368 
WRN 1:1000 Mouse Abcam ab66601 
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Anti-Goat IgG-HRP Secondary 1:10000 Donkey Santa Cruz Biotechnology sc-2020 
Anti-Mouse IgG-HRP 
Secondary 
1:10000 Donkey Santa Cruz Biotechnology sc-2314 
Anti-Rabbit IgG-HRP 
Secondary 
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Appendix Table 4 Raw data from JACKS analysis of RPE-1 WT 2nM CPT treated  
RPE-1 WT – DMSO and 2nM CPT treated enrichments compared to the day 14 control. fdr=false discovery 
rate. 
 
Gene Enrichment in DMSO neg_fdr1 pos_fdr1 Enrichment in 2nM 
CPT 
neg_fdr2 pos_fdr2 Difference in 
Enrichment 
TP53 3.478343858 1 7.03E-10 5.147071467 1 0 1.668727609 
RNF146 3.342174495 1 1.14E-08 2.8817172 1 4.63E-07 -0.460457294 
CDKN1A 1.548402497 1 0.006661002 2.376541374 1 1.45529E-04 0.828138878 
CAND1 3.251324882 1 9.85E-09 2.365157013 1 2.27E-05 -0.886167869 
KEAP1 2.483000039 1 2.16E-05 2.280486616 1 5.60E-05 -0.202513423 
PTEN 2.989153557 1 6.03E-08 2.262925838 1 5.59E-05 -0.726227719 
NEDD8 1.316840385 0.997608314 0.052826231 1.812477712 0.997608314 0.012511861 0.495637327 
H2AFZ 1.807149541 1 0.001542282 1.785069837 1 0.001542282 -0.022079704 
RNF7 1.992484214 1 8.41E-05 1.774221477 1 3.96237E-04 -0.218262737 
TINF2 1.100595288 0.999707723 0.033739 1.737620654 0.999707723 0.002630496 0.637025365 
UBE2F 2.157784094 1 1.41307E-04 1.723118723 1 0.001928239 -0.43466537 
NHP2 1.38567457 0.999210651 0.017170615 1.716903398 0.999210651 0.007104141 0.331228828 
UBC 1.078420637 0.999658144 0.051744941 1.650039221 0.999658144 0.003275532 0.571618585 
SCAF4 2.027124007 1 1.12026E-04 1.645565814 1 0.00093256 -0.381558193 
ARID2 1.568928223 1 0.002943369 1.624229057 1 0.002943369 0.055300834 
BRD7 1.222877703 1 0.02120377 1.617141085 1 0.010066749 0.394263382 
DCUN1D3 1.710527193 1 0.00108847 1.603044843 1 0.002242041 -0.107482351 
POLR2A 0.844985861 0.999743729 0.089551101 1.596495305 0.999743729 0.001625139 0.751509443 
SOD1 0.795714541 0.995957182 0.297691842 1.592816233 0.995957182 0.03638536 0.797101691 
THOC2 0.897782531 0.99942868 0.091272149 1.573142302 0.99942868 0.004594557 0.675359772 
RPS27L 0.730379459 0.994490993 0.325118111 1.565018071 0.994490993 0.04729164 0.834638612 
USP28 1.501057011 1 0.001295878 1.554639146 1 0.001113677 0.053582135 
XRCC6 1.420821193 0.996425727 0.017788114 1.526103333 0.996425727 0.017788114 0.10528214 
POLR2D 0.904087783 0.998352112 0.086472326 1.497041302 0.998352112 0.014830995 0.592953519 
UPF1 1.123865534 0.99939939 0.019163465 1.483303992 0.99939939 0.003314716 0.359438458 
HNRNPK 1.151021266 0.998457502 0.034694387 1.479347922 0.998457502 0.010137349 0.328326656 
UBE2D3 0.74016914 0.996663275 0.319471661 1.476491438 0.996663275 0.026958571 0.736322298 
POLR2E 1.219824327 0.999348419 0.037929435 1.474218168 0.999348419 0.013286426 0.25439384 
BABAM1 1.274140118 1 0.0052029 1.461341137 1 0.002744091 0.187201019 
POLR2G 1.040481506 0.998702537 0.047424725 1.453004293 0.998702537 0.008032543 0.412522788 
CHEK2 1.061693034 1 0.018781658 1.446294455 1 0.003834671 0.38460142 
CCNH 0.994625196 0.998363641 0.064727007 1.443935545 0.998363641 0.014727233 0.449310348 
VCP 1.21433551 0.999408308 0.01031894 1.436229522 0.999408308 0.003025065 0.221894012 
FANCD2 0.768656194 0.998603983 0.173537091 1.392286169 0.998603983 0.009756588 0.623629975 
SUPT5H 1.246177214 0.999366891 0.00543512 1.390878121 0.999366891 0.003472975 0.144700906 
MDM2 0.709913641 0.999296181 0.079859685 1.378700445 0.999296181 0.004918483 0.668786804 
NPM1 0.877513543 0.987281768 0.202109067 1.367397953 0.987281768 0.114464086 0.489884411 
PARG 1.224402373 0.995565538 0.042044953 1.346138689 0.995565538 0.03872594 0.121736316 
MASTL 0.883977082 0.997129735 0.081320799 1.335632111 0.997129735 0.016672547 0.451655028 
CCND1 0.823227575 0.996336636 0.12009587 1.335270642 0.996336636 0.027245401 0.512043067 
RRM1 0.820813157 0.994380199 0.17057678 1.324012755 0.994380199 0.026712064 0.503199598 
PPP4C 0.609274956 0.995421926 0.347698274 1.314252945 0.995421926 0.021822068 0.704977989 
COPS4 0.927344964 0.996519824 0.081713373 1.301229451 0.996519824 0.025235778 0.373884487 
PPP4R2 0.861925299 0.992153067 0.150266243 1.298020327 0.992153067 0.0706224 0.436095028 
TICRR 0.780954623 0.998537571 0.104551121 1.296869578 0.998537571 0.013161865 0.515914955 
TRIP13 1.067703935 0.996766587 0.066606999 1.290225504 0.996766587 0.020665527 0.222521569 
CDK4 0.866901776 0.994950855 0.125128634 1.285271644 0.994950855 0.045442305 0.418369868 
H2AFX 0.944368353 0.998598322 0.040684137 1.278443754 0.998598322 0.009308027 0.334075401 
SMC4 1.019371979 0.997535657 0.029737842 1.27160191 0.997535657 0.022179091 0.252229931 
POLR2I 1.161224126 0.999089699 0.013897347 1.27097241 0.999089699 0.006941804 0.109748284 
SMC1A 1.051782928 0.992995034 0.063262757 1.26811206 0.992995034 0.063044692 0.216329132 
DKC1 0.83340222 0.996300223 0.126259375 1.268096083 0.996300223 0.033297997 0.434693863 
WAPL 1.22277863 0.991839751 0.028081849 1.262117555 0.991839751 0.028081849 0.039338925 
SMC2 1.180896449 0.99918801 0.008957961 1.260094844 0.99918801 0.005367751 0.079198395 
PCNA 0.638126227 0.996830336 0.244456705 1.257174987 0.996830336 0.015933777 0.619048761 
UBE2I 1.001190375 0.996570528 0.060585709 1.250888446 0.996570528 0.023703545 0.249698072 
GPS1 0.596238841 0.991719994 0.35462115 1.24984891 0.991719994 0.07316407 0.653610069 
CUL3 2.544711008 1 5.87E-08 1.249203857 1 0.011268217 -1.295507151 
RAD21 0.793491497 0.992826602 0.169308031 1.243742132 0.992826602 0.063919118 0.450250635 
COPS6 0.812914627 0.995788736 0.12361223 1.228463324 0.995788736 0.037901373 0.415548697 
USP7 0.630685863 0.997173314 0.210344337 1.224209893 0.997173314 0.025440178 0.59352403 
PLK1 0.719615666 0.998089148 0.117179068 1.223724497 0.998089148 0.014438922 0.504108831 
ASCC1 1.277043384 0.999128493 0.00594499 1.222664549 0.999128493 0.008071274 -0.054378835 
STAG2 1.526033493 0.999999998 0.003144522 1.202067732 0.999999998 0.016716466 -0.323965761 
SFPQ 1.159703742 0.997777455 0.014166462 1.201488627 0.997777455 0.014166462 0.041784886 
CUL5 1.497920684 1 0.00186744 1.176298984 1 0.009052039 -0.3216217 
ATR 0.954095586 0.99380791 0.074905632 1.170592214 0.99380791 0.055728814 0.216496628 
ERCC6L 1.09147551 0.995790705 0.024750777 1.166766388 0.995790705 0.024750777 0.075290878 
SMC5 0.633037318 0.99410568 0.265722904 1.165491358 0.99410568 0.053048884 0.53245404 
MDM4 0.869317978 0.999708607 0.027373616 1.163158198 0.999708607 0.005709912 0.29384022 
POLR2H 0.815835883 0.997758477 0.068571978 1.155606006 0.997758477 0.020173711 0.339770123 
PNN 0.834358345 0.997902515 0.044707643 1.140491177 0.997902515 0.012646814 0.306132832 
TERF2 0.731185088 0.977439919 0.275266616 1.134441037 0.977439919 0.116369333 0.40325595 
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POLD3 0.750650972 0.999843055 0.023063205 1.133748119 0.999843055 0.005585801 0.383097148 
APEX2 0.499736041 0.993601958 0.427304879 1.132355275 0.993601958 0.045902673 0.632619234 
USP37 0.651572418 0.993616294 0.19983209 1.13051416 0.993616294 0.042914486 0.478941742 
TEP1 0.934910019 0.9949726 0.039248942 1.12147119 0.9949726 0.039248942 0.186561172 
DCLRE1B 0.69692639 0.987281035 0.235747477 1.113693131 0.987281035 0.063407231 0.416766741 
CHAF1A 0.873093909 0.995065372 0.06059186 1.1107891 0.995065372 0.035416204 0.237695191 
POLR2L 0.678906203 0.987939077 0.225688715 1.109801638 0.987939077 0.084695833 0.430895435 
POLA1 0.902565703 0.992727618 0.06890491 1.104647162 0.992727618 0.065451436 0.202081459 
USP5 0.647932938 0.993647465 0.192219458 1.103328188 0.993647465 0.031033385 0.455395249 
RUVBL1 0.683546411 0.990871965 0.212939865 1.097113419 0.990871965 0.082152319 0.413567009 
UBE2T 0.732915298 0.982067098 0.269670205 1.096963692 0.982067098 0.104776972 0.364048394 
TOP1 0.794316168 0.995683636 0.098703312 1.094202873 0.995683636 0.026655039 0.299886705 
MAPK8 0.987010362 0.999525364 0.041435367 1.081846805 0.999525364 0.041435367 0.094836442 
RPAIN 0.660322488 0.993352226 0.180150532 1.076282899 0.993352226 0.031759254 0.41596041 
DNAJC2 0.64827602 0.994253356 0.253706572 1.073528365 0.994253356 0.060616228 0.425252345 
TTI2 0.448339822 0.98798189 0.494958822 1.072509602 0.98798189 0.057028021 0.62416978 
UBA3 1.080529152 0.994051665 0.028282293 1.063243401 0.994051665 0.028282293 -0.017285751 
CHD3 0.995587622 0.991912216 0.028208578 1.056403021 0.991912216 0.028208578 0.0608154 
TP53BP1 1.164112135 1 0.019079977 1.054676479 1 0.022022593 -0.109435656 
APAF1 0.9340822 0.999769105 0.045435651 1.050455264 0.999769105 0.039783768 0.116373064 
NCAPD2 0.835052204 0.993107623 0.091277018 1.047960492 0.993107623 0.062031394 0.212908288 
POLL 1.023597645 0.995018218 0.033412652 1.047835562 0.995018218 0.033412652 0.024237917 
BRCA2 0.692271982 0.996405184 0.056377273 1.045421976 0.996405184 0.016202843 0.353149994 
SMG1 0.778542329 0.987292224 0.1227647 1.041164829 0.987292224 0.067803378 0.2626225 
HDAC3 0.367283077 0.973752172 0.721775953 1.03407496 0.973752172 0.185745615 0.666791883 
BRE 1.202639487 0.999999447 0.016665748 1.03378383 0.999999447 0.031759935 -0.168855657 
PPP4R3B 0.917753086 0.993541008 0.043391854 1.026217236 0.993541008 0.038987578 0.10846415 
SENP8 1.397902065 1 0.018598027 1.021660563 1 0.071898413 -0.376241502 
ASF1A 1.004582547 0.992322994 0.034672897 1.016567014 0.992322994 0.034672897 0.011984467 
THRAP3 0.993672044 1 0.049885242 1.009470709 1 0.049885242 0.015798665 
KAT8 0.313370111 0.971895592 0.732243619 1.003058995 0.983369007 0.149678934 0.689688884 
SCAF11 0.893994862 0.986336654 0.065113885 0.99912987 0.986336654 0.065113885 0.105135008 
APC 0.950329669 1 0.018941734 0.99843253 1 0.018941734 0.04810286 
TONSL 0.65221681 0.984422249 0.217480272 0.994617799 0.984422249 0.100426795 0.342400989 
POLE2 0.627275302 0.995019808 0.177439228 0.994443602 0.995019808 0.047078383 0.3671683 
CHEK1 0.571655384 0.980397889 0.380679277 0.991814227 0.980397889 0.117866344 0.420158843 
XAB2 0.57591632 0.992620544 0.216069106 0.985814455 0.992620544 0.047838964 0.409898135 
NCAPD3 0.466598138 0.985103036 0.277419456 0.979018278 0.985103036 0.070961265 0.51242014 
SUPT4H1 0.701185205 0.980619787 0.277921111 0.973487398 0.980619787 0.137983536 0.272302193 
HDAC9 1.004834047 0.999999739 0.031717342 0.969455487 0.999999739 0.031717342 -0.03537856 
NonTargetingC
ontrolGene_77 
1.053700789 0.99999303 0.044109855 0.968743708 0.99999303 0.046400078 -0.08495708 
MAPKAPK2 1.052642319 1 0.033510011 0.968173121 1 0.043107646 -0.084469198 
RUVBL2 0.488938307 0.995203032 0.311492839 0.965287131 0.995203032 0.035371872 0.476348824 
RBX1 0.939828133 0.98131896 0.097311233 0.961247747 0.98131896 0.097311233 0.021419614 
XRCC5 0.678004709 0.986959415 0.107422336 0.960492843 0.986959415 0.073694186 0.282488135 
CDK9 0.647511273 0.974297575 0.326920002 0.950730783 0.974297575 0.190145135 0.30321951 
GTF2H1 0.765687306 0.985989059 0.114474111 0.950198189 0.985989059 0.090181841 0.184510883 
DCLRE1A 1.055831103 0.999578127 0.037537926 0.942722577 0.999578127 0.037537926 -0.113108526 
POLR2K 0.553599397 0.950612481 0.466559829 0.940169905 0.950612481 0.444487672 0.386570508 
RNF126 0.729115717 0.98261248 0.109412227 0.938872003 0.98261248 0.083640997 0.209756286 
UBE2W 0.876941483 0.991327705 0.029246599 0.937995468 0.991327705 0.029246599 0.061053985 
MTA2 0.966456629 0.999859602 0.040785377 0.935385156 0.999859602 0.040785377 -0.031071473 
BCLAF1 0.931145382 1 0.096179445 0.934032771 1 0.096179445 0.002887389 
BCCIP 0.444198368 0.971715887 0.516373643 0.926439007 0.971715887 0.145883047 0.482240638 
SMARCB1 0.37323629 0.958125566 0.727687149 0.926300262 0.958125566 0.376869904 0.553063973 
EP300 0.972588809 1 0.040019774 0.919751529 1 0.040019774 -0.05283728 
PHIP 1.190806885 1 0.018075463 0.916246583 1 0.037564294 -0.274560302 
ACD 0.61831279 0.982712271 0.265566728 0.907540729 0.982712271 0.126892223 0.28922794 
POLD1 0.665823754 0.975782143 0.189344575 0.907308826 0.975782143 0.120412834 0.241485072 
DNA2 0.483948473 0.973856355 0.488303297 0.903913057 0.973856355 0.160991679 0.419964584 
SPTBN1 0.886349276 1 0.039491377 0.899216561 1 0.039491377 0.012867285 
TAF1 0.559692212 0.960873048 0.35466535 0.893400403 0.960873048 0.352142565 0.333708191 
SPRTN 0.720521563 0.991903735 0.092452466 0.89119599 0.991903735 0.043053879 0.170674427 
UBA2 0.394634327 0.971728077 0.574803006 0.888609157 0.971728077 0.25444731 0.493974829 
PPM1D 0.356217552 0.978428922 0.656240543 0.881960648 0.978428922 0.097824862 0.525743097 
MMS22L 0.443912075 0.993358946 0.316429493 0.877973182 0.993358946 0.059769482 0.434061107 
DTX4 0.768386081 0.999941958 0.048127349 0.87394936 0.999941958 0.039358656 0.10556328 
COPS3 0.644020139 0.988603626 0.215172887 0.871858795 0.988603626 0.1339793 0.227838656 
PCID2 0.448915706 0.967975412 0.478618712 0.870158424 0.967975412 0.153627593 0.421242718 
GAR1 0.607701084 0.971597461 0.245209734 0.857451133 0.971597461 0.139906761 0.249750049 
RAD51 0.346951985 0.961409067 0.70174548 0.856107413 0.961409067 0.237484521 0.509155428 
ERCC3 0.259299845 0.90174041 0.895939043 0.853554863 0.951370037 0.387855137 0.594255018 
SF3B1 0.396857231 0.985254946 0.167453355 0.850707806 0.985254946 0.055963987 0.453850575 
PRPF19 0.368630712 0.975059426 0.572795487 0.850436497 0.975059426 0.163494597 0.481805785 
TET2 0.961352491 0.999998163 0.053624086 0.848471352 0.999998163 0.056909985 -0.112881138 
RPA1 0.442165533 0.95627332 0.541128882 0.844467171 0.95627332 0.225500397 0.402301638 
CCND3 0.780095793 0.99943543 0.03918954 0.839555006 0.99943543 0.035744217 0.059459213 
UCHL3 0.734197915 0.990060866 0.101431848 0.839358628 0.990060866 0.101431848 0.105160714 
NCAPH2 0.319972736 0.958320243 0.757017051 0.836749467 0.958320243 0.375117812 0.516776731 
COPS8 0.535714299 0.942254364 0.547492294 0.83530871 0.942254364 0.355310586 0.299594411 
NonTargetingC
ontrolGene_27 
0.606066621 0.99983586 0.147679814 0.834837094 0.99983586 0.071219003 0.228770473 
PNKP 0.6016236 0.986698291 0.237818407 0.831435941 0.986698291 0.10674828 0.229812341 
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DAXX 0.457122673 0.973070034 0.417385363 0.827398984 0.973070034 0.125803507 0.370276311 
NCAPG2 0.353751211 0.964674732 0.648837051 0.823715714 0.964674732 0.248514921 0.469964503 
HUWE1 0.334594436 0.973696627 0.616699647 0.817591211 0.973696627 0.236730356 0.482996775 
UBA1 0.473635204 0.978447394 0.374095522 0.817093032 0.978447394 0.109264778 0.343457828 
DDX11 0.940904613 0.977610396 0.148517407 0.813717107 0.977610396 0.148517407 -0.127187505 
L3MBTL1 0.854595326 0.999081574 0.034925472 0.80787945 0.999081574 0.038363016 -0.046715876 
ACTL6A 0.358286421 0.970335202 0.609068499 0.807417912 0.970335202 0.221222324 0.449131491 
GADD45G 0.767118456 0.999993748 0.109459973 0.807414798 0.999993748 0.109459973 0.040296343 
SUPT6H 0.474132851 0.974460321 0.366703068 0.79248361 0.974460321 0.229857111 0.318350758 
ABL1 0.672014131 0.999996573 0.098284978 0.791247889 0.999996573 0.087390741 0.119233758 
WEE1 0.600200634 0.971297942 0.233526736 0.790030705 0.971297942 0.233526736 0.189830071 
ALKBH2 0.746975538 0.987312972 0.123447394 0.786951639 0.987312972 0.123447394 0.039976101 
XRCC2 0.467780347 0.962583472 0.408856284 0.785919281 0.962583472 0.336748755 0.318138935 
GTF2H3 0.252724093 0.928549406 0.83338472 0.776053402 0.95911275 0.292084438 0.523329309 
RFC2 0.468266061 0.937529267 0.519520376 0.763744928 0.937529267 0.394048838 0.295478867 
FANCI 0.451293692 0.938329569 0.525008094 0.763430898 0.938329569 0.347230403 0.312137205 
SSBP3 0.869913407 0.993437983 0.124852644 0.755743977 0.993437983 0.124852644 -0.11416943 
STN1 0.385883857 0.96521081 0.525693718 0.753858085 0.96521081 0.177040794 0.367974228 
EYA1 0.760901764 0.990056724 0.085153923 0.751386126 0.990056724 0.085153923 -0.009515637 
POLR2F 0.430626457 0.963045892 0.427068794 0.749887627 0.963045892 0.305987292 0.319261171 
BRCA1 0.550838477 0.955113721 0.283203934 0.748118653 0.955113721 0.262227722 0.197280176 
RPA3 0.334188058 0.948213769 0.69465913 0.745662903 0.948213769 0.251679352 0.411474845 
CSNK1D 0.582612508 0.998727585 0.105453163 0.744974884 0.998727585 0.105453163 0.162362376 
THOC1 0.376679817 0.977654268 0.511834518 0.737540124 0.977654268 0.158664095 0.360860307 
MNAT1 0.326048196 0.937788527 0.811826771 0.733528547 0.953900783 0.37848029 0.407480351 
GTF2H4 0.447515912 0.960760387 0.388348798 0.73321825 0.960760387 0.223851421 0.285702338 
BRCC3 1.10574645 0.99999999 0.063021436 0.732261474 0.99999999 0.129582776 -0.373484975 
NOP10 0.280743976 0.943532357 0.798424501 0.731713087 0.972454592 0.234961302 0.450969111 
COPS2 0.568854641 0.972442529 0.21942953 0.730050177 0.972442529 0.21942953 0.161195536 
ATMIN 0.504352778 0.945798935 0.407700882 0.729387177 0.945798935 0.392876994 0.225034399 
SERBP1 0.531703972 0.936111565 0.358438756 0.719040141 0.936111565 0.358438756 0.18733617 
SMARCE1 0.656105281 0.953730866 0.239854599 0.71802606 0.953730866 0.239854599 0.06192078 
SCAF8 0.490131615 0.997827855 0.175836763 0.715460582 0.997827855 0.162676815 0.225328967 
MTOR 0.367836152 0.97405185 0.483736938 0.712015585 0.97405185 0.233533351 0.344179434 
POLR2J 0.718039456 0.996488758 0.151021882 0.711130105 0.996488758 0.151021882 -0.006909352 
OR1E1 0.493094137 0.985974094 0.248132441 0.703764693 0.985974094 0.248132441 0.210670556 
GTF2H2 0.825960389 0.983875327 0.298260716 0.703362831 0.983875327 0.298260716 -0.122597559 
POLM 0.707251649 0.999967463 0.066705271 0.703353604 0.999967463 0.066705271 -0.003898045 
PMS2 0.67722614 0.962221154 0.15340566 0.694324152 0.962221154 0.15340566 0.017098012 
CSNK2A2 0.50986497 0.999868116 0.163497721 0.693841516 0.999868116 0.122707864 0.183976546 
RAD54L2 0.528436525 0.99939853 0.175195409 0.691670814 0.99939853 0.162887868 0.163234289 
YBX1 0.13271515 0.743065398 0.999992389 0.69050688 0.840390641 0.795249761 0.55779173 
NSMCE1 0.187589796 0.867557448 0.975699288 0.689956778 0.955246461 0.204691963 0.502366982 
PRMT1 0.376784763 0.954860129 0.508823395 0.689413228 0.954860129 0.304772787 0.312628466 
CCNB3 0.717691187 0.999788155 0.076506761 0.68796922 0.999788155 0.078724611 -0.029721968 
ECT2 0.514413137 0.945441559 0.314002487 0.683651823 0.945441559 0.278317049 0.169238686 
PMP22 0.633250013 0.999994455 0.152606457 0.683306967 0.999994455 0.152606457 0.050056954 
MCRS1 0.579872089 0.962567628 0.238472544 0.681185755 0.962567628 0.237193944 0.101313666 
RECQL 0.870503241 0.991266977 0.106949165 0.675834637 0.991266977 0.149410788 -0.194668604 
RAD1 0.323759743 0.901107482 0.81722643 0.672641228 0.901107482 0.447352348 0.348881485 
NonTargetingC
ontrolGene_19 
0.462116891 0.998943602 0.209028753 0.671242646 0.998943602 0.192844466 0.209125755 
NonTargetingC
ontrolGene_12 
0.500963774 0.995789702 0.150159785 0.670490353 0.995789702 0.150159785 0.169526579 
CHD4 0.349677869 0.948970665 0.557518574 0.665545924 0.948970665 0.318866757 0.315868055 
USP51 0.515818535 0.999505252 0.193741697 0.662421834 0.999505252 0.162255581 0.146603299 
BCAS2 0.393516836 0.952015502 0.519345734 0.658760236 0.952015502 0.321132075 0.2652434 
NUDT1 0.514664269 0.946357521 0.256553735 0.658263215 0.946357521 0.243187598 0.143598947 
LIG1 0.408442556 0.95099314 0.546549017 0.649189796 0.95099314 0.396067329 0.24074724 
SETX 0.638301636 0.956660985 0.104585117 0.648472029 0.956660985 0.104585117 0.010170393 
NonTargetingC
ontrolGene_75 
0.499186756 0.999991775 0.217961669 0.646419952 0.999991775 0.168050263 0.147233196 
RBBP8 0.501838356 0.96332858 0.333322767 0.644656332 0.96332858 0.290947083 0.142817976 
NonTargetingC
ontrolGene_42 
0.67970672 0.999344463 0.161848152 0.637643683 0.999344463 0.161848152 -0.042063037 
SIRT6 0.580681507 0.933946592 0.319914192 0.630212922 0.933946592 0.319914192 0.049531415 
KMT5B 0.648701797 0.999968266 0.103565356 0.625871686 0.999968266 0.103565356 -0.022830111 
CHFR 0.405361716 0.999662265 0.215805398 0.625034354 0.999662265 0.171961903 0.219672638 
PBRM1 0.687943917 1 0.135051244 0.624538789 1 0.135202919 -0.063405128 
POLD2 0.256301144 0.945471268 0.733883653 0.616060847 0.945471268 0.428514497 0.359759703 
CDCA5 0.471446315 0.953015111 0.410465928 0.615861184 0.953015111 0.355940538 0.144414869 
SUMO4 0.463018295 0.958853859 0.212663185 0.615268418 0.958853859 0.153849462 0.152250124 
NonTargetingC
ontrolGene_68 
0.471570905 0.999257052 0.158280513 0.614000768 0.999257052 0.158280513 0.142429863 
NOTCH3 0.629412445 0.994536715 0.114422057 0.608581735 0.994536715 0.114422057 -0.02083071 
APOBEC2 0.606607318 0.999739009 0.145825187 0.608502379 0.999739009 0.145825187 0.001895062 
PPP6C 0.216168934 0.901738276 0.895944022 0.60778159 0.927447893 0.543269057 0.391612655 
KMT5C 0.619178579 0.999795972 0.133164186 0.606664817 0.999795972 0.133164186 -0.012513762 
NFATC2IP 0.464750009 0.947512601 0.218206324 0.600491592 0.947512601 0.218206324 0.135741583 
BRD4 0.366077075 0.954687836 0.459386861 0.598675345 0.954687836 0.228469914 0.23259827 
SMARCA4 0.37031933 0.921918975 0.347630633 0.595859949 0.921918975 0.339227283 0.22554062 
INO80E 0.599795954 0.915057453 0.305161286 0.593057419 0.915057453 0.305161286 -0.006738535 
TERF1 0.300716598 0.891230903 0.881866827 0.592116642 0.891230903 0.686687749 0.291400044 
NonTargetingC
ontrolGene_32 
0.804925962 0.999981145 0.09448797 0.591144854 0.999981145 0.137054504 -0.213781108 
SIRT5 0.510897261 0.999831869 0.149802239 0.589844187 0.999831869 0.149802239 0.078946926 
DMC1 0.73527993 0.999556483 0.074692826 0.58979586 0.999556483 0.127130625 -0.14548407 
ANKRD52 0.392471217 0.919276861 0.538245639 0.587931635 0.919276861 0.36346902 0.195460418 
Chapter 8: Appendix 
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POLN 0.60916456 0.999765812 0.160303789 0.579903119 0.999765812 0.160303789 -0.029261441 
USP15 0.757389347 1 0.065138382 0.579781047 1 0.109662027 -0.177608301 
NSMCE3 0.048877426 0.698453842 0.999991203 0.577917855 0.898066455 0.917401907 0.529040428 
GPI 0.215464397 0.999992441 0.31817114 0.577055642 0.999992441 0.178502918 0.361591244 
DUT 0.532754467 0.963292454 0.264972384 0.575518723 0.963292454 0.264972384 0.042764256 
WDR70 0.274001952 0.919984796 0.444759693 0.575203873 0.919984796 0.444759693 0.30120192 
NEIL1 0.414464269 0.967157443 0.197009555 0.573720389 0.967157443 0.189189276 0.15925612 
TIMELESS 0.402455917 0.904159214 0.506353162 0.570079166 0.904159214 0.453628084 0.167623249 
USP11 0.538775995 0.977479353 0.153262321 0.558588707 0.977479353 0.153262321 0.019812712 
APOBEC3C 0.651966331 0.995992372 0.161640284 0.556137138 0.995992372 0.161640284 -0.095829193 
TRIP12 0.509089587 0.999977382 0.190500439 0.556077224 0.999977382 0.190500439 0.046987636 
CDC25A 0.355230262 0.999910282 0.237963608 0.555564563 0.999910282 0.191855954 0.200334301 
PHF11 0.5548391 0.968480013 0.214912858 0.554665489 0.968480013 0.214912858 -1.73611E-04 
KAT2B 0.68996412 0.998273194 0.149539643 0.552755272 0.998273194 0.190016003 -0.137208848 
COL1A1 0.366080096 0.911479638 0.541344177 0.549337967 0.911479638 0.460714715 0.183257871 
PHF3 0.455625991 0.999371961 0.143769059 0.547359659 0.999371961 0.143769059 0.091733668 
CUL9 0.419968504 0.91141591 0.465315529 0.542160285 0.91141591 0.465315529 0.12219178 
CIB1 0.618150028 0.992548413 0.139868079 0.541860811 0.992548413 0.139868079 -0.076289217 
UBE2R2 0.855975926 1 0.067788305 0.54117677 1 0.145224292 -0.314799156 
UBE2D1 0.526864285 0.999939613 0.17954647 0.53876379 0.999939613 0.17954647 0.011899504 
SMARCD1 0.525308641 0.999812917 0.137079121 0.536070378 0.999812917 0.137079121 0.010761737 
MGMT 0.499961864 0.992856975 0.198492016 0.535517934 0.992856975 0.198492016 0.035556071 
CHD1L 0.280722827 0.999838881 0.293622209 0.533575535 0.999838881 0.232137854 0.252852709 
XPC 0.499630599 0.991484933 0.201804197 0.532741316 0.991484933 0.201804197 0.033110717 
NOTCH4 0.534518463 0.977380485 0.170484673 0.531290536 0.977380485 0.170484673 -0.003227928 
APOBEC1 0.734016869 0.956864874 0.234856141 0.530697279 0.956864874 0.234856141 -0.20331959 
HNRNPUL1 0.391382272 0.981160424 0.318235111 0.522569156 0.981160424 0.318235111 0.131186884 
KAT5 0.255786644 0.939740242 0.67560114 0.520305005 0.939740242 0.347298061 0.26451836 
MCM10 0.464674147 0.90263807 0.293246413 0.519972377 0.90263807 0.293246413 0.05529823 
RAD54B 0.632748934 0.984425058 0.210337492 0.518024866 0.984425058 0.227586521 -0.114724068 
CDK7 -0.071350577 0.578927962 0.999996104 0.516500541 0.819337633 0.882138893 0.587851118 
TPP1 0.473110787 0.998535295 0.168111978 0.514244703 0.998535295 0.168111978 0.041133916 
TRRAP 0.328885638 0.881436828 0.64564017 0.511185861 0.881436828 0.64564017 0.182300223 
RNF138 0.457038629 0.999989483 0.198265834 0.510371562 0.999989483 0.198265834 0.053332933 
MORF4L1 0.563658653 0.994177809 0.199108881 0.508717093 0.994177809 0.199873662 -0.05494156 
UBE2V2 0.423879572 0.999897557 0.188967762 0.504683589 0.999897557 0.183107207 0.080804018 
UBE2D4 0.462303142 0.907990743 0.308397143 0.503777345 0.907990743 0.308397143 0.041474203 
RAG2 0.626378518 0.937786552 0.240309256 0.500639592 0.937786552 0.240309256 -0.125738926 
CBX5 0.366269036 0.913303254 0.48031268 0.500353207 0.913303254 0.48031268 0.134084171 
RECQL4 0.613534021 0.880369061 0.595715041 0.498982489 0.880369061 0.595715041 -0.114551532 
CTCF 0.122634174 0.784405204 0.999918614 0.498400393 0.868529592 0.614396517 0.375766219 
NOTCH2 0.510715064 0.91600724 0.344733419 0.496378634 0.91600724 0.344733419 -0.01433643 
SMC6 0.167952582 0.820466401 0.999345574 0.49276331 0.886668239 0.684501774 0.324810728 
EME1 0.526170666 0.900026124 0.209613513 0.492227079 0.900026124 0.209613513 -0.033943587 
HELB 0.568693343 0.99823044 0.173793352 0.490040257 0.99823044 0.173793352 -0.078653086 
MORF4L2 0.399172218 0.909420079 0.401249076 0.482280869 0.909420079 0.401249076 0.083108651 
ATXN3 0.298619174 0.999887003 0.248271682 0.482053423 0.999887003 0.235765562 0.183434249 
NEK9 0.476432151 0.99995695 0.192826201 0.48160664 0.99995695 0.192826201 0.005174489 
SKP1 0.72028588 0.9118113 0.411038191 0.480008109 0.9118113 0.55250199 -0.240277771 
REV3L 0.210023169 0.868753474 0.932761344 0.477629597 0.868753474 0.788736013 0.267606428 
FBXO18 0.529714634 0.999245999 0.182890444 0.475887294 0.999245999 0.182890444 -0.05382734 
FAM175A 0.475283203 0.987271407 0.244612063 0.472513313 0.987271407 0.244612063 -0.002769891 
USP47 0.446509119 0.996708864 0.31463378 0.469347993 0.996708864 0.31463378 0.022838874 
HPF1 0.396970933 0.942247654 0.482518472 0.468252681 0.942247654 0.482518472 0.071281748 
NonTargetingC
ontrolGene_45 
0.607242373 0.999896743 0.199662611 0.46347788 0.999896743 0.199662611 -0.143764493 
WRNIP1 0.32049541 0.995688479 0.305766406 0.461251274 0.995688479 0.230312625 0.140755864 
MVP 0.316961898 0.881549393 0.324692981 0.460545732 0.881549393 0.324692981 0.143583834 
NonTargetingC
ontrolGene_30 
0.314520653 0.999748986 0.285754435 0.458787573 0.999748986 0.239880679 0.14426692 
POLD4 0.325040377 0.846632852 0.684444735 0.457087069 0.846632852 0.684444735 0.132046692 
RRM2 0.04018955 0.686176125 0.999998419 0.456028331 0.837413672 0.82022985 0.415838781 
DDB1 0.051937277 0.703881747 1 0.453515238 0.843925082 0.986091054 0.40157796 
NONO 0.317595834 0.924561884 0.677445624 0.451928718 0.924561884 0.647037783 0.134332884 
NonTargetingC
ontrolGene_6 
0.50853398 0.999346524 0.207882263 0.451307325 0.999346524 0.207882263 -0.057226655 
RNF2 0.427654003 0.999627895 0.27250104 0.450762275 0.999627895 0.27250104 0.023108272 
CBX1 0.233113527 0.818043684 0.73796149 0.447070827 0.818043684 0.73796149 0.2139573 
CSNK2B 0.267964331 0.925706318 0.814131287 0.446772199 0.925706318 0.779983575 0.178807867 
PDS5A 0.223515701 0.881387988 0.943428028 0.446355887 0.903669151 0.747192437 0.222840186 
RFC1 0.418056179 0.870530865 0.493337784 0.445726261 0.870530865 0.493337784 0.027670082 
C9orf142 0.431925396 0.955815087 0.345532622 0.445515319 0.955815087 0.345532622 0.013589923 
RAD51D 0.324252353 0.892670296 0.59099305 0.445427251 0.892670296 0.524784962 0.121174897 
NonTargetingC
ontrolGene_62 
0.340278519 0.999944922 0.231304551 0.44316637 0.999944922 0.17984537 0.102887851 
SIRT1 0.31689217 0.999600581 0.201449853 0.441973199 0.999600581 0.161515408 0.125081028 
NEIL2 0.473125247 0.900745624 0.319866714 0.441030147 0.900745624 0.319866714 -0.0320951 
NonTargetingC
ontrolGene_14 
0.554486916 0.999963084 0.155978914 0.440316589 0.999963084 0.155978914 -0.114170327 
SFR1 0.401276155 0.81670404 0.6184974 0.438317301 0.81670404 0.6184974 0.037041146 
CBX3 0.373231435 0.85241978 0.418979627 0.438278363 0.85241978 0.418979627 0.065046929 
NABP2 0.592938669 0.995463463 0.162132468 0.438202643 0.995463463 0.238488437 -0.154736025 
TOP3A 0.319739642 0.888644981 0.617350779 0.437836922 0.888644981 0.617350779 0.118097279 
NELFB 0.326455677 0.92473282 0.614812545 0.436821867 0.92473282 0.614812545 0.11036619 
COPS5 -0.244384407 0.404433415 0.999999992 0.436111781 0.812575703 0.961241786 0.680496188 
ALDH2 0.537953486 0.97275521 0.275798753 0.434771805 0.97275521 0.275798753 -0.10318168 
CUL7 0.546102568 0.999988816 0.163441994 0.433301867 0.999988816 0.182839298 -0.112800701 




0.531076367 0.999999115 0.15579312 0.430043927 0.999999115 0.196061195 -0.101032441 
DLGAP  0.480816324 0.886341913 0.404700279 0.427621779 0.886341913 0.404700279 -0.053194545 
DTX3L 0.495498776 0.99393549 0.250939498 0.422698428 0.99393549 0.25449819 -0.072800349 
BRAT1 0.192455024 0.764885569 1 0.4189431 0.777359531 1 0.226488075 
APTX 0.33897098 0.902305794 0.297388906 0.416739487 0.902305794 0.297388906 0.077768507 
POT1 0.320688413 0.855717782 0.689061257 0.413581495 0.855717782 0.689061257 0.092893082 
HDAC2 0.402738613 0.869520373 0.350883165 0.408529961 0.869520373 0.350883165 0.005791348 
APLF 0.171434195 0.999572699 0.363502534 0.407066343 0.999572699 0.27377354 0.235632149 
SIRT7 0.247455597 0.999664558 0.268494609 0.407006824 0.999664558 0.184380409 0.159551227 
NonTargetingC
ontrolGene_46 
0.298967265 0.999895055 0.275815284 0.405983974 0.999895055 0.246418794 0.107016709 
MAU2 -0.147011198 0.476696072 0.999999903 0.404915335 0.829245983 0.999999903 0.551926532 
RNF111 0.504709692 0.999944988 0.188176928 0.402843904 0.999944988 0.194413077 -0.101865787 
RNF8 0.16014603 0.802892438 0.996162079 0.401770936 0.802892438 0.960191821 0.241624906 
PLRG1 0.309439362 0.857516336 0.68552123 0.401213084 0.857516336 0.68552123 0.091773722 
MSH4 0.364146544 0.993583438 0.259161096 0.398148732 0.993583438 0.259161096 0.034002187 
APOBEC3B 0.495681136 0.999967008 0.236724223 0.397779226 0.999967008 0.236724223 -0.097901909 
RIF1 0.050419085 0.70734721 0.999998123 0.396552768 0.837438824 0.999998123 0.346133683 
RAD51AP1 0.456931665 0.853380663 0.405176852 0.395344894 0.853380663 0.405176852 -0.061586771 
SIRT4 0.257673676 0.909510653 0.374848148 0.395260671 0.909510653 0.309220548 0.137586995 
ETAA1 0.322595837 0.999902643 0.221874002 0.394671315 0.999902643 0.221874002 0.072075478 
RNF40 0.172548026 0.729677955 0.999986349 0.393773291 0.799178389 0.999986349 0.221225265 
CDKN1B 0.32112048 0.999985514 0.28000831 0.393384972 0.999985514 0.277651111 0.072264492 
FBXW7 0.574566033 0.999999997 0.085417617 0.39336848 0.999999997 0.155916677 -0.181197552 
UNG 0.505883328 0.879170242 0.711741337 0.393148198 0.879170242 0.711741337 -0.11273513 
PMS2P5 0.138202807 0.642106223 0.567006492 0.389535249 0.642106223 0.567006492 0.251332441 
POLB 0.43192381 0.978148625 0.284457033 0.389073775 0.978148625 0.284457033 -0.042850035 
UBE2V1 0.246067744 0.994675609 0.311815552 0.386276349 0.994675609 0.311815552 0.140208605 
NSMCE4A 0.16462439 0.797276073 0.999942809 0.383594015 0.797276073 0.999942809 0.218969626 
SETMAR 0.328957864 0.987364155 0.317835521 0.382624947 0.987364155 0.317664523 0.053667084 
ATXN7 0.608538726 0.999322392 0.185430777 0.38193821 0.999322392 0.272883116 -0.226600516 
OPRM1 0.401464041 0.999960465 0.208737076 0.379630819 0.999960465 0.208737076 -0.021833222 
CLSPN 0.352877128 0.890889164 0.569936767 0.379519881 0.890889164 0.569936767 0.026642754 
SSBP2 0.477726997 0.999223979 0.29651219 0.377744276 0.999223979 0.29651219 -0.099982721 
POLI 0.458026212 0.870502638 0.359127809 0.377006201 0.870502638 0.359127809 -0.081020012 
NonTargetingC
ontrolGene_11 
0.327835915 0.999999893 0.249756542 0.37420295 0.999999893 0.247258081 0.046367035 
EP400 0.507184212 0.878030871 0.605255147 0.371851363 0.878030871 0.605255147 -0.13533285 
PML 0.317368004 0.999831852 0.230662228 0.36918379 0.999831852 0.230662228 0.051815786 
UBE2D2 0.393105956 0.926997804 0.271229486 0.369012697 0.926997804 0.271229486 -0.024093259 
XRCC3 0.05203835 0.701483566 1 0.368384689 0.80264027 1 0.316346339 
CCNB2 0.364482867 0.989274411 0.262865149 0.366758019 0.989274411 0.262865149 0.002275152 
USP20 0.347646686 0.997002414 0.283895858 0.365057578 0.997002414 0.283895858 0.017410892 
H3F3B 0.341607808 0.771063803 0.762949784 0.362618926 0.771063803 0.762949784 0.021011118 
UBE2K 0.253967734 1 0.303014228 0.358417001 1 0.255826373 0.104449267 
WDR76 0.279239542 0.892541247 0.274239745 0.358202341 0.892541247 0.274239745 0.078962799 
SMARCA5 0.01820058 0.665372902 0.999784118 0.358129132 0.804649048 0.999784118 0.339928553 
EXO5 0.193381234 0.775154374 0.966614507 0.357571894 0.798456092 0.966614507 0.16419066 
CDC25B 0.342002859 0.844476651 0.635585585 0.356930621 0.844476651 0.635585585 0.014927762 
SKIV2L2 0.10922438 0.791033887 0.788549952 0.35581037 0.791033887 0.788549952 0.24658599 
DCUN1D2 0.333394694 0.967274579 0.312938999 0.355547276 0.967274579 0.312938999 0.022152582 
FEN1 0.123433362 0.79899342 0.999973193 0.353708615 0.799238777 0.914509293 0.230275253 
RAD9B 0.460246134 0.907235566 0.334368469 0.353457765 0.907235566 0.334368469 -0.106788369 
RING1 0.420651615 1 0.220555776 0.352031738 1 0.239150381 -0.068619876 
MSH3 0.349040835 0.986451479 0.310510777 0.351101713 0.986451479 0.310510777 0.002060879 
HELLS 0.179866498 0.807778785 0.971985663 0.345545562 0.807778785 0.914990729 0.165679064 
TOP2A 0.130692025 0.810893181 0.622751665 0.343851907 0.810893181 0.622751665 0.213159882 
UBE2NL 0.309468499 0.944566022 0.338582809 0.343317528 0.944566022 0.338582809 0.03384903 
FANCE 0.089604266 0.750727108 0.999512955 0.34310645 0.785751133 0.999512955 0.253502184 
CDC34 0.234787574 0.943082939 0.317670536 0.341898512 0.943082939 0.317670536 0.107110937 
MAPK14 0.27530326 0.999999645 0.374315111 0.339959188 0.999999645 0.366488828 0.064655928 
HLTF 0.416922155 0.842836197 0.400106702 0.339439261 0.842836197 0.400106702 -0.077482894 
ALKBH1 0.349034622 0.999961205 0.247811976 0.338390595 0.999961205 0.247811976 -0.010644027 
TDG 0.248283136 0.776038219 0.622908194 0.332695013 0.776038219 0.622908194 0.084411878 
NonTargetingC
ontrolGene_36 
0.202147548 0.999854713 0.331837147 0.325800654 0.999854713 0.282497522 0.123653106 
NonTargetingC
ontrolGene_1 
0.366537602 0.999451714 0.280807461 0.325557884 0.999451714 0.280807461 -0.040979718 
TNP  0.361322998 0.962981376 0.371141252 0.322803806 0.962981376 0.371141252 -0.038519192 
NonTargetingC
ontrolGene_66 
0.359949368 0.999534742 0.252566243 0.322587255 0.999534742 0.252566243 -0.037362113 
ANKRD28 0.344712209 0.964281934 0.377704218 0.322374739 0.964281934 0.377704218 -0.022337469 
CCNA2 0.005150099 0.649111021 0.999949601 0.322195777 0.775593239 0.999949601 0.317045679 
CETN2 0.297006696 0.995655769 0.37745133 0.320840127 0.995655769 0.37745133 0.023833432 
USP13 0.344368252 0.999322517 0.2603818 0.320760623 0.999322517 0.2603818 -0.023607629 
CUL1 0.281142958 0.852117278 0.817536936 0.319596005 0.852117278 0.817536936 0.038453047 
OTUD7B 0.297632198 0.966178755 0.309427349 0.319494057 0.966178755 0.309427349 0.021861859 
OR6B1 0.369405735 0.780133397 0.543041925 0.318227732 0.780133397 0.543041925 -0.051178003 
RMI1 0.088313273 0.779794902 0.999979412 0.316949368 0.821870283 0.951183412 0.228636096 
HMGB2 0.529962903 0.999925107 0.189092663 0.316944303 0.999925107 0.267173602 -0.2130186 
POLE 0.005568224 0.65044863 0.865959085 0.31659369 0.791463212 0.865959085 0.311025466 
BOD1L1 -0.032829853 0.60517879 0.999999296 0.315338604 0.752132281 0.999999296 0.348168457 
ARID1B 0.359173691 0.970376264 0.301973032 0.314414093 0.970376264 0.301973032 -0.044759598 
PIF1 0.289386808 0.789502562 0.452710548 0.313727119 0.789502562 0.452710548 0.024340311 
CHTF18 0.356636942 0.982124975 0.28965022 0.31168448 0.982124975 0.28965022 -0.044952462 
PRKCG 0.307436638 0.999019977 0.26646088 0.311334514 0.999019977 0.26646088 0.003897877 
INO80B 0.116820451 0.761572409 0.998019997 0.311157558 0.789809779 0.998019997 0.194337107 
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CDC5L 0.137101956 0.81731613 0.999999994 0.308150876 0.81731613 0.94976868 0.17104892 
KLHL15 0.269454997 0.992613477 0.306523469 0.308016192 0.992613477 0.306523469 0.038561196 
NonTargetingC
ontrolGene_34 
0.399940064 0.99906883 0.28639908 0.301261661 0.99906883 0.28639908 -0.098678403 
TERF2IP 0.239063688 0.747038604 0.740824367 0.299921602 0.747038604 0.740824367 0.060857914 
SMC1B 0.274894788 0.999741633 0.333848527 0.299534361 0.999741633 0.333848527 0.024639572 
NCAPG -0.034200251 0.598434212 0.999983682 0.298910212 0.775976151 0.999983682 0.333110463 
MBD4 0.346396449 0.99826714 0.294597572 0.297892135 0.99826714 0.294597572 -0.048504314 
FAN1 0.289960407 0.997111193 0.267264115 0.297545282 0.997111193 0.267264115 0.007584876 
SMARCAL1 0.286381239 0.760780742 0.748013154 0.290849365 0.760780742 0.748013154 0.004468126 
CSNK1E 0.284173167 0.996433343 0.282415934 0.288234273 0.996433343 0.282415934 0.004061106 
HFM1 0.349526351 0.993815046 0.276872453 0.28630904 0.993815046 0.276872453 -0.063217311 
EID3 0.170894052 0.993920362 0.38559444 0.285562109 0.993920362 0.368745894 0.114668057 
NonTargetingC
ontrolGene_26 
0.326262759 0.999829527 0.263208602 0.285278571 0.999829527 0.265679618 -0.040984188 
SCAI 0.398552836 0.999862613 0.216875457 0.283933362 0.999862613 0.238601495 -0.114619474 
SMG6 -0.005461663 0.636351351 0.975220406 0.28335194 0.812123968 0.975220406 0.288813603 
MUM1 0.314494111 0.998613554 0.275787866 0.282557534 0.998613554 0.275787866 -0.031936577 
NonTargetingC
ontrolGene_7 
0.323106605 0.993980969 0.287545259 0.28242709 0.993980969 0.287545259 -0.040679515 
NonTarg tingC
ontrolGene_3 
0.442509568 0.860063864 0.436971171 0.28195196 0.860063864 0.436971171 -0.160557608 
UBE2A 0.242774433 0.966338213 0.370554378 0.281604175 0.966338213 0.370554378 0.038829742 
TRAIP 0.031801186 0.679698557 0.999999649 0.280776687 0.824114734 0.999999649 0.248975502 
MLH3 0.347832787 0.999862757 0.264575591 0.279756127 0.999862757 0.288765802 -0.06807666 
SLBP 0.144814752 0.84926528 0.520300724 0.278865115 0.84926528 0.520300724 0.134050364 
ALKBH3 0.204496952 0.999874058 0.340861998 0.276096839 0.999874058 0.315633542 0.071599888 
SIRT2 0.281448634 0.996559267 0.27428979 0.275800353 0.996559267 0.27428979 -0.00564828 
PRDM9 0.232303207 0.943546646 0.367872819 0.275581963 0.943546646 0.367872819 0.043278756 
CASP3 0.107890271 0.92594083 0.520395807 0.275472279 0.92594083 0.457113336 0.167582008 
PARP4 0.287562937 0.999779181 0.272654857 0.273920536 0.999779181 0.272654857 -0.013642401 
MDC1 0.321779889 0.7975822 0.732251606 0.271832818 0.7975822 0.732251606 -0.049947072 
PPP6R2 0.154498939 0.793930204 0.51836679 0.270382552 0.793930204 0.51836679 0.115883613 
INO80D 0.264091668 0.995796808 0.322263207 0.267929607 0.995796808 0.322263207 0.003837939 
PPP5C 0.041976523 0.956631895 0.457858901 0.267103018 0.956631895 0.442428591 0.225126496 
HMGB1 0.791723087 0.994845796 0.425398111 0.265316598 0.994845796 0.469061389 -0.526406489 
DCUN1D1 0.413050362 0.999999878 0.314919159 0.263746526 0.999999878 0.314919159 -0.149303835 
DCUN1D5 0.461718052 0.999889397 0.278144345 0.260858082 0.999889397 0.293437971 -0.200859971 
RPA4 0.269746202 0.926587876 0.347017442 0.260189787 0.926587876 0.347017442 -0.009556415 
PARK2 0.159903876 0.744557492 0.508448011 0.256986054 0.744557492 0.508448011 0.097082178 
NonTargetingC
ontrolGene_18 
0.231527536 0.999971612 0.299195533 0.256408871 0.999971612 0.299195533 0.024881335 
APOBEC3F 0.223065013 0.96743583 0.474663017 0.256227324 0.96743583 0.474663017 0.033162311 
NonTargetingC
ontrolGene_74 
0.379861196 0.998153711 0.268790737 0.255508604 0.998153711 0.294528743 -0.124352592 
COPS A 0.160935669 0.999970404 0.376272799 0.25157948 0.999970404 0.349247598 0.090643811 
MMS19 -0.176260766 0.438297367 0.99999986 0.25089863 0.725648182 0.99999986 0.427159396 
NonTargetingC
ontrolGene_71 
0.376914598 0.990797611 0.311783685 0.25000042 0.990797611 0.311783685 -0.126914178 
SMARCAD  0.336684001 0.902049214 0.473019693 0.249663968 0.902049214 0.473019693 -0.087020033 
PRDM10 0.113669381 0.750825113 0.67521091 0.248892747 0.750825113 0.67521091 0.135223366 
HDAC1 0.238744524 0.853806783 0.358107678 0.246846989 0.853806783 0.358107678 0.008102465 
CCND2 0.291705106 0.999700615 0.311027717 0.245587653 0.999700615 0.311027717 -0.046117453 
PER3 0.330918674 0.849608299 0.489903783 0.244607421 0.849608299 0.489903783 -0.086311253 
REV1 0.083720514 0.951147894 0.418264435 0.244472601 0.951147894 0.357975676 0.160752088 
ERCC8 0.151748201 0.716506865 0.709966902 0.243551989 0.716506865 0.709966902 0.091803788 
USP45 0.290465849 0.96395309 0.348616929 0.242891058 0.96395309 0.348616929 -0.047574791 
PRIMPOL 0.233167036 0.97661071 0.334150094 0.240746414 0.97661071 0.334150094 0.007579379 
USP3 0.352998415 0.90412076 0.449800464 0.240588624 0.90412076 0.449800464 -0.112409791 
BARD1 0.109171041 0.778589206 0.99981174 0.238214266 0.778589206 0.99981174 0.129043225 
RNF169 0.171406662 0.972630813 0.445966562 0.23646796 0.972630813 0.445966562 0.065061297 
TIPIN 0.245494149 0.889867239 0.384848746 0.235940062 0.889867239 0.384848746 -0.009554088 
PARK7 0.197329461 0.994823768 0.356819735 0.235497583 0.994823768 0.356819735 0.038168122 
WHSC1 0.090989869 0.984510192 0.423713962 0.233962446 0.984510192 0.423713962 0.142972577 
APOBEC3H 0.170452151 0.843921742 0.402261229 0.23169574 0.843921742 0.402261229 0.061243589 
SALL4 0.364380296 0.991028909 0.305548539 0.231390359 0.991028909 0.311969916 -0.132989936 
PARP14 0.128894718 0.999626837 0.470970352 0.230040427 0.999626837 0.422550735 0.101145709 
UIMC1 0.225093982 0.861488402 0.390302293 0.228886826 0.861488402 0.390302293 0.003792844 
BAZ1A 0.145901898 0.733462775 0.45138603 0.228754412 0.733462775 0.45138603 0.082852514 
NABP1 0.284152881 0.959632317 0.345913405 0.228583251 0.959632317 0.345913405 -0.055569631 
NonTargetingC
ontrolGene_39 
0.214876411 0.999999994 0.31495842 0.228260974 0.999999994 0.31495842 0.013384562 
MPZ 0.233931752 0.783285652 0.514905795 0.228142454 0.783285652 0.514905795 -0.005789298 
SUV39H2 0.17767884 0.994902355 0.317153685 0.227178699 0.994902355 0.317153685 0.049499858 
MSH6 0.336586656 0.807076469 0.633023141 0.226628693 0.807076469 0.633023141 -0.109957962 
HNRNPUL2 0.19112298 0.999853973 0.361544483 0.22618309 0.999853973 0.361544483 0.03506011 
ATP23 0.28894874 0.941599552 0.436241072 0.223659635 0.941599552 0.436241072 -0.065289105 
H2AFY 0.176274938 0.985621785 0.372894174 0.222470159 0.985621785 0.370549484 0.046195221 
RECQL5 0.364150897 0.807844349 0.447635835 0.221373398 0.807844349 0.447635835 -0.142777498 
PINK1 0.133626093 0.859205561 0.480296597 0.221259381 0.859205561 0.480296597 0.087633288 
PIAS2 0.174949454 0.972756723 0.373570722 0.220125931 0.972756723 0.373570722 0.045176478 
RHO 0.159588291 0.867938538 0.43694721 0.218766147 0.867938538 0.43694721 0.059177856 
ATF2 0.204044217 0.990828682 0.307924958 0.217369987 0.990828682 0.307924958 0.013325769 
BTG2 0.262777446 0.999849211 0.355808262 0.216477214 0.999849211 0.355808262 -0.046300232 
RAD18 0.268618645 0.998249125 0.318397932 0.216165221 0.998249125 0.318397932 -0.052453424 
NonTargetingC
ontrolGene_35 
0.31815717 0.999245228 0.296567827 0.21581919 0.999245228 0.341736188 -0.102337979 
CDK12 0.20957843 0.699279618 0.972174261 0.214489017 0.699279618 0.972174261 0.004910587 
NonTargetingC
ontrolGene_4 
0.235156649 0.998153433 0.304050787 0.21387682 0.998153433 0.304050787 -0.021279829 
TREX1 0.193696223 0.968436391 0.370772458 0.213614082 0.968436391 0.370772458 0.019917859 
DTX1 0.234206059 0.802545681 0.457077757 0.210779801 0.802545681 0.457077757 -0.023426259 
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POLH 0.147576642 0.817609978 0.414541812 0.208411394 0.817609978 0.414541812 0.060834752 
PAGR1 0.198099944 0.703693388 0.916817828 0.208019419 0.703693388 0.916817828 0.009919475 
RAP1A 0.19255877 0.998612783 0.393863608 0.207691058 0.998612783 0.393863608 0.015132289 
SUMO3 0.223064655 0.994900124 0.328498082 0.207681549 0.994900124 0.328498082 -0.015383107 
SMARCC1 0.022106108 0.999999991 0.479243695 0.207346811 0.999999991 0.360935491 0.185240703 
NonTargetingC
ontrolGene_76 
0.248073406 0.998182876 0.349017695 0.206145606 0.998182876 0.351532207 -0.0419278 
TCEB3 0.04505574 0.60703653 0.990465878 0.205402993 0.67279111 0.990465878 0.160347252 
LIG3 0.011577723 0.999904028 0.489055158 0.204636395 0.999904028 0.353746338 0.193058672 
DCAF11 0.34057827 0.900717935 0.386361477 0.202973579 0.900717935 0.386361477 -0.137604691 
NonTargetingC
ontrolGene_60 
0.165686803 0.939658178 0.359655223 0.201764959 0.939658178 0.359655223 0.036078156 
NonTargetingC
ontrolGene_2 
0.220282152 0.995046821 0.372114596 0.201558503 0.995046821 0.372114596 -0.018723649 
MEN1 -0.020974036 0.619235737 0.983314517 0.201416625 0.712323746 0.983314517 0.222390661 
BEND3 0.126494563 0.782060364 0.418467606 0.20107894 0.782060364 0.418467606 0.074584377 
ANP32E 0.156182167 0.877808356 0.388795789 0.200921799 0.877808356 0.388795789 0.044739633 
MBTD1 0.330697551 0.982125174 0.388244541 0.198373223 0.982125174 0.47602617 -0.132324328 
RBBP7 0.288182063 0.976664116 0.416652738 0.197204719 0.976664116 0.416652738 -0.090977344 
APBB1 0.072882493 0.998373594 0.421358868 0.196774435 0.998373594 0.368351676 0.123891943 
CDK2 -0.302984953 0.355245308 0.991668433 0.193277469 0.67768649 0.991668433 0.496262422 
MRE11 0.30082283 0.806380107 0.999979051 0.192502245 0.78700842 0.999979051 -0.108320585 
CLK2 0.071729317 0.937955813 0.53407626 0.191250954 0.937955813 0.496150193 0.119521638 
GEN1 0.276229726 0.754153117 0.671192216 0.18926765 0.754153117 0.671192216 -0.086962076 
ERCC5 0.172530907 0.788299656 0.480513536 0.188525406 0.788299656 0.480513536 0.015994499 
PARP2 0.301501907 0.943985904 0.309226463 0.18782285 0.943985904 0.309226463 -0.113679057 
SUMO1 0.188213129 0.848506551 0.352701213 0.18761212 0.848506551 0.352701213 -6.01009E-04 
KMT5A 0.044776008 0.741562051 0.574073591 0.186486525 0.741562051 0.574073591 0.141710516 
PIAS1 0.239954108 0.730146097 0.478187399 0.185935985 0.730146097 0.478187399 -0.054018124 
BLM 0.137441067 0.840181435 0.470355048 0.185412032 0.840181435 0.470355048 0.047970965 
GABBR1 0.152584097 0.830415951 0.443223333 0.185070399 0.830415951 0.443223333 0.032486301 
PPP6R3 0.198306861 0.99966489 0.346160016 0.183797564 0.99966489 0.346160016 -0.014509297 
NIPBL 0.306525747 0.754348284 0.998963233 0.183584703 0.754348284 0.998963233 -0.122941045 
NonTargetingC
ontrolGene_78 
0.245055782 0.999117535 0.350377074 0.183534855 0.999117535 0.362643208 -0.061520927 
DCUN1D4 0.203768083 0.997906465 0.37770114 0.183367651 0.997906465 0.37770114 -0.020400432 
NonTargetingC
ontrolGene_31 
0.223745852 0.999998311 0.370998384 0.183183379 0.999998311 0.370998384 -0.040562472 
SMC3 -0.098608192 0.532186486 0.999896419 0.182902796 0.66233072 0.999896419 0.281510989 
TP73 0.228221807 0.721214667 0.496816724 0.182709884 0.721214667 0.496816724 -0.045511923 
SENP2 0.235677481 0.974847315 0.384750348 0.182241795 0.974847315 0.384750348 -0.053435686 
H2AFY2 0.186008731 0.763884749 0.465235999 0.181804571 0.763884749 0.465235999 -0.004204161 
RRM2B 0.137291676 0.999997564 0.374142036 0.180935333 0.999997564 0.374142036 0.043643657 
NonTargetingC
ontrolGene_63 
0.248671566 0.995299415 0.370924813 0.180822056 0.995299415 0.370924813 -0.06784951 
USP44 0.151529559 0.66852974 0.962981781 0.177587397 0.66852974 0.962981781 0.026057838 
POLR2C 0.127829777 0.757168982 0.999999547 0.175616697 0.757168982 0.999999547 0.04778692 
NonTargetingC
ontrolGene_54 
0.01743834 0.999049499 0.483241338 0.173702573 0.999049499 0.431120013 0.156264233 
NEIL3 0.262646778 0.830465663 0.459576238 0.172120323 0.830465663 0.459576238 -0.090526454 
UHRF2 0.150949908 0.933087821 0.456677267 0.17195469 0.933087821 0.456677267 0.021004781 
TOPBP1 0.172817156 0.749373197 0.999999996 0.171156489 0.749373197 0.999999996 -0.001660668 
NonTargetingC
ontrolGene_23 
0.355351287 0.999695194 0.275977059 0.170233569 0.999695194 0.34865466 -0.185117718 
NonTargetingC
ontrolGene_50 
0.296627755 0.999974703 0.315982043 0.168711352 0.999974703 0.387102264 -0.127916402 
PRMT6 0.001627464 0.998934623 0.498427432 0.168487541 0.998934623 0.437978699 0.166860077 
ZRANB3 0.179837509 0.858872109 0.384695382 0.168383431 0.858872109 0.384695382 -0.011454078 
PPM1G 0.127716356 0.727096542 0.977161392 0.16793244 0.727096542 0.977161392 0.040216084 
NonTargetingC
ontrolGene_37 
0.233662123 0.9463425 0.377586763 0.164364524 0.9463425 0.377586763 -0.069297598 
APOBEC G 0.172558944 0.800085083 0.404673257 0.164281887 0.800085083 0.404673257 -0.008277057 
DTX3 0.098059875 0.999520968 0.402899465 0.162838927 0.999520968 0.388267478 0.064779052 
SHFM1 0.06493968 0.999991064 0.45381777 0.160719437 0.999991064 0.446457726 0.095779757 
CCNO 0.112287059 0.98679286 0.393804847 0.160042715 0.98679286 0.393804847 0.047755656 
CUL4B -0.107486351 0.99947849 0.586378269 0.155337833 0.99947849 0.421662709 0.262824184 
NonTargetingC
ontrolGene_55 
-0.138457431 0.99999849 0.618000193 0.154563035 0.99999849 0.469625734 0.293020466 
BAZ1B 0.196188049 0.677081241 0.831773684 0.150708868 0.677081241 0.831773684 -0.04547918 
TOP2B 0.100925367 0.894281573 0.517418298 0.150633053 0.894281573 0.517418298 0.049707686 
NUDT16L1 0.132170695 0.821254066 0.439119507 0.149468792 0.821254066 0.439119507 0.017298097 
PAPD7 0.026422408 0.791645969 0.607132583 0.147663324 0.791645969 0.529345001 0.121240916 
NonTargetingC
ontrolGene_64 
0.236617153 0.975822499 0.356101424 0.147135705 0.975822499 0.356101424 -0.089481447 
SLF2 0.017301604 0.968887803 0.484472338 0.146587878 0.968887803 0.484472338 0.129286273 
NOTCH1 0.161498064 0.99799131 0.40855067 0.145092521 0.99799131 0.40855067 -0.016405543 
PARPBP 0.230639358 0.997597669 0.369543954 0.141320756 0.997597669 0.408838675 -0.089318602 
KAT2A 0.056820247 0.699444162 0.992094734 0.140128499 0.699444162 0.992094734 0.083308252 
STAG1 0.227472047 0.723799903 0.633347551 0.138820487 0.723799903 0.633347551 -0.08865156 
NonTargetingC
ontrolGene_22 
0.140635653 0.998830219 0.372629334 0.135891673 0.998830219 0.372629334 -0.00474398 
TYMS 0.162326344 0.989232021 0.373620608 0.133733068 0.989232021 0.373620608 -0.028593276 
SLX4 0.134821732 0.708659367 0.999341474 0.129582422 0.708659367 0.999341474 -0.005239311 
PPP4R4 0.285672558 0.999944276 0.376532614 0.127561827 0.999944276 0.423630814 -0.158110731 
ASF1B 0.03716606 0.852870623 0.49571593 0.127174211 0.852870623 0.479460419 0.090008151 
USP4 0.281471169 0.805362863 0.589526684 0.126714937 0.805362863 0.589526684 -0.154756232 
ESCO2 0.017999061 0.582427273 0.992629276 0.126411988 0.620304456 0.992629276 0.108412928 
EXD2 0.195805746 0.986875983 0.445430619 0.126293251 0.986875983 0.445430619 -0.069512495 
USP22 0.156814152 0.642641712 0.653544646 0.126189276 0.642641712 0.653544646 -0.030624876 
AICDA 0.030042485 0.884412741 0.47259631 0.124504585 0.884412741 0.47259631 0.0944621 
TDP2 0.069773341 0.674335764 0.917993286 0.124434523 0.674335764 0.917993286 0.054661182 
POLE4 -0.041769721 0.59141024 0.999981281 0.122363122 0.609192821 0.999981281 0.164132843 
NonTargetingC
ontrolGene_49 
0.285915648 0.998539304 0.315053553 0.122197702 0.998539304 0.38688018 -0.163717947 
NonTargetingC
ontrolGene_56 
0.18444402 0.965584874 0.434281159 0.120852342 0.965584874 0.434281159 -0.063591678 
RASSF7 0.188515544 0.997777622 0.450251198 0.12080156 0.997777622 0.450251198 -0.067713984 
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IGHMBP2 0.074253192 0.733461585 0.477616102 0.119984305 0.733461585 0.477616102 0.045731113 
POLR2B -0.216481377 0.468988107 0.998193741 0.119559141 0.659020709 0.998193741 0.336040518 
USP26 0.152007057 0.977805328 0.439122437 0.118891348 0.977805328 0.439122437 -0.033115709 
CCNA1 0.034679891 0.810951228 0.598707029 0.118001615 0.810951228 0.598707029 0.083321725 
NonTargetingC
ontrolGene_15 
0.222434374 0.999989034 0.374467506 0.117216961 0.999989034 0.433866013 -0.105217413 
SENP7 0.171343024 0.8161503 0.467620277 0.115805524 0.8161503 0.467620277 -0.0555375 
TRIM29 0.189422766 0.983559316 0.416560922 0.115623442 0.983559316 0.433498953 -0.073799324 
SET -0.084422359 0.548548085 0.9998963 0.113341157 0.635075834 0.9998963 0.197763516 
MCPH1 -0.015420607 0.586576959 0.999999494 0.109815508 0.586576959 0.999999494 0.125236116 
SENP6 -0.286711438 0.322686644 0.99993276 0.10923331 0.673046944 0.99993276 0.395944748 
INO80C 0.245621527 0.99225101 0.408909174 0.109177858 0.99225101 0.442737388 -0.136443669 
CSNK2A1 -0.262970831 0.59893175 0.749365565 0.107247143 0.59893175 0.744935698 0.370217974 
NEK8 0.188480188 0.999004224 0.410909534 0.106848452 0.999004224 0.443480968 -0.081631736 
PXMP2 0.128311372 0.923308842 0.444325346 0.106613449 0.923308842 0.444325346 -0.021697924 
GADD45A 0.161994458 0.999990609 0.449042256 0.105183684 0.999990609 0.450984945 -0.056810774 
APOBEC3A 0.178830077 0.949371552 0.402239037 0.105069457 0.949371552 0.402239037 -0.073760619 
NonTargetingC
ontrolGene_16 
0.178838353 0.997641235 0.416399926 0.104253997 0.997641235 0.416399926 -0.074584356 
OGG1 -0.008340151 0.848582944 0.508307522 0.101833594 0.848582944 0.508307522 0.110173745 
H3F3A 0.226807795 0.576658748 0.533961199 0.097575286 0.576658748 0.533961199 -0.129232509 
APOBEC3D 0.211079234 0.974141819 0.417259904 0.096799085 0.974141819 0.441172526 -0.114280148 
FANCM -0.026907834 0.605209051 0.999902234 0.096339987 0.681682742 0.999902234 0.12324782 
PSIP1 0.160209525 0.882014247 0.407987723 0.095908711 0.882014247 0.407987723 -0.064300813 
SLF1 0.105642745 0.957297648 0.419842852 0.09586278 0.957297648 0.419842852 -0.009779965 
ANKRD44 0.066732909 0.998536699 0.477003499 0.095281797 0.998536699 0.477003499 0.028548888 
PARP9 0.370294465 0.997612841 0.358199205 0.091615008 0.997612841 0.469345243 -0.278679457 
RFC3 0.014504918 0.572970282 0.999999623 0.090764508 0.572970282 0.999999623 0.07625959 
ORC2 -0.106338257 0.481268607 0.87352768 0.089482728 0.594049264 0.87352768 0.195820985 
UVSSA 0.097944023 0.69812623 0.613241301 0.088044628 0.69812623 0.613241301 -0.009899394 
NonTargetingC
ontrolGene_61 
0.17001704 0.999998025 0.445386196 0.087685697 0.999998025 0.470948554 -0.082331343 
NonTargetingC
ontrolGene_21 
0.233506459 0.999999634 0.388790269 0.08762825 0.999999634 0.472359523 -0.145878209 
SHPRH 0.098958681 0.726763686 0.552152367 0.085941728 0.726763686 0.552152367 -0.013016953 
IP6K3 0.12028865 0.985510177 0.420443513 0.085326357 0.985510177 0.420443513 -0.034962294 
NonTargetingC
ontrolGene_69 
0.042761908 0.998422901 0.457736564 0.084930323 0.998422901 0.457736564 0.042168415 
NonTargetingC
ontrolGene_43 
0.323773806 0.997856576 0.39414485 0.084896178 0.997856576 0.47694779 -0.238877628 
PMS2P 0.113501082 0.943456195 0.540776061 0.084254463 0.943456195 0.540776061 -0.029246619 
SIRT3 0.044493062 0.979592947 0.513082548 0.083043652 0.979592947 0.513082548 0.03855059 
MSH2 0.269148225 0.974192869 0.401188919 0.081460828 0.974192869 0.41836272 -0.187687397 
RAD17 -0.12485428 0.503630424 0.99993315 0.079799946 0.571729947 0.99993315 0.204654226 
NonTargetingC
ontrolGene_67 
0.085174159 0.963105599 0.474021678 0.077697425 0.963105599 0.474021678 -0.007476735 
POLQ 0.206025128 0.707187804 0.452518333 0.076248616 0.707187804 0.452518333 -0.129776512 
ERCC6 0.038199894 0.742080257 0.463305052 0.073180462 0.742080257 0.463305052 0.034980568 
PMS1 0.210088274 0.958274699 0.395162706 0.07287396 0.958274699 0.471369499 -0.137214314 
KDM1A -0.079761611 0.935769267 0.576498871 0.07053469 0.935769267 0.48560199 0.1502963 
NonTargetingC
ontrolGene_8 
0.050549676 0.850087936 0.533634841 0.066427097 0.850087936 0.533634841 0.015877421 
NonTarg tingC
ontrolGene_13 
0.122333369 0.99991058 0.441098104 0.065607588 0.99991058 0.441098104 -0.056725781 
NonTargetingC
ontrolGene_38 
-0.016312358 0.995893787 0.516918944 0.0632195 0.995893787 0.516918944 0.079531857 
NonTargetingC
ontrolGene_33 
0.186983093 0.9999448 0.437487325 0.061103154 0.9999448 0.47723812 -0.125879939 
ADH5 0.217448393 0.997682785 0.454255411 0.058970422 0.997682785 0.454255411 -0.158477971 
NonTargetingC
ontrolGene_70 
0.10721369 0.999028141 0.437768735 0.057022269 0.999028141 0.437768735 -0.050191421 
DDX1 -0.23667862 0.387931432 1 0.056399734 0.617503473 1 0.293078354 
NonTargetingC
ontrolGene_40 
0.074845753 0.999499894 0.446367433 0.056313317 0.999499894 0.446367433 -0.018532436 
OR1E2 -0.179013757 0.776359 0.646068915 0.056121642 0.776359 0.639285089 0.235135399 
RAD51C -0.323902805 0.39136104 0.997588655 0.055625962 0.551480941 0.997588655 0.379528766 
CENPS 0.210625614 0.809540827 0.504680041 0.055454275 0.809540827 0.504680041 -0.155171339 
BMI1 0.072267586 0.997754667 0.473439774 0.055185658 0.997754667 0.473439774 -0.017081928 
OTUB1 -0.253278478 0.59043536 0.800128386 0.054321437 0.59043536 0.800128386 0.307599915 
PINX1 -0.12540294 0.4890233 0.974286015 0.051980864 0.617505364 0.974286015 0.177383804 
HDAC10 0.045044759 0.997973562 0.508985692 0.051578709 0.997973562 0.508985692 0.00653395 
MUS81 0.262045319 0.73378913 0.99287909 0.048414443 0.612924944 0.99287909 -0.213630876 
CCNB1 0.137667683 0.634479609 0.998111376 0.047336718 0.634018473 0.998111376 -0.090330965 
PARP15 0.062636979 0.998960655 0.514397665 0.046850503 0.998960655 0.514397665 -0.015786476 
CHRAC1 -0.165555297 0.470805861 0.883613746 0.046486978 0.542804673 0.883613746 0.212042276 
SWI5 -0.168908419 0.998147498 0.639690468 0.045976221 0.998147498 0.590926446 0.214884639 
MUTYH 0.114817047 0.663194739 0.683401713 0.045906624 0.663194739 0.683401713 -0.068910423 
FIGNL1 -0.016811797 0.606793026 0.998935428 0.043612545 0.606793026 0.998935428 0.060424343 
NonTargetingC
ontrolGene_25 
0.100703259 0.999838243 0.461086203 0.040599676 0.999838243 0.461086203 -0.060103583 
RAD9A -0.470775683 0.2339057 0.999222767 0.040428024 0.597972542 0.999222767 0.511203707 
HINFP -0.289465065 0.315293475 0.999999995 0.03964153 0.536356119 0.999999995 0.329106594 
SETDB1 -0.024883536 0.99959465 0.588933526 0.037964137 0.99959465 0.588933526 0.062847673 
EYA3 -0.248226171 0.490007368 0.978716184 0.037752302 0.537003538 0.978716184 0.285978473 
MPG 0.02048292 0.678395155 0.64260504 0.036954883 0.678395155 0.64260504 0.016471963 
NonTargetingC
ontrolGene_10 
0.033124009 0.999960589 0.470147617 0.036333663 0.999960589 0.470147617 0.003209654 
CDKN2A 0.323500887 0.999994328 0.26627578 0.036127171 0.999994328 0.462717073 -0.287373716 
MLH1 0.005062914 0.942751324 0.556658798 0.035771369 0.942751324 0.556658798 0.030708455 
NonTargetingC
ontrolGene_24 
0.011664054 0.998717176 0.549290299 0.035265353 0.998717176 0.549290299 0.023601299 
ZDHHC16 -0.15006496 0.956923154 0.713194275 0.035241763 0.956923154 0.713194275 0.185306723 
SETD2 -0.179302521 0.99309399 0.672358721 0.032913054 0.99309399 0.665279736 0.212215574 
TNKS 0.126349217 0.667495342 0.844252915 0.030902122 0.667495342 0.844252915 -0.095447096 
XPA 0.198370699 0.954356687 0.473829968 0.029963138 0.954356687 0.473829968 -0.16840756 
NFRKB -0.066215911 0.57136474 0.983903022 0.029184497 0.57136474 0.983903022 0.095400409 
RNF168 0.106702335 0.686855358 0.768789476 0.029128936 0.686855358 0.768789476 -0.077573399 
NLK 0.207005543 0.981217976 0.473667152 0.028220016 0.981217976 0.473667152 -0.178785527 
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MCM3AP -0.286180313 0.308827261 0.973219488 0.027255652 0.535656581 0.973219488 0.313435966 
NonTargetingC
ontrolGene_80 
0.067907148 0.99999086 0.476318929 0.027057008 0.99999086 0.476318929 -0.04085014 
HUS1B 0.128084867 0.999041355 0.489202098 0.026226417 0.999041355 0.529101758 -0.10185845 
RHNO1 -0.11414187 0.976984352 0.598425131 0.024436133 0.976984352 0.538649728 0.138578004 
PER2 -0.097272424 0.999727149 0.594350844 0.024410667 0.999727149 0.535196289 0.121683091 
ERCC2 -0.49491335 0.187000355 1 0.024161957 0.520286283 1 0.519075307 
HDAC4 0.101608408 0.952460343 0.448885076 0.023891255 0.952460343 0.476704027 -0.077717153 
SMARCA2 -0.028202709 0.964445153 0.590235601 0.021566155 0.964445153 0.590235601 0.049768863 
RBM7 -0.098994913 0.988203047 0.584967972 0.019306575 0.988203047 0.579838284 0.118301488 
CENPX 0.127619606 0.828940722 0.621083846 0.018985371 0.828940722 0.621083846 -0.108634234 
NonTargetingC
ontrolGene_58 
0.094635038 0.999971942 0.477072241 0.016076044 0.999971942 0.485077387 -0.078558993 
PIAS3 -0.017344841 0.955902472 0.518574108 0.015993308 0.955902472 0.518574108 0.033338149 
SPO11 0.026064919 0.999054627 0.522824139 0.010489267 0.999054627 0.522824139 -0.015575653 
DNTT 0.020176515 0.999905117 0.539049228 0.010206846 0.999905117 0.539049228 -0.009969669 
NTHL1 0.115199037 0.931538222 0.496313114 0.009576491 0.931538222 0.507212164 -0.105622546 
NonTargetingC
ontrolGene_20 
0.1619288 0.999975913 0.446068832 0.00887581 0.999975913 0.49157035 -0.15305299 
UVRAG -0.111994747 0.432851819 0.999970332 0.007630585 0.508010662 0.999970332 0.119625333 
PALB2 -0.149867519 0.501162855 0.956352073 0.007270902 0.507357419 0.956352073 0.157138421 
COPS7B -0.028425894 0.999189187 0.530865771 0.007238785 0.999189187 0.530865771 0.03566468 
OTUB2 0.00231718 0.999750694 0.497927565 0.00372368 0.999750694 0.497927565 0.0014065 
RPA2 -0.21376361 0.432295693 0.999999998 0.003205153 0.565554219 0.999999998 0.216968764 
EXO1 0.079384069 0.626652201 0.875452844 0.00281363 0.626652201 0.875452844 -0.076570439 
RAD52 0.069762424 0.728971579 0.559429461 -0.001573154 0.728971579 0.559429461 -0.071335577 
NSMCE2 -0.197583236 0.402159958 0.996527617 -0.002159382 0.560190778 0.996527617 0.195423854 
PER1 0.098799031 0.990077097 0.514606643 -0.003420442 0.990077097 0.566483139 -0.102219473 
RFC5 -0.343450701 0.321844312 1 -0.005498219 0.495744537 1 0.337952481 
MAD2L2 -0.310795125 0.337235147 0.999997565 -0.006598738 0.494569072 0.999997565 0.304196387 
ACTR8 0.022464979 0.520837149 0.99999942 -0.007928963 0.520837149 0.99999942 -0.030393941 
CRY2 0.081785464 0.8956699 0.466013717 -0.010492581 0.8956699 0.511204189 -0.092278045 
NonTargetingC
ontrolGene_51 
-0.068327269 0.984970515 0.567578657 -0.01381773 0.984970515 0.567578657 0.054509538 
POLG2 -0.189875925 0.981114272 0.681840553 -0.014193983 0.981114272 0.661018285 0.175681941 
NonTargetingC
ontrolGene_72 
0.184370111 0.99994745 0.42039104 -0.017767165 0.99994745 0.515896423 -0.202137276 
NonTargetingC
ontrolGene_53 
0.099973709 0.999999492 0.516849778 -0.018795528 0.999999492 0.530138163 -0.118769237 
TREX2 0.049093165 0.89181467 0.589818312 -0.024080832 0.89181467 0.589818312 -0.073173997 
UBE2B 0.01174031 0.967780942 0.537212607 -0.024198357 0.967780942 0.537212607 -0.035938667 
NonTargetingC
ontrolGene_57 
-0.107054688 0.999999992 0.59688114 -0.032660436 0.999999992 0.59618914 0.074394253 
PPP4R1 -0.014994947 0.856665652 0.662714626 -0.032874046 0.856665652 0.662714626 -0.017879099 
FAAP100 -0.23706679 0.348324268 0.999216741 -0.035921977 0.464012593 0.999216741 0.201144813 
BUB1B -0.402122358 0.336105544 0.999987313 -0.037794211 0.539107392 0.999987313 0.364328147 
AMN1 -0.090166737 0.99801046 0.637246295 -0.039194926 0.99801046 0.637246295 0.050971811 
TCEB1 0.160536218 0.600507844 1 -0.041932886 0.532691408 1 -0.202469104 
DNMT1 -0.323635804 0.309144761 0.999965741 -0.043745922 0.494476034 0.999965741 0.279889882 
RTEL1 -0.330234985 0.248836053 0.999998909 -0.048697101 0.448818801 0.999998909 0.281537884 
EME2 -0.058043618 0.998886994 0.583093659 -0.048859987 0.998886994 0.583093659 0.009183631 
DCLRE1C -0.115781035 0.999665045 0.605788186 -0.048911512 0.999665045 0.605788186 0.066869523 
WRN 0.131974248 0.936131005 0.479474015 -0.050541125 0.936131005 0.550005563 -0.182515373 
MYBBP1A -0.197797672 0.40555722 1 -0.051011087 0.453187843 1 0.146786585 
ATM 0.726936134 1 0.168865327 -0.051079994 1 0.540250304 -0.778016128 
TTI1 -0.573352558 0.174725054 1 -0.051534449 0.459057262 1 0.521818109 
CRY1 -0.083618706 0.920529515 0.580422196 -0.054556645 0.920529515 0.580422196 0.029062061 
NonTargetingC
ontrolGene_79 
-0.038938678 0.999287288 0.584495058 -0.056571933 0.999287288 0.584495058 -0.017633255 
MTA3 -0.030980498 0.998930186 0.547359712 -0.056767954 0.998930186 0.547359712 -0.025787456 
TOP3B -0.079061265 0.997428561 0.650585715 -0.064227809 0.997428561 0.650585715 0.014833456 
ATAD5 -0.227787361 0.639201937 0.719766489 -0.066667093 0.639201937 0.719766489 0.161120268 
SMARCC2 0.003612468 0.997555566 0.581758943 -0.067593746 0.997555566 0.581758943 -0.071206214 
NonTargetingC
ontrolGene_17 
-0.154190756 0.999962639 0.639036963 -0.069608901 0.999962639 0.633891715 0.084581856 
NonTargetingC
ontrolGene_52 
-0.114289432 0.999823905 0.686442141 -0.072605257 0.999823905 0.686442141 0.041684175 
MTA1 -0.212200519 0.620309887 0.799156054 -0.072957811 0.620309887 0.740035073 0.139242709 
ERCC6L2 -0.08184418 0.872367225 0.646306863 -0.074131153 0.872367225 0.646306863 0.007713027 
RMI2 -0.165800103 0.436135851 0.971086796 -0.076239009 0.475123909 0.971086796 0.089561095 
WDR48 0.143072651 0.618490932 0.999368917 -0.076297641 0.561616446 0.999368917 -0.219370292 
HES1 -0.027615052 0.76809946 0.612258629 -0.07793616 0.76809946 0.612258629 -0.050321108 
RNF20 -0.351332795 0.230650755 0.999999519 -0.079758738 0.412755965 0.999999519 0.271574056 
TP63 -0.037612615 0.982719463 0.659207594 -0.079866567 0.982719463 0.659207594 -0.042253952 
TCEB2 -0.67807386 0.220472453 1 -0.082553511 0.455251704 1 0.59552035 
HELQ -0.028334907 0.53104413 0.86709702 -0.083141766 0.53104413 0.86709702 -0.054806859 
UCHL5 -0.404248878 0.236702792 0.999999896 -0.08322925 0.469946513 0.999999896 0.321019628 
DDB2 -0.132236323 0.968589624 0.712817449 -0.085578697 0.968589624 0.712817449 0.046657625 
HMGN1 -0.068084139 0.991290138 0.570215911 -0.091942925 0.991290138 0.570215911 -0.023858786 
NonTargetingC
ontrolGene_44 
0.042081856 0.999913624 0.572381097 -0.092458187 0.999913624 0.587576554 -0.134540043 
SPIDR -0.06379337 0.476235924 0.816668104 -0.096322472 0.476235924 0.816668104 -0.032529102 
RFC4 -0.325879669 0.291544092 0.999840568 -0.10281324 0.458601295 0.999840568 0.223066429 
BRIP1 -0.141799403 0.47669902 0.882716175 -0.103561987 0.47669902 0.882716175 0.038237416 
RNF4 -0.341582966 0.51553963 0.863172383 -0.106123524 0.51553963 0.863172383 0.235459443 
PARP3 -0.189061477 0.999043034 0.676938494 -0.107608136 0.999043034 0.676938494 0.081453341 
NonTargetingC
ontrolGene_47 
-0.208488508 0.99765574 0.693830415 -0.107801495 0.99765574 0.679276228 0.100687013 
TCEA1 -0.032200996 0.635881387 0.597959364 -0.108261557 0.635881387 0.597959364 -0.076060561 
SUV39H1 -0.240812088 0.686927959 0.727706492 -0.109176985 0.686927959 0.727706492 0.131635103 
CUL4A -0.252242157 0.655076567 0.74258042 -0.110353907 0.655076567 0.689545238 0.14188825 
PAXIP1 0.124689613 0.640313842 0.733419247 -0.112534594 0.640313842 0.733419247 -0.237224208 
RAG1 0.0278725 0.998190338 0.609191893 -0.115658459 0.998190338 0.684703167 -0.143530959 
CCNE1 -0.087163357 0.972601188 0.624351389 -0.116624211 0.972601188 0.624351389 -0.029460854 
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RFWD3 -0.165143786 0.445843971 0.946496535 -0.117231705 0.445843971 0.946496535 0.047912081 
CDKN2D -0.075545086 0.997688613 0.685570329 -0.117830575 0.997688613 0.685570329 -0.042285489 
NonTargetingC
ontrolGene_9 
0.001714446 0.878180299 0.628679769 -0.118381474 0.878180299 0.628679769 -0.12009592 
POLK -0.190678596 0.999979036 0.682608088 -0.119929539 0.999979036 0.682608088 0.070749057 
PPP6R1 0.094075231 0.772941429 0.646705834 -0.121460479 0.772941429 0.696452101 -0.215535709 
TRIM28 -0.318105925 0.696727965 0.791868369 -0.123519183 0.696727965 0.743038716 0.194586742 
RAD23A -0.281339552 0.635087306 0.805323122 -0.123569515 0.680085256 0.805323122 0.157770037 
NonTargetingC
ontrolGene_28 
-0.151836407 0.999427371 0.645580156 -0.12665433 0.999427371 0.645580156 0.025182076 
COL21A1 -0.079655005 0.921825514 0.629774398 -0.132640326 0.921825514 0.629774398 -0.052985321 
APEX1 -0.164506127 0.975643502 0.654696958 -0.134801239 0.975643502 0.654696958 0.029704888 
RAD54L -0.067512892 0.553927821 0.930512659 -0.134807884 0.553927821 0.930512659 -0.067294992 
MSH5 -0.185385827 0.738573839 0.706570482 -0.134822708 0.738573839 0.706570482 0.05056312 
INO80 -0.316400948 0.26996301 0.998880602 -0.136755865 0.378822049 0.998880602 0.179645083 
NonTargetingC
ontrolGene_48 
-0.095008934 0.966309425 0.627350751 -0.137119687 0.966309425 0.627350751 -0.042110753 
PDS5B -0.564826034 0.164773 0.997655936 -0.137473178 0.375233179 0.997655936 0.427352856 
KDM4D -0.099761613 0.999517962 0.626749494 -0.138722503 0.999517962 0.626749494 -0.03896089 
FANCG -0.471611377 0.19714898 0.999845823 -0.145802356 0.374626323 0.999845823 0.325809021 
SMUG1 -0.241451733 0.926775706 0.722752663 -0.146968892 0.926775706 0.722752663 0.094482841 
NonTargetingC
ontrolGene_59 
0.011533528 0.980263038 0.59738111 -0.147028836 0.980263038 0.643751122 -0.158562364 
ARID1A -0.26679015 0.459801678 0.960738841 -0.153405917 0.460648157 0.960738841 0.113384233 
NonTargetingC
ontrolGene_41 
-0.174044727 0.985115366 0.664975186 -0.153847782 0.985115366 0.664975186 0.020196945 
RAD23B -0.203060898 0.726194025 0.689054646 -0.161824982 0.726194025 0.689054646 0.041235915 
USP1 -0.178477004 0.590243354 0.848664132 -0.165343827 0.590243354 0.848664132 0.013133176 
NonTargetingC
ontrolGene_65 
0.002317818 0.999999721 0.640099925 -0.16833555 0.999999721 0.650712797 -0.170653367 
WRAP53 -0.530918051 0.206508048 0.999668421 -0.171619034 0.346982738 0.999668421 0.359299017 
CTC1 -0.646536128 0.171305894 0.999977979 -0.176956051 0.398744547 0.999977979 0.469580077 
PIAS4 -0.091510459 0.530232231 0.788581482 -0.183930595 0.530232231 0.788581482 -0.092420136 
FAAP20 0.04531898 0.545811951 0.704574993 -0.191146335 0.529341341 0.704574993 -0.236465315 
ATRIP -0.430669068 0.203753298 0.998218448 -0.191529181 0.343011224 0.998218448 0.239139886 
DTX2 -0.216824845 0.671581355 0.696367427 -0.196863007 0.671581355 0.696367427 0.019961838 
ENDOV -0.20974255 0.999296873 0.717721773 -0.203881355 0.999296873 0.717721773 0.005861196 
NCAPH -0.538643734 0.127392844 0.99898725 -0.204687572 0.33424038 0.99898725 0.333956161 
UHRF1 -0.384034522 0.261600482 0.99999626 -0.220104155 0.337463247 0.99999626 0.163930368 
TADA3 -0.102741899 0.433691801 0.915647428 -0.221515107 0.433691801 0.915647428 -0.118773208 
MPLKIP -0.281904592 0.417071503 0.839815793 -0.22373901 0.417071503 0.839815793 0.058165582 
HUS1 -0.231085161 0.3202775 0.999975309 -0.242631865 0.3202775 0.999975309 -0.011546704 
ZSWIM7 -0.211411608 0.735231576 0.724270237 -0.247060996 0.735231576 0.724270237 -0.035649388 
NFE2L2 -0.251395388 0.300917887 0.994462838 -0.250111291 0.300917887 0.994462838 0.001284098 
KDM4A -0.53778644 0.166800392 0.999685556 -0.259415828 0.261393687 0.999685556 0.278370612 
NonTargetingC
ontrolGene_29 
-0.189504919 0.999999932 0.720769173 -0.262059244 0.999999932 0.720769173 -0.072554325 
FANCB -0.496912034 0.256489302 0.995133965 -0.270325579 0.334949315 0.995133965 0.226586455 
GTF2H5 -0.329634928 0.299807685 0.999989346 -0.27587607 0.299807685 0.999989346 0.053758858 
XRCC1 -0.106298568 0.503469724 0.83560372 -0.280389207 0.443528978 0.83560372 -0.174090638 
KDM2A -0.558518598 0.434804887 0.910732661 -0.283781803 0.434804887 0.910732661 0.274736795 
NonTargetingC
ontrolGene_73 
-0.110602421 0.999988159 0.74150653 -0.284517369 0.999988159 0.74150653 -0.173914947 
POLE  -0.236645108 0.308110286 0.999987142 -0.294164681 0.308110286 0.999987142 -0.057519573 
FANCL -0.396020418 0.280568326 0.999999866 -0.297233892 0.280568326 0.999999866 0.098786525 
FANCA -0.503828788 0.209442566 0.968847838 -0.306267119 0.212293296 0.968847838 0.197561669 
SSBP1 -0.24047795 0.828033245 0.768758977 -0.307391809 0.828033245 0.768758977 -0.06691386 
TDP1 -0.296059632 0.743472684 0.813004354 -0.312638648 0.743472684 0.813004354 -0.016579015 
CUL2 -0.43007583 0.180360854 0.999999866 -0.314123621 0.241613681 0.999999866 0.115952209 
ATRX -0.223235115 0.584883682 0.796610207 -0.32493211 0.584883682 0.796610207 -0.101696995 
RAD51B -0.504569208 0.161939293 0.9999845 -0.326316295 0.235724626 0.9999845 0.178252913 
UBB -0.408509311 0.712171643 0.810120028 -0.326993265 0.712171643 0.810120028 0.081516046 
ACTR5 -0.280987237 0.309331697 0.999664378 -0.329951219 0.309331697 0.999664378 -0.048963982 
CCNC -0.079634918 0.999898713 0.643277447 -0.340115894 0.999898713 0.784447098 -0.260480977 
XRCC4 -0.692794146 0.091989725 0.983404757 -0.34197341 0.175353771 0.983404757 0.350820737 
CNOT7 -0.295707409 0.288024187 0.942650234 -0.34487223 0.288024187 0.942650234 -0.049164821 
FAAP24 -0.258183287 0.289786957 0.999280513 -0.348474845 0.262097914 0.999280513 -0.090291558 
DSCC1 -0.531996416 0.140551596 0.999994766 -0.355920038 0.210479682 0.999994766 0.176076378 
ERCC4 -0.398931986 0.252285106 0.999998625 -0.369082173 0.252285106 0.999998625 0.029849814 
PRKDC -1.052365726 0.107027335 0.997540738 -0.384213058 0.283092828 0.997540738 0.668152668 
ZMPSTE24 -0.369169724 0.278722686 0.99078592 -0.386573497 0.278722686 0.99078592 -0.017403773 
CEP57 -0.724040032 0.081750529 0.999999863 -0.389291065 0.225622191 0.999999863 0.334748967 
SUMO2 -0.055497564 0.592600641 0.874235475 -0.391802644 0.592600641 0.874235475 -0.336305079 
NAE1 -0.464061867 0.106455892 0.999999565 -0.41210036 0.128353976 0.999999565 0.051961507 
ERCC1 -0.761019077 0.121299122 0.999920277 -0.41620847 0.231041197 0.999920277 0.344810607 
TERT -1.120561076 0.043657438 0.999994311 -0.429838048 0.242057508 0.999994311 0.690723029 
FZR1 -0.388999548 0.182286415 1 -0.441190194 0.167080847 1 -0.052190646 
CREBBP -0.529525138 0.200253782 0.977017433 -0.450868105 0.200253782 0.977017433 0.078657033 
PARP1 -0.497157357 0.279310195 0.90920163 -0.470447165 0.279310195 0.90920163 0.026710192 
TELO2 -0.789127642 0.081905094 0.999999997 -0.476377261 0.176882663 0.999999997 0.312750381 
POLG -0.383028325 0.400960382 0.874455448 -0.481244409 0.400960382 0.874455448 -0.098216083 
TFPT -0.301295778 0.297516508 0.890885344 -0.485778145 0.297516508 0.890885344 -0.184482367 
FANCF -0.540715666 0.115596019 0.999997085 -0.505680481 0.115596019 0.999997085 0.035035184 
ENY2 -0.971981534 0.148082476 0.971646103 -0.50606681 0.218434077 0.971646103 0.465914724 
NHEJ1 -0.731347402 0.121990341 0.989815203 -0.528542438 0.18793881 0.989815203 0.202804964 
LMNA -1.019814402 0.106849512 0.988127832 -0.539154303 0.183523833 0.988127832 0.4806601 
SIN3A -0.448706121 0.136922181 0.999999614 -0.546778344 0.119723101 0.999999614 -0.098072224 
RAD50 -0.612330237 0.043572166 0.999999891 -0.646348762 0.037270877 0.999999891 -0.034018525 
NBN 0.129128469 0.797503888 0.750377074 -0.650386391 0.561989758 0.937556694 -0.77951486 
FANCC -0.655601424 0.084856054 0.999998236 -0.657318106 0.084856054 0.999998236 -0.001716682 
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LIG4 -0.80476088 0.089990965 0.997992962 -0.690597891 0.093721735 0.997992962 0.114162988 
UBE2N -1.016751085 0.01951038 0.999808198 -0.69824877 0.068995853 0.999808198 0.318502315 
UBE2M -0.859090131 0.119797607 0.99993481 -0.713969218 0.119797607 0.99993481 0.145120913 
RNASEH2A -0.985021172 0.059056933 0.999838311 -0.714404668 0.074537796 0.999838311 0.270616503 
BAP1 -0.861019258 0.06781337 0.991006485 -0.721855485 0.073380185 0.991006485 0.139163773 
TEN1 -1.379092553 0.007574556 1 -0.895302063 0.048887649 1 0.48379049 
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Appendix Table 5 Raw data from JACKS analysis of RPE-1 WT 5nM CPT  
RPE-1 WT DMSO and 5nM CPT treated enrichments compared to the day 14 control. fdr=false discovery 
rate 
 
Gene Enrichment in 
DMSO treated 
neg_fdr1 pos_fdr1 Enrichment in 
5nM CPT treated 
neg_fdr2 pos_fdr2 Difference in 
Enrichment  
TP53 3.478343858 1 7.03E-10 5.839756226 1 0 2.361412369 
CDKN1A 1.548402497 1 0.006661002 2.273239869 1 2.21007E-04 0.724837372 
RNF146 3.342174495 1 1.14E-08 2.174441437 1 7.45E-05 -1.167733057 
CAND1 3.251324882 1 9.85E-09 2.011668366 1 1.36765E-04 -1.239656516 
PTEN 2.989153557 1 6.03E-08 1.879284785 1 6.11774E-04 -1.109868773 
BRD7 1.222877703 1 0.02120377 1.843158685 1 0.006609599 0.620280981 
UBC 1.078420637 0.999658144 0.051744941 1.814365861 0.999658144 0.003076703 0.735945224 
KEAP1 2.483000039 1 2.16E-05 1.792946949 1 9.67406E-04 -0.69005309 
NEDD8 1.316840385 0.997608314 0.052826231 1.791081182 0.997608314 0.012511861 0.474240798 
POLR2E 1.219824327 0.999348419 0.037929435 1.720186375 0.999348419 0.005864225 0.500362047 
POLR2A 0.844985861 0.999743729 0.089551101 1.666908986 0.999743729 0.001625139 0.821923125 
UBE2D3 0.74016914 0.996663275 0.319471661 1.620742576 0.996663275 0.026958571 0.880573436 
TINF2 1.100595288 0.999707723 0.033739 1.613741623 0.999707723 0.003422671 0.513146335 
ARID2 1.568928223 1 0.002943369 1.558508326 1 0.002943369 -0.010419896 
NHP2 1.38567457 0.999210651 0.017170615 1.556318991 0.999210651 0.007662606 0.170644422 
H2AFZ 1.807149541 1 0.001542282 1.528441243 1 0.00422173 -0.278708298 
THOC2 0.897782531 0.99942868 0.091272149 1.51225068 0.99942868 0.004594557 0.61446815 
VCP 1.21433551 0.999408308 0.01031894 1.511640768 0.999408308 0.003025065 0.297305259 
PARG 1.224402373 0.995565538 0.042044953 1.500145721 0.995565538 0.03872594 0.275743348 
UPF1 1.123865534 0.99939939 0.019163465 1.46767638 0.99939939 0.003314716 0.343810846 
CHEK2 1.061693034 1 0.018781658 1.467617967 1 0.003619417 0.405924933 
FANCD2 0.768656194 0.998603983 0.173537091 1.446919576 0.998603983 0.009756588 0.678263383 
TRIP13 1.067703935 0.996766587 0.066606999 1.429255489 0.996766587 0.020665527 0.361551554 
XRCC6 1.420821193 0.996425727 0.017788114 1.422047939 0.996425727 0.017788114 0.001226746 
POLR2G 1.040481506 0.998702537 0.047424725 1.408427396 0.998702537 0.008032543 0.367945891 
HNRNPK 1.151021266 0.998457502 0.034694387 1.404507885 0.998457502 0.010137349 0.253486619 
BABAM1 1.274140118 1 0.0052029 1.397745839 1 0.004027136 0.123605721 
RPS27L 0.730379459 0.994490993 0.325118111 1.386822746 0.994490993 0.04729164 0.656443286 
USP28 1.501057011 1 0.001295878 1.370255485 1 0.002906934 -0.130801526 
RRM1 0.820813157 0.994380199 0.17057678 1.357438986 0.994380199 0.026712064 0.536625829 
POLR2I 1.161224126 0.999089699 0.013897347 1.35641392 0.999089699 0.006941804 0.195189794 
MDM4 0.869317978 0.999708607 0.027373616 1.352583504 0.999708607 0.002622541 0.483265526 
RNF7 1.992484214 1 8.41E-05 1.343416666 1 0.004618119 -0.649067548 
ASCC1 1.277043384 0.999128493 0.00594499 1.34012311 0.999128493 0.00594499 0.063079726 
SOD1 0.795714541 0.995957182 0.297691842 1.338386072 0.995957182 0.064629127 0.54267153 
SUPT5H 1.246177214 0.999366891 0.00543512 1.338379085 0.999366891 0.003472975 0.092201871 
SMC2 1.180896449 0.99918801 0.008957961 1.333491509 0.99918801 0.005367751 0.15259506 
UBE2I 1.001190375 0.996570528 0.060585709 1.326586404 0.996570528 0.023703545 0.32539603 
POLR2D 0.904087783 0.998352112 0.086472326 1.321755405 0.998352112 0.019059897 0.417667622 
MASTL 0.883977082 0.997129735 0.081320799 1.30211832 0.997129735 0.016672547 0.418141238 
PPP4C 0.609274956 0.995421926 0.347698274 1.296997829 0.995421926 0.021822068 0.687722873 
SFPQ 1.159703742 0.997777455 0.014166462 1.296373927 0.997777455 0.014166462 0.136670185 
CCNH 0.994625196 0.998363641 0.064727007 1.284025028 0.998363641 0.014954456 0.289399831 
CCND1 0.823227575 0.996336636 0.12009587 1.28380045 0.996336636 0.027245401 0.460572875 
MDM2 0.709913641 0.999296181 0.079859685 1.277644984 0.999296181 0.006781752 0.567731342 
PCNA 0.638126227 0.996830336 0.244456705 1.274937065 0.996830336 0.015933777 0.636810838 
H2AFX 0.944368353 0.998598322 0.040684137 1.241928704 0.998598322 0.009308027 0.297560351 
CUL3 2.544711008 1 5.87E-08 1.238580416 1 0.007455089 -1.306130592 
DCUN1D3 1.710527193 1 0.00108847 1.237979875 1 0.010333614 -0.472547319 
APEX2 0.499736041 0.993601958 0.427304879 1.215845994 0.993601958 0.045902673 0.716109953 
UBE2F 2.157784094 1 1.41307E-04 1.215510244 1 0.012666928 -0.942273849 
COPS4 0.927344964 0.996519824 0.081713373 1.213089334 0.996519824 0.025235778 0.28574437 
ERCC6L 1.09147551 0.995790705 0.024750777 1.210834785 0.995790705 0.024750777 0.119359275 
DNAJC2 0.64827602 0.994253356 0.253706572 1.205720221 0.994253356 0.051719793 0.557444201 
WAPL 1.22277863 0.991839751 0.028081849 1.180023786 0.991839751 0.028081849 -0.042754843 
POLL 1.023597645 0.995018218 0.033412652 1.178551061 0.995018218 0.033412652 0.154953416 
TOP1 0.794316168 0.995683636 0.098703312 1.151808487 0.995683636 0.026655039 0.357492319 
NPM1 0.877513543 0.987281768 0.202109067 1.147659741 0.987281768 0.118981516 0.270146198 
PLK1 0.719615666 0.998089148 0.117179068 1.143492521 0.998089148 0.014438922 0.423876855 
RAD21 0.793491497 0.992826602 0.169308031 1.140657841 0.992826602 0.063919118 0.347166345 
CDK4 0.866901776 0.994950855 0.125128634 1.138345958 0.994950855 0.052846951 0.271444181 
TICRR 0.780954623 0.998537571 0.104551121 1.128696793 0.998537571 0.021453942 0.34774217 
DKC1 0.83340222 0.996300223 0.126259375 1.115466371 0.996300223 0.047331321 0.282064151 
PNN 0.834358345 0.997902515 0.044707643 1.107816816 0.997902515 0.012646814 0.273458471 
GPS1 0.596238841 0.991719994 0.35462115 1.10737099 0.991719994 0.07316407 0.511132149 
DCLRE1B 0.69692639 0.987281035 0.235747477 1.094696472 0.987281035 0.063407231 0.397770081 
SMC1A 1.051782928 0.992995034 0.063262757 1.092997799 0.992995034 0.063262757 0.041214871 
TP53BP1 1.164112135 1 0.019079977 1.092823541 1 0.019079977 -0.071288594 
CHAF1A 0.873093909 0.995065372 0.06059186 1.086233694 0.995065372 0.035416204 0.213139785 
RPAIN 0.660322488 0.993352226 0.180150532 1.080845942 0.993352226 0.031759254 0.420523453 
CDK9 0.647511273 0.974297575 0.326920002 1.078854698 0.974297575 0.190145135 0.431343424 
SCAF4 2.027124007 1 1.12026E-04 1.075727298 1 0.016190019 -0.951396708 
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TERF2 0.731185088 0.977439919 0.275266616 1.075640205 0.977439919 0.116369333 0.344455118 
POLE2 0.627275302 0.995019808 0.177439228 1.073688898 0.995019808 0.044821728 0.446413597 
USP37 0.651572418 0.993616294 0.19983209 1.070266226 0.993616294 0.042914486 0.418693808 
PPP4R2 0.861925299 0.992153067 0.150266243 1.069577908 0.992153067 0.107289101 0.207652609 
PPP4R3B 0.917753086 0.993541008 0.043391854 1.06908882 0.993541008 0.038987578 0.151335734 
SMC4 1.019371979 0.997535657 0.029737842 1.068668444 0.997535657 0.029737842 0.049296464 
USP5 0.647932938 0.993647465 0.192219458 1.061146175 0.993647465 0.031033385 0.413213236 
BRCA2 0.692271982 0.996405184 0.056377273 1.061041532 0.996405184 0.016202843 0.36876955 
UBE2T 0.732915298 0.982067098 0.269670205 1.055115303 0.982067098 0.104776972 0.322200005 
CHEK1 0.571655384 0.980397889 0.380679277 1.053877128 0.980397889 0.117866344 0.482221744 
TTI2 0.448339822 0.98798189 0.494958822 1.04460211 0.98798189 0.057028021 0.596262288 
SUPT4H1 0.701185205 0.980619787 0.277921111 1.042314235 0.980619787 0.137983536 0.34112903 
POLR2H 0.815835883 0.997758477 0.068571978 1.035831304 0.997758477 0.026870878 0.219995422 
ATR 0.954095586 0.99380791 0.074905632 1.033238588 0.99380791 0.061476743 0.079143002 
POLD3 0.750650972 0.999843055 0.023063205 1.021940896 0.999843055 0.009074953 0.271289925 
RUVBL2 0.488938307 0.995203032 0.311492839 1.016593204 0.995203032 0.035371872 0.527654897 
CHD3 0.995587622 0.991912216 0.028208578 1.007993134 0.991912216 0.028208578 0.012405512 
SMG1 0.778542329 0.987292224 0.1227647 1.004357639 0.987292224 0.067803378 0.22581531 
POLR2L 0.678906203 0.987939077 0.225688715 1.003353616 0.987939077 0.084695833 0.324447413 
COPS3 0.644020139 0.988603626 0.215172887 0.999708537 0.988603626 0.102567369 0.355688397 
DNA2 0.483948473 0.973856355 0.488303297 0.99511301 0.973856355 0.160991679 0.511164536 
ACD 0.61831279 0.982712271 0.265566728 0.989564378 0.982712271 0.126892223 0.371251589 
RUVBL1 0.683546411 0.990871965 0.212939865 0.985105621 0.990871965 0.084279367 0.30155921 
STAG2 1.526033493 0.999999998 0.003144522 0.978755894 0.999999998 0.039133738 -0.547277599 
NCAPD3 0.466598138 0.985103036 0.277419456 0.976242641 0.985103036 0.070961265 0.509644502 
UBA3 1.080529152 0.994051665 0.028282293 0.969169561 0.994051665 0.039658077 -0.111359591 
ASF1A 1.004582547 0.992322994 0.034672897 0.966979981 0.992322994 0.034672897 -0.037602566 
SMC5 0.633037318 0.99410568 0.265722904 0.963304287 0.99410568 0.089447773 0.330266969 
USP7 0.630685863 0.997173314 0.210344337 0.962179313 0.997173314 0.061423531 0.331493451 
CUL5 1.497920684 1 0.00186744 0.960426739 1 0.024218267 -0.537493945 
GTF2H2 0.825960389 0.983875327 0.298260716 0.95895141 0.983875327 0.298260716 0.132991021 
DCLRE1A 1.055831103 0.999578127 0.037537926 0.956168668 0.999578127 0.037537926 -0.099662434 
POLA1 0.902565703 0.992727618 0.06890491 0.949316331 0.992727618 0.06890491 0.046750628 
PNKP 0.6016236 0.986698291 0.237818407 0.948148714 0.986698291 0.10674828 0.346525114 
TEP1 0.934910019 0.9949726 0.039248942 0.942649291 0.9949726 0.039248942 0.007739273 
COPS6 0.812914627 0.995788736 0.12361223 0.933218399 0.995788736 0.094114131 0.120303772 
HDAC3 0.367283077 0.973752172 0.721775953 0.928694708 0.973752172 0.185745615 0.561411631 
RNF126 0.729115717 0.98261248 0.109412227 0.927822192 0.98261248 0.083640997 0.198706475 
TONSL 0.65221681 0.984422249 0.217480272 0.927009537 0.984422249 0.100426795 0.274792727 
XAB2 0.57591632 0.992620544 0.216069106 0.926118368 0.992620544 0.047838964 0.350202049 
SPRTN 0.720521563 0.991903735 0.092452466 0.924683153 0.991903735 0.043053879 0.204161589 
COPS8 0.535714299 0.942254364 0.547492294 0.922210493 0.942254364 0.355310586 0.386496195 
UBE2W 0.876941483 0.991327705 0.029246599 0.922045832 0.991327705 0.029246599 0.045104349 
XRCC5 0.678004709 0.986959415 0.107422336 0.915847692 0.986959415 0.073694186 0.237842984 
BCCIP 0.444198368 0.971715887 0.516373643 0.913936038 0.971715887 0.145883047 0.469737669 
PPM1D 0.356217552 0.978428922 0.656240543 0.906157907 0.978428922 0.097824862 0.549940356 
APAF1 0.9340822 0.999769105 0.045435651 0.90294845 0.999769105 0.061545504 -0.031133751 
MNAT1 0.326048196 0.937788527 0.811826771 0.901423732 0.953900783 0.37848029 0.575375535 
TET2 0.961352491 0.999998163 0.053624086 0.893825353 0.999998163 0.056907656 -0.067527137 
MAPK8 0.987010362 0.999525364 0.041435367 0.88305418 0.999525364 0.045106756 -0.103956182 
GTF2H1 0.765687306 0.985989059 0.114474111 0.881601836 0.985989059 0.090181841 0.11591453 
POLD1 0.665823754 0.975782143 0.189344575 0.874987941 0.975782143 0.120412834 0.209164186 
PHIP 1.190806885 1 0.018075463 0.874902793 1 0.037564294 -0.315904092 
UCHL3 0.734197915 0.990060866 0.101431848 0.872106967 0.990060866 0.101431848 0.137909053 
SMARCE1 0.656105281 0.953730866 0.239854599 0.861437311 0.953730866 0.239854599 0.20533203 
MAPKAPK2 1.052642319 1 0.033510011 0.851037319 1 0.05758942 -0.201605001 
DMC1 0.73527993 0.999556483 0.074692826 0.850885468 0.999556483 0.051355478 0.115605538 
NonTargetingCo
ntrolGene_77 
1.053700789 0.99999303 0.044109855 0.846338936 0.99999303 0.06474499 -0.207361852 
RBX1 0.939828133 0.98131896 0.097311233 0.844051172 0.98131896 0.097311233 -0.095776961 
UBA1 0.473635204 0.978447394 0.374095522 0.843628437 0.978447394 0.109264778 0.369993232 
NOP10 0.280743976 0.943532357 0.798424501 0.843174956 0.972454592 0.234961302 0.562430979 
RPA1 0.442165533 0.95627332 0.541128882 0.839408621 0.95627332 0.225500397 0.397243089 
DAXX 0.457122673 0.973070034 0.417385363 0.833865452 0.973070034 0.125803507 0.376742779 
PCID2 0.448915706 0.967975412 0.478618712 0.833852664 0.967975412 0.153627593 0.384936958 
GAR1 0.607701084 0.971597461 0.245209734 0.819809848 0.971597461 0.139906761 0.212108764 
KMT5B 0.648701797 0.999968266 0.103565356 0.816092391 0.999968266 0.064170549 0.167390594 
NonTargetingCo
ntrolGene_27 
0.606066621 0.99983586 0.147679814 0.812723289 0.99983586 0.071219003 0.206656668 
PMS2 0.67722614 0.962221154 0.15340566 0.808713668 0.962221154 0.15340566 0.131487528 
NCAPD2 0.835052204 0.993107623 0.091277018 0.803877949 0.993107623 0.105431735 -0.031174255 
KAT8 0.313370111 0.971895592 0.732243619 0.796492949 0.983369007 0.211176027 0.483122838 
PRPF19 0.368630712 0.975059426 0.572795487 0.793369921 0.975059426 0.163494597 0.424739209 
THOC1 0.376679817 0.977654268 0.511834518 0.793190054 0.977654268 0.158664095 0.416510237 
MTA2 0.966456629 0.999859602 0.040785377 0.789321014 0.999859602 0.072500219 -0.177135615 
GADD45G 0.767118456 0.999993748 0.109459973 0.78463892 0.999993748 0.109459973 0.017520464 
LIG1 0.408442556 0.95099314 0.546549017 0.781347689 0.95099314 0.396067329 0.372905134 
DDX11 0.940904613 0.977610396 0.148517407 0.778629729 0.977610396 0.148517407 -0.162274884 
EYA1 0.760901764 0.990056724 0.085153923 0.777243836 0.990056724 0.085153923 0.016342072 
RAD51 0.346951985 0.961409067 0.70174548 0.773769458 0.961409067 0.237484521 0.426817473 
BRE 1.202639487 0.999999447 0.016665748 0.770327538 0.999999447 0.082524807 -0.43231195 
STN1 0.385883857 0.96521081 0.525693718 0.765795192 0.96521081 0.177040794 0.379911336 
APC 0.950329669 1 0.018941734 0.764133153 1 0.032557745 -0.186196517 
SF3B1 0.396857231 0.985254946 0.167453355 0.758708257 0.985254946 0.055963987 0.361851025 
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HELB 0.568693343 0.99823044 0.173793352 0.757672203 0.99823044 0.106849088 0.18897886 
SSBP3 0.869913407 0.993437983 0.124852644 0.757239201 0.993437983 0.124852644 -0.112674206 
RBBP8 0.501838356 0.96332858 0.333322767 0.75516921 0.96332858 0.290947083 0.253330854 
CDCA5 0.471446315 0.953015111 0.410465928 0.753898202 0.953015111 0.355940538 0.282451887 
DUT 0.532754467 0.963292454 0.264972384 0.748134956 0.963292454 0.264972384 0.21538049 
SCAF11 0.893994862 0.986336654 0.065113885 0.740654074 0.986336654 0.106747942 -0.153340788 
MCRS1 0.579872089 0.962567628 0.238472544 0.735886139 0.962567628 0.237193944 0.15601405 
CSNK2B 0.267964331 0.925706318 0.814131287 0.735265482 0.925706318 0.668643136 0.46730115 
NCAPG2 0.353751211 0.964674732 0.648837051 0.734059972 0.964674732 0.248514921 0.38030876 
MMS22L 0.443912075 0.993358946 0.316429493 0.724518392 0.993358946 0.095969568 0.280606317 
FANCI 0.451293692 0.938329569 0.525008094 0.72082028 0.938329569 0.347230403 0.269526587 
HDAC9 1.004834047 0.999999739 0.031717342 0.719837671 0.999999739 0.061757606 -0.284996376 
ERCC3 0.259299845 0.90174041 0.895939043 0.712533846 0.951370037 0.387855137 0.453234001 
POLR2K 0.553599397 0.950612481 0.466559829 0.709769291 0.950612481 0.450585517 0.156169894 
UBA2 0.394634327 0.971728077 0.574803006 0.706488579 0.971728077 0.306140555 0.311854252 
RPA3 0.334188058 0.948213769 0.69465913 0.701548343 0.948213769 0.251679352 0.367360285 
SENP8 1.397902065 1 0.018598027 0.700992654 1 0.124909829 -0.696909411 
ACTL6A 0.358286421 0.970335202 0.609068499 0.698453741 0.970335202 0.221222324 0.34016732 
SKP1 0.72028588 0.9118113 0.411038191 0.697838812 0.9118113 0.411038191 -0.022447068 
TERF1 0.300716598 0.891230903 0.881866827 0.696338881 0.891230903 0.686687749 0.395622283 
EP300 0.972588809 1 0.040019774 0.693616665 1 0.07019854 -0.278972144 
NEIL1 0.414464269 0.967157443 0.197009555 0.690933754 0.967157443 0.189189276 0.276469485 
CSNK1D 0.582612508 0.998727585 0.105453163 0.688091773 0.998727585 0.105453163 0.105479265 
GTF2H3 0.252724093 0.928549406 0.83338472 0.685450757 0.95911275 0.292084438 0.432726664 
BRCC3 1.10574645 0.99999999 0.063021436 0.67906394 0.99999999 0.129582776 -0.42668251 
BRCA1 0.550838477 0.955113721 0.283203934 0.67890862 0.955113721 0.262227722 0.128070143 
NSMCE1 0.187589796 0.867557448 0.975699288 0.678901025 0.955246461 0.204691963 0.491311228 
HUWE1 0.334594436 0.973696627 0.616699647 0.669553069 0.973696627 0.246624112 0.334958633 
RFC2 0.468266061 0.937529267 0.519520376 0.668029589 0.937529267 0.394048838 0.199763528 
APOBEC3C 0.651966331 0.995992372 0.161640284 0.662949724 0.995992372 0.161640284 0.010983394 
GTF2H4 0.447515912 0.960760387 0.388348798 0.65946552 0.960760387 0.223851421 0.211949608 
RAD1 0.323759743 0.901107482 0.81722643 0.651998964 0.901107482 0.447352348 0.328239221 
YBX1 0.13271515 0.743065398 0.999992389 0.647495605 0.840390641 0.795249761 0.514780456 
RECQL 0.870503241 0.991266977 0.106949165 0.643391453 0.991266977 0.149410788 -0.227111788 
SETX 0.638301636 0.956660985 0.104585117 0.642760559 0.956660985 0.104585117 0.004458923 
BCLAF1 0.931145382 1 0.096179445 0.640527458 1 0.160306515 -0.290617924 
PMS2P5 0.138202807 0.642106223 0.567006492 0.637981541 0.642106223 0.567006492 0.499778734 
THRAP3 0.993672044 1 0.049885242 0.634770018 1 0.137171968 -0.358902026 
NonTargetingCo
ntrolGene_12 
0.500963774 0.995789702 0.150159785 0.632748896 0.995789702 0.150159785 0.131785122 
PRMT1 0.376784763 0.954860129 0.508823395 0.632347451 0.954860129 0.304772787 0.255562688 
POLR2J 0.718039456 0.996488758 0.151021882 0.628387265 0.996488758 0.151021882 -0.089652192 
NOTCH3 0.629412445 0.994536715 0.114422057 0.625477466 0.994536715 0.114422057 -0.00393498 
POLR2F 0.430626457 0.963045892 0.427068794 0.624330295 0.963045892 0.305987292 0.193703839 
SUPT6H 0.474132851 0.974460321 0.366703068 0.623610778 0.974460321 0.275097337 0.149477927 
ECT2 0.514413137 0.945441559 0.314002487 0.623015299 0.945441559 0.278317049 0.108602162 
L3MBTL1 0.854595326 0.999081574 0.034925472 0.622960338 0.999081574 0.086390665 -0.231634988 
CBX5 0.366269036 0.913303254 0.48031268 0.621978365 0.913303254 0.48031268 0.255709329 
SUMO4 0.463018295 0.958853859 0.212663185 0.619458656 0.958853859 0.153849462 0.156440361 
CUL1 0.281142958 0.852117278 0.817536936 0.618087586 0.910397649 0.806421161 0.336944628 
WEE1 0.600200634 0.971297942 0.233526736 0.61679714 0.971297942 0.233526736 0.016596506 
CCND3 0.780095793 0.99943543 0.03918954 0.613744292 0.99943543 0.067200257 -0.166351501 
ATMIN 0.504352778 0.945798935 0.407700882 0.613101145 0.945798935 0.392876994 0.108748367 
NONO 0.317595834 0.924561884 0.677445624 0.612648738 0.924561884 0.647037783 0.295052905 
TAF1 0.559692212 0.960873048 0.35466535 0.611123834 0.960873048 0.35466535 0.051431622 
ANKRD52 0.392471217 0.919276861 0.538245639 0.610599015 0.919276861 0.36346902 0.218127798 
SMC6 0.167952582 0.820466401 0.999345574 0.609708773 0.886668239 0.684501774 0.441756191 
MTOR 0.367836152 0.97405185 0.483736938 0.608388275 0.97405185 0.246902131 0.240552123 
CHD4 0.349677869 0.948970665 0.557518574 0.60731505 0.948970665 0.318866757 0.257637181 
ALKBH2 0.746975538 0.987312972 0.123447394 0.603786018 0.987312972 0.163587799 -0.14318952 
SMARCB1 0.37323629 0.958125566 0.727687149 0.59841862 0.958125566 0.618036036 0.225182331 
APOBEC1 0.734016869 0.956864874 0.234856141 0.597171999 0.956864874 0.234856141 -0.13684487 
INO80E 0.599795954 0.915057453 0.305161286 0.589979126 0.915057453 0.305161286 -0.009816828 
NCAPH2 0.319972736 0.958320243 0.757017051 0.588922948 0.958320243 0.485389183 0.268950212 
NOTCH2 0.510715064 0.91600724 0.344733419 0.588493958 0.91600724 0.344733419 0.077778894 
PBRM1 0.687943917 1 0.135051244 0.586353275 1 0.135202919 -0.101590643 
CSNK2A2 0.50986497 0.999868116 0.163497721 0.586137615 0.999868116 0.138047626 0.076272644 
PDS5A 0.223515701 0.881387988 0.943428028 0.583780693 0.903669151 0.747192437 0.360264992 
DTX4 0.768386081 0.999941958 0.048127349 0.582824383 0.999941958 0.100502891 -0.185561697 
COPS2 0.568854641 0.972442529 0.21942953 0.582187508 0.972442529 0.21942953 0.013332867 
BRD4 0.366077075 0.954687836 0.459386861 0.580963612 0.954687836 0.228469914 0.214886537 
USP11 0.538775995 0.977479353 0.153262321 0.58058747 0.977479353 0.153262321 0.041811475 
BCAS2 0.393516836 0.952015502 0.519345734 0.579187998 0.952015502 0.321132075 0.185671162 
NELFB 0.326455677 0.92473282 0.614812545 0.57875234 0.92473282 0.614812545 0.252296664 
SIRT7 0.247455597 0.999664558 0.268494609 0.575320168 0.999664558 0.161013986 0.327864571 
XRCC2 0.467780347 0.962583472 0.408856284 0.57498531 0.962583472 0.408856284 0.107204963 
MORF4L2 0.399172218 0.909420079 0.401249076 0.573253985 0.909420079 0.401249076 0.174081767 
SIRT1 0.31689217 0.999600581 0.201449853 0.57198745 0.999600581 0.143449576 0.255095279 
SPTBN1 0.886349276 1 0.039491377 0.57189824 1 0.114241101 -0.314451036 
WRNIP1 0.32049541 0.995688479 0.305766406 0.568113115 0.995688479 0.188067147 0.247617705 
SMARCD1 0.525308641 0.999812917 0.137079121 0.567089118 0.999812917 0.137079121 0.041780477 
CCNB3 0.717691187 0.999788155 0.076506761 0.5626955 0.999788155 0.128605479 -0.154995688 
TIMELESS 0.402455917 0.904159214 0.506353162 0.5614994 0.904159214 0.453628084 0.159043483 
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POLM 0.707251649 0.999967463 0.066705271 0.559886889 0.999967463 0.098898365 -0.14736476 
USP51 0.515818535 0.999505252 0.193741697 0.55982461 0.999505252 0.193024582 0.044006075 
KAT5 0.255786644 0.939740242 0.67560114 0.55391209 0.939740242 0.347298061 0.298125446 
RAD54L2 0.528436525 0.99939853 0.175195409 0.552639103 0.99939853 0.175195409 0.024202578 
APOBEC2 0.606607318 0.999739009 0.145825187 0.550721098 0.999739009 0.155543975 -0.05588622 
SCAF8 0.490131615 0.997827855 0.175836763 0.547630531 0.997827855 0.172985518 0.057498916 
NonTargetingCo
ntrolGene_42 
0.67970672 0.999344463 0.161848152 0.546956029 0.999344463 0.174973777 -0.132750691 
HNRNPUL1 0.391382272 0.981160424 0.318235111 0.543892879 0.981160424 0.318235111 0.152510606 
KLHL15 0.269454997 0.992613477 0.306523469 0.542364329 0.992613477 0.212715082 0.272909333 
COL1A1 0.366080096 0.911479638 0.541344177 0.539478509 0.911479638 0.460714715 0.173398413 
UBE2K 0.253967734 1 0.303014228 0.537837763 1 0.167608679 0.283870029 
ABL1 0.672014131 0.999996573 0.098284978 0.537551188 0.999996573 0.153482962 -0.134462944 
NEIL2 0.473125247 0.900745624 0.319866714 0.535697886 0.900745624 0.319866714 0.062572639 
CIB1 0.618150028 0.992548413 0.139868079 0.534148962 0.992548413 0.139868079 -0.084001066 
UBE2R2 0.855975926 1 0.067788305 0.529879809 1 0.145224292 -0.326096118 
NonTargetingCo
ntrolGene_5 
0.531076367 0.999999115 0.15579312 0.525815767 0.999999115 0.15579312 -0.0052606 
NFATC2IP 0.464750009 0.947512601 0.218206324 0.521167851 0.947512601 0.218206324 0.056417842 
CUL7 0.546102568 0.999988816 0.163441994 0.519258063 0.999988816 0.163441994 -0.026844505 
GPI 0.215464397 0.999992441 0.31817114 0.518411299 0.999992441 0.178502918 0.302946901 
PMP22 0.633250013 0.999994455 0.152606457 0.517318081 0.999994455 0.155612006 -0.115931932 
DTX3L 0.495498776 0.99393549 0.250939498 0.517158469 0.99393549 0.250939498 0.021659693 
UBE2NL 0.309468499 0.944566022 0.338582809 0.517101159 0.944566022 0.279276013 0.207632661 
NonTargetingCo
ntrolGene_45 
0.607242373 0.999896743 0.199662611 0.516328981 0.999896743 0.199662611 -0.090913393 
PHF11 0.5548391 0.968480013 0.214912858 0.512641038 0.968480013 0.214912858 -0.042198062 
CLSPN 0.352877128 0.890889164 0.569936767 0.509822768 0.890889164 0.569936767 0.15694564 
SIRT6 0.580681507 0.933946592 0.319914192 0.506626237 0.933946592 0.325524863 -0.07405527 
WDR70 0.274001952 0.919984796 0.444759693 0.504255918 0.919984796 0.444759693 0.230253966 
RFC1 0.418056179 0.870530865 0.493337784 0.504129285 0.870530865 0.493337784 0.086073105 
CTCF 0.122634174 0.784405204 0.999918614 0.503715478 0.868529592 0.614396517 0.381081305 
POLI 0.458026212 0.870502638 0.359127809 0.501061541 0.870502638 0.359127809 0.043035328 
ALKBH1 0.349034622 0.999961205 0.247811976 0.498782096 0.999961205 0.204675693 0.149747474 
TOP3A 0.319739642 0.888644981 0.617350779 0.498632731 0.888644981 0.617350779 0.178893089 
POLD2 0.256301144 0.945471268 0.733883653 0.496586335 0.945471268 0.428514497 0.240285191 
UBE2D1 0.526864285 0.999939613 0.17954647 0.495053981 0.999939613 0.17954647 -0.031810304 
OR1E1 0.493094137 0.985974094 0.248132441 0.49251492 0.985974094 0.248132441 -5.79217E-04 
CBX3 0.373231435 0.85241978 0.418979627 0.491329506 0.85241978 0.418979627 0.118098071 
POT1 0.320688413 0.855717782 0.689061257 0.487958919 0.855717782 0.689061257 0.167270506 
PPP6C 0.216168934 0.901738276 0.895944022 0.487417832 0.927447893 0.543269057 0.271248897 
CHFR 0.405361716 0.999662265 0.215805398 0.486359466 0.999662265 0.200026196 0.080997749 
NonTargetingCo
ntrolGene_62 
0.340278519 0.999944922 0.231304551 0.486265394 0.999944922 0.17984537 0.145986874 
ALDH  0.537953486 0.97275521 0.275798753 0.485824378 0.97275521 0.275798753 -0.052129107 
CDK7 -0.071350577 0.578927962 0.999996104 0.483990454 0.819337633 0.882138893 0.555341031 
KAT2B 0.68996412 0.998273194 0.149539643 0.478171073 0.998273194 0.190016003 -0.211793048 
RRM2 0.04018955 0.686176125 0.999998419 0.474539539 0.837413672 0.82022985 0.434349989 
POLN 0.60916456 0.999765812 0.160303789 0.474371384 0.999765812 0.203772318 -0.134793176 
EP400 0.507184212 0.878030871 0.605255147 0.473479589 0.878030871 0.605255147 -0.033704623 
TRAIP 0.031801186 0.679698557 0.999999649 0.472694744 0.84737765 0.999999649 0.440893558 
ATM 0.726936134 1 0.168865327 0.469572463 1 0.262666884 -0.257363671 
RAD9B 0.460246134 0.907235566 0.334368469 0.468056927 0.907235566 0.334368469 0.007810793 
SIRT4 0.257673676 0.909510653 0.374848148 0.462724124 0.909510653 0.309220548 0.205050448 
SERBP1 0.531703972 0.936111565 0.358438756 0.461614707 0.936111565 0.358438756 -0.070089265 
PHF3 0.455625991 0.999371961 0.143769059 0.461470369 0.999371961 0.143769059 0.005844379 
PLRG1 0.309439362 0.857516336 0.68552123 0.460723146 0.857516336 0.68552123 0.151283783 
MGMT 0.499961864 0.992856975 0.198492016 0.457827531 0.992856975 0.201493378 -0.042134332 
FBXO18 0.529714634 0.999245999 0.182890444 0.456930124 0.999245999 0.182890444 -0.07278451 
RNF111 0.504709692 0.999944988 0.188176928 0.454449697 0.999944988 0.188176928 -0.050259995 
SIRT5 0.510897261 0.999831869 0.149802239 0.453350026 0.999831869 0.164763799 -0.057547234 
NonTargetingCo
ntrolGene_68 
0.471570905 0.999257052 0.158280513 0.452439031 0.999257052 0.158280513 -0.019131874 
NonTarg tingCo
ntrolGene_19 
0.462116891 0.998943602 0.209028753 0.446095563 0.998943602 0.209028753 -0.016021328 
MCM 0 0.464674147 0.90263807 0.293246413 0.445940293 0.90263807 0.293246413 -0.018733854 
MLH3 0.347832787 0.999862757 0.264575591 0.444329427 0.999862757 0.235879208 0.096496641 
RNF138 0.457038629 0.999989483 0.198265834 0.443825224 0.999989483 0.198265834 -0.013213405 
NonTargetingCo
ntrolGene_30 
0.314520653 0.999748986 0.285754435 0.441006929 0.999748986 0.239880679 0.126486276 
NOTCH4 0.534518463 0.977380485 0.170484673 0.439284253 0.977380485 0.175613395 -0.09523421 
LIG3 0.011577723 0.999904028 0.489055158 0.433525695 0.999904028 0.209181304 0.421947972 
USP15 0.757389347 1 0.065138382 0.432773252 1 0.149444377 -0.324616096 
CHD1L 0.280722827 0.999838881 0.293622209 0.430428018 0.999838881 0.250804319 0.149705191 
RAD51D 0.324252353 0.892670296 0.59099305 0.430182478 0.892670296 0.524784962 0.105930124 
CDC25A 0.355230262 0.999910282 0.237963608 0.429454786 0.999910282 0.237963608 0.074224525 
SALL4 0.364380296 0.991028909 0.305548539 0.428955112 0.991028909 0.305548539 0.064574816 
MVP 0.316961898 0.881549393 0.324692981 0.42768818 0.881549393 0.324692981 0.110726281 
CDC25B 0.342002859 0.844476651 0.635585585 0.42616 0.844476651 0.635585585 0.084157141 
NonTargetingCo
ntrolGene_14 
0.554486916 0.999963084 0.155978914 0.425393527 0.999963084 0.155978914 -0.129093389 
RAD51AP1 0.456931665 0.853380663 0.405176852 0.42336151 0.853380663 0.405176852 -0.033570155 
FAM175A 0.475283203 0.987271407 0.244612063 0.423237489 0.987271407 0.244612063 -0.052045714 
RAD54B 0.632748934 0.984425058 0.210337492 0.422705853 0.984425058 0.227586521 -0.210043081 
PER3 0.330918674 0.849608299 0.489903783 0.422482176 0.849608299 0.489903783 0.091563502 
NUDT1 0.514664269 0.946357521 0.256553735 0.422297776 0.946357521 0.268982162 -0.092366493 
XPC 0.499630599 0.991484933 0.201804197 0.421488332 0.991484933 0.201804197 -0.078142267 
NonTargetingCo
ntrolGene_46 
0.298967265 0.999895055 0.275815284 0.418374834 0.999895055 0.246418794 0.119407569 
USP13 0.344368252 0.999322517 0.2603818 0.417389849 0.999322517 0.2603818 0.073021597 
DCUN1D5 0.461718052 0.999889397 0.278144345 0.415475729 0.999889397 0.278144345 -0.046242323 
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OPRM1 0.401464041 0.999960465 0.208737076 0.41459864 0.999960465 0.208737076 0.013134599 
INO80D 0.264091668 0.995796808 0.322263207 0.414217239 0.995796808 0.300051338 0.15012557 
RAG2 0.626378518 0.937786552 0.240309256 0.407025391 0.937786552 0.240309256 -0.219353127 
MUM1 0.314494111 0.998613554 0.275787866 0.404294631 0.998613554 0.259256963 0.08980052 
REV3L 0.210023169 0.868753474 0.932761344 0.403427825 0.868753474 0.788736013 0.193404656 
INO80B 0.116820451 0.761572409 0.998019997 0.403031862 0.789809779 0.998019997 0.286211411 
CUL9 0.419968504 0.91141591 0.465315529 0.401930022 0.91141591 0.465315529 -0.018038483 
CBX1 0.233113527 0.818043684 0.73796149 0.397965353 0.818043684 0.73796149 0.164851825 
NonTargetingCo
ntrolGene_32 
0.804925962 0.999981145 0.09448797 0.392329033 0.999981145 0.199749228 -0.412596929 
DLGAP5 0.480816324 0.886341913 0.404700279 0.391979414 0.886341913 0.404700279 -0.08883691 
COPS5 -0.244384407 0.404433415 0.999999992 0.39075595 0.812575703 0.961241786 0.635140358 
RNF8 0.16014603 0.802892438 0.996162079 0.385586498 0.802892438 0.960191821 0.225440468 
SMG6 -0.005461663 0.636351351 0.975220406 0.385116078 0.812123968 0.975220406 0.390577741 
UBE2D4 0.462303142 0.907990743 0.308397143 0.384685324 0.907990743 0.308397143 -0.077617819 
WDR76 0.279239542 0.892541247 0.274239745 0.384672844 0.892541247 0.274239745 0.105433301 
MSH4 0.364146544 0.993583438 0.259161096 0.381616126 0.993583438 0.259161096 0.017469582 
TIPIN 0.245494149 0.889867239 0.384848746 0.380421394 0.889867239 0.384848746 0.134927245 
PPM1G 0.127716356 0.727096542 0.977161392 0.379885461 0.804984645 0.977161392 0.252169105 
HELLS 0.179866498 0.807778785 0.971985663 0.379525907 0.807778785 0.914990729 0.199659409 
CHTF18 0.356636942 0.982124975 0.28965022 0.372851403 0.982124975 0.28965022 0.016214462 
UBE2D2 0.393105956 0.926997804 0.271229486 0.372065648 0.926997804 0.271229486 -0.021040308 
POLB 0.43192381 0.978148625 0.284457033 0.370537426 0.978148625 0.284457033 -0.061386383 
FBXW7 0.574566033 0.999999997 0.085417617 0.368266552 0.999999997 0.155916677 -0.20629948 
USP20 0.347646686 0.997002414 0.283895858 0.359199101 0.997002414 0.283895858 0.011552415 
NonTargetingCo
ntrolGene_3 
0.442509568 0.860063864 0.436971171 0.358485562 0.860063864 0.436971171 -0.084024006 
MORF4L1 0.563658653 0.994177809 0.199108881 0.358447101 0.994177809 0.284673044 -0.205211552 
EME1 0.526170666 0.900026124 0.209613513 0.357232765 0.900026124 0.286857971 -0.168937901 
POLD4 0.325040377 0.846632852 0.684444735 0.355934722 0.846632852 0.684444735 0.030894345 
FEN1 0.123433362 0.79899342 0.999973193 0.352818081 0.799238777 0.914509293 0.229384719 
POLR2C 0.127829777 0.757168982 0.999999547 0.352789433 0.811996895 0.999999547 0.224959657 
TRRAP 0.328885638 0.881436828 0.64564017 0.350149298 0.881436828 0.64564017 0.021263661 
APLF 0.171434195 0.999572699 0.363502534 0.349403424 0.999572699 0.27377354 0.177969229 
ETAA1 0.322595837 0.999902643 0.221874002 0.347254243 0.999902643 0.221874002 0.024658406 
CDC5L 0.137101956 0.81731613 0.999999994 0.342944453 0.81731613 0.94976868 0.205842497 
DDB1 0.051937277 0.703881747 1 0.339825989 0.843925082 0.986091054 0.287888712 
OTUD7B 0.297632198 0.966178755 0.309427349 0.338111736 0.966178755 0.309427349 0.040479537 
ATXN7 0.608538726 0.999322392 0.185430777 0.337749114 0.999322392 0.272883116 -0.270789613 
SENP2 0.235677481 0.974847315 0.384750348 0.337380603 0.974847315 0.384750348 0.101703122 
CCND2 0.291705106 0.999700615 0.311027717 0.336727776 0.999700615 0.311027717 0.04502267 
H3F3B 0.341607808 0.771063803 0.762949784 0.335336501 0.771063803 0.762949784 -0.006271307 
USP47 0.446509119 0.996708864 0.31463378 0.333616957 0.996708864 0.31463378 -0.112892162 
TDG 0.248283136 0.776038219 0.622908194 0.330918044 0.776038219 0.622908194 0.082634908 
NABP2 0.592938669 0.995463463 0.162132468 0.329018532 0.995463463 0.257108345 -0.263920136 
NonTargetingCo
ntrolGene_6 
0.50853398 0.999346524 0.207882263 0.32812489 0.999346524 0.242091075 -0.18040909 
PML 0.317368004 0.999831852 0.230662228 0.32773183 0.999831852 0.230662228 0.010363826 
MAU2 -0.147011198 0.476696072 0.999999903 0.326689848 0.829245983 0.999999903 0.473701046 
HLTF 0.416922155 0.842836197 0.400106702 0.325657169 0.842836197 0.400106702 -0.091264986 
DDX1 -0.23667862 0.387931432 1 0.322280278 0.760905597 1 0.558958898 
CUL4B -0.107486351 0.99947849 0.586378269 0.321489287 0.99947849 0.338852979 0.428975638 
KMT5C 0.619178579 0.999795972 0.133164186 0.320847875 0.999795972 0.270707591 -0.298330705 
DCUN1D2 0.333394694 0.967274579 0.312938999 0.320701093 0.967274579 0.312938999 -0.012693602 
HDAC2 0.402738613 0.869520373 0.350883165 0.318957473 0.869520373 0.350883165 -0.08378114 
BARD1 0.109171041 0.778589206 0.99981174 0.317172212 0.778589206 0.99981174 0.208001171 
ARID1B 0.359173691 0.970376264 0.301973032 0.315793487 0.970376264 0.301973032 -0.043380204 
PRKCG 0.307436638 0.999019977 0.26646088 0.314885711 0.999019977 0.26646088 0.007449074 
ATP23 0.28894874 0.941599552 0.436241072 0.314457384 0.941599552 0.436241072 0.025508645 
SCAI 0.398552836 0.999862613 0.216875457 0.31287916 0.999862613 0.238601495 -0.085673676 
RAD9A -0.470775683 0.2339057 0.999222767 0.310417717 0.724768978 0.999222767 0.7811934 
RRM2B 0.137291676 0.999997564 0.374142036 0.307500433 0.999997564 0.302887972 0.170208758 
RECQL5 0.364150897 0.807844349 0.447635835 0.303579955 0.807844349 0.447635835 -0.060570942 
TPP1 0.473110787 0.998535295 0.168111978 0.303061756 0.998535295 0.238775227 -0.170049031 
CSNK1E 0.284173167 0.996433343 0.282415934 0.302930571 0.996433343 0.282415934 0.018757404 
NonTargetingCo
ntrolGene_39 
0.214876411 0.999999994 0.31495842 0.301834677 0.999999994 0.31495842 0.086958266 
RIF1 0.050419085 0.70734721 0.999998123 0.301655759 0.837438824 0.999998123 0.251236674 
NonTargetingCo
ntrolGene_74 
0.379861196 0.998153711 0.268790737 0.299171604 0.998153711 0.294528743 -0.080689592 
HPF1 0.396970933 0.942247654 0.482518472 0.298627357 0.942247654 0.482518472 -0.098343577 
NonTargetingCo
ntrolGene_66 
0.359949368 0.999534742 0.252566243 0.298032568 0.999534742 0.252566243 -0.061916801 
NonTarg tingCo
ntrolGene_34 
0.399940064 0.99906883 0.28639908 0.297658846 0.99906883 0.28639908 -0.102281218 
RNF2 0.427654003 0.999627895 0.27250104 0.294628844 0.999627895 0.285554332 -0.133025159 
TOPBP1 0.172817156 0.749373197 0.999999996 0.292567416 0.756878038 0.999999996 0.119750259 
DCUN1D1 0.413050362 0.999999878 0.314919159 0.291088434 0.999999878 0.314919159 -0.121961928 
HFM1 0.349526351 0.993815046 0.276872453 0.289986725 0.993815046 0.276872453 -0.059539626 
NSMCE3 0.048877426 0.698453842 0.999991203 0.289393785 0.825734077 0.999991203 0.240516358 
SFR1 0.401276155 0.81670404 0.6184974 0.289223915 0.81670404 0.6184974 -0.112052241 
SUMO1 0.188213129 0.848506551 0.352701213 0.287473228 0.848506551 0.352701213 0.099260099 
FAN1 0.289960407 0.997111193 0.267264115 0.285268425 0.997111193 0.267264115 -0.004691982 
PRDM10 0.113669381 0.750825113 0.67521091 0.284730562 0.750825113 0.67521091 0.171061181 
APTX 0.33897098 0.902305794 0.297388906 0.281886138 0.902305794 0.315636768 -0.057084843 
UBE2A 0.242774433 0.966338213 0.370554378 0.281342855 0.966338213 0.370554378 0.038568423 
SENP6 -0.286711438 0.322686644 0.99993276 0.281300052 0.744935638 0.99993276 0.56801149 
SMARCA4 0.37031933 0.921918975 0.347630633 0.281229728 0.921918975 0.372150019 -0.089089601 
UBE2V1 0.246067744 0.994675609 0.311815552 0.281089026 0.994675609 0.311815552 0.035021282 




0.323106605 0.993980969 0.287545259 0.280953768 0.993980969 0.287545259 -0.042152837 
ATXN3 0.298619174 0.999887003 0.248271682 0.27978673 0.999887003 0.248271682 -0.018832445 
NABP1 0.284152881 0.959632317 0.345913405 0.279452417 0.959632317 0.345913405 -0.004700465 
UNG 0.505883328 0.879170242 0.711741337 0.278222649 0.879170242 0.711741337 -0.22766068 
SMARCAD1 0.336684001 0.902049214 0.473019693 0.277619876 0.902049214 0.473019693 -0.059064125 
PARP4 0.287562937 0.999779181 0.272654857 0.277170649 0.999779181 0.272654857 -0.010392288 
PRIMPOL 0.233167036 0.97661071 0.334150094 0.275762336 0.97661071 0.334150094 0.0425953 
RMI1 0.088313273 0.779794902 0.999979412 0.273491881 0.821870283 0.951183412 0.185178608 
MDC1 0.321779889 0.7975822 0.732251606 0.272894906 0.7975822 0.732251606 -0.048884983 
FANCE 0.089604266 0.750727108 0.999512955 0.271965705 0.785751133 0.999512955 0.182361439 
SETMAR 0.328957864 0.987364155 0.317835521 0.271506072 0.987364155 0.323505813 -0.057451792 
RING1 0.420651615 1 0.220555776 0.265710526 1 0.273389315 -0.154941089 
SUV39H2 0.17767884 0.994902355 0.317153685 0.263910814 0.994902355 0.317153685 0.086231974 
NonTargetingCo
ntrolGene_1 
0.366537602 0.999451714 0.280807461 0.263158863 0.999451714 0.296424935 -0.103378739 
SLBP 0.144814752 0.84926528 0.520300724 0.262637854 0.84926528 0.520300724 0.117823102 
RPA4 0.269746202 0.926587876 0.347017442 0.260844413 0.926587876 0.347017442 -0.008901789 
SUMO3 0.223064655 0.994900124 0.328498082 0.260134127 0.994900124 0.328498082 0.037069472 
NonTargetingCo
ntrolGene_11 
0.327835915 0.999999893 0.249756542 0.258901382 0.999999893 0.276269994 -0.068934533 
MEN  -0.020974036 0.619235737 0.983314517 0.257409713 0.712323746 0.983314517 0.278383749 
TYMS 0.162326344 0.989232021 0.373620608 0.256170237 0.989232021 0.373620608 0.093843894 
NSMCE4A 0.16462439 0.797276073 0.999942809 0.255369407 0.797276073 0.999942809 0.090745017 
COPS7A 0.160935669 0.999970404 0.376272799 0.254930687 0.999970404 0.349247598 0.093995019 
BRAT1 0.192455024 0.764885569 1 0.254676499 0.764885569 1 0.062221475 
TOP2A 0.130692025 0.810893181 0.622751665 0.254609451 0.810893181 0.622751665 0.123917426 
RPA2 -0.21376361 0.432295693 0.999999998 0.253970309 0.702065047 0.999999998 0.467733919 
CASP3 0.107890271 0.92594083 0.520395807 0.25051429 0.92594083 0.457113336 0.14262402 
RECQL4 0.613534021 0.880369061 0.595715041 0.249142842 0.877680198 0.595715041 -0.364391179 
CETN2 0.297006696 0.995655769 0.37745133 0.246762896 0.995655769 0.37745133 -0.0502438 
PRDM9 0.232303207 0.943546646 0.367872819 0.2462107 0.943546646 0.367872819 0.013907494 
SLX4 0.134821732 0.708659367 0.999341474 0.245495944 0.72475368 0.999341474 0.110674212 
NCAPG -0.034200251 0.598434212 0.999983682 0.244747076 0.775976151 0.999983682 0.278947327 
CDKN1B 0.32112048 0.999985514 0.28000831 0.244400577 0.999985514 0.299831019 -0.076719903 
NEK9 0.476432151 0.99995695 0.192826201 0.243968607 0.99995695 0.261878806 -0.232463544 
OR6B1 0.369405735 0.780133397 0.543041925 0.243770756 0.780133397 0.543041925 -0.125634979 
SSBP2 0.477726997 0.999223979 0.29651219 0.243240097 0.999223979 0.29651219 -0.2344869 
ATF2 0.204044217 0.990828682 0.307924958 0.242596009 0.990828682 0.307924958 0.038551792 
NonTargetingCo
ntrolGene_4 
0.235156649 0.998153433 0.304050787 0.241890122 0.998153433 0.304050787 0.006733474 
MPZ 0.233931752 0.783285652 0.514905795 0.241397115 0.783285652 0.514905795 0.007465363 
SMARCAL1 0.286381239 0.760780742 0.748013154 0.240007721 0.760780742 0.748013154 -0.046373519 
NonTargetingCo
ntrolGene_18 
0.231527536 0.999971612 0.299195533 0.239957248 0.999971612 0.299195533 0.008429712 
HMGB2 0.529962903 0.999925107 0.189092663 0.239609392 0.999925107 0.294548092 -0.290353511 
BAZ1A 0.145901898 0.733462775 0.45138603 0.239569294 0.733462775 0.45138603 0.093667396 
PIAS1 0.239954108 0.730146097 0.478187399 0.23956084 0.730146097 0.478187399 -3.93269E-04 
RHO 0.159588291 0.867938538 0.43694721 0.239256803 0.867938538 0.43694721 0.079668512 
SKIV2L2 0.10922438 0.791033887 0.788549952 0.238461501 0.791033887 0.788549952 0.129237121 
EID3 0.170894052 0.993920362 0.38559444 0.23843719 0.993920362 0.368745894 0.067543138 
CCNB2 0.364482867 0.989274411 0.262865149 0.237681763 0.989274411 0.349399958 -0.126801104 
PPP6R3 0.198306861 0.99966489 0.346160016 0.230222089 0.99966489 0.346160016 0.031915229 
MSH3 0.349040835 0.986451479 0.310510777 0.230086217 0.986451479 0.328355923 -0.118954618 
PPP6R2 0.154498939 0.793930204 0.51836679 0.229997991 0.793930204 0.51836679 0.075499052 
MBD4 0.346396449 0.99826714 0.294597572 0.227598825 0.99826714 0.294597572 -0.118797625 
FANCM -0.026907834 0.605209051 0.999902234 0.220675893 0.73068862 0.999902234 0.247583726 
TP73 0.228221807 0.721214667 0.496816724 0.217701868 0.721214667 0.496816724 -0.010519938 
PIF1 0.289386808 0.789502562 0.452710548 0.217233042 0.789502562 0.452710548 -0.072153766 
DCAF11 0.34057827 0.900717935 0.386361477 0.21626799 0.900717935 0.386361477 -0.12431028 
GABBR1 0.152584097 0.830415951 0.443223333 0.215827262 0.830415951 0.443223333 0.063243165 
PIAS2 0.174949454 0.972756723 0.373570722 0.215446755 0.972756723 0.373570722 0.040497302 
EXO5 0.193381234 0.775154374 0.966614507 0.214351367 0.775154374 0.966614507 0.020970133 
HELQ -0.028334907 0.53104413 0.86709702 0.214052942 0.694556398 0.86709702 0.242387849 
ZRANB3 0.179837509 0.858872109 0.384695382 0.212341904 0.858872109 0.384695382 0.032504395 
MAPK14 0.27530326 0.999999645 0.374315111 0.212086655 0.999999645 0.374315111 -0.063216605 
NIPBL 0.306525747 0.754348284 0.998963233 0.210823162 0.754348284 0.998963233 -0.095702585 
SMARCC1 0.022106108 0.999999991 0.479243695 0.210334113 0.999999991 0.360935491 0.188228004 
DTX3 0.098059875 0.999520968 0.402899465 0.209054233 0.999520968 0.388267478 0.110994358 
NUDT16L1 0.132170695 0.821254066 0.439119507 0.207721136 0.821254066 0.439119507 0.075550441 
NonTargetingCo
ntrolGene_71 
0.376914598 0.990797611 0.311783685 0.205609028 0.990797611 0.312148404 -0.171305569 
KAT2A 0.056820247 0.699444162 0.992094734 0.204592701 0.699444162 0.992094734 0.147772454 
TRIP12 0.509089587 0.999977382 0.190500439 0.204431419 0.999977382 0.327148801 -0.304658168 
ERCC6 0.038199894 0.742080257 0.463305052 0.203975228 0.742080257 0.461681238 0.165775334 
KMT5A 0.044776008 0.741562051 0.574073591 0.203807832 0.741562051 0.574073591 0.159031824 
PAGR1 0.198099944 0.703693388 0.916817828 0.202803743 0.703693388 0.916817828 0.004703799 
HDAC1 0.238744524 0.853806783 0.358107678 0.202786863 0.853806783 0.358107678 -0.035957661 
EXD2 0.195805746 0.986875983 0.445430619 0.20170656 0.986875983 0.445430619 0.005900813 
PINX1 -0.12540294 0.4890233 0.974286015 0.201252104 0.683101813 0.974286015 0.326655044 
PARP2 0.301501907 0.943985904 0.309226463 0.200860676 0.943985904 0.309226463 -0.100641231 
UIMC1 0.225093982 0.861488402 0.390302293 0.199566106 0.861488402 0.390302293 -0.025527876 
IP6K3 0.12028865 0.985510177 0.420443513 0.199388785 0.985510177 0.414284209 0.079100135 
CLK2 0.071729317 0.937955813 0.53407626 0.19870005 0.937955813 0.496150193 0.126970733 
INO80C 0.245621527 0.99225101 0.408909174 0.198253664 0.99225101 0.408909174 -0.047367863 
H2AFY2 0.186008731 0.763884749 0.465235999 0.196110382 0.763884749 0.465235999 0.010101651 
RNF169 0.171406662 0.972630813 0.445966562 0.194683429 0.972630813 0.445966562 0.023276767 
FIGNL1 -0.016811797 0.606793026 0.998935428 0.193966159 0.67263919 0.998935428 0.210777956 
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USP45 0.290465849 0.96395309 0.348616929 0.193480256 0.96395309 0.348616929 -0.096985592 
CENPS 0.210625614 0.809540827 0.504680041 0.192107366 0.809540827 0.504680041 -0.018518248 
SIRT2 0.281448634 0.996559267 0.27428979 0.190776549 0.996559267 0.312800279 -0.090672085 
RBBP7 0.288182063 0.976664116 0.416652738 0.190758643 0.976664116 0.416652738 -0.09742342 
RAD18 0.268618645 0.998249125 0.318397932 0.189786742 0.998249125 0.318397932 -0.078831902 
POLE 0.005568224 0.65044863 0.865959085 0.186585804 0.767358674 0.865959085 0.18101758 
PARP9 0.370294465 0.997612841 0.358199205 0.186371163 0.997612841 0.43324421 -0.183923302 
SENP7 0.171343024 0.8161503 0.467620277 0.185445931 0.8161503 0.467620277 0.014102907 
POLR2B -0.216481377 0.468988107 0.998193741 0.184470603 0.659020709 0.998193741 0.400951979 
TOP2B 0.100925367 0.894281573 0.517418298 0.182356958 0.894281573 0.517418298 0.081431592 
ANP32E 0.156182167 0.877808356 0.388795789 0.180876547 0.877808356 0.388795789 0.02469438 
NonTargetingCo
ntrolGene_64 
0.236617153 0.975822499 0.356101424 0.180718675 0.975822499 0.356101424 -0.055898478 
SMARCA5 0.01820058 0.665372902 0.999784118 0.179928313 0.751199328 0.999784118 0.161727733 
UBE2V2 0.423879572 0.999897557 0.188967762 0.178368788 0.999897557 0.345894655 -0.245510783 
NonTargetingCo
ntrolGene_36 
0.202147548 0.999854713 0.331837147 0.177679184 0.999854713 0.331837147 -0.024468364 
PARK2 0.159903876 0.744557492 0.508448011 0.175246668 0.744557492 0.508448011 0.015342792 
USP44 0.151529559 0.66852974 0.962981781 0.174560436 0.66852974 0.962981781 0.023030877 
ANKRD28 0.344712209 0.964281934 0.377704218 0.172785874 0.964281934 0.377704218 -0.171926334 
APBB1 0.072882493 0.998373594 0.421358868 0.170778616 0.998373594 0.368351676 0.097896124 
SMC3 -0.098608192 0.532186486 0.999896419 0.169402041 0.66233072 0.999896419 0.268010234 
NonTargetingCo
ntrolGene_23 
0.355351287 0.999695194 0.275977059 0.167967878 0.999695194 0.34865466 -0.187383409 
OR1E2 -0.179013757 0.776359 0.646068915 0.166444109 0.776359 0.639285089 0.345457867 
TNKS 0.126349217 0.667495342 0.844252915 0.165199313 0.667495342 0.844252915 0.038850096 
BOD1L1 -0.032829853 0.60517879 0.999999296 0.164328481 0.714055888 0.999999296 0.197158334 
NonTargetingCo
ntrolGene_35 
0.31815717 0.999245228 0.296567827 0.163957125 0.999245228 0.350041004 -0.154200045 
XRCC3 0.05203835 0.701483566 1 0.163840043 0.723177898 1 0.111801693 
SET -0.084422359 0.548548085 0.9998963 0.162002677 0.635075834 0.9998963 0.246425036 
PINK1 0.133626093 0.859205561 0.480296597 0.161693155 0.859205561 0.480296597 0.028067062 
POLQ 0.206025128 0.707187804 0.452518333 0.160927477 0.707187804 0.452518333 -0.045097651 
MSH2 0.269148225 0.974192869 0.401188919 0.158716909 0.974192869 0.401188919 -0.110431316 
MTA3 -0.030980498 0.998930186 0.547359712 0.156317881 0.998930186 0.472414848 0.187298379 
NEIL3 0.262646778 0.830465663 0.459576238 0.154469848 0.830465663 0.459576238 -0.108176929 
C9orf142 0.431925396 0.955815087 0.345532622 0.154014393 0.955815087 0.371053383 -0.277911002 
DTX1 0.234206059 0.802545681 0.457077757 0.15323491 0.802545681 0.457077757 -0.08097115 
USP22 0.156814152 0.642641712 0.653544646 0.148331124 0.642641712 0.653544646 -0.008483028 
NonTargetingCo
ntrolGene_78 
0.245055782 0.999117535 0.350377074 0.148248239 0.999117535 0.362643208 -0.096807544 
NonTarg tingCo
ntrolGene_49 
0.285915648 0.998539304 0.315053553 0.147943066 0.998539304 0.38688018 -0.137972582 
I HMBP2 0.074253192 0.733461585 0.477616102 0.147809134 0.733461585 0.477616102 0.073555942 
NonTargetingCo
ntrolGene_75 
0.499186756 0.999991775 0.217961669 0.144991406 0.999991775 0.383256157 -0.35419535 
PARK7 0.197329461 0.994823768 0.356819735 0.144233111 0.994823768 0.356819735 -0.05309635 
SHFM1 0.06493968 0.999991064 0.45381777 0.143637797 0.999991064 0.446457726 0.078698116 
HDAC4 0.101608408 0.952460343 0.448885076 0.143559086 0.952460343 0.448885076 0.041950678 
NonTargetingCo
ntrolGene_22 
0.140635653 0.998830219 0.372629334 0.143143418 0.998830219 0.372629334 0.002507765 
APOBEC3A 0.178830077 0.949371552 0.402239037 0.14197017 0.949371552 0.402239037 -0.036859907 
PAPD7 0.026422408 0.791645969 0.607132583 0.141606657 0.791645969 0.529345001 0.115184249 
NonTargetingCo
ntrolGene_72 
0.184370111 0.99994745 0.42039104 0.140083152 0.99994745 0.42039104 -0.044286959 
CCNO 0.112287059 0.98679286 0.393804847 0.139633915 0.98679286 0.393804847 0.027346856 
PPP5C 0.041976523 0.956631895 0.457858901 0.13830775 0.956631895 0.442428591 0.096331228 
NonTargetingCo
ntrolGene_60 
0.165686803 0.939658178 0.359655223 0.137113958 0.939658178 0.359655223 -0.028572846 
TERF2IP 0.239063688 0.747038604 0.740824367 0.135992388 0.747038604 0.740824367 -0.1030713 
NonTargetingCo
ntrolGene_76 
0.248073406 0.998182876 0.349017695 0.133920552 0.998182876 0.375299197 -0.114152854 
CDKN2A 0.323500887 0.999994328 0.26627578 0.132502962 0.999994328 0.412837869 -0.190997925 
RHNO1 -0.11414187 0.976984352 0.598425131 0.132379189 0.976984352 0.501028007 0.246521059 
NonTargetingCo
ntrolGene_40 
0.074845753 0.999499894 0.446367433 0.130582545 0.999499894 0.446367433 0.055736792 
CDC34 0.234787574 0.943082939 0.317670536 0.130091008 0.943082939 0.372836029 -0.104696566 
HNRNPUL2 0.19112298 0.999853973 0.361544483 0.129560081 0.999853973 0.381769483 -0.061562898 
UCHL5 -0.404248878 0.236702792 0.999999896 0.126944347 0.622926319 0.999999896 0.531193225 
PSIP1 0.160209525 0.882014247 0.407987723 0.125041277 0.882014247 0.407987723 -0.035168248 
NonTargetingCo
ntrolGene_37 
0.233662123 0.9463425 0.377586763 0.123764007 0.9463425 0.377586763 -0.109898116 
MRE11 0.30082283 0.806380107 0.999979051 0.118029192 0.78700842 0.999979051 -0.182793638 
POLE4 -0.041769721 0.59141024 0.999981281 0.116542184 0.609192821 0.999981281 0.158311905 
ERCC8 0.151748201 0.716506865 0.709966902 0.116078139 0.716506865 0.709966902 -0.035670062 
NonTargetingCo
ntrolGene_13 
0.122333369 0.99991058 0.441098104 0.115942881 0.99991058 0.441098104 -0.006390488 
EME2 -0.058043618 0.998886994 0.583093659 0.115628631 0.998886994 0.583093659 0.173672249 
NonTargetingCo
ntrolGene_10 
0.033124009 0.999960589 0.470147617 0.115476952 0.999960589 0.470147617 0.082352943 
HMGB1 0.791723087 0.994845796 0.425398111 0.115466441 0.994845796 0.469061389 -0.676256646 
OGG1 -0.008340151 0.848582944 0.508307522 0.115346694 0.848582944 0.508307522 0.123686845 
RAP1A 0.19255877 0.998612783 0.393863608 0.114086686 0.998612783 0.409908534 -0.078472084 
NonTargetingCo
ntrolGene_69 
0.042761908 0.998422901 0.457736564 0.112704276 0.998422901 0.457736564 0.069942368 
KDM1A -0.079761611 0.935769267 0.576498871 0.112013403 0.935769267 0.48560199 0.191775014 
NonTargetingCo
ntrolGene_20 
0.1619288 0.999975913 0.446068832 0.111386577 0.999975913 0.446068832 -0.050542223 
CSNK2A1 -0.262970831 0.59893175 0.749365565 0.111357772 0.59893175 0.744935698 0.374328603 
STAG1 0.227472047 0.723799903 0.633347551 0.109624145 0.723799903 0.633347551 -0.117847902 
RNF40 0.172548026 0.729677955 0.999986349 0.108899014 0.729677955 0.999986349 -0.063649012 
SMC1B 0.274894788 0.999741633 0.333848527 0.107651166 0.999741633 0.39971864 -0.167243622 
REV1 0.083720514 0.951147894 0.418264435 0.106932987 0.951147894 0.418264435 0.023212473 
NonTargetingCo
ntrolGene_50 
0.296627755 0.999974703 0.315982043 0.10565409 0.999974703 0.399229992 -0.190973664 
CDK2 -0.302984953 0.355245308 0.991668433 0.10517448 0.67148519 0.991668433 0.408159433 
ERCC5 0.172530907 0.788299656 0.480513536 0.104315441 0.788299656 0.480513536 -0.068215466 
AICDA 0.030042485 0.884412741 0.47259631 0.103981221 0.884412741 0.47259631 0.073938737 
USP3 0.352998415 0.90412076 0.449800464 0.103296304 0.90412076 0.449800464 -0.249702111 
NLK 0.207005543 0.981217976 0.473667152 0.10037435 0.981217976 0.473667152 -0.106631193 
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BAZ1B 0.196188049 0.677081241 0.831773684 0.100075894 0.677081241 0.831773684 -0.096112155 
NonTargetingCo
ntrolGene_70 
0.10721369 0.999028141 0.437768735 0.099053281 0.999028141 0.437768735 -0.008160409 
MSH6 0.336586656 0.807076469 0.633023141 0.098424167 0.77028725 0.633023141 -0.238162488 
APOBEC3G 0.172558944 0.800085083 0.404673257 0.097794993 0.800085083 0.404673257 -0.074763951 
PRMT6 0.001627464 0.998934623 0.498427432 0.097508662 0.998934623 0.462884498 0.095881198 
ALKBH3 0.204496952 0.999874058 0.340861998 0.097096815 0.999874058 0.402184634 -0.107400137 
CRY2 0.081785464 0.8956699 0.466013717 0.096751867 0.8956699 0.466013717 0.014966403 
NOTCH1 0.161498064 0.99799131 0.40855067 0.094979928 0.99799131 0.40855067 -0.066518136 
POLH 0.147576642 0.817609978 0.414541812 0.092886523 0.817609978 0.414541812 -0.054690119 
NonTargetingCo
ntrolGene_80 
0.067907148 0.99999086 0.476318929 0.092723087 0.99999086 0.476318929 0.024815939 
CCNA2 0.005150099 0.649111021 0.999949601 0.091905399 0.656303391 0.999949601 0.0867553 
NonTargetingCo
ntrolGene_16 
0.178838353 0.997641235 0.416399926 0.08987514 0.997641235 0.416399926 -0.088963213 
WDR48 0.143072651 0.618490932 0.999368917 0.089525909 0.618490932 0.999368917 -0.053546742 
NSMCE2 -0.197583236 0.402159958 0.996527617 0.088765279 0.581523688 0.996527617 0.286348515 
NonTargetingCo
ntrolGene_63 
0.248671566 0.995299415 0.370924813 0.088666127 0.995299415 0.415645803 -0.16000544 
NonTarg tingCo
ntrolGene_56 
0.18444402 0.965584874 0.434281159 0.084889796 0.965584874 0.434281159 -0.099554224 
OTUB2 0.00231718 0.999750694 0.497927565 0.083390052 0.999750694 0.497927565 0.081072873 
PARP14 0.128894718 0.999626837 0.470970352 0.082890299 0.999626837 0.470970352 -0.046004419 
WHSC1 0.090989869 0.984510192 0.423713962 0.08259638 0.984510192 0.423713962 -0.008393489 
PPP4R4 0.285672558 0.999944276 0.376532614 0.082416921 0.999944276 0.423630814 -0.203255637 
NonTargetingCo
ntrolGene_58 
0.094635038 0.999971942 0.477072241 0.081785473 0.999971942 0.477072241 -0.012849565 
BEND3 0.126494563 0.782060364 0.418467606 0.080444058 0.782060364 0.418467606 -0.046050506 
NFRKB -0.066215911 0.57136474 0.983903022 0.08032033 0.57136474 0.983903022 0.146536242 
SHPRH 0.098958681 0.726763686 0.552152367 0.077119567 0.726763686 0.552152367 -0.021839114 
SLF1 0.105642745 0.957297648 0.419842852 0.077101292 0.957297648 0.419842852 -0.028541453 
ATAD5 -0.227787361 0.639201937 0.719766489 0.076304936 0.639201937 0.719766489 0.304092297 
NonTargetingCo
ntrolGene_31 
0.223745852 0.999998311 0.370998384 0.073703669 0.999998311 0.431434635 -0.150042183 
UHRF2 0.150949908 0.933087821 0.456677267 0.073231661 0.933087821 0.481163607 -0.077718247 
APOBEC3B 0.495681136 0.999967008 0.236724223 0.072803602 0.999967008 0.439631995 -0.422877534 
COPS7B -0.028425894 0.999189187 0.530865771 0.071324268 0.999189187 0.530865771 0.099750163 
NonTargetingCo
ntrolGene_54 
0.01743834 0.999049499 0.483241338 0.070988352 0.999049499 0.483241338 0.053550012 
CCNB1 0.137667683 0.634479609 0.998111376 0.068262306 0.634018473 0.998111376 -0.069405377 
PPP6R1 0.094075231 0.772941429 0.646705834 0.067919262 0.772941429 0.646705834 -0.026155969 
APOBEC3D 0.211079234 0.974141819 0.417259904 0.067875679 0.974141819 0.441172526 -0.143203555 
TNP1 0.361322998 0.962981376 0.371141252 0.067462979 0.962981376 0.439422263 -0.293860019 
TRIM29 0.189422766 0.983559316 0.416560922 0.067242188 0.983559316 0.433498953 -0.122180579 
MLH1 0.005062914 0.942751324 0.556658798 0.065992863 0.942751324 0.556658798 0.060929949 
RMI2 -0.165800103 0.436135851 0.971086796 0.064624998 0.564797388 0.971086796 0.230425101 
APOBEC3F 0.223065013 0.96743583 0.474663017 0.063944441 0.96743583 0.501546132 -0.159120572 
MCPH1 -0.015420607 0.586576959 0.999999494 0.062809071 0.586576959 0.999999494 0.078229678 
PXMP2 0.128311372 0.923308842 0.444325346 0.060566703 0.923308842 0.444325346 -0.067744669 
RASSF7 0.188515544 0.997777622 0.450251198 0.060147647 0.997777622 0.450251198 -0.128367897 
CCNA1 0.034679891 0.810951228 0.598707029 0.058685624 0.810951228 0.598707029 0.024005734 
ADH5 0.217448393 0.997682785 0.454255411 0.055027897 0.997682785 0.454255411 -0.162420496 
XPA 0.198370699 0.954356687 0.473829968 0.05268071 0.954356687 0.473829968 -0.145689989 
NonTargetingCo
ntrolGene_15 
0.222434374 0.999989034 0.374467506 0.051899445 0.999989034 0.448699368 -0.170534929 
NonTarg tingCo
ntrolGene_51 
-0.068327269 0.984970515 0.567578657 0.049997001 0.984970515 0.567578657 0.11832427 
GEN  0.276229726 0.754153117 0.671192216 0.04769194 0.754153117 0.680332541 -0.228537787 
APOBEC3H 0.170452151 0.843921742 0.402261229 0.044590678 0.843921742 0.460698652 -0.125861474 
WRN 0.131974248 0.936131005 0.479474015 0.042583582 0.936131005 0.515359827 -0.089390666 
NonTargetingCo
ntrolGene_25 
0.100703259 0.999838243 0.461086203 0.041196446 0.999838243 0.461086203 -0.059506813 
MUTYH 0.114817047 0.663194739 0.683401713 0.040645969 0.663194739 0.683401713 -0.074171078 
MCM3AP -0.286180313 0.308827261 0.973219488 0.036863167 0.535656581 0.973219488 0.323043481 
EXO1 0.079384069 0.626652201 0.875452844 0.031063341 0.626652201 0.875452844 -0.048320729 
H3F3A 0.226807795 0.576658748 0.533961199 0.030838678 0.576658748 0.533961199 -0.195969117 
PMS1 0.210088274 0.958274699 0.395162706 0.030467873 0.958274699 0.471369499 -0.179620401 
PARP3 -0.189061477 0.999043034 0.676938494 0.030361073 0.999043034 0.604239028 0.21942255 
PER2 -0.097272424 0.999727149 0.594350844 0.028219027 0.999727149 0.535196289 0.125491451 
SLF2 0.017301604 0.968887803 0.484472338 0.028168707 0.968887803 0.484472338 0.010867103 
MUS81 0.262045319 0.73378913 0.99287909 0.02795188 0.612924944 0.99287909 -0.234093439 
MTA1 -0.212200519 0.620309887 0.799156054 0.027537536 0.620309887 0.740035073 0.239738055 
BMI1 0.072267586 0.997754667 0.473439774 0.027322754 0.997754667 0.473439774 -0.044944832 
MMS19 -0.176260766 0.438297367 0.99999986 0.026661134 0.59052151 0.99999986 0.202921899 
MBTD1 0.330697551 0.982125174 0.388244541 0.026545393 0.982125174 0.534368121 -0.304152158 
NonTargetingCo
ntrolGene_33 
0.186983093 0.9999448 0.437487325 0.025662743 0.9999448 0.47723812 -0.16132035 
BRIP1 -0.141799403 0.47669902 0.882716175 0.023747323 0.522385756 0.882716175 0.165546726 
NonTargetingCo
ntrolGene_61 
0.17001704 0.999998025 0.445386196 0.02287021 0.999998025 0.478553585 -0.14714683 
PARPBP 0.230639358 0.997597669 0.369543954 0.022696047 0.997597669 0.477570025 -0.207943311 
ANKRD44 0.066732909 0.998536699 0.477003499 0.022320155 0.998536699 0.477003499 -0.044412754 
NonTargetingCo
ntrolGene_38 
-0.016312358 0.995893787 0.516918944 0.021134109 0.995893787 0.516918944 0.037446467 
PIAS3 -0.017344841 0.955902472 0.518574108 0.019972651 0.955902472 0.518574108 0.037317492 
ERCC2 -0.49491335 0.187000355 1 0.016257288 0.520286283 1 0.511170639 
USP26 0.152007057 0.977805328 0.439122437 0.015538564 0.977805328 0.485622771 -0.136468493 
SMARCA2 -0.028202709 0.964445153 0.590235601 0.01530662 0.964445153 0.590235601 0.043509329 
FANCB -0.496912034 0.256489302 0.995133965 0.012910738 0.511800817 0.995133965 0.509822772 
RFC4 -0.325879669 0.291544092 0.999840568 0.007338403 0.506785614 0.999840568 0.333218072 
TCEB3 0.04505574 0.60703653 0.990465878 0.006638889 0.60703653 0.990465878 -0.038416851 
BTG2 0.262777446 0.999849211 0.355808262 0.005319547 0.999849211 0.495504378 -0.257457899 
ASF1B 0.03716606 0.852870623 0.49571593 0.004380178 0.852870623 0.49571593 -0.032785882 
CUL4A -0.252242157 0.655076567 0.74258042 0.001188571 0.655076567 0.689545238 0.253430728 
MPG 0.02048292 0.678395155 0.64260504 2.03046E-04 0.678395155 0.64260504 -0.020279874 
GADD45A 0.161994458 0.999990609 0.449042256 -0.002898601 0.999990609 0.50282161 -0.164893059 
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DCUN1D4 0.203768083 0.997906465 0.37770114 -0.003509477 0.997906465 0.503222977 -0.20727756 
TCEA1 -0.032200996 0.635881387 0.597959364 -0.004020063 0.635881387 0.597959364 0.028180932 
DNMT1 -0.323635804 0.309144761 0.999965741 -0.00542591 0.494476034 0.999965741 0.318209894 
NTHL1 0.115199037 0.931538222 0.496313114 -0.007206169 0.931538222 0.507212164 -0.122405206 
USP1 -0.178477004 0.590243354 0.848664132 -0.007316072 0.590243354 0.848664132 0.171160931 
RAD54L -0.067512892 0.553927821 0.930512659 -0.00761728 0.553927821 0.930512659 0.059895612 
CCNC -0.079634918 0.999898713 0.643277447 -0.008339125 0.999898713 0.643277447 0.071295793 
NonTargetingCo
ntrolGene_44 
0.042081856 0.999913624 0.572381097 -0.008851837 0.999913624 0.572381097 -0.050933693 
NonTarg tingCo
ntrolGene_21 
0.233506459 0.999999634 0.388790269 -0.009613137 0.999999634 0.508604389 -0.243119597 
RAD23B -0.203060898 0.726194025 0.689054646 -0.009835824 0.726194025 0.689054646 0.193225074 
UVSSA 0.097944023 0.69812623 0.613241301 -0.009961717 0.69812623 0.613241301 -0.107905739 
TDP2 0.069773341 0.674335764 0.917993286 -0.012763567 0.674335764 0.917993286 -0.082536908 
TREX1 0.193696223 0.968436391 0.370772458 -0.013178293 0.968436391 0.513313881 -0.206874516 
USP4 0.281471169 0.805362863 0.589526684 -0.013510374 0.805362863 0.589526684 -0.294981543 
OTUB1 -0.253278478 0.59043536 0.800128386 -0.014819568 0.59043536 0.800128386 0.23845891 
ATRX -0.223235115 0.584883682 0.796610207 -0.015072152 0.584883682 0.796610207 0.208162963 
SETD2 -0.179302521 0.99309399 0.672358721 -0.017574371 0.99309399 0.665279736 0.16172815 
RBM7 -0.098994913 0.988203047 0.584967972 -0.018384617 0.988203047 0.579838284 0.080610296 
APEX1 -0.164506127 0.975643502 0.654696958 -0.018606272 0.975643502 0.654696958 0.145899856 
HMGN1 -0.068084139 0.991290138 0.570215911 -0.01866383 0.991290138 0.570215911 0.049420309 
NonTargetingCo
ntrolGene_47 
-0.208488508 0.99765574 0.693830415 -0.020245779 0.99765574 0.668450185 0.18824273 
BUB1B -0.402122358 0.336105544 0.999987313 -0.022028273 0.539107392 0.999987313 0.380094085 
SPO11 0.026064919 0.999054627 0.522824139 -0.02283228 0.999054627 0.522824139 -0.0488972 
NonTargetingCo
ntrolGene_57 
-0.107054688 0.999999992 0.59688114 -0.026148089 0.999999992 0.59618914 0.080906599 
RFWD3 -0.165143786 0.445843971 0.946496535 -0.026576992 0.475789095 0.946496535 0.138566794 
CDK12 0.20957843 0.699279618 0.972174261 -0.02679629 0.610150803 0.972174261 -0.23637472 
NonTargetingCo
ntrolGene_17 
-0.154190756 0.999962639 0.639036963 -0.028920279 0.999962639 0.633891715 0.125270477 
NonTarg tingCo
ntrolGene_59 
0.011533528 0.980263038 0.59738111 -0.030943018 0.980263038 0.59738111 -0.042476546 
HUS1B 0.128084867 0.999041355 0.489202098 -0.031077675 0.999041355 0.529101758 -0.159162542 
NonTargetingCo
ntrolGene_53 
0.099973709 0.999999492 0.516849778 -0.031378864 0.999999492 0.530138163 -0.131352573 
RNF168 0.106702335 0.686855358 0.768789476 -0.03396969 0.686855358 0.768789476 -0.140672025 
NonTargetingCo
ntrolGene_26 
0.326262759 0.999829527 0.263208602 -0.036388887 0.999829527 0.537102755 -0.362651646 
NonTarg tingCo
ntrolGene_55 
-0.138457431 0.99999849 0.618000193 -0.038021567 0.99999849 0.599975444 0.100435864 
UBE2B 0.01174031 0.967780942 0.537212607 -0.04074934 0.967780942 0.537212607 -0.05248965 
FAAP20 0.04531898 0.545811951 0.704574993 -0.042167031 0.529341341 0.704574993 -0.087486012 
DNTT 0.020176515 0.999905117 0.539049228 -0.042769599 0.999905117 0.539049228 -0.062946115 
RAD23A -0.281339552 0.635087306 0.805323122 -0.043689608 0.685247005 0.805323122 0.237649945 
DTX2 -0.216824845 0.671581355 0.696367427 -0.047402807 0.671581355 0.696367427 0.169422038 
NonTargetingCo
ntrolGene_43 
0.323773806 0.997856576 0.39414485 -0.053859257 0.997856576 0.552324939 -0.377633063 
RAD17 -0.12485428 0.503630424 0.99993315 -0.054487327 0.506668585 0.99993315 0.070366953 
RAD52 0.069762424 0.728971579 0.559429461 -0.057170394 0.728971579 0.559429461 -0.126932818 
EYA3 -0.248226171 0.490007368 0.978716184 -0.061897876 0.537003538 0.978716184 0.186328295 
CENPX 0.127619606 0.828940722 0.621083846 -0.06256522 0.828940722 0.625916836 -0.190184826 
BLM 0.137441067 0.840181435 0.470355048 -0.06294413 0.840181435 0.566089673 -0.200385197 
COL21A1 -0.079655005 0.921825514 0.629774398 -0.063123225 0.921825514 0.629774398 0.016531781 
ACTR8 0.022464979 0.520837149 0.99999942 -0.067420663 0.520837149 0.99999942 -0.089885642 
RAD51C -0.323902805 0.39136104 0.997588655 -0.06830009 0.494673041 0.997588655 0.255602714 
NonTargetingCo
ntrolGene_67 
0.085174159 0.963105599 0.474021678 -0.068545734 0.963105599 0.569857509 -0.153719893 
PPP4R1 -0.014994947 0.856665652 0.662714626 -0.071834033 0.856665652 0.662714626 -0.056839086 
ATRIP -0.430669068 0.203753298 0.998218448 -0.074454101 0.419343219 0.998218448 0.356214967 
NonTargetingCo
ntrolGene_28 
-0.151836407 0.999427371 0.645580156 -0.074501536 0.999427371 0.645580156 0.077334871 
NonTarg tingCo
ntrolGene_24 
0.011664054 0.998717176 0.549290299 -0.077153816 0.998717176 0.57724664 -0.088817869 
PMS2P3 0.113501082 0.943456195 0.540776061 -0.078039733 0.943456195 0.563219438 -0.191540815 
CRY1 -0.083618706 0.920529515 0.580422196 -0.078536307 0.920529515 0.580422196 0.005082399 
DCLRE1C -0.115781035 0.999665045 0.605788186 -0.082100745 0.999665045 0.605788186 0.03368029 
NonTargetingCo
ntrolGene_41 
-0.174044727 0.985115366 0.664975186 -0.082130058 0.985115366 0.664975186 0.091914669 
SIRT3 0.044493062 0.979592947 0.513082548 -0.082310999 0.979592947 0.581317926 -0.126804061 
NonTargetingCo
ntrolGene_79 
-0.038938678 0.999287288 0.584495058 -0.082791854 0.999287288 0.584495058 -0.043853177 
SMARCC2 0.003612468 0.997555566 0.581758943 -0.083544245 0.997555566 0.581758943 -0.087156713 
NonTargetingCo
ntrolGene_65 
0.002317818 0.999999721 0.640099925 -0.088312815 0.999999721 0.650712797 -0.090630633 
POLG2 -0.189875925 0.981114272 0.681840553 -0.089534683 0.981114272 0.661667142 0.100341242 
ESCO2 0.017999061 0.582427273 0.992629276 -0.090319536 0.524945953 0.992629276 -0.108318597 
ZDHHC16 -0.15006496 0.956923154 0.713194275 -0.093779588 0.956923154 0.713194275 0.056285372 
ENDOV -0.20974255 0.999296873 0.717721773 -0.099576443 0.999296873 0.717721773 0.110166107 
SWI5 -0.168908419 0.998147498 0.639690468 -0.101241186 0.998147498 0.639690468 0.067667232 
NonTargetingCo
ntrolGene_48 
-0.095008934 0.966309425 0.627350751 -0.101481113 0.966309425 0.627350751 -0.00647218 
KDM D -0.099761613 0.999517962 0.626749494 -0.10347926 0.999517962 0.626749494 -0.003717647 
PER1 0.098799031 0.990077097 0.514606643 -0.105058018 0.990077097 0.605258762 -0.203857049 
RFC3 0.014504918 0.572970282 0.999999623 -0.110352138 0.528668119 0.999999623 -0.124857056 
HES1 -0.027615052 0.76809946 0.612258629 -0.112465904 0.76809946 0.612258629 -0.084850852 
INO80 -0.316400948 0.26996301 0.998880602 -0.117223123 0.378822049 0.998880602 0.199177825 
RFC5 -0.343450701 0.321844312 1 -0.11992326 0.461291153 1 0.22352744 
CCNE1 -0.087163357 0.972601188 0.624351389 -0.121880534 0.972601188 0.624351389 -0.034717177 
NonTargetingCo
ntrolGene_9 
0.001714446 0.878180299 0.628679769 -0.122751404 0.878180299 0.628679769 -0.12446585 
HDAC10 0.045044759 0.997973562 0.508985692 -0.122987103 0.997973562 0.630188828 -0.168031861 
ORC2 -0.106338257 0.481268607 0.87352768 -0.123683713 0.481268607 0.87352768 -0.017345456 
SPIDR -0.06379337 0.476235924 0.816668104 -0.123927058 0.476235924 0.816668104 -0.060133688 
ACTR5 -0.280987237 0.309331697 0.999664378 -0.126950838 0.394510139 0.999664378 0.1540364 
NEK8 0.188480188 0.999004224 0.410909534 -0.128595022 0.999004224 0.625124536 -0.31707521 
H2AFY 0.176274938 0.985621785 0.372894174 -0.12872809 0.985621785 0.62538959 -0.305003027 
MYBBP1A -0.197797672 0.40555722 1 -0.132564684 0.425627013 1 0.065232987 
TADA3 -0.102741899 0.433691801 0.915647428 -0.135177736 0.433691801 0.915647428 -0.032435837 
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RTEL1 -0.330234985 0.248836053 0.999998909 -0.135830601 0.403609845 0.999998909 0.194404384 
TRIM28 -0.318105925 0.696727965 0.791868369 -0.136616202 0.696727965 0.743038716 0.181489723 
AMN1 -0.090166737 0.99801046 0.637246295 -0.138100627 0.99801046 0.637246295 -0.04793389 
RNF20 -0.351332795 0.230650755 0.999999519 -0.138556007 0.393438068 0.999999519 0.212776787 
NCAPH -0.538643734 0.127392844 0.99898725 -0.139349713 0.356986697 0.99898725 0.39929402 
NonTargetingCo
ntrolGene_8 
0.050549676 0.850087936 0.533634841 -0.143105711 0.850087936 0.643417709 -0.193655387 
ERCC6L2 -0.08184418 0.872367225 0.646306863 -0.144387297 0.872367225 0.646306863 -0.062543117 
TOP3B -0.079061265 0.997428561 0.650585715 -0.146925205 0.997428561 0.650585715 -0.06786394 
TCEB1 0.160536218 0.600507844 1 -0.147892757 0.526846187 1 -0.308428975 
CUL2 -0.43007583 0.180360854 0.999999866 -0.15254424 0.345880545 0.999999866 0.27753159 
SETDB1 -0.024883536 0.99959465 0.588933526 -0.153666509 0.99959465 0.642357532 -0.128782973 
NAE1 -0.464061867 0.106455892 0.999999565 -0.155554875 0.319207002 0.999999565 0.308506992 
PALB2 -0.149867519 0.501162855 0.956352073 -0.156631389 0.501162855 0.956352073 -0.006763869 
FAAP100 -0.23706679 0.348324268 0.999216741 -0.157192908 0.384275466 0.999216741 0.079873882 
NonTargetingCo
ntrolGene_2 
0.220282152 0.995046821 0.372114596 -0.158038419 0.995046821 0.652193201 -0.378320572 
PARP15 0.062636979 0.998960655 0.514397665 -0.159400433 0.998960655 0.64254074 -0.222037413 
PAXIP1 0.124689613 0.640313842 0.733419247 -0.165483819 0.640313842 0.733419247 -0.290173432 
DSCC1 -0.531996416 0.140551596 0.999994766 -0.170333897 0.33511414 0.999994766 0.361662519 
FANCG -0.471611377 0.19714898 0.999845823 -0.171477865 0.374626323 0.999845823 0.300133512 
WRAP53 -0.530918051 0.206508048 0.999668421 -0.174942405 0.346982738 0.999668421 0.355975646 
CEP57 -0.724040032 0.081750529 0.999999863 -0.175839559 0.349820542 0.999999863 0.548200473 
SSBP1 -0.24047795 0.828033245 0.768758977 -0.177548046 0.828033245 0.768758977 0.062929903 
NonTargetingCo
ntrolGene_29 
-0.189504919 0.999999932 0.720769173 -0.189012223 0.999999932 0.720769173 4.92696E-04 
TTI1 -0.573352558 0.174725054 1 -0.189262016 0.396935071 1 0.384090542 
NonTargetingCo
ntrolGene_52 
-0.114289432 0.999823905 0.686442141 -0.191520391 0.999823905 0.686442141 -0.077230959 
RAD51B -0.504569208 0.161939293 0.9999845 -0.195945166 0.311246654 0.9999845 0.308624042 
POLK -0.190678596 0.999979036 0.682608088 -0.196547301 0.999979036 0.682608088 -0.005868705 
SMUG1 -0.241451733 0.926775706 0.722752663 -0.198764655 0.926775706 0.722752663 0.042687078 
TREX2 0.049093165 0.89181467 0.589818312 -0.2035565 0.89181467 0.696388402 -0.252649665 
ZSWIM7 -0.211411608 0.735231576 0.724270237 -0.203682179 0.735231576 0.724270237 0.007729428 
MSH5 -0.185385827 0.738573839 0.706570482 -0.204700128 0.738573839 0.706570482 -0.019314301 
RNF4 -0.341582966 0.51553963 0.863172383 -0.207547961 0.51553963 0.863172383 0.134035005 
ERCC1 -0.761019077 0.121299122 0.999920277 -0.210039984 0.320759508 0.999920277 0.550979093 
SUV39H1 -0.240812088 0.686927959 0.727706492 -0.213337842 0.686927959 0.727706492 0.027474246 
ARID1A -0.26679015 0.459801678 0.960738841 -0.215089776 0.459801678 0.960738841 0.051700373 
SUMO2 -0.055497564 0.592600641 0.874235475 -0.215503346 0.592600641 0.874235475 -0.160005782 
XRCC1 -0.106298568 0.503469724 0.83560372 -0.215936402 0.443528978 0.83560372 -0.109637833 
CHRAC1 -0.165555297 0.470805861 0.883613746 -0.223600938 0.470805861 0.883613746 -0.058045641 
DDB2 -0.132236323 0.968589624 0.712817449 -0.228168693 0.968589624 0.715183319 -0.09593237 
TP63 -0.037612615 0.982719463 0.659207594 -0.238062284 0.982719463 0.739874739 -0.200449669 
NonTargetingCo
ntrolGene_73 
-0.110602421 0.999988159 0.74150653 -0.242975996 0.999988159 0.74150653 -0.132373575 
MPLKIP -0.281904592 0.417071503 0.839815793 -0.244925047 0.417071503 0.839815793 0.036979545 
RAG1 0.0278725 0.998190338 0.609191893 -0.249445625 0.998190338 0.722315365 -0.277318125 
POLE3 -0.236645108 0.308110286 0.999987142 -0.254790943 0.308110286 0.999987142 -0.018145836 
HINFP -0.289465065 0.315293475 0.999999995 -0.263096349 0.315293475 0.999999995 0.026368716 
UVRAG -0.111994747 0.432851819 0.999970332 -0.264030964 0.319541234 0.999970332 -0.152036217 
MAD2L2 -0.310795125 0.337235147 0.999997565 -0.265201861 0.337235147 0.999997565 0.045593265 
KDM4A -0.53778644 0.166800392 0.999685556 -0.279034984 0.261393687 0.999685556 0.258751456 
CDKN2D -0.075545086 0.997688613 0.685570329 -0.285502212 0.997688613 0.747486115 -0.209957126 
FANCA -0.503828788 0.209442566 0.968847838 -0.309835357 0.212293296 0.968847838 0.193993431 
SIN3A -0.448706121 0.136922181 0.999999614 -0.310842184 0.211087626 0.999999614 0.137863936 
FANCL -0.396020418 0.280568326 0.999999866 -0.313798766 0.280568326 0.999999866 0.082221652 
CNOT7 -0.295707409 0.288024187 0.942650234 -0.314410792 0.288024187 0.942650234 -0.018703383 
PIAS4 -0.091510459 0.530232231 0.788581482 -0.317203993 0.530232231 0.788581482 -0.225693534 
ERCC4 -0.398931986 0.252285106 0.999998625 -0.317434566 0.262326445 0.999998625 0.081497421 
PDS5B -0.564826034 0.164773 0.997655936 -0.333372893 0.248176773 0.997655936 0.231453141 
TERT -1.120561076 0.043657438 0.999994311 -0.338573436 0.262906278 0.999994311 0.781987641 
FAAP24 -0.258183287 0.289786957 0.999280513 -0.338904435 0.262097914 0.999280513 -0.080721148 
KDM2A -0.558518598 0.434804887 0.910732661 -0.351084033 0.434804887 0.910732661 0.207434565 
NFE2L2 -0.251395388 0.300917887 0.994462838 -0.352666261 0.300917887 0.994462838 -0.101270872 
TFPT -0.301295778 0.297516508 0.890885344 -0.354046883 0.297516508 0.890885344 -0.052751105 
UBB -0.408509311 0.712171643 0.810120028 -0.369070703 0.712171643 0.810120028 0.039438609 
TDP1 -0.296059632 0.743472684 0.813004354 -0.374266685 0.743472684 0.813004354 -0.078207052 
BAP1 -0.861019258 0.06781337 0.991006485 -0.377923266 0.25143855 0.991006485 0.483095992 
HUS1 -0.231085161 0.3202775 0.999975309 -0.383060076 0.302094643 0.999975309 -0.151974916 
CTC1 -0.646536128 0.171305894 0.999977979 -0.38840447 0.270798243 0.999977979 0.258131658 
TCEB2 -0.67807386 0.220472453 1 -0.389656589 0.32884493 1 0.288417272 
GTF2H5 -0.329634928 0.299807685 0.999989346 -0.414480078 0.299807685 0.999989346 -0.084845149 
TELO2 -0.789127642 0.081905094 0.999999997 -0.424255838 0.196901763 0.999999997 0.364871804 
POLG -0.383028325 0.400960382 0.874455448 -0.425626497 0.400960382 0.874455448 -0.042598172 
CREBBP -0.529525138 0.200253782 0.977017433 -0.433716988 0.200253782 0.977017433 0.09580815 
UHRF1 -0.384034522 0.261600482 0.99999626 -0.456693592 0.254843006 0.99999626 -0.07265907 
XRCC4 -0.692794146 0.091989725 0.983404757 -0.470787491 0.154492811 0.983404757 0.222006655 
FZR1 -0.388999548 0.182286415 1 -0.484611118 0.156141661 1 -0.09561157 
NBN 0.129128469 0.797503888 0.750377074 -0.487505531 0.562629286 0.937556694 -0.616634 
NHEJ1 -0.731347402 0.121990341 0.989815203 -0.49821906 0.18793881 0.989815203 0.233128341 
FANCF -0.540715666 0.115596019 0.999997085 -0.508393866 0.115596019 0.999997085 0.0323218 
PRKDC -1.052365726 0.107027335 0.997540738 -0.513309908 0.243221648 0.997540738 0.539055817 
LMNA -1.019814402 0.106849512 0.988127832 -0.539698478 0.183523833 0.988127832 0.480115925 
PARP1 -0.497157357 0.279310195 0.90920163 -0.551684532 0.279310195 0.90920163 -0.054527175 
RAD50 -0.612330237 0.043572166 0.999999891 -0.559317575 0.048090896 0.999999891 0.053012663 
ENY2 -0.971981534 0.148082476 0.971646103 -0.582950593 0.218434077 0.971646103 0.389030941 
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UBE2N -1.016751085 0.01951038 0.999808198 -0.610289182 0.068995853 0.999808198 0.406461904 
RNASEH2A -0.985021172 0.059056933 0.999838311 -0.632305411 0.106612141 0.999838311 0.35271576 
ZMPSTE24 -0.369169724 0.278722686 0.99078592 -0.636975557 0.182120681 0.99078592 -0.267805832 
FANCC -0.655601424 0.084856054 0.999998236 -0.658633483 0.084856054 0.999998236 -0.003032059 
UBE2M -0.859090131 0.119797607 0.99993481 -0.72567155 0.119797607 0.99993481 0.133418581 
LIG4 -0.80476088 0.089990965 0.997992962 -0.757120665 0.089990965 0.997992962 0.047640215 
TEN1 -1.379092553 0.007574556 1 -0.911606024 0.048887649 1 0.467486529 
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Appendix Table 6 Raw data from JACKS analysis of RPE-1 WRN-/- G7-C5 2nM CPT treated 






neg_fdr1 pos_fdr1 Enrichment 
in 2nM CPT 
treated 
neg_fdr2 pos_fdr2 Difference in 
Enrichment 
TP53 3.637109045 1 5.46E-11 4.419451518 1 4.16E-15 0.782342473 
CAND1 4.183380117 1 1.11E-13 3.132955448 1 2.38E-08 -1.050424669 
CDKN1A 1.924779332 1 0.001048617 2.448484547 1 9.32E-05 0.523705215 
KEAP1 2.699222891 1 1.25E-05 2.44652434 1 5.48E-05 -0.25269855 
H2AFZ 2.337796569 1 1.45593E-04 2.064925972 1 4.34633E-04 -0.272870597 
RNF146 1.613932235 1 0.002145623 1.82378186 1 7.17001E-04 0.209849624 
DCUN1D1 1.913524529 0.999999878 0.001247478 1.669027209 0.999999878 0.005822329 -0.24449732 
SHFM1 1.249332624 0.999991064 0.043570209 1.64713178 0.999991064 0.008886461 0.397799156 
PTEN 2.062337291 1 8.08E-05 1.549065134 1 0.00216206 -0.513272157 
CHEK2 1.229560498 1 0.009185668 1.435746473 1 0.003619417 0.206185975 
USP28 1.762497827 1 6.49627E-04 1.430325046 1 0.003641298 -0.33217278 
THRAP3 1.810836217 1 0.002800992 1.428189331 1 0.020693888 -0.382646886 
DCUN1D3 1.408137125 1 0.003451057 1.419206881 1 0.003451057 0.011069756 
ENDOV 0.754041756 0.999296873 0.092010657 1.395377416 0.999296873 0.004744135 0.64133566 
CUL3 0.840845144 1 0.034681949 1.338961146 1 0.002718399 0.498116001 
UBE2F 1.337548482 1 0.012666928 1.325802917 1 0.012666928 -0.011745565 
BRD7 1.489069964 1 0.010066749 1.277715667 1 0.018878619 -0.211354297 
GADD45G 0.883990326 0.999993748 0.109459973 1.222322068 0.999993748 0.041460106 0.338331742 
NonTargetingC
ontrolGene_65 
1.115776499 0.999999721 0.024735777 1.220818747 0.999999721 0.020960806 0.105042248 
ARID2 1.162854276 1 0.016857352 1.21791499 1 0.016563163 0.055060714 
BABAM1 1.173245523 1 0.008274041 1.200070548 1 0.006162554 0.026825025 
MAPK14 0.185072057 0.999999645 0.376640212 1.179456144 0.999999645 0.031913612 0.994384087 
RNF7 1.415388362 1 0.003231386 1.153328231 1 0.011142591 -0.262060131 
TP53BP1 1.215534642 1 0.019079977 1.144680494 1 0.019079977 -0.070854149 
POLD3 0.870732149 0.999843055 0.017371545 1.137858109 0.999843055 0.009074953 0.267125961 
NonTargetingC
ontrolGene_39 
1.085840933 0.999999994 0.018460583 1.136184892 0.999999994 0.018460583 0.05034396 
NonTargetingC
ontrolGene_15 
1.087590023 0.999989034 0.020152083 1.10524716 0.999989034 0.020152083 0.017657137 
NonTargetingC
ontrolGene_21 
0.942578583 0.999999634 0.041218556 1.077546489 0.999999634 0.031770949 0.134967905 
MAPKAPK2 1.397347909 1 0.011555573 1.077481678 1 0.033510011 -0.31986623 
GTF2H2 1.961668809 0.983875327 0.267484538 1.074963012 0.983875327 0.298260716 -0.886705797 
ALKBH3 1.03208538 0.999874058 0.018670212 1.071606352 0.999874058 0.016989885 0.039520972 
UBE2R2 1.492722275 1 0.007215625 1.066847242 1 0.051198162 -0.425875032 
CDC25A 0.702769648 0.999910282 0.128917776 1.063434141 0.999910282 0.04050902 0.360664493 
NonTargetingC
ontrolGene_62 
0.935723402 0.999944922 0.050467137 1.028436902 0.999944922 0.033843428 0.0927135 
MLH3 0.703739216 0.999862757 0.198237753 1.025975051 0.999862757 0.079853147 0.322235835 
SCAF4 1.556523332 1 0.001688265 1.02002515 1 0.02861133 -0.536498182 
DCUN1D5 1.012400106 0.999889397 0.055911449 1.009958814 0.999889397 0.055911449 -0.002441292 
APEX1 0.65644442 0.986387666 0.15599156 1.001139974 0.986387666 0.065603277 0.344695554 
DNTT 0.593982275 0.999905117 0.199584509 0.99845473 0.999905117 0.042664065 0.404472456 
CUL4B 0.899230132 0.99947849 0.082157943 0.991105566 0.99947849 0.079295321 0.091875434 
NonTargetingC
ontrolGene_77 
0.737982307 0.99999303 0.075778326 0.962959885 0.99999303 0.044109855 0.224977578 
NonTargetingC
ontrolGene_31 
0.841536407 0.999998311 0.059923502 0.958248072 0.999998311 0.056064085 0.116711665 
USP15 1.204233595 1 0.005702571 0.955727311 1 0.023808551 -0.248506284 
RAP1A 0.79085845 0.998612783 0.094062905 0.944740099 0.998612783 0.060393377 0.15388165 
UBE2V2 0.866885109 0.999897557 0.067595817 0.935976249 0.999897557 0.058887722 0.069091139 
DMC1 0.97365822 0.999556483 0.040784214 0.934853111 0.999556483 0.040784214 -0.038805108 
NonTargetingC
ontrolGene_75 
0.788548297 0.999991775 0.080257338 0.913523639 0.999991775 0.05583858 0.124975342 
NonTargetingC
ontrolGene_50 
0.706495225 0.999974703 0.108990837 0.906095497 0.999974703 0.06010541 0.199600271 
PHIP 1.555423036 1 0.002998833 0.901569002 1 0.037564294 -0.653854034 
ALKBH1 0.764467305 0.999961205 0.074890232 0.894976706 0.999961205 0.06579161 0.1305094 
ADH5 0.649487858 0.997682785 0.200187542 0.881587223 0.997682785 0.132963441 0.232099365 
STAG2 0.910011189 0.999999998 0.04127621 0.872694811 0.999999998 0.053813247 -0.037316378 
HDAC10 0.575578682 0.997973562 0.150096766 0.867220266 0.997973562 0.059408089 0.291641584 
GPI 0.903424872 0.999992441 0.067431384 0.865478577 0.999992441 0.097925025 -0.037946296 
KDM4D 0.586380313 0.999517962 0.145442715 0.865240119 0.999517962 0.073901812 0.278859806 
CUL5 0.947067415 1 0.024841794 0.863849097 1 0.034917742 -0.083218318 
CHD3 0.860047447 0.991912216 0.03497551 0.863097043 0.991912216 0.03497551 0.003049596 
BCLAF1 1.258631342 1 0.05446127 0.859766431 1 0.096179445 -0.398864911 
PBRM1 0.538902517 1 0.135202919 0.857354921 1 0.076475389 0.318452403 
UBB 0.940360605 0.998261617 0.070544342 0.848197903 0.998261617 0.096012842 -0.092162702 
OPRM1 0.638831562 0.999960465 0.17818549 0.836470421 0.999960465 0.104987069 0.197638858 
KMT5B 0.555582098 0.999968266 0.103565356 0.836104112 0.999968266 0.058861614 0.280522014 
APC 0.957395823 1 0.018941734 0.831975132 1 0.029096505 -0.125420692 
NonTargetingC
ontrolGene_32 
0.603489486 0.999981145 0.137054504 0.823480419 0.999981145 0.09448797 0.219990933 
CCNC 0.989700421 0.999898713 0.038233546 0.821383817 0.999898713 0.071515853 -0.168316603 
NonTargetingC
ontrolGene_44 
0.881331038 0.999913624 0.054235963 0.819015233 0.999913624 0.059356689 -0.062315805 
DCLRE1A 0.444507797 0.999578127 0.19438612 0.805795347 0.999578127 0.054793111 0.36128755 
NEK8 0.648001286 0.999004224 0.12826138 0.78792341 0.999004224 0.097016192 0.139922125 
MORF4L1 0.863124411 0.994177809 0.115523685 0.78164414 0.994177809 0.125312048 -0.081480272 
SWI5 1.269691047 0.998147498 0.017408436 0.777569192 0.998147498 0.087297344 -0.492121855 
RRM2B 0.818345656 0.999997564 0.057020947 0.777525681 0.999997564 0.057020947 -0.040819975 
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FBXW7 0.657002771 0.999999997 0.053402788 0.776078442 0.999999997 0.034006552 0.11907567 
LIG3 0.958547004 0.999904028 0.049596982 0.770592546 0.999904028 0.101936788 -0.187954458 
CIB1 1.12793543 0.992548413 0.025260605 0.759379027 0.992548413 0.116390644 -0.368556404 
PARK7 0.545330686 0.994823768 0.18605194 0.757489933 0.994823768 0.093968135 0.212159247 
NonTargetingC
ontrolGene_11 
0.970242748 0.999999893 0.040242436 0.756090544 0.999999893 0.106425244 -0.214152204 
WRNIP 0.867869928 0.995688479 0.068674602 0.754740093 0.995688479 0.094922128 -0.113129835 
COPS7A 0.52883645 0.999970404 0.26042997 0.75331933 0.999970404 0.216411231 0.224482879 
NonTargetingC
ontrolGene_16 
0.645572386 0.997641235 0.146197913 0.750912508 0.997641235 0.146197913 0.105340122 
PARP 5 0.747436582 0.998960655 0.111632352 0.747373176 0.998960655 0.111632352 -6.34E-05 
SETX 0.622007128 0.956660985 0.104585117 0.746319196 0.956660985 0.104585117 0.124312069 
HNRNPUL2 0.539293252 0.999853973 0.170076124 0.745773901 0.999853973 0.096429535 0.206480649 
EP300 0.920734605 1 0.040019774 0.743966822 1 0.07019854 -0.176767783 
NonTargetingC
ontrolGene_29 
0.827318964 0.999999932 0.09844609 0.738864773 0.999999932 0.130085938 -0.08845419 
AMN1 0.424605461 0.99801046 0.323548996 0.728948559 0.99801046 0.111304787 0.304343097 
SIRT1 0.564277419 0.999600581 0.143449576 0.727098804 0.999600581 0.095579646 0.162821385 
RING1 1.022707347 1 0.042515799 0.726982875 1 0.133823247 -0.295724471 
NonTargetingC
ontrolGene_5 
0.772001259 0.999999115 0.093009819 0.726109736 0.999999115 0.099706887 -0.045891523 
CCND2 1.155280239 0.999700615 0.030604037 0.722768889 0.999700615 0.165212122 -0.43251135 
NonTargetingC
ontrolGene_13 
1.144701666 0.99991058 0.017856836 0.718665386 0.99991058 0.130325742 -0.42603628 
POLM 0.801592713 0.999967463 0.066705271 0.714121999 0.999967463 0.097842657 -0.087470714 
NonTargetingC
ontrolGene_14 
0.429882391 0.999963084 0.155978914 0.71191403 0.999963084 0.145117706 0.282031639 
UBE2K 0.758379402 1 0.09853474 0.707851177 1 0.100765604 -0.050528226 
HDAC9 0.877381213 0.999999739 0.047327388 0.707746053 0.999999739 0.072304092 -0.169635161 
RHNO1 0.421562628 0.976984352 0.373780185 0.702651507 0.976984352 0.224533712 0.281088879 
VCP 0.431072228 0.999408308 0.249430452 0.701182096 0.999408308 0.138655802 0.270109868 
BTG2 0.510983469 0.999849211 0.213299326 0.700937781 0.999849211 0.155672065 0.189954313 
NonTargetingC
ontrolGene_40 
0.574456905 0.999499894 0.21770554 0.700767603 0.999499894 0.169740492 0.126310698 
NonTargetingC
ontrolGene_25 
0.445567268 0.999838243 0.307673837 0.699521131 0.999838243 0.137210699 0.253953862 
CHD1L 0.484239835 0.999838881 0.232137854 0.695355324 0.999838881 0.150055814 0.211115488 
SCAF8 0.371369871 0.997827855 0.239387643 0.690964507 0.997827855 0.162676815 0.319594636 
SETD2 0.273034952 0.99309399 0.513673877 0.690455684 0.99309399 0.202534748 0.417420733 
NonTargetingC
ontrolGene_73 
0.742149713 0.999988159 0.129180192 0.68951654 0.999988159 0.129288874 -0.052633173 
SSBP 0.548660955 0.993437983 0.16441545 0.684736982 0.993437983 0.124852644 0.136076027 
NonTargetingC
ontrolGene_17 
0.874359175 0.999962639 0.08666355 0.683871456 0.999962639 0.158511496 -0.19048772 
MGMT 0.5893579 0.992856975 0.198492016 0.683168129 0.992856975 0.198492016 0.093810229 
BRE 0.611588262 0.999999447 0.110837116 0.679816485 0.999999447 0.094768601 0.068228223 
PARP4 0.392938001 0.999779181 0.272654857 0.679559674 0.999779181 0.14485674 0.286621673 
POLN 0.268999203 0.999765812 0.268906068 0.679246118 0.999765812 0.160303789 0.410246915 
MTA2 0.646520614 0.999859602 0.093462295 0.679207279 0.999859602 0.089278041 0.032686664 
CSNK1D 0.545477831 0.998727585 0.105453163 0.667517767 0.998727585 0.105453163 0.122039936 
SMARCD1 0.47605373 0.999812917 0.137079121 0.666710623 0.999812917 0.137079121 0.190656892 
NonTargetingC
ontrolGene_61 
0.662323769 0.999998025 0.099334073 0.664419004 0.999998025 0.099334073 0.002095235 
CUL7 0.628216038 0.999988816 0.163441994 0.65894483 0.999988816 0.163441994 0.030728792 
HMGB1 1.694407556 0.994845796 0.415375388 0.656166342 0.994845796 0.425398111 -1.038241213 
NonTargetingC
ontrolGene_45 
0.397105327 0.999896743 0.199662611 0.653278894 0.999896743 0.186011917 0.256173567 
DTX3 0.737634812 0.999520968 0.119553352 0.647522684 0.999520968 0.150091408 -0.090112128 
RNF169 0.481951257 0.972630813 0.366785716 0.640488181 0.972630813 0.283651505 0.158536924 
RBBP7 0.536164888 0.976664116 0.293233037 0.636998869 0.976664116 0.275603875 0.100833981 
DDB2 0.720493292 0.968589624 0.160772799 0.634941137 0.968589624 0.160772799 -0.085552154 
NonTargetingC
ontrolGene_72 
0.784391457 0.99994745 0.127178242 0.630700522 0.99994745 0.172966586 -0.153690935 
SPO11 0.663956501 0.999054627 0.170621179 0.626498847 0.999054627 0.176194418 -0.037457654 
NonTargetingC
ontrolGene_55 
0.842905405 0.99999849 0.080526688 0.625637162 0.99999849 0.12981327 -0.217268243 
NonTargetingC
ontrolGene_53 
0.655786659 0.999999492 0.134195552 0.622757804 0.999999492 0.134195552 -0.033028855 
NonTargetingC
ontrolGene_26 
0.383025967 0.999829527 0.259075986 0.621562338 0.999829527 0.220187151 0.238536371 
DCLRE1C 0.543979667 0.999665045 0.176864689 0.619746328 0.999665045 0.176864689 0.075766661 
SIRT2 0.390986491 0.996559267 0.249293392 0.616328123 0.996559267 0.204201368 0.225341632 
SETDB1 0.718518165 0.99959465 0.136331363 0.613335451 0.99959465 0.173017035 -0.105182713 
NonTargetingC
ontrolGene_7 
0.276893181 0.993980969 0.287545259 0.608470957 0.993980969 0.226999156 0.331577776 
DTX4 0.87622649 0.999941958 0.039358656 0.607227651 0.999941958 0.100502891 -0.268998839 
TEP1 0.374019303 0.9949726 0.237436036 0.596955138 0.9949726 0.114384796 0.222935834 
CLK2 0.509362595 0.937955813 0.278473867 0.596019401 0.937955813 0.278473867 0.086656806 
RNF138 0.576114373 0.999989483 0.198265834 0.595763207 0.999989483 0.198265834 0.019648835 
KMT5C 0.59658192 0.999795972 0.133164186 0.593814699 0.999795972 0.133164186 -0.002767221 
CDKN2A 0.557702545 0.999994328 0.121225582 0.590888218 0.999994328 0.121225582 0.033185673 
PRKCG 0.785255421 0.999019977 0.081378241 0.584353198 0.999019977 0.179427851 -0.200902223 
NonTargetingC
ontrolGene_43 
0.56944774 0.997856576 0.218475022 0.580453646 0.997856576 0.218475022 0.011005907 
SMARCC1 0.782707832 0.999999991 0.063694768 0.576877453 0.999999991 0.147043368 -0.205830379 
UBE2A 0.729293709 0.966338213 0.202457118 0.571200805 0.966338213 0.235013798 -0.158092905 
SPTBN1 0.964621729 1 0.039491377 0.569070109 1 0.114241101 -0.39555162 
APAF1 0.610550203 0.999769105 0.083972321 0.566042609 0.999769105 0.104031181 -0.044507594 
NonTargetingC
ontrolGene_52 
0.574133995 0.999823905 0.175982262 0.559811466 0.999823905 0.175982262 -0.014322529 
CSNK1E 0.571772806 0.996433343 0.238423719 0.559306324 0.996433343 0.238423719 -0.012466482 
NonTargetingC
ontrolGene_33 
0.432852845 0.9999448 0.251025669 0.557691706 0.9999448 0.197425308 0.124838861 
PER1 0.573266394 0.990077097 0.206151482 0.549827899 0.990077097 0.206151482 -0.023438496 
NOTCH4 0.428439293 0.977380485 0.175613395 0.548574333 0.977380485 0.170484673 0.120135041 
PHF3 0.474240672 0.999371961 0.143769059 0.546285628 0.999371961 0.143769059 0.072044956 
NonTargetingC
ontrolGene_66 
0.42221828 0.999534742 0.250390998 0.545449526 0.999534742 0.214881587 0.123231247 
NonTargetingC
ontrolGene_68 
0.615209971 0.999257052 0.158280513 0.54315201 0.999257052 0.158280513 -0.072057961 
USP13 0.530616015 0.999322517 0.259214001 0.539095272 0.999322517 0.259214001 0.008479257 
RAG1 0.201577337 0.998190338 0.471223399 0.538275325 0.998190338 0.290667958 0.336697989 
RASSF7 0.780672 0.997777622 0.132805625 0.536353228 0.997777622 0.29600717 -0.244318772 
PMS2P3 0.753672138 0.943456195 0.238305977 0.535839944 0.943456195 0.366467735 -0.217832195 
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ETAA1 0.520689404 0.999902643 0.215226257 0.535724118 0.999902643 0.215226257 0.015034714 
NonTargetingC
ontrolGene_57 
0.562209165 0.999999992 0.175381736 0.5336008 0.999999992 0.187047653 -0.028608365 
NOTCH1 0.40927441 0.99799131 0.362305799 0.532465972 0.99799131 0.299947195 0.123191562 
XPC 0.40177247 0.991484933 0.201804197 0.532446875 0.991484933 0.201804197 0.130674405 
TPP1 0.374238031 0.998535295 0.210486575 0.531910258 0.998535295 0.168111978 0.157672227 
POLK 0.655462282 0.999979036 0.139778175 0.5315357 0.999979036 0.163570562 -0.123926582 
DTX3L 0.608383799 0.99393549 0.250939498 0.530919818 0.99393549 0.250939498 -0.077463982 
NonTargetingC
ontrolGene_70 
0.451394425 0.999028141 0.261998587 0.530905506 0.999028141 0.249237726 0.079511081 
CDKN2D 0.218410673 0.997688613 0.451990342 0.523799382 0.997688613 0.345746038 0.305388709 
PMP22 0.509906221 0.999994455 0.155612006 0.523674552 0.999994455 0.155612006 0.013768332 
FBXO18 0.368446992 0.999245999 0.230101554 0.522274759 0.999245999 0.182890444 0.153827767 
MBTD1 0.45330823 0.982125174 0.318080321 0.52191348 0.982125174 0.318080321 0.068605249 
PARP3 0.483256554 0.999043034 0.280436872 0.520313593 0.999043034 0.280436872 0.037057039 
PARPBP 0.642183018 0.997597669 0.16658308 0.519001302 0.997597669 0.16658308 -0.123181716 
NonTargetingC
ontrolGene_23 
0.616944964 0.999695194 0.246673432 0.515168563 0.999695194 0.255795637 -0.101776401 
SETMAR 0.467507602 0.987364155 0.30982586 0.513821275 0.987364155 0.30982586 0.046313673 
NonTargetingC
ontrolGene_34 
0.615222345 0.99906883 0.231426952 0.513175072 0.99906883 0.249456668 -0.102047272 
EME1 0.240399694 0.900026124 0.323672826 0.511270615 0.900026124 0.209613513 0.270870921 
CCNB3 0.420477938 0.999788155 0.164253439 0.509888716 0.999788155 0.128605479 0.089410778 
APOBEC3C 0.502549543 0.995992372 0.161640284 0.50931792 0.995992372 0.161640284 0.006768377 
OTUB2 0.219326652 0.999750694 0.461871695 0.505340629 0.999750694 0.257785958 0.286013976 
RAD18 0.430555916 0.998249125 0.240765977 0.505303235 0.998249125 0.223023743 0.074747319 
POLR2J 0.697300413 0.996488758 0.151021882 0.502906991 0.996488758 0.19139029 -0.194393422 
NonTargetingC
ontrolGene_35 
0.400855796 0.999245228 0.283514144 0.499830634 0.999245228 0.283514144 0.098974839 
NonTargetingC
ontrolGene_74 
0.533101985 0.998153711 0.268790737 0.499039531 0.998153711 0.268790737 -0.034062455 
TRIM29 0.596549482 0.983559316 0.2416772 0.498917126 0.983559316 0.264995431 -0.097632356 
ALKBH2 0.224700618 0.987312972 0.302122659 0.49859343 0.987312972 0.197386863 0.273892812 
APBB1 0.551155499 0.998373594 0.226218434 0.497371905 0.998373594 0.226218434 -0.053783594 
SCAI 0.469562418 0.999862613 0.19869465 0.496843174 0.999862613 0.19869465 0.027280756 
NonTargetingC
ontrolGene_49 
0.34298216 0.998539304 0.29558584 0.495160116 0.998539304 0.29558584 0.152177956 
NonTargetingC
ontrolGene_19 
0.404776442 0.998943602 0.209028753 0.491409802 0.998943602 0.209028753 0.08663336 
UBE2NL 0.497566341 0.944566022 0.279276013 0.489996532 0.944566022 0.279276013 -0.007569808 
NonTargetingC
ontrolGene_36 
0.686722804 0.999854713 0.159474854 0.483352549 0.999854713 0.25340258 -0.203370255 
RNF111 0.441368269 0.999944988 0.188176928 0.48044543 0.999944988 0.188176928 0.039077161 
PHF11 0.332481806 0.968480013 0.295161343 0.480167494 0.968480013 0.214912858 0.147685688 
IP6K3 0.53701283 0.985510177 0.288481443 0.479787981 0.985510177 0.288481443 -0.057224849 
KAT2B 0.42985505 0.998273194 0.200766073 0.478286948 0.998273194 0.190016003 0.048431898 
FAN1 0.301635968 0.997111193 0.267264115 0.478023524 0.997111193 0.267264115 0.176387557 
MDM2 0.745521652 0.999296181 0.097379709 0.477444649 0.999296181 0.182974552 -0.268077003 
SIRT3 0.404523722 0.979592947 0.363779079 0.476295174 0.979592947 0.363779079 0.071771452 
HMGN1 0.4192672 0.991290138 0.37957964 0.47618887 0.991290138 0.37957964 0.05692167 
NonTargetingC
ontrolGene_76 
0.691064923 0.998182876 0.25151439 0.471000114 0.998182876 0.282525502 -0.220064809 
NonTargetingC
ontrolGene_4 
0.46303319 0.998153433 0.278982803 0.47088869 0.998153433 0.278982803 0.0078555 
NonTarg tingC
ontrolGene_38 
0.51641731 0.995893787 0.201545788 0.470878267 0.995893787 0.201545788 -0.045539044 
NonTargetingC
ontrolGene_2 
0.264286784 0.995046821 0.372114596 0.470633481 0.995046821 0.372114596 0.206346697 
PML 0.488228284 0.999831852 0.218708286 0.468552129 0.999831852 0.218708286 -0.019676155 
SMARCC2 0.410964454 0.997555566 0.354861922 0.468354447 0.997555566 0.354861922 0.057389993 
CHFR 0.165861963 0.999662265 0.363249416 0.46807362 0.999662265 0.200026196 0.302211657 
COPS7B 0.611463743 0.999189187 0.167304159 0.460364341 0.999189187 0.278102552 -0.151099402 
NonTargetingC
ontrolGene_20 
0.626507886 0.999975913 0.153631625 0.458975915 0.999975913 0.201741731 -0.167531971 
ANKRD44 0.16699919 0.998536699 0.477003499 0.458728677 0.998536699 0.266477136 0.291729487 
NOTCH3 0.325262779 0.994536715 0.209763614 0.458123839 0.994536715 0.179718803 0.13286106 
PARG 0.020726856 0.995565538 0.622838059 0.456644728 0.995565538 0.385421367 0.435917871 
TRIP12 0.560416204 0.999977382 0.190500439 0.456631153 0.999977382 0.201815044 -0.103785051 
OTUD7B 0.386903391 0.966178755 0.309427349 0.455064676 0.966178755 0.309427349 0.068161284 
NonTargetingC
ontrolGene_42 
0.332722267 0.999344463 0.204766592 0.454930772 0.999344463 0.174973777 0.122208505 
MSH3 0.026441893 0.986451479 0.474160079 0.454169464 0.986451479 0.310510777 0.427727571 
SIRT7 0.54942449 0.999664558 0.161013986 0.45107144 0.999664558 0.184380409 -0.098353049 
TREX1 0.394221984 0.968436391 0.369414995 0.447250178 0.968436391 0.369414995 0.053028194 
SLF1 0.331791474 0.957297648 0.353040755 0.446807449 0.957297648 0.353040755 0.115015975 
SIRT5 0.325008676 0.999831869 0.199559323 0.446786604 0.999831869 0.162101104 0.121777928 
BRCA2 0.592009836 0.996405184 0.09897257 0.446394884 0.996405184 0.1621038 -0.145614951 
NonTargetingC
ontrolGene_58 
0.495866089 0.999971942 0.263850838 0.445091973 0.999971942 0.263850838 -0.050774116 
NonTargetingC
ontrolGene_79 
0.287755961 0.999287288 0.397960225 0.442644833 0.999287288 0.362981881 0.154888872 
HELB 0.175850019 0.99823044 0.346842636 0.441062781 0.99823044 0.173793352 0.265212762 
PXMP2 0.3207126 0.923308842 0.444325346 0.436667673 0.923308842 0.444325346 0.115955073 
RBM7 0.339287006 0.988203047 0.519220154 0.435074116 0.988203047 0.515253133 0.09578711 
ATXN3 0.449466818 0.999887003 0.235765562 0.429514311 0.999887003 0.235765562 -0.019952507 
TYMS 0.419183302 0.989232021 0.359659598 0.425976972 0.989232021 0.359659598 0.00679367 
MSH2 0.154440696 0.974192869 0.401188919 0.423366563 0.974192869 0.401188919 0.268925867 
MSH4 0.13750266 0.993583438 0.376483249 0.415122076 0.993583438 0.259161096 0.277619416 
RAD54B 0.471432234 0.984425058 0.227586521 0.413843268 0.984425058 0.227586521 -0.057588967 
MAPK8 0.507464271 0.999525364 0.154640654 0.413722088 0.999525364 0.184534957 -0.093742183 
NonTargetingC
ontrolGene_28 
0.456158885 0.999427371 0.378668407 0.412023138 0.999427371 0.378668407 -0.044135747 
NonTargetingC
ontrolGene_18 
0.412725737 0.999971612 0.247231389 0.411376662 0.999971612 0.247231389 -0.001349075 
UBE2B 0.451727534 0.967780942 0.392128864 0.410982706 0.967780942 0.392128864 -0.040744828 
EME2 -0.099482512 0.998886994 0.583093659 0.408470392 0.998886994 0.3321133 0.507952905 
CSNK2A2 0.646189847 0.999868116 0.137312201 0.407699656 0.999868116 0.182703161 -0.238490191 
UBE2D2 0.182881841 0.926997804 0.390062159 0.405907499 0.926997804 0.271229486 0.223025658 
NonTargetingC
ontrolGene_54 
0.418244042 0.999049499 0.300327216 0.40514397 0.999049499 0.300327216 -0.013100072 
RAD54L2 0.664238302 0.99939853 0.162887868 0.400571613 0.99939853 0.260367602 -0.263666689 
PARP2 0.345429586 0.943985904 0.309226463 0.398061421 0.943985904 0.309226463 0.052631834 
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CCNB2 0.376528949 0.989274411 0.262865149 0.397750621 0.989274411 0.262865149 0.021221672 
CDKN1B 0.677757422 0.999985514 0.201300535 0.397069302 0.999985514 0.277651111 -0.28068812 
WDR76 0.30878335 0.892541247 0.274239745 0.390062068 0.892541247 0.274239745 0.081278718 
BRCC3 0.664420303 0.99999999 0.129582776 0.388382964 0.99999999 0.255489982 -0.276037339 
APLF 0.655931164 0.999572699 0.268687357 0.384863065 0.999572699 0.27377354 -0.271068098 
SUMO3 0.197318756 0.994900124 0.328498082 0.38453705 0.994900124 0.328498082 0.187218294 
NABP2 0.257027611 0.995463463 0.268568282 0.384230148 0.995463463 0.241334357 0.127202537 
ARID1B 0.437270751 0.970376264 0.301973032 0.382051584 0.970376264 0.301973032 -0.055219167 
REV1 0.28110326 0.951147894 0.357975676 0.380428671 0.951147894 0.321946653 0.099325411 
USP45 0.350124502 0.96395309 0.348616929 0.37826907 0.96395309 0.348616929 0.028144567 
APOBEC3B 0.455785012 0.999967008 0.236724223 0.376857898 0.999967008 0.236724223 -0.078927113 
MVP 0.370491355 0.881549393 0.324692981 0.372667385 0.881549393 0.324692981 0.00217603 
NonTargetingC
ontrolGene_78 
0.439750883 0.999117535 0.344349493 0.370486312 0.999117535 0.344349493 -0.069264571 
KDM1A 0.126091589 0.935769267 0.48560199 0.369710622 0.935769267 0.48560199 0.243619034 
HMGB2 0.610550215 0.999925107 0.189092663 0.366230624 0.999925107 0.267173602 -0.244319591 
NEK9 0.379792037 0.99995695 0.203498892 0.364414308 0.99995695 0.203498892 -0.015377729 
TET2 0.92998819 0.999998163 0.053624086 0.360776459 0.999998163 0.242515829 -0.569211731 
NonTargetingC
ontrolGene_10 
0.61658203 0.999960589 0.219092132 0.360179291 0.999960589 0.391518669 -0.256402739 
UBA3 0.392609834 0.994051665 0.225515477 0.355250245 0.994051665 0.225515477 -0.037359589 
NonTargetingC
ontrolGene_41 
0.469740183 0.985115366 0.413667613 0.354506413 0.985115366 0.46541422 -0.11523377 
ASF1A 0.384600608 0.992322994 0.189662944 0.353617343 0.992322994 0.20076454 -0.030983265 
POLG2 0.262933392 0.981114272 0.378952066 0.351476926 0.981114272 0.378952066 0.088543534 
POLL 0.398054248 0.995018218 0.277494893 0.351231205 0.995018218 0.278194075 -0.046823043 
H2AFY 0.382537403 0.985621785 0.33088071 0.350773271 0.985621785 0.33088071 -0.031764132 
PRIMPOL 0.364305535 0.97661071 0.334150094 0.349123989 0.97661071 0.334150094 -0.015181546 
SF3B1 0.482900631 0.985254946 0.16687755 0.346819767 0.985254946 0.221569382 -0.136080864 
APOBEC3D 0.508483866 0.974141819 0.330086098 0.342770008 0.974141819 0.369387537 -0.165713858 
OGG1 0.019844109 0.848582944 0.508307522 0.341602815 0.905134815 0.508307522 0.321758706 
RNF2 0.444681803 0.999627895 0.27250104 0.340723931 0.999627895 0.283344358 -0.103957872 
SLF2 0.281679594 0.968887803 0.484472338 0.340229842 0.968887803 0.484472338 0.058550248 
ALDH2 0.486546867 0.97275521 0.275798753 0.33901215 0.97275521 0.293154395 -0.147534717 
INO80C 0.351330512 0.99225101 0.408909174 0.337524099 0.99225101 0.408909174 -0.013806413 
UBE2D1 0.376058569 0.999939613 0.225241959 0.336397705 0.999939613 0.225688434 -0.039660864 
ATM 1.201579498 1 0.032047214 0.334287078 1 0.323193756 -0.86729242 
ABL1 0.479701063 0.999996573 0.153482962 0.32569033 0.999996573 0.223556899 -0.154010733 
NonTargetingC
ontrolGene_47 
0.36075394 0.99765574 0.332556735 0.319896864 0.99765574 0.332556735 -0.040857076 
ATF2 0.28052765 0.990828682 0.307924958 0.317288998 0.990828682 0.307924958 0.036761348 
SALL4 0.211574193 0.991028909 0.311969916 0.31433645 0.991028909 0.305548539 0.102762257 
NonTargetingC
ontrolGene_63 
0.450400929 0.995299415 0.36581474 0.313060714 0.995299415 0.370924813 -0.137340215 
NonTargetingC
ontrolGene_80 
0.716584864 0.99999086 0.162519131 0.312501616 0.99999086 0.371721322 -0.404083248 
PRMT6 0.595771426 0.998934623 0.20570671 0.311601101 0.998934623 0.405066951 -0.284170324 
NonTargetingC
ontrolGene_6 
0.281308535 0.999346524 0.242091075 0.310968158 0.999346524 0.242091075 0.029659623 
NonTarg tingC
ontrolGene_71 
0.291871577 0.990797611 0.311783685 0.30834454 0.990797611 0.311783685 0.016472964 
USP47 0.340678368 0.996708864 0.31463378 0.308208677 0.996708864 0.31463378 -0.032469691 
NTHL1 0.242248578 0.931538222 0.398161732 0.306280651 0.931538222 0.398161732 0.064032073 
NonTargetingC
ontrolGene_22 
0.66793684 0.998830219 0.201771406 0.305431058 0.998830219 0.372629334 -0.362505783 
NonTargetingC
ontrolGene_67 
0.16588145 0.963105599 0.474021678 0.298881325 0.963105599 0.474021678 0.132999875 
USP20 0.570717433 0.997002414 0.24448993 0.298748207 0.997002414 0.297860276 -0.271969226 
PARP14 -0.052090885 0.999626837 0.55035571 0.296650416 0.999626837 0.422550735 0.348741301 
USP11 0.29021863 0.977479353 0.267347445 0.292297743 0.977479353 0.267347445 0.002079113 
PINK1 -0.232957626 0.859205561 0.7120578 0.292016342 0.859205561 0.480296597 0.524973968 
SENP8 0.793514012 1 0.117722982 0.29177947 1 0.300314728 -0.501734542 
NABP1 0.425386447 0.959632317 0.345913405 0.291399708 0.959632317 0.345913405 -0.133986739 
PPP5C 0.111652577 0.956631895 0.442428591 0.288826821 0.956631895 0.442428591 0.177174244 
RAG2 0.130665655 0.937786552 0.382911203 0.288541948 0.937786552 0.279899438 0.157876293 
APOBEC3A 0.295508196 0.949371552 0.402239037 0.287559727 0.949371552 0.402239037 -0.007948469 
RHO 0.17738965 0.867938538 0.43694721 0.286215907 0.867938538 0.43694721 0.108826257 
SSBP2 0.30010202 0.999223979 0.29651219 0.283602099 0.999223979 0.29651219 -0.016499921 
APOBEC2 0.219990172 0.999739009 0.307701603 0.280765648 0.999739009 0.307701603 0.060775476 
PMS1 0.231855822 0.958274699 0.395162706 0.279624556 0.958274699 0.395162706 0.047768733 
NonTargetingC
ontrolGene_59 
0.316415105 0.980263038 0.392473977 0.276595121 0.980263038 0.392473977 -0.039819984 
SMUG1 0.266987691 0.926775706 0.400235835 0.275533631 0.926775706 0.400235835 0.008545941 
ERCC6 0.109759631 0.742080257 0.463305052 0.272885837 0.742080257 0.461681238 0.163126206 
PPP6R3 0.427865803 0.99966489 0.323761886 0.272166394 0.99966489 0.346160016 -0.155699409 
RPA4 0.10962224 0.926587876 0.418620376 0.271949767 0.926587876 0.347017442 0.162327527 
NonTargetingC
ontrolGene_48 
0.112659323 0.966309425 0.585852947 0.27182476 0.966309425 0.563951342 0.159165437 
SERBP1 -0.055402979 0.936111565 0.549367782 0.271075829 0.936111565 0.436697139 0.326478808 
NUDT1 0.09702177 0.946357521 0.410731261 0.268617241 0.946357521 0.322648734 0.171595472 
TNP1 0.162474561 0.962981376 0.406564069 0.268559553 0.962981376 0.371141252 0.106084993 
PIAS3 0.220998256 0.955902472 0.518574108 0.265580921 0.955902472 0.518574108 0.044582665 
MUM1 0.586028663 0.998613554 0.166129122 0.264817817 0.998613554 0.275787866 -0.321210846 
MBD4 0.308408146 0.99826714 0.294597572 0.262546439 0.99826714 0.294597572 -0.045861707 
NEIL2 0.079645045 0.900745624 0.42471125 0.261775171 0.900745624 0.380534521 0.182130126 
CCNO 0.107660869 0.98679286 0.393804847 0.258422772 0.98679286 0.393804847 0.150761903 
NonTargetingC
ontrolGene_51 
0.298982513 0.984970515 0.390025888 0.257662825 0.984970515 0.390025888 -0.041319688 
CCND3 0.223063909 0.99943543 0.257562988 0.257309752 0.99943543 0.257562988 0.034245843 
USP51 0.300470978 0.999505252 0.300943535 0.256327081 0.999505252 0.303779222 -0.044143897 
RECQL 0.491747529 0.991266977 0.227210593 0.255184663 0.991266977 0.346060971 -0.236562866 
USP26 0.303958027 0.977805328 0.414615829 0.253714322 0.977805328 0.414615829 -0.050243705 
NonTargetingC
ontrolGene_24 
0.279661214 0.998717176 0.426064512 0.253466775 0.998717176 0.426064512 -0.026194439 
NonTargetingC
ontrolGene_27 
0.373422582 0.99983586 0.219087331 0.253053387 0.99983586 0.273662572 -0.120369195 
CENPS -0.165737356 0.809540827 0.654784225 0.251987209 0.809540827 0.504680041 0.417724565 
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SUV39H1 0.035520359 0.686927959 0.727706492 0.251722001 0.816719917 0.727706492 0.216201642 
OR1E2 -0.046680827 0.776359 0.639285089 0.250135218 0.776359 0.639285089 0.296816044 
GADD45A 0.237855855 0.999990609 0.416522956 0.248290086 0.999990609 0.416522956 0.010434231 
INO80D 0.124782837 0.995796808 0.385321677 0.246581288 0.995796808 0.322263207 0.121798451 
APOBEC3H 0.230781046 0.843921742 0.402261229 0.243273363 0.843921742 0.402261229 0.012492317 
C9orf142 0.226359013 0.955815087 0.345532622 0.239141833 0.955815087 0.345532622 0.012782819 
ATXN7 0.629376656 0.999322392 0.185430777 0.235773668 0.999322392 0.300331243 -0.393602988 
LMNA 0.137809714 0.703254743 0.988127832 0.235251507 0.703254743 0.988127832 0.097441793 
CRY2 0.274015564 0.8956699 0.466013717 0.23469537 0.8956699 0.466013717 -0.039320194 
HES1 0.06007948 0.76809946 0.612258629 0.233702749 0.801786985 0.612258629 0.173623269 
NonTargetingC
ontrolGene_1 
0.349701776 0.999451714 0.280807461 0.233483269 0.999451714 0.296424935 -0.116218507 
NonTarg tingC
ontrolGene_37 
0.163785092 0.9463425 0.377586763 0.230307412 0.9463425 0.377586763 0.066522319 
CDC 4 0.227487745 0.943082939 0.317670536 0.229082209 0.943082939 0.317670536 0.001594464 
UBE2V1 0.676775662 0.994675609 0.203828569 0.228322742 0.994675609 0.311815552 -0.44845292 
HDAC4 0.264719905 0.952460343 0.448885076 0.227808383 0.952460343 0.448885076 -0.036911521 
SUV39H2 0.381515643 0.994902355 0.317153685 0.227320766 0.994902355 0.317153685 -0.154194876 
XPA 0.459401382 0.954356687 0.428896985 0.226625495 0.954356687 0.473829968 -0.232775887 
GABBR1 0.116340011 0.830415951 0.443223333 0.22158859 0.830415951 0.443223333 0.105248579 
HUS1B 0.153822685 0.999041355 0.489202098 0.220769523 0.999041355 0.489202098 0.066946838 
CCNE1 0.314320619 0.972601188 0.463674971 0.219653256 0.972601188 0.463674971 -0.094667364 
NonTargetingC
ontrolGene_60 
0.251793551 0.939658178 0.359655223 0.216847108 0.939658178 0.359655223 -0.034946444 
NonTargetingC
ontrolGene_64 
0.164850469 0.975822499 0.356101424 0.216614764 0.975822499 0.356101424 0.051764296 
NonTargetingC
ontrolGene_12 
0.412477701 0.995789702 0.156773149 0.214065217 0.995789702 0.301779753 -0.198412484 
BMI1 0.423723041 0.997754667 0.342022959 0.213148011 0.997754667 0.45990931 -0.210575031 
DCUN1D4 0.375164322 0.997906465 0.339737976 0.209996603 0.997906465 0.37770114 -0.165167719 
POLB 0.387642184 0.978148625 0.284457033 0.208822909 0.978148625 0.362603932 -0.178819275 
HDAC1 0.017750919 0.853806783 0.481902706 0.206801755 0.853806783 0.358107678 0.189050836 
NEIL1 0.47341097 0.967157443 0.197009555 0.206092534 0.967157443 0.321605993 -0.267318436 
NonTargetingC
ontrolGene_56 
0.065607191 0.965584874 0.434281159 0.203833701 0.965584874 0.434281159 0.138226511 
ANKRD28 0.279343555 0.964281934 0.377704218 0.203733426 0.964281934 0.377704218 -0.075610129 
PSIP1 0.182814347 0.882014247 0.407987723 0.202226528 0.882014247 0.407987723 0.01941218 
SCAF11 0.578619509 0.986336654 0.170906471 0.198772805 0.986336654 0.377734284 -0.379846704 
ATMIN 0.146735323 0.945798935 0.623082988 0.196221937 0.945798935 0.623082988 0.049486614 
NonTargetingC
ontrolGene_46 
0.426426405 0.999895055 0.246418794 0.191663436 0.999895055 0.327708527 -0.234762968 
PRDM9 0.278200216 0.943546646 0.367872819 0.191049834 0.943546646 0.367872819 -0.087150382 
PNN -0.193308689 0.997902515 0.687712017 0.190054384 0.997902515 0.399103118 0.383363073 
SMARCA2 -0.183015484 0.964445153 0.662672832 0.189519252 0.964445153 0.590235601 0.372534736 
MTA3 0.497542296 0.998930186 0.238585568 0.189440643 0.998930186 0.472414848 -0.308101653 
PPP4R4 0.354292349 0.999944276 0.355000241 0.186939341 0.999944276 0.415491344 -0.167353008 
NonTargetingC
ontrolGene_9 
0.177854682 0.878180299 0.570687847 0.185133451 0.878180299 0.570687847 0.007278769 
TP63 0.323737216 0.982719463 0.431918923 0.184529845 0.982719463 0.471691556 -0.139207372 
TOP3B 0.187319284 0.997428561 0.478796616 0.181748161 0.997428561 0.478796616 -0.005571123 
L3MBTL1 0.193188911 0.999081574 0.329772844 0.175355944 0.999081574 0.329772844 -0.017832967 
ZSWIM7 0.27737294 0.743131832 0.724270237 0.172618176 0.743131832 0.724270237 -0.104754765 
MLH1 -0.083837356 0.942751324 0.581493012 0.172563029 0.942751324 0.556658798 0.256400385 
DCAF11 0.011343408 0.900717935 0.487812003 0.170446097 0.900717935 0.386361477 0.159102689 
HDAC2 0.242624258 0.869520373 0.350883165 0.166968371 0.869520373 0.350883165 -0.075655887 
NonTargetingC
ontrolGene_30 
0.220571779 0.999748986 0.331340985 0.164977284 0.999748986 0.357644257 -0.055594495 
WRN 0.194002836 0.936131005 0.479474015 0.163784773 0.936131005 0.479474015 -0.030218064 
HNRNPUL1 0.065258696 0.981160424 0.437871191 0.163553397 0.981160424 0.388394168 0.098294701 
SUMO1 0.209439311 0.848506551 0.352701213 0.159560717 0.848506551 0.352701213 -0.049878594 
IGHMBP2 0.051354525 0.733461585 0.477616102 0.159362388 0.733461585 0.477616102 0.108007863 
CRY1 0.109280694 0.920529515 0.580422196 0.157846794 0.920529515 0.580422196 0.048566101 
ANP32E 0.090454976 0.877808356 0.403546598 0.157621012 0.877808356 0.388795789 0.067166036 
MCM10 0.018534883 0.90263807 0.48159913 0.156753517 0.90263807 0.396343306 0.138218634 
RAD23B 0.125553414 0.726194025 0.689054646 0.155677338 0.726194025 0.689054646 0.030123924 
ZDHHC16 -0.619488517 0.841054331 0.906549519 0.15437286 0.957586173 0.713194275 0.773861376 
MSH5 -0.152193068 0.738573839 0.706570482 0.153969319 0.810969531 0.706570482 0.306162388 
H2AFY2 0.148010251 0.763884749 0.465235999 0.149223636 0.763884749 0.465235999 0.001213385 
COL21A1 0.147885849 0.921825514 0.550247241 0.147630492 0.921825514 0.550247241 -2.55358E-04 
SUMO4 -0.2977552 0.958853859 0.703876238 0.14750239 0.958853859 0.448380721 0.44525759 
WHSC1 0.324311081 0.984510192 0.413699041 0.147316887 0.984510192 0.423713962 -0.176994195 
POLH 0.221447455 0.817609978 0.414541812 0.143453016 0.817609978 0.414541812 -0.077994439 
BLM -0.044631219 0.840181435 0.566089673 0.143088336 0.840181435 0.470355048 0.187719554 
PAXIP1 0.004171241 0.640313842 0.733419247 0.140747098 0.640313842 0.733419247 0.136575857 
RAD52 0.052618481 0.728971579 0.559429461 0.139358087 0.728971579 0.559429461 0.086739606 
APOBEC3F -0.069098036 0.96743583 0.558607065 0.137463363 0.96743583 0.495537325 0.206561399 
ASF1B 0.2770417 0.852870623 0.479460419 0.135389719 0.852870623 0.479460419 -0.14165198 
EXO1 0.0038375 0.626652201 0.875452844 0.133688975 0.626652201 0.875452844 0.129851475 
SMC1B 0.406920037 0.999741633 0.330922427 0.132101041 0.999741633 0.39971864 -0.274818997 
TIPIN -0.066041576 0.889867239 0.561447242 0.131938246 0.889867239 0.431000282 0.197979822 
APOBEC3G 0.172594923 0.800085083 0.404673257 0.130130582 0.800085083 0.404673257 -0.042464341 
NBN 0.323243153 0.877525563 0.750377074 0.127117548 0.797503888 0.750377074 -0.196125605 
EID3 0.245719157 0.993920362 0.368745894 0.126087803 0.993920362 0.389930596 -0.119631355 
RAD9B 0.092239963 0.907235566 0.416475499 0.125768599 0.907235566 0.416475499 0.033528636 
CUL4A 0.155945046 0.655076567 0.689545238 0.125635587 0.655076567 0.689545238 -0.030309459 
HFM1 0.370797409 0.993815046 0.276872453 0.125293337 0.993815046 0.383542611 -0.245504072 
SENP2 0.335707035 0.974847315 0.384750348 0.124786415 0.974847315 0.384750348 -0.210920621 
H3F3A 0.239065004 0.576658748 0.533961199 0.123420012 0.576658748 0.533961199 -0.115644991 
MORF4L2 -0.08291946 0.909420079 0.609511379 0.12316091 0.909420079 0.584895047 0.20608037 
COPS4 -0.369197186 0.962367229 0.784286744 0.123057171 0.962367229 0.715195378 0.492254357 
FAM175A 0.288665055 0.987271407 0.317198107 0.122177976 0.987271407 0.412046859 -0.166487079 
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TRIM28 -0.035181148 0.696727965 0.743038716 0.120099747 0.696727965 0.743038716 0.155280895 
UNG -0.151604107 0.879170242 0.711741337 0.119793468 0.879170242 0.711741337 0.271397575 
DCUN1D2 0.483637729 0.967274579 0.312938999 0.119728117 0.967274579 0.397567792 -0.363909612 
UBE2D4 0.530167178 0.907990743 0.308397143 0.117439635 0.907990743 0.445140961 -0.412727543 
DTX1 0.353444764 0.802545681 0.457077757 0.115984764 0.802545681 0.457077757 -0.237460001 
AICDA 0.223795156 0.884412741 0.47259631 0.113797368 0.884412741 0.47259631 -0.109997789 
SMARCA4 0.07564986 0.921918975 0.428203393 0.113699745 0.921918975 0.428203393 0.038049885 
LIG1 -0.323826434 0.526211125 0.979584009 0.113695322 0.903825925 0.894261113 0.437521757 
RECQL4 -0.704082691 0.477553355 0.944230596 0.103531557 0.877680198 0.595715041 0.807614248 
NonTargetingC
ontrolGene_8 
0.0252258 0.850087936 0.533634841 0.103184482 0.850087936 0.533634841 0.077958682 
PER2 0.190416275 0.999727149 0.535196289 0.098989114 0.999727149 0.535196289 -0.091427161 
NFATC2IP 0.402180172 0.947512601 0.218206324 0.097418092 0.947512601 0.414063697 -0.30476208 
XRCC5 0.135621641 0.986959415 0.419954995 0.09500498 0.986959415 0.419954995 -0.040616661 
XRCC1 0.138081457 0.636133304 0.83560372 0.093587426 0.636133304 0.83560372 -0.044494031 
RECQL5 0.063694102 0.807844349 0.449528537 0.09254501 0.807844349 0.449528537 0.028850908 
NonTargetingC
ontrolGene_69 
0.227566212 0.998422901 0.457736564 0.091697192 0.998422901 0.457736564 -0.13586902 
PIF1 0.053836296 0.789502562 0.452710548 0.091245429 0.789502562 0.452710548 0.037409133 
CBX3 0.182938952 0.85241978 0.418979627 0.090643746 0.85241978 0.418979627 -0.092295206 
BEND3 0.131089838 0.782060364 0.418467606 0.087865329 0.782060364 0.418467606 -0.043224508 
TOP2A 0.036454574 0.810893181 0.622751665 0.086579172 0.810893181 0.622751665 0.050124599 
CHTF18 -0.044743262 0.982124975 0.541052539 0.08562101 0.982124975 0.470831958 0.130364272 
POLQ 0.068675702 0.707187804 0.452518333 0.084371766 0.707187804 0.452518333 0.015696064 
MTA1 0.027925211 0.620309887 0.740035073 0.083837069 0.620309887 0.740035073 0.055911858 
RFC1 -0.008355058 0.870530865 0.507184656 0.08255101 0.870530865 0.507184656 0.090906068 
RAD51AP1 0.282305351 0.853380663 0.405176852 0.076032306 0.853380663 0.509234634 -0.206273046 
TCEA1 -0.041161416 0.635881387 0.597959364 0.074564313 0.635881387 0.597959364 0.115725729 
USP22 -0.028193361 0.642641712 0.653544646 0.074009799 0.642641712 0.653544646 0.10220316 
NLK 0.152660664 0.981217976 0.473667152 0.073554147 0.981217976 0.473667152 -0.079106517 
PPP6R1 -0.180540057 0.772941429 0.696452101 0.070165085 0.772941429 0.646705834 0.250705142 
ERCC6L2 0.257779422 0.872367225 0.646306863 0.06056496 0.872367225 0.646306863 -0.197214462 
UIMC1 0.246243792 0.861488402 0.390302293 0.059326254 0.861488402 0.444985534 -0.186917537 
MSH6 0.049096949 0.77028725 0.633023141 0.056577325 0.77028725 0.633023141 0.007480376 
RNF168 0.249943224 0.723921583 0.768789476 0.054766667 0.686855358 0.768789476 -0.195176557 
DTX2 0.074069585 0.671581355 0.696367427 0.05381061 0.671581355 0.696367427 -0.020258975 
PPP6R2 -0.243076337 0.793930204 0.728714928 0.045462184 0.793930204 0.582901683 0.288538521 
SENP7 0.330744832 0.8161503 0.467620277 0.044435137 0.8161503 0.467620277 -0.286309695 
ATAD5 -0.056820094 0.639201937 0.719766489 0.043432205 0.639201937 0.719766489 0.100252299 
SLBP -0.199307395 0.84926528 0.689545481 0.039423417 0.84926528 0.520300724 0.238730812 
BAZ1A 0.152587803 0.733462775 0.45138603 0.039047852 0.733462775 0.474065524 -0.113539951 
PRDM10 0.018883294 0.750825113 0.67521091 0.032405396 0.750825113 0.67521091 0.013522102 
MPG -0.149772922 0.678395155 0.722356284 0.03185652 0.678395155 0.64260504 0.181629442 
PARP9 0.194337967 0.997612841 0.43324421 0.026209723 0.997612841 0.476439733 -0.168128245 
UCHL3 0.13091457 0.990060866 0.431779794 0.017147081 0.990060866 0.484845025 -0.11376749 
TP73 0.003021666 0.721214667 0.496816724 0.016865918 0.721214667 0.496816724 0.013844253 
RNF126 0.03207365 0.98261248 0.48642391 0.015435248 0.98261248 0.48642391 -0.016638402 
PIAS2 0.433295828 0.972756723 0.373570722 0.011042594 0.972756723 0.489889098 -0.422253234 
HLTF 0.215943345 0.842836197 0.400106702 0.008822015 0.842836197 0.491351357 -0.20712133 
APOBEC1 6.31454E-04 0.956864874 0.499361168 0.008738493 0.956864874 0.499361168 0.008107039 
ASCC1 0.771740111 0.999128493 0.059553489 0.006423457 0.999128493 0.494072896 -0.765316655 
OR1E1 0.38709719 0.985974094 0.259163815 0.006129547 0.985974094 0.49547548 -0.380967643 
SSBP1 0.190719099 0.828033245 0.733551418 0.005723336 0.828033245 0.7423631 -0.184995763 
CSNK2A1 0.114166939 0.59893175 0.744935698 0.004215594 0.59893175 0.744935698 -0.109951345 
BAZ1B -0.285309055 0.677081241 0.831773684 0.002834699 0.677081241 0.831773684 0.288143755 
CCND1 -0.135735032 0.869752987 0.68862852 9.76677E-04 0.869752987 0.641848467 0.136711709 
TREX2 0.328076149 0.89181467 0.529610279 -0.00218478 0.89181467 0.589818312 -0.330260929 
ZRANB3 0.267796074 0.858872109 0.384695382 -0.004053803 0.858872109 0.503880464 -0.271849876 
ERCC4 -0.582410528 0.171687831 0.999998625 -0.006311267 0.49479728 0.999998625 0.576099261 
OR6B1 -0.020739962 0.780133397 0.543041925 -0.006429892 0.780133397 0.543041925 0.01431007 
SMARCAL1 0.085000324 0.760780742 0.748013154 -0.011956131 0.760780742 0.748013154 -0.096956455 
SIRT6 0.16482436 0.933946592 0.491069507 -0.027412561 0.933946592 0.526319988 -0.192236921 
RNF40 -1.144754447 0.019481974 0.999986349 -0.028827287 0.710868279 0.999986349 1.11592716 
KLHL15 0.40765917 0.992613477 0.275391024 -0.031211822 0.992613477 0.525682708 -0.438870991 
DLGAP5 -0.091161529 0.886341913 0.585898305 -0.040257893 0.886341913 0.585898305 0.050903635 
EYA1 0.096844369 0.990056724 0.455516153 -0.04049906 0.990056724 0.53979723 -0.137343429 
SIRT4 -0.115909667 0.909510653 0.616954509 -0.040541048 0.909510653 0.607658791 0.075368619 
OTUB1 0.08380161 0.59043536 0.800128386 -0.040880799 0.59043536 0.800128386 -0.124682409 
USP3 0.232671829 0.90412076 0.449800464 -0.048132813 0.90412076 0.545462659 -0.280804642 
STAG1 0.074002938 0.723799903 0.633347551 -0.049438275 0.723799903 0.705338843 -0.123441213 
UHRF2 0.187028524 0.933087821 0.456677267 -0.049617575 0.933087821 0.541887984 -0.236646099 
COL1A1 0.249914919 0.911479638 0.561336024 -0.056901749 0.911479638 0.616873471 -0.306816668 
APTX 0.053021535 0.902305794 0.503230052 -0.058995877 0.902305794 0.55735868 -0.112017412 
UBC -0.801976588 0.305068474 0.98099411 -0.059050896 0.680768834 0.98099411 0.742925692 
PARK2 0.168701095 0.744557492 0.508448011 -0.059535046 0.744557492 0.558212871 -0.228236141 
NEIL3 0.170400308 0.830465663 0.459576238 -0.062925562 0.830465663 0.559838615 -0.23332587 
ERCC5 0.067635461 0.788299656 0.480513536 -0.07624458 0.788299656 0.579596243 -0.14388004 
ANKRD52 0.05420815 0.830515882 0.982790897 -0.077679179 0.763937201 0.982790897 -0.131887329 
TADA3 -0.363449042 0.433691801 0.915647428 -0.078706003 0.433691801 0.915647428 0.28474304 
EXD2 0.467668765 0.986875983 0.445430619 -0.079378146 0.986875983 0.577746051 -0.547046911 
PPP4R3B -0.085563086 0.993541008 0.583369414 -0.082536945 0.993541008 0.583369414 0.003026141 
SHPRH 0.008478531 0.726763686 0.552152367 -0.082853496 0.726763686 0.585907914 -0.091332026 
NonTargetingC
ontrolGene_3 
0.005532232 0.860063864 0.556267724 -0.085311621 0.860063864 0.58586819 -0.090843853 
PPP4R1 -0.188117089 0.856665652 0.694032596 -0.085795205 0.856665652 0.662714626 0.102321884 
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CHRAC1 -0.145499585 0.470805861 0.883613746 -0.086188938 0.470805861 0.883613746 0.059310647 
PIAS1 -0.046448663 0.730146097 0.594026501 -0.094716277 0.730146097 0.594026501 -0.048267615 
RNASEH2A -0.433064026 0.182239122 0.999838311 -0.100734202 0.407589848 0.999838311 0.332329824 
USP1 -0.268746332 0.590243354 0.848664132 -0.101292794 0.590243354 0.848664132 0.167453538 
ECT2 -0.416490353 0.601225405 0.863494177 -0.104058134 0.601225405 0.863494177 0.312432218 
TDP1 0.063966399 0.868239207 0.786153488 -0.108869623 0.868239207 0.813004354 -0.172836022 
UVSSA -0.080539004 0.69812623 0.613241301 -0.109398277 0.69812623 0.613241301 -0.028859273 
HPF1 0.202930995 0.942247654 0.495465149 -0.114787885 0.942247654 0.598148943 -0.31771888 
CBX1 0.108481757 0.818043684 0.73796149 -0.115511477 0.732768406 0.73796149 -0.223993234 
MDM4 -0.272131062 0.999708607 0.750459003 -0.120556767 0.999708607 0.701052302 0.151574295 
CASP3 0.045602456 0.92594083 0.520395807 -0.122515028 0.92594083 0.595479011 -0.168117484 
KMT5A 0.069387497 0.741562051 0.574073591 -0.124254304 0.741562051 0.589666108 -0.193641801 
USP4 0.095010668 0.805362863 0.589526684 -0.124857406 0.805362863 0.619356451 -0.219868073 
NOTCH2 0.039655919 0.91600724 0.518683693 -0.127144125 0.91600724 0.625304146 -0.166800044 
GEN1 0.135956313 0.754153117 0.671192216 -0.127435798 0.754153117 0.717346874 -0.263392111 
PER3 0.078220487 0.849608299 0.489903783 -0.132105967 0.849608299 0.626409073 -0.210326454 
TOP1 -0.787746898 0.304162692 0.965118595 -0.133298574 0.593986618 0.965118595 0.654448324 
NUDT16L1 0.181216111 0.821254066 0.439119507 -0.136536639 0.821254066 0.626962619 -0.317752749 
CREBBP 0.052174079 0.548938199 0.977017433 -0.138574936 0.420105411 0.977017433 -0.190749015 
TERF2IP -0.177971527 0.747038604 0.740824367 -0.139410868 0.747038604 0.740824367 0.038560659 
SMARCAD1 0.053450148 0.902049214 0.573219163 -0.153093248 0.902049214 0.648090642 -0.206543396 
PMS2 0.305918679 0.962221154 0.340576221 -0.154685312 0.962221154 0.638062213 -0.460603991 
PAPD7 -0.181913822 0.791645969 0.677664409 -0.154780646 0.791645969 0.677664409 0.027133176 
SUMO2 -0.81598687 0.592600641 0.874235475 -0.158564629 0.592600641 0.874235475 0.657422242 
INO80E -0.338749577 0.854418796 0.789865255 -0.159554037 0.854418796 0.709819692 0.17919554 
FAAP20 -0.051728204 0.529341341 0.704574993 -0.163049879 0.529341341 0.704574993 -0.111321675 
EYA3 0.024634086 0.537003538 0.978716184 -0.164652103 0.537003538 0.978716184 -0.189286189 
HNRNPK -0.15426426 0.998457502 0.62563868 -0.166001737 0.998457502 0.62563868 -0.011737477 
CHD4 0.064941475 0.842817081 0.901051259 -0.169529344 0.617171486 0.901051259 -0.234470819 
PLRG1 -0.180752334 0.511586171 0.948788813 -0.17983506 0.511586171 0.948788813 9.17274E-04 
POLI 0.013854053 0.870502638 0.548205948 -0.18215919 0.870502638 0.664697319 -0.196013243 
UBE2W -0.291609078 0.991327705 0.777638042 -0.184987553 0.991327705 0.75196683 0.106621525 
RAD51C -0.2608917 0.39136104 0.997588655 -0.187334279 0.417094838 0.997588655 0.073557421 
TOP2B -0.211270017 0.894281573 0.707130718 -0.202720287 0.894281573 0.707130718 0.00854973 
POLE -0.330480148 0.65044863 0.865959085 -0.203500907 0.65044863 0.865959085 0.126979241 
MUTYH -0.163272742 0.663194739 0.683401713 -0.203807178 0.663194739 0.683401713 -0.040534436 
BRIP1 -0.627539607 0.360874066 0.9361424 -0.206801674 0.47669902 0.882716175 0.420737933 
PRKDC -0.27479796 0.322483042 0.997540738 -0.207842338 0.337385664 0.997540738 0.066955622 
DNMT1 -0.696213569 0.099572518 0.999965741 -0.208180516 0.398664484 0.999965741 0.488033053 
CETN2 0.17810407 0.995655769 0.37745133 -0.21355994 0.995655769 0.688944595 -0.39166401 
EP400 -0.246309596 0.584723843 0.934499724 -0.214073555 0.584723843 0.934499724 0.032236041 
RMI2 -0.282193033 0.436135851 0.971086796 -0.21437492 0.436135851 0.971086796 0.067818113 
KDM2A -0.243077433 0.434804887 0.910732661 -0.215050117 0.434804887 0.910732661 0.028027317 
POLD4 -0.081457374 0.72269126 0.774671345 -0.21602438 0.72269126 0.774671345 -0.134567006 
TDG -0.030070008 0.776038219 0.622908194 -0.221651095 0.776038219 0.69564578 -0.191581087 
TIMELESS -0.753367836 0.095802368 0.999719417 -0.231443128 0.465176593 0.999719417 0.521924709 
NPM1 -0.121955727 0.971362538 0.666090951 -0.236842999 0.971362538 0.666090951 -0.114887273 
SPIDR -0.022112482 0.476235924 0.816668104 -0.238385035 0.476235924 0.816668104 -0.216272554 
WRAP53 -0.397013136 0.268762888 0.999668421 -0.245486584 0.346982738 0.999668421 0.151526551 
PMS2P5 0.011898812 0.642106223 0.567006492 -0.246312061 0.642106223 0.567006492 -0.258210873 
RBBP8 -0.069836369 0.642743577 0.850956524 -0.253103248 0.483882031 0.850956524 -0.183266879 
SMG6 -0.265206384 0.420174475 0.975220406 -0.263211491 0.420174475 0.975220406 0.001994893 
CENPX 0.025693368 0.828940722 0.621083846 -0.26866434 0.828940722 0.713266541 -0.294357708 
ERCC8 -0.195362159 0.716506865 0.739113123 -0.272484995 0.716506865 0.739113123 -0.077122836 
GTF2H5 -0.366482448 0.299807685 0.999989346 -0.276417372 0.299807685 0.999989346 0.090065076 
HELQ -0.07609044 0.53104413 0.86709702 -0.27830037 0.53104413 0.86709702 -0.20220993 
PARP1 -0.123123771 0.420140741 0.90920163 -0.280067512 0.361300018 0.90920163 -0.156943742 
PIAS4 -0.073605927 0.530232231 0.788581482 -0.281359099 0.530232231 0.788581482 -0.207753171 
MRE11 -0.459386299 0.159442554 0.999979051 -0.287002511 0.308853834 0.999979051 0.172383787 
CBX5 -0.077902855 0.913303254 0.641256109 -0.3079524 0.913303254 0.743051663 -0.230049545 
ENY2 -0.286884167 0.262644554 0.971646103 -0.311861656 0.262644554 0.971646103 -0.024977489 
ATP23 0.047240205 0.941599552 0.509040395 -0.312384151 0.941599552 0.771902937 -0.359624355 
PPP4R2 0.027219553 0.780268214 0.884977733 -0.321735999 0.570779587 0.884977733 -0.348955552 
FANCI -0.573468796 0.250591065 0.995192091 -0.325300647 0.380371193 0.995192091 0.248168149 
CCNA1 0.193270341 0.810951228 0.598707029 -0.327567746 0.810951228 0.772818133 -0.520838087 
POLR2D -0.656392465 0.767441941 0.897448418 -0.333372204 0.774231543 0.897448418 0.323020261 
H3F3B -0.287782191 0.596271997 0.851687166 -0.33407007 0.596271997 0.851687166 -0.046287879 
TNKS -0.073346311 0.632422958 0.844252915 -0.335362567 0.632422958 0.844252915 -0.262016256 
SUPT5H 0.014366953 0.999366891 0.54817901 -0.340921473 0.999366891 0.76591109 -0.355288426 
POLR2A -0.990280666 0.2211972 0.975422533 -0.34321534 0.763345102 0.854275904 0.647065327 
MPZ -0.150188406 0.783285652 0.721277278 -0.348634103 0.783285652 0.79012249 -0.198445696 
RNF20 -0.482384041 0.169146504 0.999999519 -0.348933319 0.230650755 0.999999519 0.133450722 
CDK12 -0.380291063 0.461626646 0.972174261 -0.349726391 0.461626646 0.972174261 0.030564672 
ATRX -0.270503893 0.584883682 0.796610207 -0.358354038 0.584883682 0.796610207 -0.087850145 
FANCB -0.234435856 0.334949315 0.995133965 -0.359238293 0.324218933 0.995133965 -0.124802437 
CDCA5 -0.482313731 0.84546838 0.843402935 -0.366377621 0.84546838 0.843402935 0.11593611 
RAD54L -0.213438121 0.553927821 0.930512659 -0.368570607 0.553927821 0.930512659 -0.155132486 
BAP1 -0.058185386 0.452201464 0.991006485 -0.36955053 0.25405261 0.991006485 -0.311365144 
CNOT7 -0.07746357 0.430372424 0.942650234 -0.376370911 0.288024187 0.942650234 -0.298907342 
SMG1 -0.142718598 0.671159782 0.889597163 -0.383043016 0.65746305 0.889597163 -0.240324418 
USP44 -0.290345117 0.5445791 0.973182489 -0.38402573 0.5445791 0.973182489 -0.093680613 
RAD23A -0.237262111 0.635087306 0.805323122 -0.385837997 0.635087306 0.805323122 -0.148575886 
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POLD2 -0.259372698 0.407668588 0.982634944 -0.386508862 0.334274577 0.982634944 -0.127136164 
NFE2L2 -0.349002704 0.300917887 0.994462838 -0.394113255 0.300917887 0.994462838 -0.045110551 
POLD1 -0.07078397 0.657827464 0.971842685 -0.404476043 0.346799236 0.971842685 -0.333692073 
FANCA -0.397122824 0.209442566 0.968847838 -0.4064322 0.209442566 0.968847838 -0.009309375 
POLA1 -0.030920581 0.992727618 0.791658424 -0.406565914 0.83158969 0.809082136 -0.375645333 
NFRKB -0.554723843 0.295007312 0.983903022 -0.411184381 0.390152558 0.983903022 0.143539462 
SFR1 0.295270277 0.81670404 0.6184974 -0.415250096 0.640166994 0.894819057 -0.710520373 
NSMCE2 -0.574637705 0.193492295 0.996527617 -0.418030714 0.25462394 0.996527617 0.156606991 
XRCC4 -0.379964724 0.175353771 0.983404757 -0.418575907 0.175353771 0.983404757 -0.038611183 
MPLKIP 0.023924658 0.523320306 0.839815793 -0.418786098 0.417071503 0.839815793 -0.442710756 
ATRIP -0.321344961 0.241456283 0.998218448 -0.422427568 0.203753298 0.998218448 -0.101082607 
DUT -0.720547004 0.198585301 0.992138582 -0.43176538 0.358134174 0.992138582 0.288781624 
PDS5B -0.604185155 0.164773 0.997655936 -0.43965332 0.191064986 0.997655936 0.164531835 
BRCA1 -0.439426985 0.240341187 0.988927882 -0.442884549 0.240341187 0.988927882 -0.003457564 
SMARCA5 -0.781953997 0.089334214 0.999784118 -0.444778386 0.332306224 0.999784118 0.337175611 
SMC4 -0.600801606 0.725181501 0.91147312 -0.448302506 0.725181501 0.91147312 0.1524991 
CDK2 -0.292723056 0.355245308 0.991668433 -0.454953795 0.355245308 0.991668433 -0.162230739 
POLE3 -0.665859111 0.130317511 0.999987142 -0.459125558 0.234506104 0.999987142 0.206733553 
NAE1 -0.778033725 0.011012103 0.999999565 -0.459312284 0.106455892 0.999999565 0.318721441 
ORC2 -0.18252488 0.481268607 0.87352768 -0.460619321 0.481268607 0.87352768 -0.278094441 
POLG 0.163107171 0.665474388 0.874455448 -0.467272193 0.400960382 0.874455448 -0.630379363 
PPM1G -0.702791598 0.202151406 0.977161392 -0.470878614 0.348028758 0.977161392 0.231912985 
RAD51 -0.796837665 0.096633806 0.99987961 -0.472373821 0.237502187 0.99987961 0.324463845 
TINF2 -1.028007517 0.063877364 0.999488823 -0.486489463 0.298488608 0.999488823 0.541518054 
HELLS -0.349264632 0.378136086 0.971985663 -0.490390349 0.378136086 0.971985663 -0.141125717 
MUS81 -0.266691818 0.394675737 0.99287909 -0.494046882 0.261371504 0.99287909 -0.227355064 
RAD9A -0.846315292 0.082922686 0.999222767 -0.494088297 0.2339057 0.999222767 0.352226995 
DSCC1 -0.546825262 0.140551596 0.999994766 -0.496870933 0.167690344 0.999994766 0.049954329 
CLSPN -0.896090088 0.111173048 0.995842411 -0.508595584 0.313806293 0.995842411 0.387494504 
RNF4 -0.088933354 0.51553963 0.863172383 -0.521311604 0.51553963 0.863172383 -0.432378249 
SKIV2L2 -0.529143601 0.430956169 0.899222865 -0.524483166 0.430956169 0.899222865 0.004660435 
FIGNL1 -0.262646066 0.401254241 0.998935428 -0.531311839 0.256950171 0.998935428 -0.268665774 
TFPT -0.45742285 0.297516508 0.890885344 -0.532598399 0.297516508 0.890885344 -0.075175549 
NSMCE1 -0.598416985 0.133137564 0.99991118 -0.542011303 0.133137564 0.99991118 0.056405682 
TERF1 -0.992601749 0.149199926 0.989034776 -0.544728384 0.329831688 0.989034776 0.447873365 
INO80B -0.561273872 0.204278007 0.998019997 -0.549015665 0.204278007 0.998019997 0.012258207 
NONO -0.753868163 0.076990814 0.999999975 -0.549691125 0.13960147 0.999999975 0.204177038 
FANCG -0.794734076 0.082113337 0.999845823 -0.55395964 0.189304986 0.999845823 0.240774436 
RBX1 -0.140676752 0.98131896 0.778330918 -0.560172399 0.98131896 0.852992763 -0.419495646 
ESCO2 -0.402338495 0.248389248 0.992629276 -0.560417497 0.196685607 0.992629276 -0.158079002 
ERCC1 -0.311874506 0.26756681 0.999920277 -0.56073461 0.174877559 0.999920277 -0.248860104 
POLR2K -0.547115875 0.283843607 0.987262845 -0.5610864 0.283843607 0.987262845 -0.013970525 
CDC25B -0.247796174 0.43383429 0.990217901 -0.566451208 0.252367631 0.990217901 -0.318655034 
SKP1 -0.702689721 0.14306062 0.999801217 -0.5706111 0.177808843 0.999801217 0.132078622 
RAD50 -0.489597988 0.063442841 0.999999891 -0.583400633 0.050991002 0.999999891 -0.093802644 
RFC2 -1.064713944 0.047321048 0.999995591 -0.599979962 0.142577215 0.999995591 0.464733982 
RTEL1 -1.11978688 0.007576526 0.999998909 -0.602639123 0.111441801 0.999998909 0.517147757 
WDR48 -0.231509292 0.45692757 0.999368917 -0.602990246 0.169767239 0.999368917 -0.371480954 
MMS22L -0.793495734 0.03248745 0.99993567 -0.603354765 0.101274561 0.99993567 0.190140969 
KAT2A -0.36384287 0.423700318 0.992094734 -0.604800975 0.262923643 0.992094734 -0.240958106 
CSNK2B -0.773429184 0.098440714 0.999938691 -0.61731956 0.172515794 0.999938691 0.156109625 
PALB2 -0.641031163 0.21624328 0.956352073 -0.620629099 0.21624328 0.956352073 0.020402064 
ERCC6L 0.007079137 0.995790705 0.555695391 -0.623186355 0.995790705 0.885943006 -0.630265492 
XAB2 -0.926183863 0.047322107 0.99997275 -0.623250272 0.176883581 0.99997275 0.302933591 
CCNB1 -0.529895584 0.191625285 0.998111376 -0.633722182 0.191625285 0.998111376 -0.103826598 
FANCM -0.876834687 0.030852823 0.999902234 -0.635320229 0.122080628 0.999902234 0.241514458 
ACTR5 -0.87055273 0.087369321 0.999664378 -0.638139641 0.215516903 0.999664378 0.232413089 
POLR2F 0.121671562 0.924083994 0.863874008 -0.648241283 0.216537678 0.932523806 -0.769912845 
MAU2 -1.187186929 0.010802878 0.999999903 -0.653013289 0.083182623 0.999999903 0.534173639 
RIF1 -0.757641121 0.07591614 0.999998123 -0.659779458 0.084137059 0.999998123 0.097861663 
FZR1 -1.588116053 0.00038546 1 -0.662356468 0.113022711 1 0.925759585 
RPAIN -0.414738535 0.250850992 0.977445656 -0.666151419 0.205984554 0.977445656 -0.251412885 
MTOR -0.920480362 0.02129748 0.999949697 -0.670037909 0.069209453 0.999949697 0.250442453 
PCID2 -0.884616949 0.040644676 0.999999883 -0.672258493 0.131259 0.999999883 0.212358456 
NHEJ1 -0.213508435 0.341147889 0.989815203 -0.676938549 0.121990341 0.989815203 -0.463430114 
POLR2B -1.237591596 0.015752097 0.998193741 -0.67906433 0.164797606 0.998193741 0.558527266 
KDM4A -0.49933554 0.166800392 0.999685556 -0.682373284 0.125797803 0.999685556 -0.183037743 
TCEB3 -0.188593485 0.502933479 0.990465878 -0.684066061 0.201967185 0.990465878 -0.495472576 
WAPL -0.522721443 0.200987195 0.99976222 -0.687034511 0.159477215 0.99976222 -0.164313069 
EXO5 0.003804552 0.755495107 0.99160132 -0.690318315 0.173995496 0.99160132 -0.694122867 
MCM3AP -0.683803436 0.210290216 0.973219488 -0.697906683 0.210290216 0.973219488 -0.014103247 
WEE1 -0.824870782 0.069213929 0.994310613 -0.706964784 0.102905994 0.994310613 0.117905998 
MDC1 -0.633752064 0.122963509 0.986434394 -0.712525084 0.122963509 0.986434394 -0.07877302 
PINX1 -0.429198595 0.343672826 0.974286015 -0.727670555 0.148550039 0.974286015 -0.298471961 
CEP57 -0.773227332 0.0800124 0.999999863 -0.740468004 0.081750529 0.999999863 0.032759328 
FANCD2 -1.088568212 0.026977856 0.999999968 -0.740484905 0.087721872 0.999999968 0.348083307 
XRCC2 -1.741692264 1.81706E-04 1 -0.756996584 0.095199366 1 0.98469568 
DNA2 -0.723821688 0.129489668 0.997085571 -0.759194908 0.120860467 0.997085571 -0.03537322 
SLX4 -0.22461791 0.431754272 0.999341474 -0.764041416 0.102953521 0.999341474 -0.539423506 
TONSL -1.091450007 0.015216284 0.999999969 -0.788608386 0.064721645 0.999999969 0.30284162 
INO80 -0.770050885 0.072838474 0.998880602 -0.792653027 0.072838474 0.998880602 -0.022602142 
UBE2N -0.615617321 0.068995853 0.999808198 -0.798045422 0.068995853 0.999808198 -0.182428101 
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RAD51B -0.588208221 0.161939293 0.9999845 -0.803178354 0.090436675 0.9999845 -0.214970134 
RFC3 -1.378255029 0.006771308 0.999999623 -0.81157798 0.082919225 0.999999623 0.566677049 
ARID1A -0.618188406 0.226680273 0.960738841 -0.812530373 0.184496925 0.960738841 -0.194341967 
ZMPSTE24 -0.558575163 0.201849785 0.99078592 -0.812754609 0.15261029 0.99078592 -0.254179446 
PLK1 -0.88297001 0.062117327 0.999800348 -0.82665493 0.062117327 0.999800348 0.05631508 
FANCF -0.880508953 0.057681808 0.999997085 -0.828182287 0.072455227 0.999997085 0.052326666 
FANCL -0.931558177 0.060321741 0.999999866 -0.848813544 0.075039619 0.999999866 0.082744633 
FANCC -0.967553578 0.033990772 0.999998236 -0.859797121 0.063798999 0.999998236 0.107756457 
BCCIP -0.90379916 0.076493307 0.998808704 -0.877725026 0.076493307 0.998808704 0.026074134 
POLE2 -1.150349447 0.010574456 0.999980808 -0.879842489 0.048521821 0.999980808 0.270506958 
TRIP13 -1.3216832 0.011234718 0.999999981 -0.881127716 0.082199218 0.999999981 0.440555484 
SET -0.465083823 0.178291556 0.9998963 -0.88318351 0.057764581 0.9998963 -0.418099686 
H2AFX -1.091814939 0.022759205 0.998820878 -0.88477279 0.075135148 0.998820878 0.207042149 
COPS3 -0.654159443 0.155518309 0.998901311 -0.885562102 0.092317752 0.998901311 -0.231402658 
SIN3A -0.484052363 0.136922181 0.999999614 -0.899553376 0.026352754 0.999999614 -0.415501013 
PAGR1 -0.038248802 0.690643539 0.995113011 -0.899703365 0.076743601 0.995113011 -0.861454563 
TOPBP1 -1.165191087 0.004157882 0.999999996 -0.90770613 0.02212246 0.999999996 0.257484957 
SPRTN -1.058543444 0.030000709 0.993980344 -0.908052049 0.030000709 0.993980344 0.150491395 
MEN1 -0.4611888 0.27247094 0.983314517 -0.911678551 0.09665337 0.983314517 -0.450489751 
DAXX -0.346772858 0.439790132 0.982592441 -0.916448612 0.145857946 0.982592441 -0.569675754 
ACD -0.647378812 0.475876179 0.956128584 -0.92148248 0.394842748 0.956128584 -0.274103668 
CDK7 -0.792099281 0.095364152 0.999996104 -0.928166635 0.08089796 0.999996104 -0.136067355 
CUL9 -0.160142107 0.761002897 0.98584922 -0.937779347 0.117847898 0.98584922 -0.777637239 
NCAPH -0.39841296 0.208162732 0.99898725 -0.939882303 0.029502951 0.99898725 -0.541469343 
BRD4 -0.813463944 0.021255954 0.999964741 -0.94164872 0.009627659 0.999964741 -0.128184776 
RMI1 -0.874985046 0.011457508 0.999979412 -0.944868933 0.011457508 0.999979412 -0.069883887 
BOD1L1 -1.35686258 0.007127861 0.999999296 -0.950526083 0.05004508 0.999999296 0.406336497 
SMC6 -0.749373936 0.115589293 0.999345574 -0.951857428 0.069491368 0.999345574 -0.202483492 
UCHL5 -0.848664058 0.04510004 0.999999896 -0.967003466 0.028532625 0.999999896 -0.118339408 
BRAT1 -1.36580548 0.011198467 1 -0.971405489 0.051218805 1 0.394399991 
POLR2C -1.170845748 0.002845873 0.999999547 -0.97772117 0.018445818 0.999999547 0.193124578 
XRCC6 -0.275399909 0.454490881 0.996737637 -0.981191285 0.174617053 0.996737637 -0.705791375 
FEN1 -0.842482854 0.041761688 0.999973193 -0.982866703 0.031779646 0.999973193 -0.14038385 
UVRAG -0.747707651 0.053359959 0.999970332 -0.985840327 0.019068122 0.999970332 -0.238132676 
MAD2L2 -0.647439858 0.123894209 0.999997565 -0.989182582 0.04891888 0.999997565 -0.341742724 
RAD51D -1.204626601 3.57746E-04 0.999999993 -0.996679735 0.002946491 0.999999993 0.207946866 
RFC4 -0.678043817 0.10153731 0.999840568 -1.016422469 0.039813359 0.999840568 -0.338378651 
CCNH -1.098149855 0.041573014 0.999833994 -1.017280978 0.041573014 0.999833994 0.080868877 
BARD1 -1.101677725 0.012679529 0.99981174 -1.019574485 0.012679529 0.99981174 0.08210324 
MCPH1 -1.170602984 0.024615128 0.999999494 -1.025635243 0.060706551 0.999999494 0.144967741 
TDP2 -1.032263923 0.077108027 0.983092246 -1.028173277 0.077108027 0.983092246 0.004090647 
SMC2 -1.307130038 0.011944405 0.998050525 -1.02818608 0.027175902 0.998050525 0.278943958 
NSMCE4A -0.757125785 0.142025292 0.999942809 -1.03116117 0.069580756 0.999942809 -0.274035385 
NOP10 -1.798550851 4.39915E-04 0.999999242 -1.033936912 0.027159473 0.999999242 0.764613939 
LIG4 -0.679846136 0.093721735 0.997992962 -1.043615304 0.069856744 0.997992962 -0.363769168 
TELO2 -1.0466678 0.020409205 0.999999997 -1.04415919 0.026209223 0.999999997 0.002508609 
TRRAP -0.432937763 0.220991377 0.997020082 -1.048408028 0.050000856 0.997020082 -0.615470265 
RUVBL2 -0.946541451 0.027503608 0.999999577 -1.049570572 0.022568603 0.999999577 -0.103029121 
RFWD3 -0.112206586 0.445843971 0.946496535 -1.058130786 0.037563129 0.992271177 -0.945924199 
FAAP100 -0.512444848 0.224899745 0.999216741 -1.060241098 0.018813012 0.999216741 -0.54779625 
COPS2 -0.756981794 0.104368911 0.992713471 -1.065427188 0.065578765 0.992713471 -0.308445394 
PNKP -1.136093305 0.014696263 0.999999942 -1.067761284 0.014696263 0.999999942 0.06833202 
TERF2 -1.115888815 0.068957806 0.996613913 -1.080329436 0.068957806 0.996613913 0.035559378 
SMC3 -0.72417382 0.067091927 0.999896419 -1.09232109 0.022195719 0.999896419 -0.36814727 
CUL1 -0.90409899 0.044775354 0.99998777 -1.093015737 0.01572293 0.99998777 -0.188916747 
RNF8 -0.628339642 0.182009248 0.996162079 -1.098184297 0.044856782 0.996162079 -0.469844654 
MMS19 -1.125260016 0.011497232 0.99999986 -1.099794684 0.011497232 0.99999986 0.025465332 
PRMT1 -0.766863791 0.057656701 0.999836497 -1.110068541 0.028165463 0.999836497 -0.34320475 
SFPQ -0.797533619 0.08729688 0.99600134 -1.117727153 0.047558183 0.99600134 -0.320193534 
STN1 -1.88081306 1.41E-05 1 -1.122406617 0.007663879 1 0.758406444 
MCRS1 -0.198485558 0.962567628 0.872466732 -1.148282773 0.064286512 0.992857054 -0.949797215 
TCEB1 -2.669195655 6.17E-05 1 -1.149358747 0.062229635 1 1.519836908 
RPA3 -1.067680934 0.018489401 0.999948141 -1.150671855 0.015560347 0.999948141 -0.082990921 
CCNA2 -1.211916047 0.007778821 0.999949601 -1.153710844 0.008711261 0.999949601 0.058205203 
USP5 -0.658834391 0.120216542 0.999889437 -1.157335238 0.015286393 0.999889437 -0.498500847 
TOP3A -1.285875929 0.002395589 0.999999999 -1.161114816 0.006062652 0.999999999 0.124761113 
SMARCE1 -0.491514325 0.30174795 0.990164848 -1.164894581 0.045333147 0.990164848 -0.673380256 
PDS5A -1.064705268 0.0216274 0.999995695 -1.164927729 0.021278258 0.999995695 -0.10022246 
POLE4 -1.178396344 0.008462805 0.999981281 -1.179143396 0.008462805 0.999981281 -7.47052E-04 
REV3L -0.719340895 0.128238355 0.995825835 -1.185438941 0.037567482 0.995825835 -0.466098046 
NIPBL -0.021505529 0.723613776 0.998963233 -1.187241645 0.03039099 0.998963233 -1.165736117 
DCLRE1B -1.475193697 0.005452934 0.999992796 -1.188381406 0.026447696 0.999992796 0.286812292 
CUL2 -1.201813259 0.004118064 0.999999866 -1.191513602 0.004118064 0.999999866 0.010299658 
FANCE -0.374700006 0.291835479 0.999512955 -1.212084086 0.018464133 0.999512955 -0.83738408 
CDK9 -0.900017544 0.060387965 0.999986787 -1.213756632 0.022903835 0.999986787 -0.313739088 
XRCC3 -1.781357524 5.11E-05 1 -1.218389766 0.007189884 1 0.562967759 
KAT5 -0.743932276 0.035189382 0.999736495 -1.22279869 0.002133019 0.999736495 -0.478866414 
WDR70 -0.666586827 0.258358485 0.99662953 -1.237391643 0.030334227 0.99662953 -0.570804817 
NCAPH2 -1.78970588 4.32932E-04 0.999999184 -1.257723465 0.01515208 0.999999184 0.531982415 
BCAS2 -1.578471705 4.00525E-04 0.999999806 -1.25909061 0.002490513 0.999999806 0.319381096 
POT1 -1.181794295 0.008773476 0.999990622 -1.261567322 0.008759856 0.999990622 -0.079773027 
USP37 -0.966626136 0.033446632 0.999898899 -1.266010258 0.009538152 0.999898899 -0.299384123 
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DDX11 -0.697966048 0.099787007 0.999667691 -1.272050669 0.016553886 0.999667691 -0.574084621 
CHAF1A -1.184469777 0.009374157 0.998605523 -1.283797124 0.009374157 0.998605523 -0.099327347 
NCAPG2 -1.174082813 0.014953177 0.999979983 -1.292271738 0.009892353 0.999979983 -0.118188925 
PRPF19 -1.361645177 0.005370152 0.999912334 -1.299906695 0.006445654 0.999912334 0.061738482 
CTC1 -1.377217576 0.016902436 0.999977979 -1.338439423 0.017874802 0.999977979 0.038778152 
ACTR8 -1.15863525 0.006640216 0.99999942 -1.342805207 0.006640216 0.99999942 -0.184169957 
SUPT6H -1.30210622 0.003204183 0.999391397 -1.346508394 0.002192787 0.999391397 -0.044402174 
CHEK1 -1.093926255 0.042520934 0.9943534 -1.349115942 0.030196048 0.9943534 -0.255189687 
NSMCE3 -0.894120324 0.049769056 0.999991203 -1.3505984 0.004434808 0.999991203 -0.456478076 
CTCF -1.100229591 0.017737472 0.999918614 -1.360838827 0.004521795 0.999918614 -0.260609236 
PPM1D -1.369722623 0.002520059 0.999999741 -1.372427049 0.00339156 0.999999741 -0.002704425 
RPA1 -0.727411903 0.113189097 0.99954152 -1.378780295 0.012422433 0.99954152 -0.651368392 
GTF2H3 -1.519340119 0.001156798 1 -1.382376736 0.002539689 1 0.136963383 
POLR2L -1.117776771 0.104012539 0.993747536 -1.393657294 0.056272173 0.993747536 -0.275880524 
SENP6 -0.966817294 0.031025098 0.99993276 -1.399317383 0.003163164 0.99993276 -0.432500089 
NCAPG -1.05251781 0.009488512 0.999983682 -1.40934757 7.91929E-04 0.999983682 -0.356829759 
RPA2 -1.762918732 4.44E-05 0.999999998 -1.411851302 0.00071642 0.999999998 0.351067431 
RRM2 -1.204187425 0.011680714 0.999998419 -1.424287046 0.005798221 0.999998419 -0.22009962 
HUS1 -1.073470889 0.023548946 0.999975309 -1.425281073 0.008665098 0.999975309 -0.351810185 
NCAPD2 -1.09751632 0.011498671 0.999998189 -1.426483828 0.00370183 0.999998189 -0.328967508 
POLR2E -1.228713453 0.02472649 0.999997744 -1.431356536 0.01599537 0.999997744 -0.202643083 
POLR2I -1.222019544 0.008578353 0.999989168 -1.438908304 0.002173743 0.999989168 -0.21688876 
TCEB2 -2.259599213 6.44071E-04 1 -1.445869727 0.020401517 1 0.813729486 
POLR2G -0.966309782 0.08584976 0.997446221 -1.449288038 0.02298401 0.997446221 -0.482978256 
GAR1 -1.239506831 0.004803577 0.99968861 -1.455748526 0.001938396 0.99968861 -0.216241696 
RUVBL1 -1.207594764 0.011953263 0.999640183 -1.457363316 0.006023867 0.999640183 -0.249768551 
TERT -0.93550575 0.043657438 0.999994311 -1.46148728 0.011895478 0.999994311 -0.52598153 
THOC1 -1.117748795 0.008044671 1 -1.477450377 0.0008028 1 -0.359701582 
DKC1 -1.723840294 0.00093827 1 -1.480855467 0.002915943 1 0.242984827 
RAD1 -0.656703975 0.157551584 0.999593394 -1.494929447 0.009070256 0.999593394 -0.838225472 
UBE2M -0.205219669 0.349407984 0.99993481 -1.520406397 0.013448764 0.99993481 -1.315186728 
NELFB -1.417982038 0.001030236 1 -1.531413779 4.06312E-04 1 -0.113431741 
DNAJC2 -1.191751575 0.033749097 0.99865042 -1.538257656 0.012146219 0.99865042 -0.346506081 
USP7 -1.593965581 0.001227715 0.999984213 -1.549029393 0.002057157 0.999984213 0.044936187 
PCNA -1.412811519 0.003589444 0.999618781 -1.568113786 0.002009772 0.999618781 -0.155302268 
UHRF1 -1.065785415 0.049728807 0.99999626 -1.587701079 0.009246655 0.99999626 -0.521915664 
HUWE1 -0.702532895 0.078641477 0.999999817 -1.596982179 1.34554E-04 0.999999817 -0.894449284 
BUB1B -1.434479359 0.00267785 0.999987313 -1.60912752 9.15767E-04 0.999987313 -0.174648161 
SMARCB1 -1.716772614 6.22164E-04 0.999998637 -1.617203561 8.83765E-04 0.999998637 0.099569053 
FAAP24 -0.582044687 0.222473765 0.999280513 -1.621957738 0.004598138 0.999280513 -1.039913051 
SMC5 -1.925713208 2.01292E-04 0.999999999 -1.630922062 0.001524546 0.999999999 0.294791146 
COPS5 -2.028623032 3.88E-05 0.999999992 -1.646664021 3.90347E-04 0.999999992 0.381959011 
UBA1 -1.24526508 0.002783611 0.99999971 -1.654802776 1.41407E-04 0.99999971 -0.409537696 
RAD21 -0.519600211 0.357823622 0.999354912 -1.676750447 0.005329002 0.999354912 -1.157150236 
GTF2H1 -0.829130719 0.053833741 0.999999996 -1.678853589 0.00030453 0.999999996 -0.849722871 
COPS8 -1.663333664 0.006818796 0.99994207 -1.682113005 0.006818796 0.99994207 -0.018779341 
CDC5L -1.42965042 2.59402E-04 0.999999994 -1.71613481 1.26E-05 0.999999994 -0.286484391 
MNAT1 -1.311795888 0.014918815 0.999979182 -1.73333385 0.001325347 0.999979182 -0.421537963 
RAD17 -0.880442422 0.053973242 0.99993315 -1.737684228 6.01653E-04 0.99993315 -0.857241806 
MASTL -0.833094228 0.148431181 0.999652537 -1.744976627 0.00312717 0.999652537 -0.911882399 
CDK4 -1.473893228 0.004491811 0.999987981 -1.749106476 0.001354917 0.999987981 -0.275213248 
SUPT4H1 -1.516636128 0.004245821 0.999999516 -1.749716082 0.001090094 0.999999516 -0.233079954 
TICRR -1.448249424 5.50578E-04 0.999999997 -1.753394181 4.27E-05 0.999999997 -0.305144758 
NCAPD3 -1.233330497 0.015783266 0.999902021 -1.763442244 8.81809E-04 0.999902021 -0.530111747 
HINFP -1.706086417 3.27379E-04 0.999999995 -1.76827554 2.85187E-04 0.999999995 -0.062189124 
UBE2D3 -1.207927626 0.080523003 0.997770826 -1.775148831 0.020062569 0.997770826 -0.567221206 
UPF1 -1.19957807 0.015677525 0.999880087 -1.775906133 0.00107922 0.999880087 -0.576328063 
RRM1 -1.636329246 0.00109815 0.999991166 -1.782620212 0.00109815 0.999991166 -0.146290967 
NHP2 -1.639825021 0.002643368 1 -1.786761276 0.002025525 1 -0.146936254 
PPP6C -1.998909197 5.32E-07 1 -1.797060991 1.06E-05 1 0.201848206 
YBX1 -1.379274439 0.022518939 0.999992389 -1.798431746 0.007244031 0.999992389 -0.419157307 
KAT8 -1.437697142 0.002727836 0.999999975 -1.807534096 0.00050914 0.999999975 -0.369836954 
TRAIP -1.209129942 0.007893198 0.999999649 -1.812264011 2.30569E-04 0.999999649 -0.603134069 
RFC5 -2.425112489 5.90E-06 1 -1.823390275 0.00046692 1 0.601722215 
DDX1 -1.378724108 0.001313713 1 -1.82719798 4.66E-05 1 -0.448473871 
ERCC3 -1.760516956 5.42456E-04 0.999999988 -1.850893063 4.87564E-04 0.999999988 -0.090376107 
COPS6 -1.70234368 1.70337E-04 0.999999928 -1.851681278 7.18E-05 0.999999928 -0.149337598 
UBE2I -1.857194193 3.52961E-04 0.999999985 -1.852599508 3.52961E-04 0.999999985 0.004594685 
GTF2H4 -1.698199808 5.56E-05 1 -1.923618712 2.12E-05 1 -0.225418904 
ATR -2.065496376 2.43E-05 0.999999984 -1.931260496 7.88E-05 0.999999984 0.13423588 
DDB1 -1.966787967 1.88E-05 1 -1.932212746 2.80E-05 1 0.034575221 
UBE2T -1.46189205 0.002758927 1 -1.94316124 3.02241E-04 1 -0.48126919 
ACTL6A -1.45375353 0.001180502 0.999999998 -1.959770588 3.31E-05 0.999999998 -0.506017059 
POLR2H -1.686699446 6.92E-05 0.999999145 -1.977422406 5.65E-06 0.999999145 -0.290722959 
APEX2 -1.497452787 0.002050515 1 -1.995979125 2.83E-05 1 -0.498526338 
TAF1 -1.707180647 7.05455E-04 0.999999984 -2.004350022 1.10472E-04 0.999999984 -0.297169375 
TTI1 -1.948727945 1.48665E-04 1 -2.010812949 1.48665E-04 1 -0.062085004 
UBA2 -2.227382007 3.47E-06 1 -2.159435995 1.48E-05 1 0.067946012 
TEN1 -1.747074838 0.00100213 1 -2.172888685 1.12756E-04 1 -0.425813847 
RPS27L -0.55064821 0.278173592 0.999927292 -2.236196283 6.53192E-04 0.999927292 -1.685548074 
MYBBP1A -1.945216456 2.34E-06 1 -2.306948637 3.40E-08 1 -0.361732181 
GPS1 -1.485381024 0.003835013 1 -2.342625635 4.32E-06 1 -0.857244612 
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HDAC3 -1.800735298 0.00131368 0.999994236 -2.358322124 5.19E-05 0.999994236 -0.557586826 
ERCC2 -2.031793893 8.59E-06 1 -2.3761029 2.62E-07 1 -0.344309007 
TTI2 -1.574691533 7.25004E-04 1 -2.394994331 5.29E-07 1 -0.820302798 
PPP4C -1.876858279 4.78466E-04 1 -2.516808574 4.21E-06 1 -0.639950295 
SMC1A -2.224393211 1.48E-05 1 -2.588422409 2.15E-06 1 -0.364029198 
THOC2 -2.254248673 5.15E-06 1 -3.002180348 1.85E-09 1 -0.747931676 
NEDD8 -2.550288055 1.10133E-04 1 -3.029734725 5.40E-06 1 -0.47944667 
SOD1 -2.481368529 2.69E-05 1 -3.037825906 4.71E-07 1 -0.556457377 
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Appendix Table 7 Raw data from JACKS analysis of RPE-1 WRN-/- E5-C6 2nM CPT treated 
RPE-1 WRN-/- E5-C6 DMSO and 2nM CPT treated enrichment compared to the day 14 control. fdr=false 
discovery rate 
 
Gene Enrichment in 
DMSO treated 
neg_fdr1 pos_fdr1 Enrichment in 
2nM CPT treated 
neg_fdr2 pos_fdr2 Difference in 
Enrichment 
TP53 3.918153179 1 2.64E-12 5.306634686 1 0 1.388481507 
CDKN1A 2.036870903 1 6.24645E-04 3.295639221 1 1.86E-07 1.258768318 
RNF146 3.56227894 1 2.12E-09 2.453289102 1 2.36E-05 -1.108989837 
KEAP1 2.594822889 1 1.25E-05 2.339274939 1 5.48E-05 -0.25554795 
CHEK2 1.247259903 1 0.009185668 1.99436911 1 1.41196E-04 0.747109207 
USP28 1.603918558 1 8.32433E-04 1.716103418 1 6.49627E-04 0.11218486 
CAND1 3.231152638 1 6.81E-09 1.642912406 1 0.001106907 -1.588240232 
SMARCC1 1.003112762 0.999999991 0.021047167 1.568040976 0.999999991 9.12208E-04 0.564928214 
BRD7 1.416358089 1 0.010986801 1.480277336 1 0.010066749 0.063919247 
H2AFZ 1.777501455 1 0.001542282 1.463637824 1 0.005033477 -0.313863631 
PBRM1 1.193528155 1 0.01852567 1.461257554 1 0.005421536 0.267729398 
CUL5 1.818181804 1 1.68233E-04 1.439142198 1 0.002760659 -0.379039605 
EME2 0.986820686 0.998886994 0.052980102 1.411284412 0.998886994 0.010547111 0.424463726 
MAPKAPK2 1.460605137 1 0.01130881 1.327556216 1 0.013529806 -0.133048921 
PER2 1.045032969 0.999727149 0.022100274 1.249239073 0.999727149 0.008183094 0.204206104 
THRAP3 1.291547318 1 0.021767884 1.23048065 1 0.02444419 -0.061066668 
DCUN1D3 1.666081912 1 0.00108847 1.217957235 1 0.010333614 -0.448124677 
TET2 0.991425845 0.999998163 0.053624086 1.213573395 0.999998163 0.031904811 0.22214755 
UBE2K 1.043207285 1 0.025280854 1.162241367 1 0.014994861 0.119034082 
MAPK14 0.8277983 0.999999645 0.083696301 1.136631036 0.999999645 0.031913612 0.308832736 
SUPT5H 1.403929047 0.999366891 0.003472975 1.123641901 0.999366891 0.008598454 -0.280287147 
ARID2 1.066631776 1 0.018974867 1.078537466 1 0.018974867 0.01190569 
APOBEC2 1.059793339 0.999739009 0.035022547 1.074336874 0.999739009 0.035022547 0.014543536 
RRM2B 0.899647429 0.999997564 0.049546731 1.048482702 0.999997564 0.036143911 0.148835272 
TP53BP1 0.962612578 1 0.022022593 1.047478064 1 0.019079977 0.084865486 
PARP14 1.010372447 0.999626837 0.023795514 1.04081158 0.999626837 0.022964683 0.030439134 
POLD3 0.553705154 0.999843055 0.065463816 1.039863382 0.999843055 0.009218103 0.486158228 
CDKN2A 1.076312674 0.999994328 0.016039924 1.028589858 0.999994328 0.022886344 -0.047722816 
PTEN 2.745001951 1 3.15E-07 0.99244664 1 0.029941261 -1.752555311 
L3MBTL1 0.987041605 0.999081574 0.025714311 0.957674863 0.999081574 0.025714311 -0.029366742 
MDM2 1.449800679 0.999296181 0.004918483 0.94067799 0.999296181 0.041152517 -0.50912269 
GADD45A 0.830832025 0.999990609 0.044147667 0.928466177 0.999990609 0.044147667 0.097634152 
PHIP 1.071003407 1 0.025331803 0.927840362 1 0.037564294 -0.143163044 
RNF7 1.428066461 1 0.003231386 0.9206441 1 0.030025696 -0.507422362 
KMT5B 0.895130964 0.999968266 0.057891409 0.916719205 0.999968266 0.057891409 0.021588241 
APC 0.75159499 1 0.032557745 0.909708036 1 0.019712713 0.158113046 
UBE2W 0.90753358 0.991327705 0.029246599 0.898846268 0.991327705 0.029246599 -0.008687312 
HMGB1 1.143875284 0.994845796 0.425398111 0.893215535 0.994845796 0.425398111 -0.250659749 
SPTBN1 0.909714479 1 0.039491377 0.888133264 1 0.041254712 -0.021581214 
TOP3B 0.749867675 0.997428561 0.062329899 0.868364988 0.997428561 0.048787354 0.118497313 
RNF111 0.874928609 0.999944988 0.091761042 0.85562231 0.999944988 0.093278795 -0.019306299 
SUMO4 0.927410874 0.958853859 0.147639042 0.852880268 0.958853859 0.147639042 -0.074530606 
PML 0.757810702 0.999831852 0.10294274 0.837361395 0.999831852 0.093532818 0.079550693 
SWI5 0.885942314 0.998147498 0.077222507 0.828727023 0.998147498 0.077222507 -0.057215291 
MAPK8 0.91134231 0.999525364 0.041435367 0.827212106 0.999525364 0.048598135 -0.084130205 
MTA3 0.709332894 0.998930186 0.13087276 0.824647197 0.998930186 0.13087276 0.115314304 
UBE2R2 0.84921193 1 0.067788305 0.819486332 1 0.067788305 -0.029725598 
HELB 0.525719853 0.99823044 0.173793352 0.809748126 0.99823044 0.106849088 0.284028274 




0.757368612 0.999998025 0.082040893 0.782913609 0.999998025 0.082040893 0.025544997 
ZDHHC16 0.800769612 0.995336677 0.129119902 0.767079937 0.995336677 0.129119902 -0.033689675 
SF3B1 0.732419476 0.985254946 0.055963987 0.751230631 0.985254946 0.055963987 0.018811154 
PMP22 0.749758006 0.999994455 0.152606457 0.738716729 0.999994455 0.152606457 -0.011041277 
PARP4 0.54574345 0.999779181 0.221653661 0.736429078 0.999779181 0.14485674 0.190685628 
SENP8 1.476254336 1 0.01590188 0.714325011 1 0.124909829 -0.761929325 




0.7523863 0.999999992 0.112474331 0.710651358 0.999999992 0.112474331 -0.041734942 
UBE2V1 0.577155183 0.994675609 0.225568527 0.708928566 0.994675609 0.203828569 0.131773384 




0.583968942 0.999971612 0.173463696 0.700089144 0.999971612 0.130600039 0.116120203 




0.36061044 0.999999721 0.312403609 0.697320733 0.999999721 0.121340675 0.336710293 
UBE2D1 0.522238267 0.999939613 0.17954647 0.69710035 0.999939613 0.17954647 0.174862083 




0.79606286 0.99999849 0.091522014 0.694255218 0.99999849 0.122819381 -0.101807642 
NABP2 0.750616787 0.995463463 0.148398876 0.693377237 0.995463463 0.148398876 -0.05723955 
FAN1 0.698880577 0.997111193 0.153197142 0.67878919 0.997111193 0.153197142 -0.020091387 
BABAM1 0.88700819 1 0.026096888 0.67207442 1 0.067618745 -0.214933769 
KLHL15 0.62007801 0.992613477 0.200722476 0.666783402 0.992613477 0.200722476 0.046705392 
RNF2 0.694381393 0.999627895 0.223458862 0.666278151 0.999627895 0.223458862 -0.028103242 
NUDT1 0.49296662 0.946357521 0.256553735 0.66427748 0.946357521 0.243187598 0.171310861 
SIRT7 0.493944552 0.999664558 0.17410725 0.663679594 0.999664558 0.161013986 0.169735042 
HNRNPUL2 0.783864031 0.999853973 0.094660594 0.663675253 0.999853973 0.102242903 -0.120188778 
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SUMO3 0.41165291 0.994900124 0.328498082 0.66321678 0.994900124 0.205953361 0.251563869 
ALKBH1 0.93779704 0.999961205 0.063956104 0.662387961 0.999961205 0.106630108 -0.27540908 
CCNO 0.490503341 0.98679286 0.256102712 0.661197939 0.98679286 0.175819175 0.170694598 
EID3 0.564534238 0.993920362 0.192573057 0.659204179 0.993920362 0.178650241 0.094669941 
CHFR 0.591545976 0.999662265 0.171961903 0.655337968 0.999662265 0.171961903 0.063791992 
BTG2 0.722338577 0.999849211 0.155672065 0.650109149 0.999849211 0.155672065 -0.072229429 
USP51 0.826300765 0.999505252 0.13682832 0.648850429 0.999505252 0.162255581 -0.177450335 
SMC4 0.484554713 0.997535657 0.242196184 0.64462712 0.997535657 0.181319391 0.160072407 








0.530303035 0.999975913 0.191127262 0.639141923 0.999975913 0.153631625 0.108838889 
TPP1 0.574471158 0.998535295 0.168111978 0.638128406 0.998535295 0.168111978 0.063657248 
UBE2V2 0.484862322 0.999897557 0.183107207 0.625348673 0.999897557 0.162851504 0.140486351 
DCUN1D4 0.72934462 0.997906465 0.17463028 0.622340222 0.997906465 0.193257327 -0.107004398 




0.50781918 0.99999086 0.231225941 0.620529147 0.99999086 0.200711474 0.112709967 
CUL3 1.849361366 1 6.74E-05 0.615986277 1 0.091624684 -1.233375089 
OTUB2 0.475933019 0.999750694 0.257785958 0.615105594 0.999750694 0.255736908 0.139172574 
UCHL3 0.618015717 0.990060866 0.114264449 0.613269838 0.990060866 0.114264449 -0.004745878 
PARP9 0.693401931 0.997612841 0.168838305 0.606122223 0.997612841 0.184516048 -0.087279708 
CHTF18 0.591117725 0.982124975 0.268349384 0.603670755 0.982124975 0.268349384 0.01255303 
MLH3 0.51888002 0.999862757 0.218820537 0.597743987 0.999862757 0.198237753 0.078863967 
RAD18 0.482957799 0.998249125 0.223023743 0.593543142 0.998249125 0.223023743 0.110585342 
CDKN1B 0.628867119 0.999985514 0.201300535 0.587037245 0.999985514 0.201300535 -0.041829875 
SETDB1 0.247599246 0.99959465 0.435121798 0.582601829 0.99959465 0.173017035 0.335002583 
APAF1 0.827337792 0.999769105 0.061545504 0.581450918 0.999769105 0.104031181 -0.245886874 
COPS7A 0.47308801 0.999970404 0.26042997 0.577403665 0.999970404 0.26042997 0.104315655 
BCLAF1 0.894307703 1 0.096179445 0.576575488 1 0.162566663 -0.317732215 
INO80D 0.476855636 0.995796808 0.300051338 0.573929008 0.995796808 0.278782051 0.097073372 
GTF2H2 0.714451821 0.983875327 0.298260716 0.570046575 0.983875327 0.301401438 -0.144405246 
RING1 0.652205231 1 0.133823247 0.566536411 1 0.164469045 -0.08566882 
MUM1 0.616114465 0.998613554 0.166129122 0.565557937 0.998613554 0.166129122 -0.050556528 
PNN 0.602925912 0.997902515 0.128412393 0.560371122 0.997902515 0.146268002 -0.04255479 




0.555166515 0.9999448 0.197425308 0.553713911 0.9999448 0.197425308 -0.001452604 
DCLRE1C 0.340740794 0.999665045 0.307463955 0.546163025 0.999665045 0.176864689 0.205422231 
CCND3 0.71823042 0.99943543 0.03918954 0.542933541 0.99943543 0.086114234 -0.175296879 
ERCC6L 0.601470647 0.995790705 0.213520175 0.535496423 0.995790705 0.213520175 -0.065974224 
PARPBP 0.525003161 0.997597669 0.16658308 0.532843984 0.997597669 0.16658308 0.007840823 




0.606338154 0.999748986 0.234064461 0.523252681 0.999748986 0.239880679 -0.083085472 
POLK 0.668530595 0.999979036 0.139778175 0.522146731 0.999979036 0.163570562 -0.146383864 








0.557721552 0.999981145 0.137054504 0.51794066 0.999981145 0.139321668 -0.039780892 
HMGB2 0.523032318 0.999925107 0.189092663 0.517448609 0.999925107 0.189092663 -0.005583709 
BRE 0.84278433 0.999999447 0.068616703 0.517120351 0.999999447 0.133672493 -0.325663979 
APOBEC3D 0.42801509 0.974141819 0.330086098 0.515727801 0.974141819 0.330086098 0.087712711 




0.369197226 0.995893787 0.263359967 0.513767138 0.995893787 0.201545788 0.144569912 




0.602750216 0.999963084 0.155978914 0.510866653 0.999963084 0.155978914 -0.091883564 




0.527007543 0.999988159 0.182175157 0.507416791 0.999988159 0.182175157 -0.019590752 




0.444841736 0.999346524 0.207882263 0.504199225 0.999346524 0.207882263 0.059357489 
PRMT6 0.666582208 0.998934623 0.174713701 0.504186053 0.998934623 0.20570671 -0.162396155 
GPI 0.404094552 0.999992441 0.202680477 0.499911233 0.999992441 0.178502918 0.095816681 
TOP2B 0.448178862 0.894281573 0.408842915 0.499691792 0.894281573 0.408842915 0.05151293 
LIG3 0.424258743 0.999904028 0.209181304 0.499533674 0.999904028 0.209181304 0.075274931 




0.548980939 0.998422901 0.258809733 0.495610511 0.998422901 0.258809733 -0.053370428 
FAM175A 0.479566935 0.987271407 0.244612063 0.495577105 0.987271407 0.244612063 0.01601017 




0.564446193 0.999534742 0.214881587 0.494207226 0.999534742 0.214881587 -0.070238966 
USP15 0.627588579 1 0.102165018 0.493932028 1 0.137014551 -0.133656551 
CUL7 0.37652266 0.999988816 0.186250394 0.493344358 0.999988816 0.163441994 0.116821698 
ETAA1 0.405330558 0.999902643 0.221874002 0.492504954 0.999902643 0.215226257 0.087174396 
SPO11 0.562913556 0.999054627 0.179772372 0.489827256 0.999054627 0.198459518 -0.073086301 
SMARCA4 0.34360244 0.921918975 0.347630633 0.487533933 0.921918975 0.339227283 0.143931493 
MDM4 0.477970149 0.999708607 0.168291238 0.487202731 0.999708607 0.168291238 0.009232582 




0.589573042 0.999999492 0.134195552 0.485434502 0.999999492 0.190222317 -0.10413854 
CHD3 0.242909638 0.991912216 0.264105085 0.482869816 0.991912216 0.128179922 0.239960178 
APOBEC3F 0.483666491 0.96743583 0.35574373 0.480259593 0.96743583 0.35574373 -0.003406898 
CIB1 0.50685177 0.992548413 0.150193736 0.479898864 0.992548413 0.150193736 -0.026952906 
HMGN1 0.298857582 0.991290138 0.433557475 0.479401924 0.991290138 0.37957964 0.180544342 








0.446477396 0.999829527 0.239639066 0.463617073 0.999829527 0.239639066 0.017139677 
CETN2 0.550808786 0.995655769 0.37745133 0.462078631 0.995655769 0.37745133 -0.088730156 
NFATC2IP 0.424640164 0.947512601 0.218206324 0.460692265 0.947512601 0.218206324 0.036052101 





0.333635745 0.999854713 0.282497522 0.457435076 0.999854713 0.25340258 0.12379933 
STAG2 0.948955124 0.999999998 0.039133738 0.457273909 0.999999998 0.169663828 -0.491681215 
PPP4R4 0.565859999 0.999944276 0.252353018 0.457054465 0.999944276 0.297974671 -0.108805535 
NCAPD3 0.470509736 0.985103036 0.277419456 0.456601991 0.985103036 0.277419456 -0.013907745 
SMARCA2 0.323640881 0.964445153 0.590235601 0.456079374 0.964445153 0.590235601 0.132438493 
HDAC9 0.797607268 0.999999739 0.04781332 0.453199665 0.999999739 0.152346015 -0.344407603 








0.508930766 0.999944922 0.17984537 0.449767395 0.999944922 0.17984537 -0.059163372 




0.449510902 0.999257052 0.158280513 0.446400573 0.999257052 0.158280513 -0.003110329 
NEIL1 0.317900485 0.967157443 0.24442714 0.444497599 0.967157443 0.197009555 0.126597114 








0.345059881 0.939658178 0.359655223 0.443297732 0.939658178 0.359655223 0.098237851 
ALKBH  0.377003054 0.987312972 0.219222666 0.442771765 0.987312972 0.197386863 0.065768711 




0.483664369 0.999999893 0.235386492 0.436349719 0.999999893 0.235386492 -0.047314649 
EYA1 0.48690574 0.990056724 0.176995001 0.434747212 0.990056724 0.183770167 -0.052158528 
RAG1 0.361012759 0.998190338 0.338792589 0.433814601 0.998190338 0.321678892 0.072801843 
POLR2J 0.568604356 0.996488758 0.15697495 0.433098966 0.996488758 0.19139029 -0.135505389 
SENP2 0.214275131 0.974847315 0.384750348 0.432673991 0.974847315 0.384750348 0.21839886 
DNTT 0.4047412 0.999905117 0.259683811 0.429312566 0.999905117 0.259683811 0.024571365 
ACD 0.544021638 0.982712271 0.293678069 0.427247312 0.982712271 0.326101539 -0.116774326 
SSBP3 0.623986766 0.993437983 0.124852644 0.427056566 0.993437983 0.185494114 -0.1969302 
SCAI 0.471900266 0.999862613 0.19869465 0.42231885 0.999862613 0.199032325 -0.049581415 
ASCC1 0.534403215 0.999128493 0.143995512 0.420767794 0.999128493 0.196789527 -0.11363542 
HNRNPUL1 0.216378027 0.981160424 0.388394168 0.419144869 0.981160424 0.318235111 0.202766842 
NEK8 0.285219297 0.999004224 0.346263726 0.418819836 0.999004224 0.262314706 0.133600539 
PER1 0.241221496 0.990077097 0.397443467 0.418202201 0.990077097 0.255339764 0.176980706 
ANKRD44 0.406450716 0.998536699 0.266477136 0.416666823 0.998536699 0.266477136 0.010216107 
REV1 0.448386697 0.951147894 0.321946653 0.415013411 0.951147894 0.321946653 -0.033373286 
COL21A1 0.36952199 0.921825514 0.428542352 0.410865251 0.921825514 0.428542352 0.041343261 
MBD4 0.440550445 0.99826714 0.294597572 0.409673065 0.99826714 0.294597572 -0.03087738 
TP63 0.26780186 0.982719463 0.431918923 0.408332276 0.982719463 0.423601302 0.140530416 
PPP4R1 0.306569255 0.856665652 0.489049591 0.407658857 0.856665652 0.489049591 0.101089601 
NLK 0.393970517 0.981217976 0.403358995 0.406648325 0.981217976 0.403358995 0.012677808 
PPP5C 0.125275454 0.956631895 0.442428591 0.406459459 0.956631895 0.442428591 0.281184005 
POLM 0.40810916 0.999967463 0.144842318 0.406259208 0.999967463 0.144842318 -0.001849953 
DCLRE1A 0.306682872 0.999578127 0.22869833 0.406009474 0.999578127 0.19438612 0.099326602 
SMC1B 0.377737938 0.999741633 0.330922427 0.405007968 0.999741633 0.330922427 0.027270029 




0.201352276 0.99991058 0.441098104 0.400881779 0.99991058 0.315682899 0.199529502 
MLH1 0.348836987 0.942751324 0.556658798 0.400023892 0.942751324 0.556658798 0.051186906 
APOBEC3B 0.478030331 0.999967008 0.236724223 0.398346609 0.999967008 0.236724223 -0.079683722 
ATF2 0.337588499 0.990828682 0.307924958 0.397948363 0.990828682 0.307924958 0.060359864 
TRIP12 0.801437788 0.999977382 0.115849535 0.39735146 0.999977382 0.216413463 -0.404086328 
SALL4 0.301770579 0.991028909 0.305548539 0.394879304 0.991028909 0.305548539 0.093108725 
HFM1 0.284045827 0.993815046 0.276872453 0.393087445 0.993815046 0.276872453 0.109041618 
OPRM1 0.4538093 0.999960465 0.208737076 0.391884358 0.999960465 0.208737076 -0.061924942 
ASF1A 0.550189138 0.992322994 0.122385749 0.391550945 0.992322994 0.189662944 -0.158638193 








0.431468873 0.999998311 0.259655304 0.390332111 0.999998311 0.259655304 -0.041136762 
POLN 0.42466064 0.999765812 0.203772318 0.387524619 0.999765812 0.203772318 -0.037136021 
CDKN2D 0.362619019 0.997688613 0.353913927 0.387047896 0.997688613 0.353913927 0.024428877 
UBE2D2 0.114218376 0.926997804 0.397916567 0.385938519 0.926997804 0.271229486 0.271720143 




0.396707043 0.998153711 0.268790737 0.382535706 0.998153711 0.268790737 -0.014171336 
WRN 0.362875233 0.936131005 0.40821908 0.382226945 0.936131005 0.40821908 0.019351713 
CCNB3 0.190681699 0.999788155 0.302991582 0.380762076 0.999788155 0.164253439 0.190080377 








0.345251499 0.999049499 0.300327216 0.368578545 0.999049499 0.300327216 0.023327046 
NOTCH2 0.36232832 0.91600724 0.344733419 0.364655833 0.91600724 0.344733419 0.002327513 
POLB 0.106171882 0.978148625 0.403850581 0.364038274 0.978148625 0.284457033 0.257866392 




0.231425763 0.999028141 0.396127636 0.361063402 0.999028141 0.300418543 0.129637639 




0.498496568 0.99983586 0.177729949 0.359044809 0.99983586 0.219087331 -0.139451759 
USP26 0.310404761 0.977805328 0.414615829 0.358409275 0.977805328 0.414615829 0.048004514 








0.445261074 0.999344463 0.174973777 0.356076837 0.999344463 0.201913395 -0.089184238 
BMI1 0.429925984 0.997754667 0.342022959 0.355973035 0.997754667 0.350783085 -0.073952949 
CUL B 0.342742539 0.99947849 0.338852979 0.35556182 0.99947849 0.338852979 0.012819281 








0.435479611 0.999245228 0.283514144 0.353314281 0.999245228 0.286029607 -0.082165331 








0.643911897 0.999895055 0.16967695 0.351951523 0.999895055 0.246418794 -0.291960374 
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0.45488947 0.999695194 0.255795637 0.350795929 0.999695194 0.275977059 -0.104093542 
UHRF2 0.411501315 0.933087821 0.456677267 0.350134221 0.933087821 0.456677267 -0.061367094 
NEK9 0.516847455 0.99995695 0.192826201 0.349908293 0.99995695 0.203498892 -0.166939163 
BLM 0.347615033 0.840181435 0.436421852 0.349758741 0.840181435 0.436421852 0.002143708 
PHF3 0.653772108 0.999371961 0.143769059 0.348247775 0.999371961 0.20887769 -0.305524333 
CDC34 0.297428344 0.943082939 0.317670536 0.345126037 0.943082939 0.317670536 0.047697693 








0.335233999 0.999838243 0.307673837 0.343322402 0.999838243 0.307673837 0.008088402 




0.280676615 0.9463425 0.377586763 0.341239998 0.9463425 0.377586763 0.060563384 




0.340452217 0.999451714 0.280807461 0.337867041 0.999451714 0.280807461 -0.002585176 
USP13 0.245060932 0.999322517 0.281251701 0.336442633 0.999322517 0.2603818 0.091381701 
C9orf142 0.238422044 0.955815087 0.345532622 0.336274866 0.955815087 0.345532622 0.097852822 




0.341944374 0.998539304 0.29558584 0.332801479 0.998539304 0.29558584 -0.009142895 
RAD9B 0.26516734 0.907235566 0.345670085 0.332643662 0.907235566 0.334368469 0.067476322 
H2AFY 0.310571824 0.985621785 0.33088071 0.331540806 0.985621785 0.33088071 0.020968982 
POLI 0.269547295 0.870502638 0.359127809 0.331118884 0.870502638 0.359127809 0.061571588 
RNF138 0.479140873 0.999989483 0.198265834 0.330356928 0.999989483 0.234045998 -0.148783944 








0.401850783 0.998182876 0.282525502 0.327858204 0.998182876 0.305339414 -0.073992579 
MTA2 0.279366666 0.999859602 0.254401532 0.323991756 0.999859602 0.254135987 0.044625089 
RBX1 0.612450769 0.98131896 0.258394512 0.323007721 0.98131896 0.425444544 -0.289443048 
RAD23A 0.153860624 0.732912694 0.805323122 0.322161905 0.787557378 0.805323122 0.16830128 
NTHL1 0.274808226 0.931538222 0.398161732 0.317382998 0.931538222 0.398161732 0.042574772 
PAPD7 0.322462555 0.791645969 0.529345001 0.31648681 0.791645969 0.529345001 -0.005975745 








0.288458787 0.999999115 0.233332762 0.314134508 0.999999115 0.233332762 0.025675721 
USP4 0.353579339 0.805362863 0.589526684 0.313983876 0.805362863 0.589526684 -0.039595463 
WHSC1 0.32143443 0.984510192 0.413699041 0.313391228 0.984510192 0.413699041 -0.008043203 




0.292574188 0.999999994 0.31495842 0.308103597 0.999999994 0.31495842 0.015529409 
RAD54L2 0.274891876 0.99939853 0.260367602 0.305897435 0.99939853 0.260367602 0.031005559 




0.321881252 0.984970515 0.390025888 0.303338514 0.984970515 0.390025888 -0.018542738 
NEIL2 0.155575779 0.900745624 0.397738309 0.303114871 0.900745624 0.380534521 0.147539092 
DCUN1D1 0.648972147 0.999999878 0.200346762 0.301212246 0.999999878 0.314919159 -0.347759901 
TNP1 0.421060159 0.962981376 0.371141252 0.300943354 0.962981376 0.371141252 -0.120116805 
NUDT16L1 0.323249415 0.821254066 0.439119507 0.30017573 0.821254066 0.439119507 -0.023073685 
DDB2 0.198809745 0.968589624 0.450929984 0.300047383 0.968589624 0.404525838 0.101237638 




0.318560959 0.990797611 0.311783685 0.297692572 0.990797611 0.311783685 -0.020868387 
APOBEC3A 0.194000969 0.949371552 0.402239037 0.296551136 0.949371552 0.402239037 0.102550168 
CRY1 0.158222825 0.920529515 0.580422196 0.29601171 0.920529515 0.580422196 0.137788885 
CCNE1 0.192712876 0.972601188 0.463674971 0.295325936 0.972601188 0.463674971 0.10261306 
SUV39H2 0.317757697 0.994902355 0.317153685 0.292419783 0.994902355 0.317153685 -0.025337914 
KMT5A -0.012395479 0.741562051 0.574073591 0.290783927 0.741562051 0.574073591 0.303179406 
XRCC5 0.342041613 0.986959415 0.306909583 0.288543698 0.986959415 0.306909583 -0.053497915 
KMT5C 0.24853645 0.999795972 0.270707591 0.288355953 0.999795972 0.270707591 0.039819503 
IP6K3 0.268021518 0.985510177 0.381365811 0.287722155 0.985510177 0.381365811 0.019700637 
CDC25A 0.360648794 0.999910282 0.237963608 0.28706602 0.999910282 0.259541979 -0.073582774 




0.317911015 0.999823905 0.348407925 0.28361007 0.999823905 0.348407925 -0.034300945 
MSH3 0.357705032 0.986451479 0.310510777 0.283592992 0.986451479 0.310510777 -0.07411204 




0.383920257 0.999991775 0.24927865 0.28133581 0.999991775 0.29031418 -0.102584447 




0.237891321 0.998943602 0.279968177 0.280420832 0.998943602 0.274483067 0.042529511 
FBXO18 0.299554974 0.999245999 0.240653207 0.280327849 0.999245999 0.240653207 -0.019227125 
WDR76 0.242738902 0.892541247 0.274239745 0.279850942 0.892541247 0.274239745 0.03711204 
RAP1A 0.372657024 0.998612783 0.358073562 0.27932769 0.998612783 0.38918289 -0.093329334 
DNAJC2 0.335537311 0.994253356 0.528340234 0.277621554 0.994253356 0.528340234 -0.057915757 
SLF1 0.301911579 0.957297648 0.353040755 0.276060938 0.957297648 0.353040755 -0.025850641 
SMARCC2 0.333888351 0.997555566 0.354861922 0.273864256 0.997555566 0.375418645 -0.060024095 
APBB1 0.20667197 0.998373594 0.368351676 0.268406143 0.998373594 0.368351676 0.061734173 
XPC 0.263205128 0.991484933 0.266992798 0.267165043 0.991484933 0.266992798 0.003959915 
MCRS1 0.141427235 0.962567628 0.660978706 0.266643451 0.962567628 0.577988276 0.125216217 
POLR2L 0.222073915 0.987939077 0.577094208 0.265233557 0.987939077 0.577094208 0.043159642 








0.191787141 0.850087936 0.533634841 0.261750129 0.850087936 0.533634841 0.069962988 
SUMO2 0.049117805 0.592600641 0.874235475 0.261093149 0.644335166 0.874235475 0.211975344 




0.183715823 0.998830219 0.372629334 0.256776702 0.998830219 0.372629334 0.073060879 
MPZ 0.308026472 0.783285652 0.514905795 0.255731597 0.783285652 0.514905795 -0.052294875 




0.275823959 0.975822499 0.356101424 0.25493944 0.975822499 0.356101424 -0.020884519 









0.287012647 0.999499894 0.402289811 0.253456627 0.999499894 0.402289811 -0.033556021 
DTX3L 0.143921107 0.99393549 0.378693194 0.25189452 0.99393549 0.333028172 0.107973413 
DCAF11 0.154268696 0.900717935 0.386361477 0.24956088 0.900717935 0.386361477 0.095292184 
SMUG1 0.312520351 0.926775706 0.400235835 0.248607357 0.926775706 0.400235835 -0.063912995 
ERCC6 0.249360089 0.742080257 0.461681238 0.247996607 0.742080257 0.461681238 -0.001363482 
DCUN1D5 0.358675655 0.999889397 0.278144345 0.247872547 0.999889397 0.293437971 -0.110803108 
HDAC4 0.179418356 0.952460343 0.448885076 0.245672844 0.952460343 0.448885076 0.066254488 
KDM1A 0.235802164 0.935769267 0.48560199 0.245526299 0.935769267 0.48560199 0.009724135 
DTX3 0.261791691 0.999520968 0.388267478 0.244130959 0.999520968 0.388267478 -0.017660731 




0.329036991 0.999287288 0.397960225 0.243255653 0.999287288 0.397960225 -0.085781338 








0.079018771 0.997856576 0.47694779 0.240609246 0.997856576 0.417835492 0.161590475 
MSH2 0.320010717 0.974192869 0.401188919 0.240570668 0.974192869 0.401188919 -0.079440049 
INO80C 0.014942282 0.99225101 0.485442928 0.240040087 0.99225101 0.408909174 0.225097804 
SERBP1 0.021064294 0.936111565 0.541077159 0.239644209 0.936111565 0.436697139 0.218579916 
PARP2 0.249235535 0.943985904 0.309226463 0.239431905 0.943985904 0.309226463 -0.009803631 
PMS1 0.258294827 0.958274699 0.395162706 0.239067185 0.958274699 0.395162706 -0.019227642 
TIPIN 0.31039752 0.889867239 0.384848746 0.238033357 0.889867239 0.384848746 -0.072364162 
GABBR1 0.054176411 0.830415951 0.443223333 0.235800469 0.830415951 0.443223333 0.181624058 




0.254885887 0.99906883 0.28639908 0.227902327 0.99906883 0.28639908 -0.02698356 
ANKRD28 0.090820312 0.964281934 0.405411693 0.227067987 0.964281934 0.377704218 0.136247675 
PIF1 0.308361184 0.789502562 0.452710548 0.225785047 0.789502562 0.452710548 -0.082576136 
SETD2 -0.114424351 0.99309399 0.672358721 0.225461408 0.99309399 0.513673877 0.339885759 
CSNK1E 0.359561972 0.996433343 0.282415934 0.224393108 0.996433343 0.288671942 -0.135168864 
RASSF7 0.091390315 0.997777622 0.450251198 0.223541113 0.997777622 0.450251198 0.132150798 












0.2176404 0.963105599 0.474021678 0.221101728 0.963105599 0.474021678 0.003461328 




0.195065807 0.966309425 0.563951342 0.219416584 0.966309425 0.563951342 0.024350777 
PPP6R1 0.101003442 0.772941429 0.646705834 0.218368227 0.773394928 0.646705834 0.117364786 
MGMT 0.218978288 0.992856975 0.313217262 0.216487967 0.992856975 0.313217262 -0.002490321 
USP1 0.024186031 0.590243354 0.848664132 0.213801799 0.696120545 0.848664132 0.189615768 
PHF11 0.196859794 0.968480013 0.31960288 0.212622165 0.968480013 0.31960288 0.015762371 
APOBEC3G 0.220990788 0.800085083 0.404673257 0.211510399 0.800085083 0.404673257 -0.009480388 
HDAC2 0.247099876 0.869520373 0.350883165 0.211469392 0.869520373 0.350883165 -0.035630484 
RAD54B 0.283304926 0.984425058 0.274302318 0.210107769 0.984425058 0.303339357 -0.073197157 




0.227570329 0.995299415 0.370924813 0.208483062 0.995299415 0.370924813 -0.019087267 
NEIL3 0.187890614 0.830465663 0.459576238 0.207078229 0.830465663 0.459576238 0.019187615 
HDAC3 -0.050780051 0.836458763 0.963541237 0.206054887 0.950775197 0.823837204 0.256834939 




0.178323363 0.985115366 0.493287977 0.204577607 0.985115366 0.493287977 0.026254244 
USP3 0.236840047 0.90412076 0.449800464 0.204257416 0.90412076 0.449800464 -0.032582631 
PARP15 0.217914831 0.998960655 0.477792218 0.204229197 0.998960655 0.477792218 -0.013685634 
AMN1 0.20519385 0.99801046 0.457817368 0.202608216 0.99801046 0.457817368 -0.002585634 
POLA1 0.092590672 0.992727618 0.751616353 0.202502085 0.992727618 0.737074663 0.109911413 
ASF1B 0.190560893 0.852870623 0.479460419 0.199910858 0.852870623 0.479460419 0.009349965 
USP11 0.339891841 0.977479353 0.267347445 0.196739558 0.977479353 0.299292053 -0.143152283 
PSIP1 0.107449096 0.882014247 0.407987723 0.196660676 0.882014247 0.407987723 0.08921158 
PIAS1 0.180534579 0.730146097 0.478187399 0.195791403 0.730146097 0.478187399 0.015256825 
PINK1 0.142806541 0.859205561 0.480296597 0.195335499 0.859205561 0.480296597 0.052528958 
DMC1 0.4960421 0.999556483 0.128005462 0.194553459 0.999556483 0.317474323 -0.301488641 
ERCC5 0.193455577 0.788299656 0.480513536 0.193324345 0.788299656 0.480513536 -1.31232E-04 
RECQL4 0.051804521 0.877680198 0.595715041 0.193149989 0.877680198 0.595715041 0.141345468 
MCM10 0.339184671 0.90263807 0.293246413 0.192509367 0.90263807 0.394994315 -0.146675305 
SIRT3 0.102638457 0.979592947 0.513082548 0.192111243 0.979592947 0.513082548 0.089472786 




0.178788056 0.860063864 0.436971171 0.187915267 0.860063864 0.436971171 0.009127211 
UVSSA 0.202607389 0.69812623 0.613241301 0.187799928 0.69812623 0.613241301 -0.014807461 
TREX1 0.176890245 0.968436391 0.370772458 0.186492946 0.968436391 0.370772458 0.009602701 




0.277800767 0.999427371 0.44594415 0.184313989 0.999427371 0.495138712 -0.093486778 
KDM2A -0.143111278 0.451542273 0.910732661 0.183116806 0.680644401 0.910732661 0.326228084 
ARID1B 0.103647065 0.970376264 0.395840165 0.182717563 0.970376264 0.363498145 0.079070498 
SCAF8 0.070530316 0.997827855 0.427710487 0.18264722 0.997827855 0.356655799 0.112116904 
SMARCAD1 0.30035202 0.902049214 0.473019693 0.180094551 0.902049214 0.483473467 -0.12025747 
APOBEC3C 0.317211694 0.995992372 0.264095215 0.179379647 0.995992372 0.335288309 -0.137832048 
UBA3 0.477811961 0.994051665 0.225515477 0.177551812 0.994051665 0.337183058 -0.300260149 
NPM1 0.228364612 0.971362538 0.666090951 0.17740322 0.971362538 0.666090951 -0.050961392 




0.226435304 0.995046821 0.372114596 0.17628256 0.995046821 0.372114596 -0.050152744 
HDAC1 0.212494995 0.853806783 0.358107678 0.174707043 0.853806783 0.358107678 -0.037787952 
PMS2 0.150503098 0.962221154 0.400871549 0.173102264 0.962221154 0.400871549 0.022599166 
PRIMPOL 0.183810092 0.97661071 0.334150094 0.172617552 0.97661071 0.334150094 -0.01119254 
COPS7B 0.189604923 0.999189187 0.476153164 0.172573142 0.999189187 0.476153164 -0.01703178 
DLGAP5 0.253387846 0.886341913 0.404700279 0.172241313 0.886341913 0.422190703 -0.081146533 
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0.221323901 0.997641235 0.416399926 0.1670684 0.997641235 0.416399926 -0.054255501 
USP20 0.149593467 0.997002414 0.352491499 0.163548311 0.997002414 0.352491499 0.013954844 
BAZ1A 0.169490984 0.733462775 0.45138603 0.162771296 0.733462775 0.45138603 -0.006719688 
OR1E2 0.031494679 0.776359 0.639285089 0.161866345 0.776359 0.639285089 0.130371666 
CBX3 0.124908817 0.85241978 0.418979627 0.161719234 0.85241978 0.418979627 0.036810417 
RBM7 0.170017875 0.988203047 0.538082584 0.160336863 0.988203047 0.538082584 -0.009681012 
APOBEC3H 0.245912685 0.843921742 0.402261229 0.15950453 0.843921742 0.402261229 -0.086408155 
UIMC1 0.293940925 0.861488402 0.390302293 0.159137612 0.861488402 0.390302293 -0.134803313 
TCEA1 0.107978306 0.635881387 0.597959364 0.158382789 0.635881387 0.597959364 0.050404484 
ENDOV 0.236910853 0.999296873 0.470078315 0.157013489 0.999296873 0.505355303 -0.079897365 
PRKCG 0.308605373 0.999019977 0.26646088 0.155734414 0.999019977 0.348687818 -0.152870958 
PPP4R3B 0.18626974 0.993541008 0.444203171 0.154957265 0.993541008 0.444203171 -0.031312475 
MUTYH -0.051843351 0.663194739 0.683401713 0.154697633 0.663194739 0.683401713 0.206540984 
EME1 0.503476096 0.900026124 0.209613513 0.151809809 0.900026124 0.35856155 -0.351666287 
NOTCH3 0.347803895 0.994536715 0.209763614 0.147983046 0.994536715 0.346213408 -0.19982085 
PARK7 0.162411492 0.994823768 0.356819735 0.146151782 0.994823768 0.356819735 -0.016259709 
USP45 0.277689591 0.96395309 0.348616929 0.144852222 0.96395309 0.355162977 -0.132837369 
DTX2 0.02331751 0.671581355 0.696367427 0.139547395 0.671581355 0.696367427 0.116229885 
MPG 0.068866513 0.678395155 0.64260504 0.138438328 0.678395155 0.64260504 0.069571815 
MORF4L1 0.121746272 0.994177809 0.39585355 0.136957891 0.994177809 0.39585355 0.015211618 
HNRNPK 0.526083294 0.998457502 0.296670182 0.133953218 0.998457502 0.603972521 -0.392130076 
SLBP 0.139355251 0.84926528 0.520300724 0.13327944 0.84926528 0.520300724 -0.006075811 
SLF2 0.013611913 0.968887803 0.484472338 0.133209372 0.968887803 0.484472338 0.119597459 
CCNB2 0.113270481 0.989274411 0.381245164 0.132743084 0.989274411 0.381245164 0.019472603 
CCNC 0.161689526 0.999898713 0.571692998 0.132473348 0.999898713 0.571692998 -0.029216179 
USP47 0.222621293 0.996708864 0.335923692 0.132084192 0.996708864 0.376874263 -0.0905371 
TFPT 0.18230516 0.674985546 0.890885344 0.131803399 0.674985546 0.890885344 -0.050501761 
SCAF11 0.154415351 0.986336654 0.377734284 0.129559681 0.986336654 0.377734284 -0.024855669 
ALDH2 0.205288599 0.97275521 0.360095874 0.128638342 0.97275521 0.389625096 -0.076650257 
ADH5 0.300261747 0.997682785 0.454255411 0.127568439 0.997682785 0.454255411 -0.172693307 




0.112091075 0.878180299 0.570687847 0.124616003 0.878180299 0.570687847 0.012524928 
ATRX 0.020093607 0.584883682 0.796610207 0.122231692 0.620375092 0.796610207 0.102138085 
NOTCH1 0.160431152 0.99799131 0.40855067 0.122009758 0.99799131 0.40855067 -0.038421394 
VCP 0.171777739 0.999408308 0.397997887 0.12198891 0.999408308 0.397997887 -0.049788829 
UBE2B 0.089930816 0.967780942 0.537212607 0.113808699 0.967780942 0.537212607 0.023877883 
POLH 0.082071271 0.817609978 0.414541812 0.113645775 0.817609978 0.414541812 0.031574504 
RECQL 0.204531622 0.991266977 0.346060971 0.110290712 0.991266977 0.394390206 -0.094240911 
NABP1 0.130917209 0.959632317 0.37841813 0.109498228 0.959632317 0.37841813 -0.021418982 
CCNA1 0.22803564 0.810951228 0.598707029 0.108449837 0.810951228 0.598707029 -0.119585803 
BEND3 0.191734163 0.782060364 0.418467606 0.108326766 0.782060364 0.418467606 -0.083407397 
ATM 0.943915105 1 0.081241606 0.106493679 1 0.466444914 -0.837421426 
EXD2 0.212897749 0.986875983 0.445430619 0.106370928 0.986875983 0.445430619 -0.106526822 
BRCA2 0.144455879 0.996405184 0.390630433 0.104315302 0.996405184 0.390630433 -0.040140576 
HES1 0.063669629 0.76809946 0.612258629 0.099168713 0.76809946 0.612258629 0.035499084 
CDCA5 0.209257724 0.953015111 0.687248839 0.098594465 0.953015111 0.733014267 -0.110663259 
SETMAR 0.130645154 0.987364155 0.40481647 0.0952048 0.987364155 0.40481647 -0.035440354 
TDP2 0.259346777 0.711202432 0.917993286 0.094098262 0.674335764 0.917993286 -0.165248515 
PARK2 -0.002213953 0.744557492 0.558212871 0.091904438 0.744557492 0.519731198 0.094118391 
XPA 0.39221296 0.954356687 0.428896985 0.091243623 0.954356687 0.473829968 -0.300969337 
OTUD7B 0.181131674 0.966178755 0.371732999 0.091099419 0.966178755 0.413043431 -0.090032255 
HDAC10 0.10296821 0.997973562 0.508985692 0.089846358 0.997973562 0.508985692 -0.013121852 
CSNK1D 0.455645118 0.998727585 0.147949752 0.089806427 0.998727585 0.407814328 -0.365838691 
NOTCH4 0.146490144 0.977380485 0.393068506 0.089508113 0.977380485 0.406041051 -0.056982031 
USP22 -0.08988158 0.642641712 0.653544646 0.087887047 0.642641712 0.653544646 0.177768626 
CCND1 0.097377397 0.869752987 0.641848467 0.087067703 0.869752987 0.641848467 -0.010309694 
HLTF 0.21653935 0.842836197 0.400106702 0.086164078 0.842836197 0.462500405 -0.130375272 
BUB1B -0.219697257 0.468920428 0.999987313 0.084848879 0.576205996 0.999987313 0.304546136 
CENPS 0.176204454 0.809540827 0.504680041 0.084507524 0.809540827 0.504680041 -0.09169693 
TRIM28 -0.020763468 0.696727965 0.743038716 0.083263708 0.696727965 0.743038716 0.104027176 
RPA4 0.246804945 0.926587876 0.347017442 0.08264088 0.926587876 0.418620376 -0.164164065 
TDG 0.171354519 0.776038219 0.622908194 0.081982776 0.776038219 0.622908194 -0.089371742 
POLL 0.139099851 0.995018218 0.414511884 0.078584312 0.995018218 0.42431045 -0.060515538 
RAD23B -0.049204152 0.726194025 0.689054646 0.074848626 0.726194025 0.689054646 0.124052777 
PIAS3 0.059787001 0.955902472 0.518574108 0.074456 0.955902472 0.518574108 0.014668999 
SENP7 0.030641338 0.8161503 0.467620277 0.07047571 0.8161503 0.467620277 0.039834372 
RAD52 0.107879973 0.728971579 0.559429461 0.06997367 0.728971579 0.559429461 -0.037906303 
PXMP2 0.063277829 0.923308842 0.444325346 0.067883797 0.923308842 0.444325346 0.004605968 
PER3 0.063532836 0.849608299 0.489903783 0.065916041 0.849608299 0.489903783 0.002383204 
RHO -0.094953519 0.867938538 0.600412196 0.065020096 0.867938538 0.484596608 0.159973616 
SKIV2L2 0.133767643 0.791033887 0.788549952 0.06338899 0.791033887 0.788549952 -0.070378653 
CUL9 0.022738544 0.851605881 0.855499456 0.06283844 0.851605881 0.855499456 0.040099895 
INO80E 0.075453653 0.854418796 0.665537272 0.06000491 0.854418796 0.665537272 -0.015448743 
HPF1 0.34620325 0.942247654 0.482518472 0.059949205 0.942247654 0.576728887 -0.286254045 
ERCC6L2 0.082971582 0.872367225 0.646306863 0.059204415 0.872367225 0.646306863 -0.023767167 
UBE2D4 0.201658186 0.907990743 0.395428014 0.055146625 0.907990743 0.445565858 -0.146511561 
RUVBL1 -0.153454706 0.662185567 0.999640183 0.054300845 0.820973379 0.999640183 0.207755551 
POLG -0.010706466 0.665474388 0.874455448 0.053156036 0.665474388 0.874455448 0.063862501 
AICDA 0.092415873 0.884412741 0.47259631 0.052877257 0.884412741 0.47259631 -0.039538617 
POLQ 0.163186408 0.707187804 0.452518333 0.052289266 0.707187804 0.452518333 -0.110897142 
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RECQL5 0.306297541 0.807844349 0.447635835 0.051651412 0.807844349 0.449528537 -0.254646128 
PRDM9 0.168769325 0.943546646 0.367872819 0.04784386 0.943546646 0.449775634 -0.120925464 
DTX1 0.046182582 0.802545681 0.457077757 0.044109694 0.802545681 0.457077757 -0.002072888 
OTUB1 -0.228427007 0.59043536 0.800128386 0.037539574 0.59043536 0.800128386 0.265966582 
SHPRH 0.121492533 0.726763686 0.552152367 0.037051661 0.726763686 0.552152367 -0.084440872 
TP73 0.153404834 0.721214667 0.496816724 0.035157299 0.721214667 0.496816724 -0.118247535 
IGHMBP2 0.022171585 0.733461585 0.477616102 0.03294178 0.733461585 0.477616102 0.010770195 
ERCC8 0.078879398 0.716506865 0.709966902 0.028140536 0.716506865 0.709966902 -0.050738862 
CLK2 -0.110313539 0.937955813 0.60099048 0.026897751 0.937955813 0.53407626 0.13721129 
ARID1A -0.004515786 0.524709241 0.960738841 0.026415831 0.524709241 0.960738841 0.030931617 
H3F3B -0.069808624 0.771063803 0.851687166 0.024440463 0.771063803 0.851687166 0.094249087 
PMS2P3 0.047253518 0.943456195 0.540776061 0.023999063 0.943456195 0.540776061 -0.023254455 
PARG -0.381310333 0.995565538 0.775369659 0.02111252 0.995565538 0.622838059 0.402422853 
CTC1 -0.604107134 0.186351673 0.999977979 0.020211568 0.51582487 0.999977979 0.624318701 
SUV39H1 -0.171821126 0.686927959 0.727706492 0.013962166 0.686927959 0.727706492 0.185783291 
PMS2P5 0.137426805 0.642106223 0.567006492 0.0133464 0.642106223 0.567006492 -0.124080405 
CSNK2A1 -0.195308596 0.59893175 0.749365565 0.011347324 0.59893175 0.744935698 0.20665592 
PRDM10 -0.023312679 0.750825113 0.67521091 0.007033971 0.750825113 0.67521091 0.03034665 
RNF4 0.016632553 0.51553963 0.863172383 0.00622785 0.51553963 0.863172383 -0.010404703 
MTA1 -0.061503087 0.620309887 0.740035073 0.005178521 0.620309887 0.740035073 0.066681608 
COPS4 0.172337992 0.962367229 0.715195378 -0.00226884 0.962367229 0.752958171 -0.174606832 
USP44 -0.035793351 0.66852974 0.962981781 -0.003191434 0.66852974 0.962981781 0.032601917 
RFC1 0.187239317 0.870530865 0.493337784 -0.004610795 0.870530865 0.507184656 -0.191850113 
MVP -0.003233065 0.881549393 0.509313399 -0.008949586 0.881549393 0.509313399 -0.005716522 
UBB 0.131580167 0.998261617 0.703563445 -0.011506907 0.998261617 0.764261501 -0.143087074 
ATAD5 -0.180263996 0.639201937 0.719766489 -0.012020629 0.639201937 0.719766489 0.168243367 
RNF169 -0.178212041 0.972630813 0.673874758 -0.012568394 0.972630813 0.576521082 0.165643647 
SIRT6 0.115883981 0.933946592 0.491069507 -0.012902396 0.933946592 0.526319988 -0.128786376 
POLD4 -0.152430023 0.72269126 0.774671345 -0.018536418 0.72269126 0.774671345 0.133893605 
COL1A1 -0.008019083 0.911479638 0.616873471 -0.021235504 0.911479638 0.616873471 -0.013216421 
POLR2B -0.267503378 0.468988107 0.998193741 -0.025249103 0.611948588 0.998193741 0.242254275 
CHEK1 -0.210828802 0.613334613 0.9943534 -0.028889947 0.717628982 0.9943534 0.181938854 
CTCF -0.278839908 0.470432027 0.999918614 -0.031313419 0.707214958 0.999918614 0.247526489 
APEX1 0.04505838 0.975643502 0.654696958 -0.032401345 0.975643502 0.654696958 -0.077459725 
RBBP7 -0.173001878 0.976664116 0.670460655 -0.037495341 0.976664116 0.605891961 0.135506536 
RAD51AP1 0.261280461 0.853380663 0.405176852 -0.043143269 0.853380663 0.540512803 -0.30442373 
TEP1 0.298852919 0.9949726 0.275978287 -0.046895012 0.9949726 0.544646231 -0.345747931 
OR6B1 0.034434096 0.780133397 0.543041925 -0.048782563 0.780133397 0.543041925 -0.083216659 
MBTD1 0.123132222 0.982125174 0.487072459 -0.049491053 0.982125174 0.549045505 -0.172623275 
REV3L -0.195390357 0.586466619 0.995825835 -0.053169669 0.677729369 0.995825835 0.142220689 
SETX -0.061594389 0.956660985 0.560406733 -0.056988341 0.956660985 0.560406733 0.004606048 
TOP2A -0.104540464 0.810893181 0.622751665 -0.061311358 0.810893181 0.622751665 0.043229106 
PIAS4 -0.027867095 0.530232231 0.788581482 -0.064941031 0.530232231 0.788581482 -0.037073936 
CUL4A -0.088287072 0.655076567 0.689545238 -0.065496881 0.655076567 0.689545238 0.022790191 
ORC2 -0.169288907 0.481268607 0.87352768 -0.067722992 0.481268607 0.87352768 0.101565915 
WRNIP1 -0.039180542 0.995688479 0.564859139 -0.068806024 0.995688479 0.564859139 -0.029625482 
SMC5 -0.613505342 0.187778569 0.999999999 -0.076743469 0.649455476 0.999999999 0.536761873 
DAXX -0.297105535 0.439790132 0.982592441 -0.077652638 0.641892997 0.982592441 0.219452897 
PARP1 -0.098941001 0.420140741 0.90920163 -0.080462653 0.420140741 0.90920163 0.018478348 
CDK2 -0.357679166 0.355245308 0.991668433 -0.083488204 0.539835242 0.991668433 0.274190962 
UBE2A -0.134213747 0.966338213 0.624669305 -0.090238379 0.966338213 0.624669305 0.043975368 
MPLKIP -0.050214801 0.504591767 0.839815793 -0.090727672 0.504591767 0.839815793 -0.040512871 
POLE -0.19943263 0.65044863 0.865959085 -0.093914916 0.65044863 0.865959085 0.105517715 
MSH6 -0.017441367 0.77028725 0.633023141 -0.095550842 0.77028725 0.633023141 -0.078109475 
RAD54L 0.065435368 0.565077241 0.930512659 -0.097263653 0.553927821 0.930512659 -0.162699021 
UNG -0.140507607 0.879170242 0.711741337 -0.097954022 0.879170242 0.711741337 0.042553586 
TNKS -0.113515915 0.632422958 0.844252915 -0.102750963 0.632422958 0.844252915 0.010764952 
PALB2 -0.017023307 0.507357419 0.956352073 -0.109382034 0.501162855 0.956352073 -0.092358726 
H2AFY2 -0.101809783 0.763884749 0.608864689 -0.112067979 0.763884749 0.608864689 -0.010258196 
BRIP1 -0.085205865 0.47669902 0.882716175 -0.112335334 0.47669902 0.882716175 -0.027129469 
KAT5 -0.131731425 0.544346065 0.999736495 -0.113515061 0.544346065 0.999736495 0.018216364 
TOP1 -0.250919421 0.593986618 0.965118595 -0.113775851 0.593986618 0.965118595 0.13714357 
DUT -0.148361159 0.579846774 0.992138582 -0.11814688 0.579846774 0.992138582 0.030214279 
FAAP20 -0.029570021 0.529341341 0.704574993 -0.12000869 0.529341341 0.704574993 -0.090438669 
MORF4L2 -0.054651735 0.909420079 0.609511379 -0.123335851 0.909420079 0.609511379 -0.068684116 
UPF1 0.156450488 0.948328204 0.827507694 -0.129993137 0.701914317 0.999880087 -0.286443626 
FANCC -0.472839968 0.141034121 0.999998236 -0.130770543 0.376495571 0.999998236 0.342069425 
H3F3A -0.066562921 0.576658748 0.533961199 -0.13224946 0.576658748 0.533961199 -0.065686538 
COPS2 -0.081647004 0.620978721 0.992713471 -0.132313589 0.620978721 0.992713471 -0.050666585 
GEN1 0.121114146 0.754153117 0.671192216 -0.133598753 0.754153117 0.717346874 -0.254712899 
NHEJ1 -0.275904963 0.320688385 0.989815203 -0.137074163 0.368523332 0.989815203 0.1388308 
KAT2A -0.258826185 0.451517864 0.992094734 -0.140848258 0.536768849 0.992094734 0.117977927 
CHRAC1 -0.146265724 0.470805861 0.883613746 -0.141548985 0.470805861 0.883613746 0.004716739 
HELQ -0.117832957 0.53104413 0.86709702 -0.148396953 0.53104413 0.86709702 -0.030563996 
SMG1 -0.001027006 0.748581794 0.889597163 -0.154371649 0.671159782 0.889597163 -0.153344643 
SPIDR -0.160869561 0.476235924 0.816668104 -0.163306594 0.476235924 0.816668104 -0.002437032 
CBX1 -0.322394083 0.732768406 0.73796149 -0.165062075 0.732768406 0.73796149 0.157332007 
ECT2 -0.285309725 0.601225405 0.863494177 -0.16529244 0.601225405 0.863494177 0.120017286 
CDK12 -0.12669623 0.564415163 0.972174261 -0.168720419 0.564415163 0.972174261 -0.042024189 
HELLS -0.3323148 0.378136086 0.971985663 -0.169311399 0.508538198 0.971985663 0.163003401 
TERF1 -0.13534812 0.599924359 0.989034776 -0.173441923 0.599924359 0.989034776 -0.038093803 
ZMPSTE24 -0.271713141 0.31252721 0.99078592 -0.18626921 0.342656174 0.99078592 0.085443931 
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SMARCE1 -0.302947089 0.467321058 0.990164848 -0.189759385 0.506807517 0.990164848 0.113187704 
RNF168 -0.167531462 0.686855358 0.768789476 -0.190727785 0.686855358 0.768789476 -0.023196323 
RFWD3 -0.123203367 0.445843971 0.946496535 -0.19492709 0.445843971 0.946496535 -0.071723723 
NFE2L2 -0.33470849 0.300917887 0.994462838 -0.19573084 0.315725366 0.994462838 0.13897765 
ZSWIM7 -0.083677693 0.743131832 0.724270237 -0.196197051 0.735231576 0.724270237 -0.112519358 
SFPQ -0.57681843 0.185355112 0.99600134 -0.205258684 0.483148886 0.99600134 0.371559746 
MEN1 -0.496261129 0.27247094 0.983314517 -0.208255789 0.482053675 0.983314517 0.28800534 
WEE1 -0.155452837 0.513030134 0.994310613 -0.211778417 0.513030134 0.994310613 -0.056325581 
POLR2G -0.019972112 0.726226515 0.997446221 -0.212864322 0.608440782 0.997446221 -0.19289221 
CDC25B -0.240849288 0.43383429 0.990217901 -0.217992272 0.43383429 0.990217901 0.022857016 
CCNB1 -0.431339642 0.244388192 0.998111376 -0.219921533 0.43057925 0.998111376 0.211418108 
PPM1G -0.26147433 0.439542171 0.977161392 -0.220610115 0.439542171 0.977161392 0.040864215 
PINX1 -0.287599591 0.411515389 0.974286015 -0.221432877 0.437576953 0.974286015 0.066166714 
ACTR8 -0.411475434 0.290246766 0.99999942 -0.224807063 0.442959091 0.99999942 0.186668371 
NCAPH2 -0.571878906 0.191663105 0.999999184 -0.228129586 0.461935274 0.999999184 0.34374932 
SPRTN -0.325328722 0.359037223 0.993980344 -0.228243527 0.401269127 0.993980344 0.097085195 
RAD21 -0.197435806 0.524806212 0.999354912 -0.232340701 0.524806212 0.999354912 -0.034904895 
DCLRE1B -0.428985616 0.368748407 0.999992796 -0.233025953 0.491971737 0.999992796 0.195959663 
BAZ1B -0.161895191 0.677081241 0.831773684 -0.236830325 0.677081241 0.831773684 -0.074935134 
SMC2 -0.435588738 0.306500359 0.998050525 -0.246408633 0.445587659 0.998050525 0.189180105 
PAXIP1 -0.162524062 0.640313842 0.733419247 -0.247736084 0.640313842 0.733419247 -0.085212022 
CHAF1A -0.320935796 0.408536458 0.998605523 -0.254401494 0.417980079 0.998605523 0.066534302 
CLSPN -0.362088605 0.350724578 0.995842411 -0.25568384 0.400633478 0.995842411 0.106404765 
UBE2D3 -0.164298771 0.584918544 0.997770826 -0.256125828 0.584918544 0.997770826 -0.091827057 
SMARCAL1 -0.191703632 0.734519105 0.748013154 -0.258188722 0.734519105 0.748013154 -0.06648509 
RNF8 -0.420300366 0.309963928 0.996162079 -0.264000625 0.403392721 0.996162079 0.156299741 
FAAP100 -0.350651232 0.348295658 0.999216741 -0.265090255 0.348324268 0.999216741 0.085560977 
EXO5 -0.250611934 0.483459042 0.99160132 -0.267014669 0.483459042 0.99160132 -0.016402734 
NFRKB -0.019030058 0.57136474 0.983903022 -0.269946772 0.457232904 0.983903022 -0.250916714 
STAG1 0.097146543 0.723799903 0.633347551 -0.271542088 0.723799903 0.800676248 -0.36868863 
SMARCA5 -0.259388098 0.390297438 0.999784118 -0.276523034 0.390297438 0.999784118 -0.017134937 
ATMIN -0.073792073 0.945798935 0.687818418 -0.281206628 0.945798935 0.717556338 -0.207414554 
CNOT7 -0.426368207 0.288024187 0.942650234 -0.284916952 0.288024187 0.942650234 0.141451255 
TADA3 -0.580141432 0.433691801 0.915647428 -0.287635052 0.433691801 0.915647428 0.29250638 
NIPBL -0.327330488 0.525388835 0.998963233 -0.295695572 0.525388835 0.998963233 0.031634916 
CHD4 -0.516423917 0.501435684 0.901051259 -0.302107709 0.501435684 0.901051259 0.214316207 
EXO1 -0.265627482 0.626652201 0.875452844 -0.316215182 0.626652201 0.875452844 -0.0505877 
TCEB3 -0.360643752 0.392677042 0.990465878 -0.326566923 0.392677042 0.990465878 0.034076829 
PPP4R2 -0.244939295 0.570779587 0.884977733 -0.331330644 0.570779587 0.884977733 -0.086391349 
ACTR5 -0.260340651 0.309331697 0.999664378 -0.335459641 0.309331697 0.999664378 -0.07511899 
SMG6 -0.6453912 0.290383003 0.975220406 -0.336765894 0.420174475 0.975220406 0.308625306 
NBN 0.08695752 0.797503888 0.750377074 -0.337560003 0.618038755 0.937556694 -0.424517523 
GTF2H4 -0.422854362 0.275615179 1 -0.341758269 0.293305429 1 0.081096092 
UCHL5 -0.577541186 0.133405401 0.999999896 -0.34195548 0.248764813 0.999999896 0.235585706 
RFC4 -0.716468546 0.10153731 0.999840568 -0.342002964 0.291544092 0.999840568 0.374465582 
EP400 -0.107096777 0.603096792 0.934499724 -0.342791618 0.584723843 0.934499724 -0.235694841 
INO80 -0.448952636 0.225029413 0.998880602 -0.344610666 0.26996301 0.998880602 0.10434197 
RBBP8 -0.342988327 0.462614282 0.850956524 -0.347030497 0.462614282 0.850956524 -0.00404217 
CUL1 -0.305524858 0.340697374 0.99998777 -0.347179148 0.340697374 0.99998777 -0.041654289 
COPS3 -0.227953783 0.442367828 0.998901311 -0.348516407 0.384372956 0.998901311 -0.120562624 
TAF1 -0.327362859 0.387331098 0.999999984 -0.355485229 0.387331098 0.999999984 -0.02812237 
FANCM -0.475851292 0.163779083 0.999902234 -0.355635242 0.235438146 0.999902234 0.12021605 
GAR1 -0.304532452 0.362184186 0.99968861 -0.365152671 0.343440901 0.99968861 -0.060620218 
XRCC1 -0.223303714 0.443528978 0.83560372 -0.373783118 0.443528978 0.83560372 -0.150479403 
RMI2 -0.384013037 0.359083547 0.971086796 -0.375905162 0.359083547 0.971086796 0.008107876 
RAD1 -0.762895421 0.148316872 0.999593394 -0.376440405 0.325790703 0.999593394 0.386455016 
POLR2C -0.50033028 0.157098961 0.999999547 -0.380740339 0.223820267 0.999999547 0.119589942 
LIG1 -0.512431584 0.526211125 0.979584009 -0.384275107 0.526211125 0.979584009 0.128156477 
SENP6 -0.352317624 0.287750183 0.99993276 -0.385500519 0.287750183 0.99993276 -0.033182896 
EYA3 -0.456112416 0.442394633 0.978716184 -0.387686053 0.442394633 0.978716184 0.068426364 
SFR1 -0.156771023 0.81670404 0.894819057 -0.390192821 0.640166994 0.894819057 -0.233421798 
POLR2F -0.562227633 0.216537678 0.932523806 -0.397437876 0.294463502 0.932523806 0.164789757 
NSMCE2 -0.556001856 0.193492295 0.996527617 -0.399262842 0.25462394 0.996527617 0.156739013 
USP7 -0.391609257 0.305594303 0.999984213 -0.402061931 0.305594303 0.999984213 -0.010452674 
BRCA1 -0.407897117 0.240341187 0.988927882 -0.403056485 0.240341187 0.988927882 0.004840632 
BARD1 -0.245556819 0.383219376 0.99981174 -0.404384838 0.263085177 0.99981174 -0.158828019 
RNF40 -0.53170703 0.314960506 0.999986349 -0.409308039 0.377800215 0.999986349 0.12239899 
POT1 -0.473156679 0.27823922 0.999990622 -0.410456241 0.289223339 0.999990622 0.062700438 
RNASEH2A -0.774272995 0.074537796 0.999838311 -0.412804047 0.182239122 0.999838311 0.361468949 
UBE2I -0.498894992 0.273549919 0.999999985 -0.41353856 0.311095516 0.999999985 0.085356432 
MCM3AP -0.571487276 0.210290216 0.973219488 -0.414577182 0.245791437 0.973219488 0.156910094 
RMI1 -0.453799452 0.143321541 0.999979412 -0.416007829 0.15028984 0.999979412 0.037791622 
UVRAG -0.571651452 0.117036679 0.999970332 -0.416051718 0.187861322 0.999970332 0.155599734 
TICRR -0.797400874 0.045540757 0.999999997 -0.416743566 0.230127031 0.999999997 0.380657308 
PAGR1 -0.325517228 0.344956722 0.995113011 -0.417768757 0.301574201 0.995113011 -0.092251529 
FANCI -0.586703828 0.250591065 0.995192091 -0.425331133 0.341551623 0.995192091 0.161372695 
MDC1 -0.260384407 0.368398642 0.986434394 -0.427783586 0.235619766 0.986434394 -0.167399179 
ATRIP -0.443349339 0.203753298 0.998218448 -0.427978459 0.203753298 0.998218448 0.01537088 
FANCA -0.628314974 0.209442566 0.968847838 -0.435673566 0.209442566 0.968847838 0.192641408 
FANCF -0.781412813 0.058292815 0.999997085 -0.444210884 0.134503467 0.999997085 0.337201928 
CSNK2B -0.726343327 0.098440714 0.999938691 -0.4474661 0.202035915 0.999938691 0.278877227 
CREBBP -0.584821188 0.200253782 0.977017433 -0.447778848 0.200253782 0.977017433 0.13704234 
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FAAP24 -0.340509812 0.262097914 0.999280513 -0.448306062 0.262097914 0.999280513 -0.10779625 
FEN1 -0.623830581 0.100825771 0.999973193 -0.450553621 0.196283072 0.999973193 0.17327696 
SMC1A -0.740754463 0.131619159 1 -0.453336412 0.275896418 1 0.287418051 
RAD51B -0.549552869 0.161939293 0.9999845 -0.456481337 0.161939293 0.9999845 0.093071533 
PDS5B -0.599265121 0.164773 0.997655936 -0.458760261 0.191064986 0.997655936 0.14050486 
COPS8 -0.531819356 0.295386634 0.99994207 -0.459321251 0.315067169 0.99994207 0.072498105 
MTOR -0.414611926 0.179431512 0.999949697 -0.461006804 0.179431512 0.999949697 -0.046394878 
RPAIN -0.736503038 0.205984554 0.977445656 -0.463024302 0.250850992 0.977445656 0.273478736 
SLX4 -0.446272706 0.231739994 0.999341474 -0.4639301 0.231739994 0.999341474 -0.017657394 
PDS5A -0.875842427 0.042144701 0.999995695 -0.468175233 0.208321058 0.999995695 0.407667195 
PRMT1 -0.776165098 0.057656701 0.999836497 -0.469090598 0.169360935 0.999836497 0.3070745 
NSMCE4A -0.633510441 0.144094622 0.999942809 -0.470068139 0.221355976 0.999942809 0.163442302 
TERF2 -0.434257981 0.320585828 0.996613913 -0.47126373 0.320585828 0.996613913 -0.037005749 
UBC -0.500661645 0.319689711 0.98099411 -0.475523583 0.319689711 0.98099411 0.025138062 
POLD2 -0.318331019 0.334274577 0.982634944 -0.479593426 0.334274577 0.982634944 -0.161262406 
ENY2 -0.375068238 0.262644554 0.971646103 -0.482395224 0.218434077 0.971646103 -0.107326987 
POLR2K -0.599130386 0.283843607 0.987262845 -0.482978015 0.283843607 0.987262845 0.116152371 
PCNA -0.525227676 0.210773824 0.999618781 -0.484398215 0.210773824 0.999618781 0.040829461 
POLR2H -0.311275572 0.3367429 0.999999145 -0.491210287 0.189479666 0.999999145 -0.179934715 
KDM4A -0.666794788 0.125797803 0.999685556 -0.494144558 0.166800392 0.999685556 0.17265023 
PRPF19 -0.368776851 0.304999985 0.999912334 -0.495298886 0.234990742 0.999912334 -0.126522036 
RAD17 -0.429162084 0.243071081 0.99993315 -0.496070957 0.22734203 0.99993315 -0.066908873 
PLRG1 -0.412979263 0.343606608 0.948788813 -0.501635898 0.343606608 0.948788813 -0.088656635 
ESCO2 -0.574482163 0.196685607 0.992629276 -0.502442957 0.196685607 0.992629276 0.072039206 
HINFP -0.79221487 0.06620008 0.999999995 -0.503922395 0.198246862 0.999999995 0.288292475 
XAB2 -0.511185044 0.176883581 0.99997275 -0.506123258 0.176883581 0.99997275 0.005061786 
SMARCB1 -0.566741201 0.195990515 0.999998637 -0.509017206 0.195990515 0.999998637 0.057723996 
CDK4 -0.889478248 0.06897007 0.999987981 -0.510104937 0.238138286 0.999987981 0.379373311 
LMNA -0.569427782 0.183523833 0.988127832 -0.510726506 0.183910288 0.988127832 0.058701276 
NCAPG -0.706636908 0.057577289 0.999983682 -0.512604221 0.144898496 0.999983682 0.194032687 
COPS6 -0.470339935 0.212521005 0.999999928 -0.51767767 0.211926691 0.999999928 -0.047337735 
NOP10 -0.476179328 0.209605617 0.999999242 -0.521170097 0.209605617 0.999999242 -0.044990769 
POLE4 -0.42725172 0.219300567 0.999981281 -0.522554491 0.190544578 0.999981281 -0.095302771 
FIGNL1 -0.635831087 0.256950171 0.998935428 -0.525543682 0.256950171 0.998935428 0.110287405 
FANCE -0.364772348 0.291835479 0.999512955 -0.528331463 0.247125549 0.999512955 -0.163559115 
MUS81 -0.249320524 0.394675737 0.99287909 -0.531680644 0.261371504 0.99287909 -0.28236012 
CCNA2 -0.465565996 0.191396525 0.999949601 -0.533169747 0.173826648 0.999949601 -0.067603751 
SUPT6H -0.369824995 0.259662653 0.999391397 -0.533852523 0.171471244 0.999391397 -0.164027529 
USP37 -0.630890187 0.138351985 0.999898899 -0.535352006 0.185518057 0.999898899 0.095538181 
RRM1 -1.032482639 0.034982101 0.999991166 -0.537000329 0.206941584 0.999991166 0.49548231 
RTEL1 -0.717936118 0.059114878 0.999998909 -0.537148512 0.123143958 0.999998909 0.180787606 
WRAP53 -0.856791271 0.086903678 0.999668421 -0.539435383 0.206508048 0.999668421 0.317355888 
TOP3A -1.001860485 0.011708291 0.999999999 -0.543032157 0.147739849 0.999999999 0.458828328 
XRCC6 -0.493731367 0.30899219 0.996737637 -0.548909689 0.30899219 0.996737637 -0.055178322 
TRRAP -0.722812973 0.093073137 0.997020082 -0.549214967 0.176588043 0.997020082 0.173598006 
PRKDC -0.662192669 0.214157339 0.997540738 -0.550745767 0.243221648 0.997540738 0.111446902 
H2AFX -0.444842418 0.204068226 0.998820878 -0.550884741 0.16413212 0.998820878 -0.106042324 
CCNH -0.607541695 0.192832043 0.999833994 -0.553776106 0.20405674 0.999833994 0.053765589 
BCCIP -0.799570442 0.076493307 0.998808704 -0.570549457 0.162389922 0.998808704 0.229020985 
ANKRD52 -0.613407251 0.231288577 0.982790897 -0.575989171 0.231288577 0.982790897 0.037418081 
COPS5 -0.528190762 0.189865129 0.999999992 -0.577799119 0.177449129 0.999999992 -0.049608356 
ATR -0.409950543 0.29311123 0.999999984 -0.582986911 0.222781367 0.999999984 -0.173036368 
RPA2 -0.611746352 0.103269561 0.999999998 -0.585976995 0.103269561 0.999999998 0.025769357 
FZR1 -0.833828486 0.046563153 1 -0.586179003 0.113022711 1 0.247649484 
UBA1 -1.044494546 0.009561138 0.99999971 -0.587854726 0.11056439 0.99999971 0.45663982 
DNMT1 -0.700092374 0.099572518 0.999965741 -0.591410006 0.133473953 0.999965741 0.108682367 
MNAT1 -0.645490908 0.157051272 0.999979182 -0.603328955 0.157051272 0.999979182 0.042161953 
RAD51C -0.761398497 0.113616994 0.997588655 -0.604908202 0.152715579 0.997588655 0.156490296 
INO80B -0.595322664 0.204278007 0.998019997 -0.605130526 0.204278007 0.998019997 -0.009807862 
LIG4 -0.719846315 0.089990965 0.997992962 -0.6368925 0.093721735 0.997992962 0.082953815 
XRCC4 -0.822417214 0.091989725 0.983404757 -0.640573753 0.091989725 0.983404757 0.181843462 
NCAPD2 -0.825278566 0.039432398 0.999998189 -0.653554924 0.085051438 0.999998189 0.171723642 
FANCB -0.543948709 0.243223748 0.995133965 -0.656515485 0.233938209 0.995133965 -0.112566777 
DDB1 -0.808233965 0.049577004 1 -0.659886016 0.091273938 1 0.14834795 
RIF1 -0.81251909 0.056789732 0.999998123 -0.662089165 0.079041381 0.999998123 0.150429925 
ERCC1 -0.953958407 0.050180246 0.999920277 -0.663101208 0.122859932 0.999920277 0.290857198 
RAD50 -0.83067853 0.015008192 0.999999891 -0.664566307 0.037270877 0.999999891 0.166112223 
RFC2 -0.70393894 0.139953401 0.999995591 -0.667040553 0.139953401 0.999995591 0.036898388 
UHRF1 -0.85512478 0.088687066 0.99999626 -0.668005213 0.157106615 0.99999626 0.187119568 
RRM2 -0.775229811 0.072519205 0.999998419 -0.672004664 0.103864803 0.999998419 0.103225146 
DSCC1 -0.92511543 0.034456733 0.999994766 -0.680968072 0.104580418 0.999994766 0.244147359 
UBE2N -0.667674535 0.068995853 0.999808198 -0.685292861 0.068995853 0.999808198 -0.017618326 
BOD1L1 -0.598619201 0.141601523 0.999999296 -0.689650975 0.118693167 0.999999296 -0.091031774 
FANCG -0.884314386 0.064052494 0.999845823 -0.689936771 0.097001355 0.999845823 0.194377615 
SMC6 -0.62827312 0.132391657 0.999345574 -0.692233339 0.126184411 0.999345574 -0.063960219 
TRAIP -0.671298382 0.096031914 0.999999649 -0.694102841 0.096031914 0.999999649 -0.022804458 
CUL2 -0.875200656 0.023571088 0.999999866 -0.698554752 0.057999767 0.999999866 0.176645904 
NCAPH -0.606933255 0.102639616 0.99898725 -0.699930989 0.083483881 0.99898725 -0.092997734 
TIMELESS -0.503827473 0.193906466 0.999719417 -0.708976581 0.095802368 0.999719417 -0.205149108 
CDC5L -0.760661737 0.037544845 0.999999994 -0.714861575 0.041418212 0.999999994 0.045800162 
ERCC2 -1.218816117 0.004226068 1 -0.71876319 0.07463958 1 0.500052928 
TINF2 -1.052697794 0.062390672 0.999488823 -0.718827813 0.161866225 0.999488823 0.333869981 
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TERT -1.119248487 0.02682869 0.999994311 -0.724382429 0.095245018 0.999994311 0.394866058 
NONO -0.88124444 0.046848806 0.999999975 -0.72967408 0.078795352 0.999999975 0.15157036 
WAPL -0.636602806 0.159477215 0.99976222 -0.730159163 0.159477215 0.99976222 -0.093556357 
UBE2M -1.011751636 0.065861773 0.99993481 -0.731412428 0.119797607 0.99993481 0.280339207 
POLR2I -0.8634729 0.055039592 0.999989168 -0.737157999 0.082150629 0.999989168 0.126314902 
TOPBP1 -0.80870758 0.031817037 0.999999996 -0.737404821 0.040861579 0.999999996 0.071302759 
RPA1 -0.881774299 0.106025686 0.99954152 -0.744955761 0.113189097 0.99954152 0.136818538 
MCPH1 -0.83176374 0.075980889 0.999999494 -0.744990395 0.091723762 0.999999494 0.086773346 
BAP1 -1.029589117 0.055763061 0.991006485 -0.748150896 0.073380185 0.991006485 0.281438221 
SUPT4H1 -1.00091772 0.040545034 0.999999516 -0.753356508 0.108986745 0.999999516 0.247561211 
POLD1 -0.59733313 0.23555842 0.971842685 -0.7635773 0.180360624 0.971842685 -0.16624417 
MRE11 -0.830435636 0.025047042 0.999979051 -0.76726737 0.026157005 0.999979051 0.063168266 
HUS1 -1.050795745 0.023548946 0.999975309 -0.76941399 0.070467648 0.999975309 0.281381755 
PPM1D -0.818972432 0.056433841 0.999999741 -0.776477356 0.066088169 0.999999741 0.042495076 
MMS22L -0.737394842 0.03248745 0.99993567 -0.781802697 0.03248745 0.99993567 -0.044407855 
POLE2 -0.798156747 0.056564907 0.999980808 -0.782549004 0.056564907 0.999980808 0.015607742 
NCAPG2 -0.5285561 0.165792029 0.999979983 -0.783565264 0.071478728 0.999979983 -0.255009164 
NSMCE1 -0.942989575 0.026233199 0.99991118 -0.789847179 0.04901269 0.99991118 0.153142396 
FANCL -1.147402801 0.028245279 0.999999866 -0.795178247 0.075039619 0.999999866 0.352224554 
RAD51D -0.552894054 0.065205148 0.999999993 -0.812298023 0.01025387 0.999999993 -0.259403969 
USP5 -1.150485989 0.011361343 0.999889437 -0.817007808 0.050377951 0.999889437 0.333478181 
RPA3 -0.872642189 0.035653258 0.999948141 -0.822775077 0.038869502 0.999948141 0.049867112 
SET -0.769576973 0.061630068 0.9998963 -0.828279842 0.057764581 0.9998963 -0.058702869 
BCAS2 -0.744492885 0.04473404 0.999999806 -0.831270247 0.02787142 0.999999806 -0.086777362 
TTI2 -0.992372638 0.027257807 1 -0.844982689 0.044712493 1 0.147389949 
RFC3 -0.934650532 0.054169331 0.999999623 -0.850623585 0.065608785 0.999999623 0.084026948 
PLK1 -0.96255131 0.037840371 0.999800348 -0.852781467 0.060230761 0.999800348 0.109769843 
MAD2L2 -0.958167287 0.04891888 0.999997565 -0.854889164 0.060539348 0.999997565 0.103278123 
NSMCE3 -0.683360615 0.092704172 0.999991203 -0.857143886 0.049769056 0.999991203 -0.173783271 
PNKP -0.80267637 0.039702197 0.999999942 -0.882698709 0.029025251 0.999999942 -0.080022339 
GTF2H5 -1.1004463 0.046745333 0.999989346 -0.885029409 0.089697707 0.999989346 0.215416891 
RPS27L -0.79402782 0.175372193 0.999927292 -0.888757007 0.161479949 0.999927292 -0.094729186 
RAD9A -0.927458863 0.067132826 0.999222767 -0.899193871 0.067132826 0.999222767 0.028264992 
TELO2 -1.172716219 0.013985229 0.999999997 -0.904726878 0.026209223 0.999999997 0.26798934 
SMC3 -0.799894537 0.049865107 0.999896419 -0.904917567 0.031973568 0.999896419 -0.10502303 
STN1 -0.782629209 0.041530494 1 -0.90720345 0.026988165 1 -0.124574241 
MYBBP1A -1.025202232 0.010018794 1 -0.907860429 0.021683468 1 0.117341803 
RAD51 -0.92356063 0.050711825 0.99987961 -0.918172083 0.050711825 0.99987961 0.005388548 
DNA2 -0.928731648 0.081324841 0.997085571 -0.923324836 0.081324841 0.997085571 0.005406812 
CEP57 -0.930663582 0.050797872 0.999999863 -0.923494477 0.050797872 0.999999863 0.007169105 
CDK7 -1.363152748 0.015968789 0.999996104 -0.924442309 0.08089796 0.999996104 0.438710439 
RUVBL2 -1.026203446 0.016083642 0.999999577 -0.926984443 0.021748041 0.999999577 0.099219003 
RNF20 -1.019072896 0.010500752 0.999999519 -0.940470732 0.012461345 0.999999519 0.078602164 
POLE3 -1.136498113 0.016674233 0.999987142 -0.942941383 0.037850299 0.999987142 0.193556729 
NAE1 -0.902197182 0.003232546 0.999999565 -0.945431998 0.002753912 0.999999565 -0.043234815 
DKC1 -1.364076727 0.004014222 1 -0.94665081 0.038135829 1 0.417425917 
PCID2 -1.117308148 0.017776905 0.999999883 -0.948072863 0.038148711 0.999999883 0.169235285 
KAT8 -1.064025104 0.016068004 0.999999975 -0.956548954 0.026863206 0.999999975 0.10747615 
MAU2 -0.759045329 0.065961298 0.999999903 -0.956681973 0.027342485 0.999999903 -0.197636644 
DDX11 -0.702699161 0.099787007 0.999667691 -0.965268804 0.039129554 0.999667691 -0.262569643 
TTI1 -0.981426123 0.035783619 1 -0.971939182 0.035783619 1 0.00948694 
BRD4 -0.978677301 0.00735117 0.999964741 -0.97966693 0.00735117 0.999964741 -9.89629E-04 
THOC1 -1.135449125 0.00467572 1 -0.980254858 0.009298454 1 0.155194267 
ERCC4 -1.17532617 0.021366124 0.999998625 -0.996613955 0.027251309 0.999998625 0.178712215 
TRIP13 -1.157043288 0.018400542 0.999999981 -1.00968538 0.04055486 0.999999981 0.147357908 
XRCC2 -1.428955421 0.001033272 1 -1.039231745 0.014944617 1 0.389723677 
TCEB1 -1.148363345 0.062229635 1 -1.039256167 0.064334891 1 0.109107178 
MMS19 -0.955069116 0.015777023 0.99999986 -1.047373414 0.011497232 0.99999986 -0.092304299 
GPS1 -1.318401276 0.005457301 1 -1.053639719 0.022171922 1 0.264761557 
BRAT1 -1.313133015 0.011780141 1 -1.062487689 0.034624716 1 0.250645326 
THOC2 -0.887437463 0.057304135 1 -1.063706268 0.030945577 1 -0.176268805 
CDK9 -1.244433753 0.014249275 0.999986787 -1.091568735 0.022903835 0.999986787 0.152865019 
POLR2E -0.940954896 0.049066423 0.999997744 -1.097184709 0.030720381 0.999997744 -0.156229814 
ACTL6A -0.883006151 0.034442895 0.999999998 -1.126201443 0.007771734 0.999999998 -0.243195292 
XRCC3 -1.044307076 0.008138937 1 -1.133775622 0.008138937 1 -0.089468546 
WDR48 -0.805916784 0.083168093 0.999368917 -1.137592992 0.019257388 0.999368917 -0.331676209 
SKP1 -1.083960198 0.030424549 0.999801217 -1.147246997 0.027967785 0.999801217 -0.0632868 
NHP2 -1.16013315 0.024016887 1 -1.1522589 0.029844428 1 0.00787425 
GTF2H1 -0.788830166 0.053833741 0.999999996 -1.152725526 0.00674735 0.999999996 -0.36389536 
HUWE1 -1.257218042 0.002142485 0.999999817 -1.205818042 0.003067944 0.999999817 0.0514 
GTF2H3 -1.258468818 0.003311299 1 -1.207175857 0.003468343 1 0.051292961 
TONSL -1.084045325 0.015216284 0.999999969 -1.299648315 0.006929571 0.999999969 -0.21560299 
ERCC3 -1.2986242 0.005283572 0.999999988 -1.30640378 0.005283572 0.999999988 -0.00777958 
UBA2 -1.305414106 0.003216039 1 -1.309865231 0.003216039 1 -0.004451125 
SIN3A -1.271089547 0.001289953 0.999999614 -1.336380532 0.001179733 0.999999614 -0.065290985 
FANCD2 -1.316814696 0.005691331 0.999999968 -1.337736594 0.005691331 0.999999968 -0.020921898 
PPP4C -1.406453222 0.004950314 1 -1.35771761 0.007296962 1 0.048735611 
DDX1 -1.320938371 0.001313713 1 -1.381278713 0.001067527 1 -0.060340342 
TEN1 -2.140373648 9.97E-05 1 -1.422936264 0.006507468 1 0.717437384 
UBE2T -1.655701088 0.00159295 1 -1.433609433 0.002758927 1 0.222091656 
APEX2 -1.562788136 4.97825E-04 1 -1.455040441 0.001166236 1 0.107747694 
PPP6C -1.387606335 2.98722E-04 1 -1.529751089 6.39E-05 1 -0.142144754 
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NELFB -1.261256265 0.00158733 1 -1.551796828 0.00021724 1 -0.290540563 
YBX1 -1.42193616 0.022518939 0.999992389 -1.650778084 0.010570368 0.999992389 -0.228841924 
RFC5 -1.827748116 0.00031227 1 -1.88080396 0.00031227 1 -0.053055844 
TCEB2 -1.694335472 0.005673604 1 -1.933593904 0.002100758 1 -0.239258432 
SOD1 -1.90269645 6.62355E-04 1 -1.958146027 6.62355E-04 1 -0.055449577 
NEDD8 -1.946809783 0.001163337 1 -2.594518288 7.17E-05 1 -0.647708504 
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Appendix Table 8 Raw data from JACKS analysis of combined WRN-/- clones  
JACKS analysis of both RPE-1 WRN-/- knockouts combined. DMSO and 2nM CPT treated 





neg_fdr1 pos_fdr1 Enrichment 
in 2nM CPT 
treated 
neg_fdr2 pos_fdr2 Difference in 
Enrichment 
TP53 3.780649719 1 0 4.882959231 1 0 1.102309512 
CAND1 3.71483349 1 0 2.397332707 1 0 -1.317500784 
KEAP1 2.664762701 1 0 2.375701355 1 0 -0.289061346 
RNF146 2.561658263 1 0 2.018131327 1 0 -0.543526936 
PTEN 2.400244039 1 0 1.284624803 1 0 -1.115619236 
H2AFZ 2.075238905 1 0 1.814288593 1 0 -0.260950312 
CDKN1A 1.981593159 1 0 2.866886267 1 0 0.885293109 
USP28 1.629193356 1 0 1.530397607 1 0 -0.098795749 
THRAP3 1.574434371 1 0 1.261210653 1 1.77E-09 -0.313223719 
DCUN1D3 1.525251596 1 0 1.326244967 1 0 -0.199006629 
MAPKAPK2 1.433026426 1 0 1.22082305 1 3.20E-10 -0.212203376 
HMGB1 1.420952668 0.994845796 0.04638784 0.805133723 0.994845796 0.304018437 -0.615818946 
BRD7 1.414047873 1 0 1.397732382 1 1.15E-13 -0.016315491 
SCAF4 1.380476377 1 0 0.581517162 1 9.32560E-04 -0.798959214 
RNF7 1.3766905 1 0 1.048062627 1 1.50E-11 -0.328627873 
CUL3 1.351041982 1 0 0.973057337 1 1.12E-12 -0.377984645 
CUL5 1.345666481 1 0 1.158972336 1 7.21E-11 -0.186694146 
PHIP 1.326156713 1 0 0.843872759 1 3.96E-06 -0.482283954 
UBE2F 1.308285667 1 0 0.954460831 1 1.36E-08 -0.353824836 
DCUN1D1 1.211584188 0.999999878 1.10E-06 0.853288222 0.999999878 0.001247478 -0.358295966 
UBE2R2 1.147405648 1 1.80E-14 0.958229954 1 1.08E-08 -0.189175694 
CHEK2 1.14285313 1 1.50E-14 1.668447564 1 0 0.525594434 
GTF2H2 1.107164199 0.983875327 0.145122058 0.623143049 0.983875327 0.298260716 -0.484021151 
SENP8 1.096096436 1 6.02E-10 0.556490357 1 0.010517296 -0.539606079 
MDM2 1.077640404 0.999296181 0.004918483 1.012205373 0.999296181 0.004918483 -0.06543503 
TP53BP1 1.076412296 1 8.99E-15 1.143918732 1 2.70E-12 0.067506437 
ATM 1.070934019 1 2.20E-14 0.190049773 1 0.179495883 -0.880884246 
BABAM1 1.059587988 1 9.09E-14 0.93035329 1 2.51E-09 -0.129234698 
BCLAF1 1.056312331 1 2.58E-09 0.74306358 1 1.33712E-04 -0.313248751 
ARID2 1.026393204 1 1.72E-11 1.141843247 1 5.66E-10 0.115450042 
STAG2 0.925733828 0.999999998 1.68E-08 0.681305843 0.999999998 5.51359E-04 -0.244427985 
SPTBN1 0.92352555 1 1.18E-11 0.799794767 1 7.57E-08 -0.123730783 
TET2 0.868679723 0.999998163 1.65E-05 0.734337162 0.999998163 4.93467E-04 -0.134342561 
UBE2K 0.86602612 1 5.33E-10 0.911106868 1 9.30E-09 0.045080748 
RING1 0.860412284 1 3.16E-10 0.681559998 1 1.27E-05 -0.178852286 
EP300 0.858144239 1 2.69E-09 0.545855075 1 0.001349538 -0.312289164 
USP15 0.856921972 1 2.26E-09 0.705523916 1 1.28E-05 -0.151398056 
APC 0.848068732 1 9.15E-13 0.852200408 1 5.15E-09 0.004131676 
HDAC9 0.843939239 0.999999739 2.35E-06 0.589104319 0.999999739 0.002259987 -0.25483492 
PBRM1 0.838419351 1 5.26E-10 1.153112979 1 4.16E-12 0.314693628 
BRCC3 0.83648652 0.99999999 8.91E-08 0.557806123 0.99999999 0.003909831 -0.278680397 
SHFM1 0.804097548 0.999991064 9.83826E-04 1.05601668 0.999991064 8.04E-05 0.251919132 
SWI5 0.753642647 0.998147498 0.016672518 0.677646015 0.998147498 0.017408436 -0.075996632 
GADD45G 0.747285192 0.999993748 3.24E-05 0.866979208 0.999993748 3.24E-05 0.119694016 
RRM2B 0.743096063 0.999997564 2.19E-05 0.760344611 0.999997564 5.17E-05 0.017248548 
ALKBH1 0.720454955 0.999961205 3.49156E-04 0.63961773 0.999961205 0.001822755 -0.080837225 
BRE 0.720307951 0.999999447 4.98E-06 0.584352947 0.999999447 4.65350E-04 -0.135955004 
NonTargetingC
ontrolGene_55 
0.70259513 0.99999849 1.36E-05 0.65319339 0.99999849 1.34198E-04 -0.04940174 
NonTargetingC
ontrolGene_39 
0.692004312 0.999999994 5.83E-08 0.698904228 0.999999994 1.21E-05 0.006899916 
NonTargetingC
ontrolGene_11 
0.67753482 0.999999893 9.60E-07 0.604846657 0.999999893 9.67E-05 -0.072688163 
NonTargetingC
ontrolGene_57 
0.674066369 0.999999992 7.33E-08 0.685819306 0.999999992 2.88E-06 0.011752936 
CDKN2A 0.666188865 0.999994328 5.11E-05 0.564315547 0.999994328 0.002634496 -0.101873318 
FBXW7 0.665627843 0.999999997 2.26E-08 0.584264808 0.999999997 4.52E-06 -0.081363036 
SMARCC1 0.660232787 0.999999991 4.92E-05 1.063346715 0.999999991 8.23E-08 0.403113928 
GPI 0.655552422 0.999992441 6.80E-05 0.76658223 0.999992441 7.11E-05 0.111029807 
PMP22 0.639085119 0.999994455 4.99E-05 0.587115184 0.999994455 0.001038143 -0.051969934 
NonTargetingC
ontrolGene_53 
0.636888948 0.999999492 4.57E-06 0.55023286 0.999999492 6.42542E-04 -0.086656088 
KMT B 0.626968491 0.999968266 2.00202E-04 0.734895267 0.999968266 2.00202E-04 0.107926776 
DCUN1D5 0.624999801 0.999889397 9.95428E-04 0.601770462 0.999889397 0.002315351 -0.023229339 
TRIP12 0.62444937 0.999977382 2.03559E-04 0.369383832 0.999977382 0.080042355 -0.255065539 
POLD3 0.621145838 0.999843055 0.0116702 1.035401475 0.999843055 0.001412508 0.414255637 
DMC1 0.621051635 0.999556483 0.00399165 0.595023953 0.999556483 0.006828284 -0.026027682 
LIG3 0.620940502 0.999904028 8.32202E-04 0.632635319 0.999904028 8.32202E-04 0.011694817 
NonTargetingC
ontrolGene_29 
0.618577823 0.999999932 6.14E-07 0.683543433 0.999999932 1.23E-05 0.06496561 
NonTargetingC
ontrolGene_77 
0.617473452 0.99999303 5.09E-05 0.690088401 0.99999303 5.09E-05 0.072614949 
CDKN1B 0.61709428 0.999985514 1.30372E-04 0.577411957 0.999985514 0.001065661 -0.039682322 
NonTargetingC
ontrolGene_65 
0.612021749 0.999999721 9.86E-05 0.867697389 0.999999721 2.51E-06 0.255675639 
HNRNPUL2 0.610040971 0.999853973 0.001095076 0.691219338 0.999853973 0.001095076 0.081178367 
CCND2 0.605520818 0.999700615 0.002694468 0.550500518 0.999700615 0.016504253 -0.055020301 
BTG2 0.604172203 0.999849211 0.001357102 0.558642667 0.999849211 0.006648606 -0.045529536 
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SUPT5H 0.599016965 0.999366891 0.043557499 0.383837843 0.999366891 0.165792744 -0.215179121 
POLK 0.595002737 0.999979036 1.88678E-04 0.497133746 0.999979036 0.004474451 -0.097868991 
NonTargetingC
ontrolGene_31 
0.593831844 0.999998311 1.52E-05 0.501258018 0.999998311 0.001617568 -0.092573826 
ABL 0.593230388 0.999996573 3.08E-05 0.459653883 0.999996573 0.003047945 -0.133576505 
MLH3 0.593204773 0.999862757 0.002090355 0.752323181 0.999862757 0.001235189 0.159118408 
NonTargetingC
ontrolGene_21 
0.585254329 0.999999634 1.22E-05 0.763611874 0.999999634 3.29E-06 0.178357545 
SF3B  0.579396337 0.985254946 0.055963987 0.612393346 0.985254946 0.055963987 0.032997009 
NonTargetingC
ontrolGene_73 
0.577477456 0.999988159 1.06571E-04 0.55961053 0.999988159 9.89499E-04 -0.017866926 
NonTargetingC
ontrolGene_62 
0.577379538 0.999944922 4.95698E-04 0.635084653 0.999944922 6.02202E-04 0.057705115 
APOBEC  0.572565752 0.999739009 0.002348917 0.574366439 0.999739009 0.019162219 0.001800686 
MAPK8 0.566340281 0.999525364 0.004271726 0.46250209 0.999525364 0.023054877 -0.103838191 
NonTargetingC
ontrolGene_15 
0.566209689 0.999989034 6.56E-05 0.636497585 0.999989034 6.56E-05 0.070287896 
APAF1 0.564224284 0.999769105 0.002078053 0.465141959 0.999769105 0.027624344 -0.099082325 
ALKBH3 0.562823813 0.999874058 0.001002856 0.588225467 0.999874058 0.001002856 0.025401653 
NonTargetingC
ontrolGene_61 
0.553759191 0.999998025 2.24E-05 0.681089059 0.999998025 1.78E-05 0.127329867 
OPRM 0.552603887 0.999960465 3.55817E-04 0.58495829 0.999960465 4.25577E-04 0.032354403 
CCNC 0.546436096 0.999898713 9.11581E-04 0.498547821 0.999898713 0.005136349 -0.047888275 
DTX4 0.545644156 0.999941958 5.22375E-04 0.361762644 0.999941958 0.039358656 -0.183881511 
PML 0.545069654 0.999831852 9.13534E-04 0.651063165 0.999831852 9.13534E-04 0.105993511 
POLM 0.540611668 0.999967463 2.92833E-04 0.35615257 0.999967463 0.066705271 -0.184459098 
COPS7A 0.540010627 0.999970404 2.13912E-04 0.635992245 0.999970404 2.13912E-04 0.095981618 
RNF138 0.534510623 0.999989483 9.47E-05 0.459899632 0.999989483 0.004480214 -0.074610991 
CSNK2A2 0.532594871 0.999868116 0.001186958 0.544573956 0.999868116 0.003030681 0.011979086 
POLR2J 0.532341188 0.996488758 0.031601176 0.351443951 0.996488758 0.151021882 -0.180897237 
APLF 0.529142949 0.999572699 0.003845712 0.347901121 0.999572699 0.140914785 -0.181241828 
NonTargetingC
ontrolGene_75 
0.529023829 0.999991775 5.93E-05 0.562528026 0.999991775 5.93E-05 0.033504198 
RNF111 0.525412441 0.999944988 4.95109E-04 0.516009999 0.999944988 0.004738232 -0.009402442 
HMGB2 0.522127063 0.999925107 6.74039E-04 0.399134148 0.999925107 0.023984364 -0.122992915 
NonTargetingC
ontrolGene_13 
0.52075134 0.99991058 8.04781E-04 0.525905224 0.99991058 0.003421882 0.005153884 
UBB 0.519589051 0.998261617 0.015645446 0.459802721 0.998261617 0.034310504 -0.059786329 
NonTargetingC
ontrolGene_80 
0.516617099 0.99999086 8.23E-05 0.434920375 0.99999086 0.005591504 -0.081696724 
NonTargetingC
ontrolGene_5 
0.505012743 0.999999115 7.96E-06 0.5327731 0.999999115 4.29E-05 0.027760358 
NonTarg tingC
ontrolGene_17 
0.503587214 0.999962639 2.70110E-04 0.539397878 0.999962639 2.70110E-04 0.035810664 
USP51 0.501717557 0.999505252 0.004452736 0.360309703 0.999505252 0.114374938 -0.141407854 
RAP1A 0.500532375 0.998612783 0.011681693 0.536763786 0.998612783 0.011681693 0.03623141 
ASCC1 0.49811437 0.999128493 0.00594499 0.384261298 0.999128493 0.033274023 -0.113853071 
ADH5 0.497604805 0.997682785 0.020854938 0.433824815 0.997682785 0.075431164 -0.06377999 
UBE2V2 0.495062267 0.999897557 0.008744066 0.709706194 0.999897557 9.21987E-04 0.214643927 
MUM1 0.492953984 0.998613554 0.012478017 0.404227019 0.998613554 0.079069859 -0.088726965 
NonTargetingC
ontrolGene_44 
0.488759769 0.999913624 7.77386E-04 0.465584214 0.999913624 0.002495472 -0.023175555 
PPP6R3 0.488312575 0.99966489 0.00301599 0.545409792 0.99966489 0.005075611 0.057097217 
NonTargetingC
ontrolGene_32 
0.487240044 0.999981145 2.81435E-04 0.603360524 0.999981145 1.69695E-04 0.11612048 
RNF  0.486421736 0.999627895 0.003348943 0.397403402 0.999627895 0.044668243 -0.089018334 
NonTargetingC
ontrolGene_33 
0.484884898 0.9999448 4.23622E-04 0.528295185 0.9999448 4.23622E-04 0.043410286 
PRMT6 0.483663265 0.998934623 0.009588391 0.359151993 0.998934623 0.101765205 -0.124511273 
SIRT7 0.482690951 0.999664558 0.008296838 0.679147777 0.999664558 0.00301898 0.196456826 
NonTargetingC
ontrolGene_72 
0.480336807 0.99994745 4.72952E-04 0.39963753 0.99994745 0.007824834 -0.080699277 
PARP14 0.475955977 0.999626837 0.003226101 0.546448914 0.999626837 0.003226101 0.070492937 
CIB1 0.475729751 0.992548413 0.025260605 0.510048948 0.992548413 0.025260605 0.034319197 
PER2 0.47495386 0.999727149 0.00339372 0.638425871 0.999727149 0.002455659 0.163472011 
APOBEC3B 0.471566128 0.999967008 2.96928E-04 0.344691696 0.999967008 0.029337291 -0.126874432 
NonTargetingC
ontrolGene_20 
0.469784036 0.999975913 2.16780E-04 0.48839396 0.999975913 0.001041003 0.018609924 
NonTargetingC
ontrolGene_50 
0.465077379 0.999974703 2.25329E-04 0.555771499 0.999974703 2.25329E-04 0.09069412 
NEK9 0.464138712 0.99995695 3.87452E-04 0.392599903 0.99995695 0.005484981 -0.071538808 
MTA2 0.459937769 0.999859602 9.21074E-04 0.549706268 0.999859602 9.21074E-04 0.089768499 
NonTargetingC
ontrolGene_14 
0.45962608 0.999963084 0.00114248 0.5735945 0.999963084 3.32241E-04 0.11396842 
CUL4B 0.458145133 0.99947849 0.02373075 0.627326828 0.99947849 0.00469359 0.169181694 
KDM4D 0.457881597 0.999517962 0.004285615 0.546130405 0.999517962 0.004285615 0.088248808 
L3MBTL1 0.448549201 0.999081574 0.008265831 0.438369968 0.999081574 0.025714311 -0.010179234 
UBE2D1 0.446005868 0.999939613 3.71956E-04 0.532087137 0.999939613 3.71956E-04 0.086081269 
DTX3 0.445993898 0.999520968 0.004311289 0.462618887 0.999520968 0.004929058 0.016624989 
RAD54L2 0.441613523 0.99939853 0.005413231 0.366415641 0.99939853 0.077274196 -0.075197882 
PARP4 0.441207455 0.999779181 0.003532065 0.588376143 0.999779181 0.001987368 0.147168688 
SPO11 0.440523093 0.999054627 0.008508354 0.39419453 0.999054627 0.03058186 -0.046328562 
DCLRE1C 0.439258507 0.999665045 0.003014598 0.511329958 0.999665045 0.003039399 0.072071452 
SMARCD1 0.439054503 0.999812917 8.99585E-04 0.477127937 0.999812917 8.99585E-04 0.038073433 
GADD45A 0.438377593 0.999990609 3.44089E-04 0.58719145 0.999990609 8.45E-05 0.148813857 
ATXN7 0.438054318 0.999322392 0.006098476 0.234934797 0.999322392 0.185430777 -0.203119521 
NonTargetingC
ontrolGene_10 
0.435850165 0.999960589 3.54701E-04 0.294254513 0.999960589 0.074023295 -0.141595652 
PPP4R4 0.434472337 0.999944276 5.01513E-04 0.333106255 0.999944276 0.020397537 -0.101366083 
CUL7 0.433422121 0.999988816 0.012468535 0.63763587 0.999988816 1.00655E-04 0.204213749 
MAPK14 0.432621729 0.999999645 0.031913612 1.051226212 0.999999645 3.19E-06 0.618604483 
NonTargetingC
ontrolGene_66 
0.432438554 0.999534742 0.004187319 0.470671385 0.999534742 0.004846813 0.038232831 
ENDOV 0.431718755 0.999296873 0.05576269 0.706112442 0.999296873 0.004744135 0.274393687 
PHF3 0.429249272 0.999371961 0.005652352 0.24354206 0.999371961 0.143769059 -0.185707212 
ETAA1 0.425787409 0.999902643 8.76214E-04 0.460235881 0.999902643 0.001088294 0.034448472 
PARPBP 0.424973272 0.997597669 0.015217751 0.451113463 0.997597669 0.015217751 0.026140191 
TOP3B 0.424643615 0.997428561 0.014521913 0.453857253 0.997428561 0.014521913 0.029213638 
NonTargetingC
ontrolGene_46 
0.424113318 0.999895055 9.44504E-04 0.24491873 0.999895055 0.148125069 -0.179194588 
NonTargetingC
ontrolGene_58 
0.422820494 0.999971942 2.52520E-04 0.469815113 0.999971942 4.41038E-04 0.046994619 
SSBP3 0.421469778 0.993437983 0.043362548 0.443163633 0.993437983 0.043362548 0.021693855 
UBE2V1 0.420652204 0.994675609 0.047919518 0.401848007 0.994675609 0.098856355 -0.018804197 
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SCAI 0.420522941 0.999862613 8.99863E-04 0.47343267 0.999862613 8.99863E-04 0.052909728 
NonTargetingC
ontrolGene_18 
0.420055402 0.999971612 3.34138E-04 0.534444927 0.999971612 2.55488E-04 0.114389524 
CSNK D 0.419082963 0.998727585 0.008019149 0.392565503 0.998727585 0.008019149 -0.02651746 
OR1E1 0.413202416 0.985974094 0.126233158 0.211729227 0.985974094 0.248132441 -0.201473189 
NonTargetingC
ontrolGene_36 
0.411416588 0.999854713 0.001307583 0.407017463 0.999854713 0.011271617 -0.004399126 
PRKCG 0.410102594 0.999019977 0.00464534 0.426009496 0.999019977 0.00464534 0.015906902 
CDC25A 0.408003566 0.999910282 0.008634941 0.637391526 0.999910282 8.07461E-04 0.229387961 
NonTargetingC
ontrolGene_23 
0.40757624 0.999695194 0.002743251 0.455177167 0.999695194 0.002987649 0.047600927 
DCUN1D4 0.40680066 0.997906465 0.018841813 0.28593611 0.997906465 0.173372281 -0.12086455 
DTX3L 0.405785974 0.99393549 0.054580589 0.31124357 0.99393549 0.218128527 -0.094542404 
ATXN3 0.404211008 0.999887003 0.001016977 0.398205588 0.999887003 0.00727392 -0.00600542 
NonTargetingC
ontrolGene_27 
0.397068013 0.99983586 0.001477259 0.330735188 0.99983586 0.013059877 -0.066332825 
NonTargetingC
ontrolGene_52 
0.396289499 0.999823905 0.001584858 0.408618897 0.999823905 0.001635808 0.012329398 
SMC1B 0.395636349 0.999741633 0.002325299 0.268317428 0.999741633 0.179939828 -0.127318922 
DNTT 0.395335601 0.999905117 0.021585552 0.669130393 0.999905117 8.53944E-04 0.273794792 
PARP15 0.392727398 0.998960655 0.009475103 0.490895442 0.998960655 0.009354107 0.098168044 
COPS7B 0.392335746 0.999189187 0.007297314 0.30570364 0.999189187 0.093333243 -0.086632105 
USP13 0.391000319 0.999322517 0.005109626 0.484376913 0.999322517 0.005109626 0.093376595 
NonTargetingC
ontrolGene_30 
0.389232728 0.999748986 0.002259127 0.344988384 0.999748986 0.031354421 -0.044244344 
SIRT2 0.388601478 0.996559267 0.030678412 0.526506191 0.996559267 0.030678412 0.137904713 
EME2 0.388490505 0.998886994 0.052980102 0.694460128 0.998886994 0.01001705 0.305969623 
NonTargetingC
ontrolGene_25 
0.388253539 0.999838243 0.00125695 0.474133612 0.999838243 0.00125695 0.085880073 
HUS1B 0.388115183 0.999041355 0.004398793 0.434485439 0.999041355 0.004398793 0.046370256 
FAM175A 0.387743296 0.987271407 0.093731501 0.427498771 0.987271407 0.093731501 0.039755475 
CSNK1E 0.385829527 0.996433343 0.0209335 0.414738216 0.996433343 0.0209335 0.028908689 
MBD4 0.38429344 0.99826714 0.01559574 0.286849987 0.99826714 0.124263594 -0.097443453 
NonTargetingC
ontrolGene_68 
0.382843694 0.999257052 0.004565265 0.435331252 0.999257052 0.004565265 0.052487558 
CCND3 0.381878377 0.99943543 0.00508113 0.368383988 0.99943543 0.014618537 -0.01349439 
NonTargetingC
ontrolGene_40 
0.381707216 0.999499894 0.004500951 0.383985712 0.999499894 0.012446087 0.002278496 
VCP 0.380663469 0.999408308 0.115960073 0.445378003 0.999408308 0.115960073 0.064714534 
PARP9 0.380135273 0.997612841 0.02148443 0.292829225 0.997612841 0.116161208 -0.087306048 
NABP2 0.379958104 0.995463463 0.040828833 0.401198838 0.995463463 0.053278296 0.021240734 
KMT5C 0.377729386 0.999795972 0.002133781 0.468576244 0.999795972 0.00183625 0.090846858 
PARP3 0.377534789 0.999043034 0.008612698 0.364711571 0.999043034 0.014761129 -0.012823218 
TPP1 0.374375486 0.998535295 0.033884411 0.52196074 0.998535295 0.013182345 0.147585254 
RASSF7 0.373452444 0.997777622 0.016291481 0.478504465 0.997777622 0.016291481 0.105052021 
NonTargetingC
ontrolGene_16 
0.373050855 0.997641235 0.021228882 0.355295326 0.997641235 0.037950373 -0.017755529 
HMGN1 0.372967155 0.991290138 0.07502529 0.494512239 0.991290138 0.07502529 0.121545084 
NonTargetingC
ontrolGene_76 
0.371211128 0.998182876 0.016354114 0.204345213 0.998182876 0.282525502 -0.166865915 
NonTargetingC
ontrolGene_34 
0.371181524 0.99906883 0.008380531 0.332940118 0.99906883 0.030198034 -0.038241405 
NonTargetingC
ontrolGene_45 
0.370487942 0.999896743 0.004318142 0.487847147 0.999896743 9.29316E-04 0.117359206 
BRCA2 0.370112981 0.996405184 0.042518312 0.315360738 0.996405184 0.056377273 -0.054752243 
NonTargetingC
ontrolGene_74 
0.367605282 0.998153711 0.01006237 0.403316133 0.998153711 0.01006237 0.035710851 
NonTargetingC
ontrolGene_28 
0.36658831 0.999427371 0.005153663 0.298052854 0.999427371 0.086884385 -0.068535456 
MORF4L1 0.363938231 0.994177809 0.067987997 0.486329144 0.994177809 0.052399719 0.122390913 
NonTargetingC
ontrolGene_54 
0.362734997 0.999049499 0.006297343 0.406441463 0.999049499 0.006297343 0.043706465 
KLHL15 0.360490538 0.992613477 0.066478705 0.37644078 0.992613477 0.0844281 0.015950242 
ERCC6L 0.358707564 0.995790705 0.213520175 0.049922004 0.995790705 0.555695391 -0.30878556 
NonTargetingC
ontrolGene_35 
0.357578289 0.999245228 0.003725956 0.424121648 0.999245228 0.003725956 0.066543359 
XPA 0.357339003 0.993392091 0.059471178 0.141780998 0.954356687 0.428896985 -0.215558005 
HNRNPK 0.356378549 0.998457502 0.261427864 -0.015565502 0.998457502 0.62563868 -0.371944051 
NonTargetingC
ontrolGene_1 
0.355844712 0.999451714 0.004934576 0.334330826 0.999451714 0.023971943 -0.021513886 
USP20 0.355692311 0.997002414 0.026978272 0.286162769 0.997002414 0.162864684 -0.069529542 
APBB1 0.355131855 0.998373594 0.014637654 0.354006385 0.998373594 0.015964916 -0.00112547 
CETN2 0.35460406 0.995655769 0.039098081 0.068307935 0.995655769 0.37745133 -0.286296125 
SIRT5 0.354220257 0.999831869 0.013453383 0.516763721 0.999831869 0.00151318 0.162543464 
BMI1 0.352369933 0.997754667 0.020207996 0.204463573 0.997754667 0.308308753 -0.14790636 
DCLRE1A 0.351353819 0.999578127 0.037537926 0.635528611 0.999578127 0.003796861 0.284174792 
NonTargetingC
ontrolGene_22 
0.350770169 0.998830219 0.010528025 0.271999942 0.998830219 0.092824935 -0.078770227 
MTA3 0.348877561 0.998930186 0.028972608 0.497897982 0.998930186 0.009628326 0.149020422 
NonTargetingC
ontrolGene_42 
0.348404496 0.999344463 0.005899834 0.358950532 0.999344463 0.012576335 0.010546036 
WRNIP1 0.34775209 0.995688479 0.038803687 0.279885654 0.995688479 0.068674602 -0.067866436 
EID3 0.345537235 0.993920362 0.033445914 0.454098837 0.993920362 0.033445914 0.108561601 
NonTargetingC
ontrolGene_6 
0.345091361 0.999346524 0.005881284 0.352098914 0.999346524 0.014500667 0.007007552 
SSBP2 0.344780471 0.999223979 0.005553309 0.440524355 0.999223979 0.005553309 0.095743884 
SETDB1 0.338835545 0.99959465 0.025967371 0.530761453 0.99959465 0.003648154 0.191925909 
NonTargetingC
ontrolGene_70 
0.336333096 0.999028141 0.008746729 0.373952829 0.999028141 0.011058207 0.037619733 
FAN1 0.334292717 0.997111193 0.04354769 0.445414878 0.997111193 0.025999263 0.111122161 
NonTargetingC
ontrolGene_12 
0.33273271 0.995789702 0.03789268 0.317835317 0.995789702 0.064401746 -0.014897393 
NonTargetingC
ontrolGene_69 
0.332020731 0.998422901 0.014193895 0.235994229 0.998422901 0.167837849 -0.096026502 
FBXO18 0.331325496 0.999245999 0.016078336 0.446257693 0.999245999 0.006786008 0.114932198 
NonTargetingC
ontrolGene_4 
0.330069122 0.998153433 0.008364475 0.400529292 0.998153433 0.008364475 0.07046017 
NonTarg tingC
ontrolGene_19 
0.327650085 0.998943602 0.007157745 0.391017486 0.998943602 0.007157745 0.063367401 
XPC 0.326291855 0.991484933 0.073349615 0.363972356 0.991484933 0.073349615 0.037680501 
NonTargetingC
ontrolGene_78 
0.325914855 0.999117535 0.007942183 0.380848028 0.999117535 0.009004957 0.054933173 
TEP1 0.324913872 0.9949726 0.039248942 0.273729046 0.9949726 0.060813472 -0.051184827 
APOBEC3C 0.322713832 0.995992372 0.024509088 0.341754004 0.995992372 0.024509088 0.019040172 
SMARCC2 0.322416404 0.997555566 0.035640779 0.414638668 0.997555566 0.021999903 0.092222264 
NonTargetingC
ontrolGene_24 
0.322082532 0.998717176 0.011545412 0.193601174 0.998717176 0.224472566 -0.128481358 
NonTargetingC
ontrolGene_49 
0.320907077 0.998539304 0.010744462 0.391545649 0.998539304 0.010744462 0.070638572 
ASF1A 0.319272519 0.992322994 0.052847818 0.281847308 0.992322994 0.078059183 -0.037425211 
PER1 0.31881728 0.990077097 0.046747196 0.370799589 0.990077097 0.046747196 0.051982309 
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POLN 0.318643353 0.999765812 0.036343344 0.53615097 0.999765812 0.002107696 0.217507617 
USP47 0.318408794 0.996708864 0.029620225 0.2157136 0.996708864 0.287164197 -0.102695194 
MGMT 0.317540213 0.992856975 0.099133255 0.455019015 0.992856975 0.064287229 0.137478802 
NOTCH1 0.316544751 0.99799131 0.018078207 0.333733918 0.99799131 0.029665091 0.017189167 
NonTargetingC
ontrolGene_7 
0.31491605 0.993980969 0.047783905 0.39284619 0.993980969 0.047783905 0.07793014 
TRIM29 0.31386602 0.983559316 0.100666804 0.33745407 0.983559316 0.100666804 0.02358805 
DCUN1D2 0.312723456 0.984290555 0.141385004 0.177600562 0.967274579 0.312938999 -0.135122894 
XRCC5 0.309914669 0.986959415 0.107422336 0.323023533 0.986959415 0.107422336 0.013108863 
NEK8 0.309596514 0.999004224 0.042093234 0.474675121 0.999004224 0.008961985 0.165078608 
KAT2B 0.307057539 0.998273194 0.028104344 0.389908742 0.998273194 0.015541253 0.082851204 
NonTargetingC
ontrolGene_47 
0.306757887 0.99765574 0.021098336 0.310791598 0.99765574 0.04698073 0.004033711 
RAD5 B 0.304162007 0.984425058 0.140174476 0.274528116 0.984425058 0.177073626 -0.029633892 
NonTargetingC
ontrolGene_79 
0.302522343 0.999287288 0.006414411 0.311348573 0.999287288 0.014131042 0.008826231 
WHSC1 0.302353485 0.984510192 0.139408268 0.216286702 0.984510192 0.413699041 -0.086066783 
CHFR 0.301523902 0.999662265 0.153952361 0.615694513 0.999662265 0.003039611 0.314170611 
NEIL1 0.301168815 0.967157443 0.189189276 0.265750256 0.967157443 0.189189276 -0.03541856 
HFM1 0.30109423 0.993815046 0.055664585 0.217983263 0.993815046 0.251415801 -0.083110967 
APEX1 0.300810019 0.986387666 0.065603277 0.360220973 0.986387666 0.065603277 0.059410954 
RECQL 0.298974779 0.991266977 0.078597211 0.140569235 0.991266977 0.2470642 -0.158405544 
CDKN2D 0.298209479 0.997688613 0.042023876 0.437850069 0.997688613 0.020802479 0.13964059 
RAD18 0.298142599 0.998249125 0.050929143 0.450371639 0.998249125 0.015757876 0.15222904 
OTUB2 0.297765795 0.999750694 0.037376045 0.548732809 0.999750694 0.002243756 0.250967013 
NonTargetingC
ontrolGene_26 
0.295640379 0.999829527 0.034993675 0.528281388 0.999829527 0.001534256 0.232641009 
INO80D 0.293555004 0.995796808 0.030140106 0.374182358 0.995796808 0.030140106 0.080627354 
CCNB3 0.293298687 0.999788155 0.022138254 0.456908576 0.999788155 0.001906605 0.16360989 
HELB 0.29299867 0.99823044 0.106849088 0.538636834 0.99823044 0.015926043 0.245638164 
CHD1L 0.292987055 0.999838881 0.073850499 0.5300549 0.999838881 0.001450073 0.237067845 
UBE2W 0.292891339 0.991327705 0.029563568 0.364210194 0.991327705 0.029246599 0.071318855 
NonTargetingC
ontrolGene_43 
0.29231445 0.997856576 0.03606656 0.392809727 0.997856576 0.019290817 0.100495276 
SETX 0.291782851 0.956660985 0.104585117 0.317566368 0.956660985 0.104585117 0.025783517 
SUV39H2 0.2903352 0.994902355 0.045878801 0.290941911 0.994902355 0.061952346 6.06712E-04 
SETMAR 0.290158846 0.987364155 0.113722601 0.265677857 0.987364155 0.185355033 -0.024480989 
SUMO3 0.284507942 0.994900124 0.058241085 0.414948814 0.994900124 0.045898881 0.130440871 
H2AFY 0.284487746 0.985621785 0.147696522 0.36418835 0.985621785 0.129403932 0.079700604 
APOBEC3D 0.283831042 0.974141819 0.179150259 0.298232319 0.974141819 0.179150259 0.014401276 
RBM7 0.282116241 0.988203047 0.063805676 0.306439256 0.988203047 0.063805676 0.024323015 
CCNO 0.281015056 0.98679286 0.11886426 0.340015929 0.98679286 0.175819175 0.059000873 
ATF2 0.27989972 0.990828682 0.045309388 0.325797682 0.990828682 0.045309388 0.045897962 
NOTCH3 0.279051841 0.994536715 0.049169561 0.237636011 0.994536715 0.114422057 -0.04141583 
NonTargetingC
ontrolGene_63 
0.278342969 0.995299415 0.042305269 0.207110735 0.995299415 0.196013782 -0.071232233 
SIRT1 0.278034755 0.999600581 0.081784444 0.469954879 0.999600581 0.003594773 0.191920124 
NBN 0.276836002 0.987415375 0.113261628 -0.060881643 0.724451774 0.937556694 -0.337717644 
CHD3 0.273891523 0.991912216 0.048094907 0.436939112 0.991912216 0.028208578 0.16304759 
MBTD1 0.273463496 0.982125174 0.160873438 0.222705313 0.982125174 0.290413856 -0.050758182 
DDB2 0.2731059 0.968589624 0.160772799 0.273755276 0.968589624 0.160772799 6.49376E-04 
RHNO1 0.270739638 0.976984352 0.179474098 0.389184167 0.976984352 0.179474098 0.11844453 
SALL4 0.269472786 0.991028909 0.066567689 0.342949621 0.991028909 0.066567689 0.073476835 
EYA1 0.268738498 0.990056724 0.085153923 0.195426153 0.990056724 0.132520655 -0.073312345 
SCAF11 0.26811892 0.986336654 0.065113885 0.079104103 0.986336654 0.377734284 -0.189014818 
HDAC10 0.267719267 0.997973562 0.059408089 0.428646326 0.997973562 0.018237943 0.160927059 
CHTF18 0.267446266 0.982124975 0.268635277 0.418264792 0.982124975 0.160875227 0.150818525 
CCNB2 0.264641371 0.989274411 0.06775385 0.304612589 0.989274411 0.06775385 0.039971218 
PIAS2 0.264414624 0.972756723 0.160096169 0.272418686 0.972756723 0.160096169 0.008004062 
EXD2 0.260114925 0.986875983 0.118116153 0.11481086 0.986875983 0.445430619 -0.145304065 
ALDH2 0.258837975 0.97275521 0.153001844 0.288262464 0.97275521 0.153001844 0.029424489 
ALKBH2 0.255972649 0.987312972 0.123447394 0.411091039 0.987312972 0.11418325 0.15511839 
UBE2B 0.255472975 0.967780942 0.289971524 0.233775701 0.967780942 0.304857666 -0.021697274 
NFATC2IP 0.252042261 0.947512601 0.218206324 0.121382344 0.947512601 0.275703548 -0.130659917 
NonTargetingC
ontrolGene_71 
0.248729409 0.990797611 0.082821504 0.251502022 0.990797611 0.09384638 0.002772613 
IP6K3 0.24869553 0.985510177 0.261311076 0.366627851 0.985510177 0.130408409 0.117932321 
USP26 0.247892988 0.977805328 0.149971481 0.264518575 0.977805328 0.149971481 0.016625587 
RNF126 0.246198189 0.98261248 0.109412227 0.251276394 0.98261248 0.164481931 0.005078205 
UBE2A 0.246079362 0.966338213 0.202457118 0.226299418 0.966338213 0.215018048 -0.019779944 
SENP2 0.246070925 0.974847315 0.146240917 0.264530422 0.974847315 0.146240917 0.018459497 
POLB 0.244658146 0.978148625 0.174796863 0.265622816 0.978148625 0.174796863 0.02096467 
UCHL3 0.24363087 0.990060866 0.101431848 0.374510574 0.990060866 0.089452209 0.130879705 
MSH4 0.242499292 0.993583438 0.109662339 0.354194538 0.993583438 0.057749062 0.111695246 
ANKRD44 0.242222142 0.998536699 0.082898651 0.391287426 0.998536699 0.013169709 0.149065284 
PARK7 0.242084991 0.994823768 0.093968135 0.397829964 0.994823768 0.046586084 0.155744973 
PRIMPOL 0.242040708 0.97661071 0.210503611 0.17725626 0.97661071 0.334150094 -0.064784448 
HPF1 0.241950447 0.95693271 0.387605613 -0.041836997 0.942247654 0.598148943 -0.283787444 
TREX1 0.241874686 0.968436391 0.22084864 0.284359476 0.968436391 0.22084864 0.042484789 
NLK 0.241516324 0.981217976 0.164190091 0.23979725 0.981217976 0.164190091 -0.001719074 
TYMS 0.240775365 0.989232021 0.11574737 0.365677549 0.989232021 0.096911808 0.124902184 
TP63 0.240091417 0.982719463 0.090971624 0.275620695 0.982719463 0.090971624 0.035529278 
NonTargetingC
ontrolGene_41 
0.239816851 0.985115366 0.133961703 0.225228609 0.985115366 0.177444699 -0.014588243 
AMN  0.239650803 0.99801046 0.076797633 0.39469997 0.99801046 0.01790586 0.155049168 
SUMO4 0.239471242 0.958853859 0.153849462 0.336405766 0.958853859 0.147639042 0.096934524 
ARID1B 0.239336629 0.970376264 0.161373934 0.299220747 0.970376264 0.161373934 0.059884118 
NonTargetingC
ontrolGene_51 
0.238327345 0.984970515 0.135265368 0.213970822 0.984970515 0.207121895 -0.024356522 
POLL 0.236422868 0.995018218 0.159188182 0.179110228 0.995018218 0.277494893 -0.057312641 
PMS2P3 0.236185822 0.943456195 0.238305977 0.306158536 0.943456195 0.238305977 0.069972713 
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ATP23 0.235994159 0.941599552 0.274281335 0.070621624 0.941599552 0.436241072 -0.165372535 
MSH2 0.233902642 0.974192869 0.177064168 0.308988389 0.974192869 0.177064168 0.075085747 
NonTargetingC
ontrolGene_59 
0.231359382 0.980263038 0.177632659 0.200372817 0.980263038 0.272549319 -0.030986565 
USP45 0.229490877 0.96395309 0.324422189 0.190311299 0.96395309 0.348616929 -0.039179579 
OTUD7B 0.227653101 0.966178755 0.232707468 0.224016278 0.966178755 0.232707468 -0.003636823 
NonTargetingC
ontrolGene_64 
0.22727685 0.990930841 0.081622427 0.221574407 0.990930841 0.119824781 -0.005702443 
UBA3 0.227110791 0.994051665 0.225515477 0.194253218 0.994051665 0.225515477 -0.032857572 
CASP3 0.226501624 0.92594083 0.457113336 0.108437048 0.92594083 0.457113336 -0.118064576 
RAG1 0.223570868 0.998190338 0.160315949 0.428302169 0.998190338 0.016286954 0.204731302 
PHF11 0.222249927 0.968480013 0.154324222 0.273383743 0.968480013 0.154324222 0.051133816 
PMS1 0.221985715 0.978795846 0.134546777 0.29158645 0.978795846 0.134546777 0.069600735 
NABP1 0.221793017 0.959632317 0.345913405 0.19988208 0.959632317 0.345913405 -0.021910938 
SLF1 0.220285557 0.957297648 0.306099134 0.245619091 0.957297648 0.306099134 0.025333535 
USP11 0.217504752 0.977479353 0.153262321 0.286116402 0.977479353 0.153262321 0.068611651 
MCM10 0.215114907 0.90263807 0.293246413 0.149431244 0.90263807 0.293246413 -0.065683663 
APOBEC3A 0.215090634 0.949371552 0.238896378 0.274141769 0.949371552 0.238896378 0.059051135 
NonTargetingC
ontrolGene_38 
0.215052384 0.995893787 0.201545788 0.366193733 0.995893787 0.036955918 0.151141349 
CCNE1 0.214694849 0.972601188 0.146505559 0.264904043 0.972601188 0.146505559 0.050209194 
CDC34 0.209531106 0.946296811 0.317670536 0.153817668 0.943082939 0.317670536 -0.055713438 
PARP2 0.208953479 0.943985904 0.297513822 0.211901002 0.943985904 0.297513822 0.002947523 
NonTargetingC
ontrolGene_2 
0.208693395 0.995046821 0.136350417 0.324611356 0.995046821 0.044578614 0.115917961 
INO80C 0.207558446 0.99225101 0.187459633 0.371020118 0.99225101 0.069740913 0.163461671 
SLF2 0.205178958 0.968887803 0.156328463 0.221612245 0.968887803 0.156328463 0.016433287 
EME1 0.203600489 0.900026124 0.209613513 0.211420226 0.900026124 0.209613513 0.007819737 
REV1 0.202925071 0.951147894 0.271200076 0.241681523 0.951147894 0.271200076 0.038756452 
RAG2 0.200055096 0.937786552 0.240309256 0.258659168 0.937786552 0.240309256 0.058604073 
CLK2 0.198658705 0.937955813 0.278473867 0.262170316 0.937955813 0.278473867 0.06351161 
TNP1 0.197293209 0.962981376 0.371141252 0.318391006 0.962981376 0.333167618 0.121097798 
WDR76 0.196970169 0.892541247 0.274239745 0.224860815 0.892541247 0.274239745 0.027890646 
PMS2 0.195093203 0.962221154 0.15340566 0.13657562 0.962221154 0.340576221 -0.058517583 
ZRANB3 0.194522664 0.938815439 0.384695382 0.098666971 0.858872109 0.384695382 -0.095855693 
C9orf142 0.193324192 0.955815087 0.316585533 0.271802852 0.955815087 0.316585533 0.07847866 
UHRF2 0.193013849 0.933087821 0.456677267 0.066623524 0.933087821 0.456677267 -0.126390324 
NTHL1 0.18867166 0.931538222 0.38384766 0.233612229 0.931538222 0.38384766 0.044940569 
MSH3 0.186463019 0.986451479 0.247644469 0.320912521 0.986451479 0.121936687 0.134449502 
TIPIN 0.183204973 0.889867239 0.384848746 0.265142106 0.889867239 0.384848746 0.081937132 
TREX2 0.183004734 0.89181467 0.529610279 0.12557543 0.89181467 0.529610279 -0.057429304 
POLG2 0.180518051 0.981114272 0.343501744 0.311396422 0.981114272 0.169971554 0.130878371 
SIRT3 0.178576941 0.979592947 0.233911855 0.292432662 0.979592947 0.183663475 0.113855722 
PRDM9 0.17826664 0.943546646 0.34954151 0.20412231 0.943546646 0.34954151 0.025855671 
WRN 0.177266638 0.936131005 0.40821908 0.151011892 0.936131005 0.40821908 -0.026254747 
SMARCAD1 0.174777969 0.936207121 0.473019693 -0.017353946 0.902049214 0.622217972 -0.192131915 
SCAF8 0.171836859 0.997827855 0.168020195 0.40334465 0.997827855 0.019549306 0.231507791 
PIAS3 0.17155595 0.958700981 0.316221072 0.251899811 0.958700981 0.316221072 0.080343861 
KDM1A 0.16823756 0.935769267 0.48560199 0.253609091 0.935769267 0.48560199 0.085371531 
USP3 0.167786814 0.917147685 0.449800464 0.043360556 0.90412076 0.449800464 -0.124426258 
COL21A1 0.167778746 0.921825514 0.428542352 0.119986131 0.921825514 0.428542352 -0.047792615 
RPA4 0.167017561 0.926587876 0.347017442 0.181410584 0.926587876 0.347017442 0.014393024 
NOTCH4 0.166960522 0.977380485 0.170484673 0.266921016 0.977380485 0.170484673 0.099960495 
UBE2NL 0.166633867 0.944566022 0.279276013 0.251374784 0.944566022 0.279276013 0.084740917 
NonTargetingC
ontrolGene_48 
0.165261062 0.966373778 0.202973428 0.213548714 0.966373778 0.202973428 0.048287652 
APOBEC3H 0.162242019 0.904946719 0.402261229 0.095607824 0.843921742 0.402261229 -0.066634195 
AICDA 0.161501069 0.884412741 0.47259631 0.138016618 0.884412741 0.47259631 -0.023484452 
APOBEC3F 0.159174248 0.96743583 0.35574373 0.314082977 0.96743583 0.293077531 0.154908729 
PSIP1 0.156430306 0.93413416 0.407987723 0.211061805 0.93413416 0.407987723 0.054631499 
UIMC1 0.154384826 0.883241569 0.390302293 0.098556143 0.861488402 0.390302293 -0.055828683 
NonTargetingC
ontrolGene_67 
0.153967297 0.963105599 0.390496479 0.24093281 0.963105599 0.332049606 0.086965513 
ANP32E 0.153300459 0.877808356 0.388795789 0.187589064 0.877808356 0.388795789 0.034288606 
ANKRD28 0.152893569 0.964281934 0.377704218 0.251201613 0.964281934 0.321462594 0.098308043 
PPP4R3B 0.151566138 0.993541008 0.289907362 0.124838129 0.993541008 0.41143344 -0.026728009 
NonTargetingC
ontrolGene_56 
0.151342002 0.965584874 0.357298286 0.221640334 0.965584874 0.309736136 0.070298332 
CCNA1 0.150725106 0.89570662 0.598707029 -0.098121843 0.810951228 0.772818133 -0.248846949 
SIRT4 0.149045264 0.909510653 0.309220548 0.152027514 0.909510653 0.309220548 0.00298225 
ERCC6L2 0.148076626 0.872367225 0.646306863 0.107302968 0.872367225 0.646306863 -0.040773658 
RAD9B 0.147544194 0.907235566 0.334368469 0.192702924 0.907235566 0.334368469 0.045158729 
SMUG1 0.1472134 0.926775706 0.400235835 0.248068567 0.926775706 0.400235835 0.100855166 
MDM4 0.146831288 0.999708607 0.287065518 0.261281725 0.999708607 0.168291238 0.114450438 
NonTargetingC
ontrolGene_60 
0.146573353 0.939658178 0.359655223 0.216129305 0.939658178 0.359655223 0.069555952 
APTX 0.144711795 0.902305794 0.297388906 0.161522247 0.902305794 0.297388906 0.016810452 
HDAC4 0.143203584 0.973538072 0.386053811 0.245737917 0.973538072 0.238157352 0.102534333 
TDP1 0.142542786 0.868239207 0.538929836 0.097960217 0.868239207 0.673210986 -0.044582569 
NEIL3 0.142031465 0.896172364 0.459576238 0.027930553 0.830465663 0.467663953 -0.114100912 
RBX1 0.141672537 0.98131896 0.425444544 -0.148053283 0.98131896 0.794602751 -0.28972582 
APOBEC3G 0.140118289 0.90021691 0.404673257 0.050768097 0.800085083 0.404673257 -0.089350192 
UBE2D4 0.138821871 0.907990743 0.308397143 0.104870014 0.907990743 0.395428014 -0.033951857 
HDAC2 0.1370304 0.869520373 0.350883165 0.115575604 0.869520373 0.350883165 -0.021454797 
TOP2B 0.135564847 0.894281573 0.408842915 0.117990479 0.894281573 0.517418298 -0.017574368 
RBBP7 0.135333979 0.976664116 0.33148424 0.301965475 0.976664116 0.210022957 0.166631496 
RAD51AP1 0.132745745 0.853380663 0.405176852 0.018187688 0.853380663 0.509234634 -0.114558058 
NUDT16L1 0.131287501 0.821254066 0.439119507 0.046686767 0.821254066 0.439119507 -0.084600733 
CRY2 0.129611472 0.8956699 0.466013717 0.172439114 0.8956699 0.466013717 0.042827643 
BLM 0.129371988 0.840181435 0.436421852 0.13648684 0.840181435 0.436421852 0.007114852 
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SENP7 0.123584502 0.8161503 0.467620277 0.056526078 0.8161503 0.467620277 -0.067058424 
NUDT1 0.122611348 0.946357521 0.275364442 0.325970243 0.946357521 0.243187598 0.203358895 
SETD2 0.121207959 0.99309399 0.513673877 0.426999537 0.99309399 0.062154088 0.305791578 
PXMP2 0.120340814 0.923308842 0.444325346 0.215942139 0.923308842 0.444325346 0.095601326 
UBE2D2 0.118536728 0.926997804 0.271229486 0.382316171 0.992420459 0.068215873 0.263779443 
RNF169 0.117617402 0.972630813 0.414805696 0.30086676 0.972630813 0.246322687 0.183249359 
ASF1B 0.116777237 0.852870623 0.479460419 0.051367014 0.852870623 0.479460419 -0.065410223 
PPP5C 0.110552053 0.956631895 0.442428591 0.281103806 0.973158705 0.241571653 0.170551753 
ERCC5 0.103642324 0.848849287 0.480513536 0.057582936 0.788299656 0.480513536 -0.046059388 
RECQL5 0.102736796 0.807844349 0.447635835 0.08806141 0.807844349 0.447635835 -0.014675385 
POLH 0.102428561 0.817609978 0.414541812 0.1000875 0.817609978 0.414541812 -0.002341061 
NonTargetingC
ontrolGene_37 
0.101472603 0.9463425 0.377586763 0.20227871 0.9463425 0.377586763 0.100806107 
CRY1 0.1010152 0.920529515 0.580422196 0.223529528 0.964071396 0.32335744 0.122514328 
DLGAP5 0.100321714 0.886341913 0.404700279 0.097130312 0.886341913 0.404700279 -0.003191402 
CENPX 0.098720051 0.828940722 0.621083846 0.083969871 0.828940722 0.621083846 -0.014750179 
SUMO1 0.097856858 0.848506551 0.352701213 0.142370419 0.848506551 0.352701213 0.04451356 
HDAC1 0.096414509 0.853806783 0.358107678 0.154248431 0.853806783 0.358107678 0.057833922 
HNRNPUL1 0.096412513 0.981160424 0.345787108 0.320727583 0.981160424 0.169556184 0.22431507 
NonTargetingC
ontrolGene_9 
0.095661587 0.90585647 0.570687847 0.163250246 0.90585647 0.570687847 0.067588659 
PPP4R1 0.095560872 0.856665652 0.489049591 0.147535793 0.856665652 0.489049591 0.051974921 
MORF4L2 0.094237103 0.909420079 0.494279508 0.177075585 0.909420079 0.401249076 0.082838482 
HLTF 0.093128655 0.842836197 0.400106702 0.06514597 0.842836197 0.400106702 -0.027982685 
SIRT6 0.091291004 0.933946592 0.459625065 0.114097657 0.933946592 0.459625065 0.022806653 
ZSWIM7 0.08698657 0.743131832 0.724270237 0.041751048 0.743131832 0.724270237 -0.045235522 
H3F3A 0.086270988 0.576658748 0.533961199 -0.004415697 0.576658748 0.533961199 -0.090686685 
POLI 0.086103946 0.870502638 0.359127809 0.092447095 0.870502638 0.359127809 0.006343149 
PNN 0.083741379 0.997902515 0.399103118 0.157535298 0.997902515 0.399103118 0.073793919 
GEN1 0.083582114 0.754153117 0.671192216 -0.176486198 0.754153117 0.864396786 -0.260068312 
ERCC6 0.082830531 0.742080257 0.461681238 0.092587625 0.742080257 0.461681238 0.009757094 
MLH1 0.082806956 0.942751324 0.556658798 0.275851238 0.955400396 0.401396437 0.193044282 
PMS2P5 0.074679353 0.642106223 0.567006492 -0.116507271 0.642106223 0.567006492 -0.191186623 
NonTargetingC
ontrolGene_3 
0.074084781 0.860063864 0.436971171 0.048634142 0.860063864 0.436971171 -0.025450639 
SMARCA4 0.072900555 0.921918975 0.377932557 0.198592881 0.921918975 0.339227283 0.125692327 
RAD52 0.072831603 0.728971579 0.559429461 0.052162223 0.728971579 0.559429461 -0.020669381 
RFC1 0.071794516 0.870530865 0.493337784 0.108414506 0.870530865 0.493337784 0.03661999 
CBX5 0.07170902 0.913303254 0.48031268 0.104542209 0.913303254 0.48031268 0.032833189 
SSBP1 0.071095589 0.828033245 0.733551418 0.153453365 0.860183173 0.733551418 0.082357776 
RHO 0.071087397 0.867938538 0.43694721 0.166538785 0.909660554 0.43694721 0.095451389 
NEIL2 0.071063685 0.900745624 0.380534521 0.181492715 0.900745624 0.319866714 0.11042903 
COL1A1 0.070699394 0.911479638 0.561336024 -0.04826752 0.911479638 0.616873471 -0.118966914 
SMARCA2 0.070306953 0.964445153 0.590235601 0.322357521 0.974002741 0.233975331 0.252050568 
KMT5A 0.069522462 0.741562051 0.574073591 0.153058425 0.741562051 0.574073591 0.083535963 
SHPRH 0.067273972 0.726763686 0.552152367 0.047209532 0.726763686 0.552152367 -0.020064439 
MVP 0.066447168 0.881549393 0.399734471 0.166258094 0.881549393 0.324692981 0.099810927 
PARK2 0.062026844 0.744557492 0.508448011 0.0638596 0.744557492 0.508448011 0.001832755 
POLG 0.061416315 0.665474388 0.874455448 -0.13190285 0.437368476 0.874455448 -0.193319165 
POLQ 0.061363685 0.707187804 0.452518333 0.017129579 0.707187804 0.452518333 -0.044234106 
NonTargetingC
ontrolGene_8 
0.059979106 0.850087936 0.533634841 0.151755925 0.914641727 0.533634841 0.091776818 
BAZ1A 0.059171876 0.733462775 0.45138603 0.010258444 0.733462775 0.474065524 -0.048913432 
DTX2 0.059149442 0.671581355 0.696367427 0.059870984 0.671581355 0.696367427 7.21542E-04 
ACD 0.05905609 0.982712271 0.619669651 -0.119693955 0.982712271 0.822760624 -0.178750045 
DTX1 0.058132955 0.802545681 0.457077757 0.131552243 0.802545681 0.457077757 0.073419289 
UVSSA 0.057129501 0.69812623 0.613241301 -0.039138155 0.69812623 0.613241301 -0.096267656 
BEND3 0.056015667 0.782060364 0.418467606 0.110372716 0.784672403 0.418467606 0.054357049 
CENPS 0.054459324 0.809540827 0.504680041 0.203240104 0.862437361 0.504680041 0.14878078 
USP4 0.054275234 0.805362863 0.589526684 -0.008597673 0.805362863 0.589526684 -0.062872907 
PER3 0.053455331 0.849608299 0.489903783 0.023467064 0.849608299 0.489903783 -0.029988267 
APOBEC1 0.051404986 0.956864874 0.431690689 0.177653356 0.956864874 0.234856141 0.12624837 
DCAF11 0.051353841 0.900717935 0.386361477 0.209398226 0.928979972 0.386361477 0.158044384 
H2AFY2 0.050363606 0.763884749 0.465235999 0.096400817 0.763884749 0.465235999 0.046037211 
NOTCH2 0.050195055 0.91600724 0.441506818 0.078694461 0.91600724 0.441506818 0.028499406 
OGG1 0.047976145 0.848582944 0.508307522 0.177432534 0.905574911 0.508307522 0.129456389 
PAPD7 0.047281708 0.791645969 0.529345001 0.114457158 0.791645969 0.529345001 0.06717545 
STAG1 0.04708998 0.723799903 0.633347551 -0.160781946 0.723799903 0.800676248 -0.207871927 
IGHMBP2 0.043940273 0.733461585 0.477616102 0.103525082 0.740019751 0.477616102 0.059584809 
CBX3 0.043742116 0.85241978 0.418979627 0.114289415 0.85241978 0.418979627 0.070547299 
TP73 0.041507452 0.721214667 0.496816724 0.055569235 0.721214667 0.496816724 0.014061783 
SERBP1 0.038793009 0.936111565 0.518464993 0.220617858 0.936111565 0.358438756 0.181824848 
SLBP 0.033742092 0.84926528 0.520300724 0.173241302 0.853138404 0.520300724 0.13949921 
MPZ 0.032867989 0.783285652 0.569902016 0.020854632 0.783285652 0.569902016 -0.012013356 
TDG 0.031650583 0.776038219 0.622908194 -0.019491399 0.776038219 0.622908194 -0.051141982 
SFR1 0.031078724 0.81670404 0.746105984 -0.292719309 0.640166994 0.928438731 -0.323798032 
HES1 0.02421712 0.76809946 0.612258629 0.171440941 0.873871288 0.612258629 0.147223822 
OR6B1 0.021637562 0.780133397 0.543041925 0.018962446 0.780133397 0.543041925 -0.002675116 
PIAS1 0.020815564 0.730146097 0.55679566 0.067473984 0.730146097 0.478187399 0.04665842 
GABBR1 0.020545675 0.830415951 0.443223333 0.184983578 0.901884705 0.443223333 0.164437902 
PIF1 0.020289941 0.789502562 0.452710548 0.018396824 0.789502562 0.452710548 -0.001893117 
MCRS1 0.012858545 0.962567628 0.702009461 -0.423860616 0.149047656 0.992857054 -0.436719161 
PIAS4 0.011073816 0.534303065 0.788581482 -0.093289501 0.530232231 0.788581482 -0.104363316 
NPM1 0.006458503 0.971362538 0.666090951 -0.17786433 0.971362538 0.666090951 -0.184322833 
CUL4A 1.27857E-04 0.655076567 0.689545238 0.060368814 0.655076567 0.689545238 0.060240957 
TCEA1 -0.001069823 0.635881387 0.597959364 -0.022496842 0.635881387 0.597959364 -0.021427019 
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ATRX -0.008123802 0.584883682 0.796610207 -0.035329702 0.584883682 0.796610207 -0.0272059 
ZDHHC16 -0.017123259 0.956923154 0.713194275 0.48690153 0.995336677 0.041969904 0.504024789 
MUTYH -0.023928773 0.663194739 0.683401713 -0.02014341 0.663194739 0.683401713 0.003785363 
OR1E2 -0.025011978 0.776359 0.639285089 0.197193827 0.852952844 0.639285089 0.222205804 
PINK1 -0.025210376 0.859205561 0.651866215 0.244384851 0.96440717 0.320335471 0.269595227 
MSH5 -0.025418707 0.738573839 0.706570482 0.12375609 0.825296938 0.706570482 0.149174798 
PPP6R2 -0.026983184 0.793930204 0.658974471 0.105752555 0.793930204 0.51836679 0.13273574 
INO80E -0.027526916 0.854418796 0.709819692 0.029373156 0.854418796 0.665537272 0.056900072 
RNF4 -0.033967332 0.51553963 0.863172383 -0.124752913 0.51553963 0.863172383 -0.090785581 
MSH6 -0.036633742 0.77028725 0.633023141 0.01904652 0.77028725 0.633023141 0.055680262 
SUV39H1 -0.039423558 0.686927959 0.727706492 0.115434501 0.816719917 0.727706492 0.154858059 
ATMIN -0.046955331 0.945798935 0.687818418 0.04392406 0.945798935 0.623082988 0.09087939 
RNF168 -0.047566662 0.686855358 0.768789476 -0.164856187 0.686855358 0.830175809 -0.117289524 
WDR70 -0.050524705 0.848053481 0.934631013 -0.281808111 0.258358485 0.99662953 -0.231283407 
RAD23B -0.052195755 0.726194025 0.689054646 0.115874171 0.763368188 0.689054646 0.168069926 
PAXIP1 -0.052223525 0.640313842 0.733419247 -0.016965229 0.640313842 0.733419247 0.035258296 
PARG -0.052295033 0.995565538 0.710100661 0.328664906 0.995565538 0.08609987 0.380959939 
NIPBL -0.054320967 0.690169452 0.998963233 -0.664244679 0.009330906 0.998963233 -0.609923712 
PPP6R1 -0.054649076 0.772941429 0.696452101 0.090973048 0.773394928 0.646705834 0.145622124 
TNKS -0.054790498 0.632422958 0.844252915 -0.129374758 0.632422958 0.844252915 -0.074584259 
SMC4 -0.056325241 0.997535657 0.765303894 0.043632767 0.997535657 0.644779088 0.099958008 
TRIM28 -0.057614478 0.696727965 0.743038716 0.078759989 0.712365564 0.743038716 0.136374467 
SMARCAL1 -0.062285927 0.734519105 0.748013154 -0.059324134 0.734519105 0.748013154 0.002961793 
TOP2A -0.066506104 0.810893181 0.622751665 0.0102456 0.810893181 0.622751665 0.076751705 
ORC2 -0.070942293 0.481268607 0.87352768 -0.159008641 0.481268607 0.87352768 -0.088066348 
PRDM10 -0.072691583 0.750825113 0.688004874 -0.056324044 0.750825113 0.688004874 0.016367539 
FAAP20 -0.079637557 0.529341341 0.704574993 -0.036089269 0.529341341 0.704574993 0.043548288 
XRCC1 -0.081948717 0.443528978 0.83560372 -0.126488948 0.443528978 0.83560372 -0.04454023 
ATAD5 -0.08405132 0.639201937 0.719766489 0.134662609 0.805147372 0.719766489 0.218713929 
CUL9 -0.086283682 0.694477132 0.98584922 -0.322826362 0.117847898 0.98584922 -0.23654268 
ERCC8 -0.087778064 0.716506865 0.739113123 0.053983414 0.716506865 0.709966902 0.141761477 
CBX1 -0.089547682 0.732768406 0.73796149 -0.105540314 0.732768406 0.73796149 -0.015992632 
MPLKIP -0.103811915 0.417071503 0.839815793 -0.132896713 0.417071503 0.839815793 -0.029084798 
RFWD3 -0.105139018 0.445843971 0.946496535 -0.551501004 0.037563129 0.992271177 -0.446361986 
KDM2A -0.107119257 0.434804887 0.910732661 0.024361476 0.635097672 0.910732661 0.131480733 
TFPT -0.107978674 0.297516508 0.890885344 -0.171899425 0.297516508 0.890885344 -0.063920751 
SPIDR -0.108790252 0.476235924 0.816668104 -0.110521777 0.476235924 0.816668104 -0.001731525 
CDCA5 -0.111481331 0.84546838 0.843402935 -0.0494265 0.907590288 0.843402935 0.062054831 
CSNK2A1 -0.115433546 0.59893175 0.749365565 0.014463681 0.59893175 0.744935698 0.129897227 
RAD23A -0.11667256 0.635087306 0.805323122 0.040814137 0.732912694 0.805323122 0.157486697 
RAD54L -0.126592922 0.553927821 0.930512659 -0.251373537 0.553927821 0.930512659 -0.124780615 
PARP1 -0.127914059 0.279310195 0.90920163 -0.187085541 0.279310195 0.90920163 -0.059171482 
MPG -0.128031749 0.678395155 0.824092206 0.074923027 0.678395155 0.64260504 0.202954776 
MTA1 -0.132868177 0.620309887 0.876758892 0.040637312 0.620309887 0.740035073 0.173505489 
POLA1 -0.134563873 0.83158969 0.809082136 -0.193146133 0.83158969 0.809082136 -0.05858226 
EXO1 -0.137875464 0.626652201 0.875452844 -0.037928988 0.626652201 0.875452844 0.099946476 
POLD4 -0.142312237 0.72269126 0.811369298 -0.080783908 0.72269126 0.774671345 0.061528329 
COPS4 -0.144612611 0.962367229 0.784286744 -0.05340531 0.962367229 0.773073404 0.091207301 
TERF2IP -0.14896781 0.747038604 0.873688043 -0.018517477 0.747038604 0.740824367 0.130450334 
EP400 -0.150950959 0.584723843 0.934499724 -0.316936187 0.584723843 0.934499724 -0.165985229 
RBBP8 -0.151290976 0.462614282 0.850956524 -0.197376254 0.462614282 0.850956524 -0.046085278 
CHD4 -0.151945071 0.501435684 0.901051259 -0.171329026 0.501435684 0.901051259 -0.019383955 
UNG -0.154785905 0.879170242 0.843624469 0.039821732 0.879170242 0.711741337 0.194607637 
HELQ -0.160854123 0.53104413 0.86709702 -0.164474864 0.53104413 0.86709702 -0.003620741 
PAGR1 -0.165923582 0.281102876 0.995113011 -0.54044677 0.043982902 0.995113011 -0.374523187 
CHRAC1 -0.168534433 0.470805861 0.883613746 -0.124666104 0.470805861 0.883613746 0.04386833 
ECT2 -0.171151274 0.601225405 0.863494177 -0.074990814 0.601225405 0.863494177 0.09616046 
USP1 -0.176650435 0.590243354 0.881468859 0.006881274 0.590243354 0.848664132 0.183531709 
LMNA -0.176655961 0.183523833 0.988127832 -0.025482483 0.561094561 0.988127832 0.151173478 
SKIV2L2 -0.180172562 0.430956169 0.899222865 -0.177050851 0.430956169 0.899222865 0.003121711 
USP22 -0.183838769 0.642641712 0.845438996 0.016899146 0.642641712 0.653544646 0.200737915 
POLR2A -0.188104143 0.763345102 0.854275904 -0.144072004 0.763345102 0.854275904 0.044032139 
POLE -0.190543829 0.65044863 0.865959085 -0.030158808 0.65044863 0.865959085 0.160385021 
H3F3B -0.196597617 0.596271997 0.851687166 -0.195591112 0.596271997 0.851687166 0.001006505 
CNOT7 -0.19949701 0.288024187 0.942650234 -0.339063476 0.288024187 0.942650234 -0.139566466 
OTUB1 -0.203434471 0.59043536 0.901421273 0.039150756 0.59043536 0.800128386 0.242585227 
CCND1 -0.207573164 0.869752987 0.817524746 0.018562789 0.869752987 0.641848467 0.226135953 
POLD2 -0.208542476 0.334274577 0.982634944 -0.432094866 0.156285504 0.982634944 -0.223552389 
SMG1 -0.222482737 0.65746305 0.889597163 -0.177078894 0.65746305 0.889597163 0.045403843 
MASTL -0.223354855 0.386713651 0.999652537 -0.639203315 0.094058397 0.999652537 -0.41584846 
USP44 -0.227671854 0.241357596 0.973182489 -0.170397989 0.5445791 0.973182489 0.057273865 
POLR2F -0.230876499 0.216537678 0.932523806 -0.331050991 0.216537678 0.932523806 -0.100174492 
DAXX -0.234092082 0.370287653 0.982592441 -0.477385848 0.145857946 0.982592441 -0.243293766 
PLRG1 -0.236438298 0.343606608 0.948788813 -0.264427117 0.343606608 0.948788813 -0.027988819 
CREBBP -0.238700169 0.200253782 0.977017433 -0.188856336 0.200253782 0.977017433 0.049843833 
PALB2 -0.24104358 0.21624328 0.956352073 -0.176502208 0.274097763 0.956352073 0.064541372 
MUS81 -0.241066367 0.112188123 0.99287909 -0.42869439 0.064088194 0.99287909 -0.187628023 
ENY2 -0.245632696 0.218434077 0.971646103 -0.343604578 0.148082476 0.971646103 -0.097971882 
COPS2 -0.250094945 0.104368911 0.992713471 -0.33552651 0.104368911 0.992713471 -0.085431565 
POLD1 -0.250258657 0.301446908 0.971842685 -0.581528504 0.180360624 0.971842685 -0.331269846 
EXO5 -0.251552149 0.104557156 0.99160132 -0.396324564 0.075588121 0.99160132 -0.144772415 
TCEB3 -0.25591657 0.201967185 0.990465878 -0.510498133 0.085807102 0.990465878 -0.254581563 
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PPP4R2 -0.258368916 0.570779587 0.884977733 -0.24878398 0.570779587 0.884977733 0.009584936 
POLR2D -0.260322916 0.767441941 0.897448418 -0.048427783 0.984172942 0.843884706 0.211895132 
XRCC4 -0.265056586 0.091989725 0.983404757 -0.304627427 0.091989725 0.983404757 -0.03957084 
BRIP1 -0.268506001 0.360874066 0.9361424 -0.077691499 0.47669902 0.882716175 0.190814502 
CDC25B -0.270526747 0.054812273 0.990217901 -0.361589008 0.054812273 0.990217901 -0.091062261 
TADA3 -0.276603476 0.433691801 0.915647428 -0.092572502 0.433691801 0.915647428 0.184030973 
NFRKB -0.27995273 0.08237066 0.983903022 -0.357797074 0.08237066 0.983903022 -0.077844344 
BAZ1B -0.280345078 0.496971196 0.944780978 -0.029115166 0.677081241 0.831773684 0.251229912 
FANCE -0.282976853 0.158677652 0.999512955 -0.811396026 0.004383402 0.999512955 -0.528419174 
MDC1 -0.283865123 0.102756888 0.986434394 -0.400415896 0.102756888 0.986434394 -0.116550774 
REV3L -0.2873757 0.128238355 0.995825835 -0.504624834 0.040619012 0.995825835 -0.217249134 
ARID1A -0.288305518 0.184496925 0.960738841 -0.245123096 0.308653699 0.960738841 0.043182423 
EYA3 -0.291394047 0.191554347 0.978716184 -0.158867981 0.442394633 0.978716184 0.132526066 
CDK12 -0.29236442 0.250431647 0.972174261 -0.24979598 0.354350191 0.972174261 0.042568439 
DNAJC2 -0.295825188 0.294286911 0.99865042 -0.5565439 0.134663326 0.99865042 -0.260718712 
RMI2 -0.299420629 0.260218835 0.971086796 -0.205945675 0.359083547 0.971086796 0.093474953 
NHEJ1 -0.302506788 0.09166317 0.989815203 -0.285530055 0.121990341 0.989815203 0.016976733 
KAT2A -0.306548812 0.071147396 0.992094734 -0.216879083 0.262923643 0.992094734 0.08966973 
TDP2 -0.309533973 0.130991125 0.983092246 -0.366988197 0.130991125 0.983092246 -0.057454224 
HELLS -0.311522354 0.252129036 0.971985663 -0.161144545 0.378136086 0.971985663 0.150377809 
SUMO2 -0.323885876 0.592600641 0.874235475 -0.069132051 0.592600641 0.874235475 0.254753825 
PINX1 -0.325346997 0.148550039 0.974286015 -0.369962275 0.148550039 0.974286015 -0.044615277 
FANCA -0.325681171 0.209442566 0.968847838 -0.241885307 0.209442566 0.968847838 0.083795864 
LIG1 -0.327713059 0.179085725 0.980101586 -0.080180537 0.57090815 0.979584009 0.247532523 
ZMPSTE24 -0.330617725 0.054864878 0.99078592 -0.375909008 0.054864878 0.99078592 -0.045291282 
ATRIP -0.362903422 0.013917203 0.998218448 -0.438694531 0.013917203 0.998218448 -0.075791109 
CDK2 -0.367593312 0.074984106 0.991668433 -0.208285683 0.355245308 0.991668433 0.15930763 
MCM3AP -0.371072936 0.210290216 0.973219488 -0.222155907 0.245791437 0.973219488 0.148917029 
BRCA1 -0.374522909 0.099649059 0.988927882 -0.260872849 0.240341187 0.988927882 0.113650061 
SLX4 -0.37594172 0.006668479 0.999341474 -0.540291908 0.005926732 0.999341474 -0.164350188 
SMG6 -0.383253541 0.223016344 0.975220406 -0.254386024 0.290383003 0.975220406 0.128867517 
NFE2L2 -0.384092026 0.049834458 0.994462838 -0.222560303 0.300917887 0.994462838 0.161531723 
ANKRD52 -0.384924158 0.154881923 0.982790897 -0.268656035 0.235897498 0.982790897 0.116268123 
ESCO2 -0.40137917 0.066336516 0.992629276 -0.403177491 0.089727079 0.992629276 -0.001798321 
TOP1 -0.40296529 0.304162692 0.965118595 -0.19365018 0.593986618 0.965118595 0.209315111 
FANCB -0.403402649 0.037634452 0.995133965 -0.46657312 0.037634452 0.995133965 -0.063170471 
RAD21 -0.406114979 0.186882038 0.999354912 -0.964551829 0.005329002 0.999354912 -0.55843685 
CCNB1 -0.407993398 0.016997613 0.998111376 -0.393095395 0.043718332 0.998111376 0.014898003 
MEN1 -0.413336532 0.09665337 0.983314517 -0.427910931 0.09665337 0.983314517 -0.0145744 
SMARCE1 -0.42066373 0.045333147 0.990164848 -0.408545593 0.146678665 0.990164848 0.012118136 
PPM1G -0.423367672 0.202151406 0.977161392 -0.330068097 0.202151406 0.977161392 0.093299575 
PRKDC -0.424578433 0.02213336 0.997540738 -0.282321823 0.132195725 0.997540738 0.14225661 
FIGNL1 -0.42895911 0.009581148 0.998935428 -0.20521407 0.256950171 0.998935428 0.22374504 
BAP1 -0.43689325 0.055763061 0.991006485 -0.492074184 0.06781337 0.991006485 -0.055180934 
NCAPD3 -0.43785277 0.091343379 0.999902021 -0.642718683 0.051026323 0.999902021 -0.204865913 
FAAP24 -0.439601311 0.008315086 0.999280513 -0.800356355 0.004598138 0.999280513 -0.360755044 
DUT -0.442240628 0.07075276 0.992138582 -0.306662989 0.198585301 0.992138582 0.135577639 
FAAP100 -0.44520896 0.006553714 0.999216741 -0.623841474 0.006553714 0.999216741 -0.178632513 
UPF1 -0.445585181 0.069818791 0.999880087 -0.878174722 0.009081953 0.999880087 -0.432589541 
RECQL4 -0.463617245 0.477553355 0.944230596 0.049375513 0.877680198 0.595715041 0.512992758 
INO80 -0.46532329 0.010074584 0.998880602 -0.41133481 0.030687121 0.998880602 0.053988481 
KAT5 -0.465335388 0.003449885 0.999736495 -0.690271907 0.002133019 0.999736495 -0.224936519 
XRCC6 -0.472190397 0.045700529 0.996737637 -0.804499098 0.029361264 0.996737637 -0.332308701 
SPRTN -0.475781513 0.030000709 0.993980344 -0.480296074 0.030000709 0.993980344 -0.004514561 
TRRAP -0.484532015 0.026819265 0.997020082 -0.503288197 0.050000856 0.997020082 -0.018756181 
NCAPH -0.489256463 0.017134412 0.99898725 -0.761227683 0.009114748 0.99898725 -0.27197122 
POLR2L -0.491628573 0.150546855 0.993747536 -0.657855516 0.110634723 0.993747536 -0.166226943 
COPS3 -0.495542472 0.006412714 0.998901311 -0.635829813 0.006412714 0.998901311 -0.14028734 
LIG4 -0.503665564 0.018063341 0.997992962 -0.534381482 0.034925692 0.997992962 -0.030715918 
RPAIN -0.503958507 0.202989095 0.977445656 -0.450691353 0.205984554 0.977445656 0.053267154 
WDR48 -0.50522505 0.008246915 0.999368917 -0.723194509 0.005679749 0.999368917 -0.21796946 
CLSPN -0.50941712 0.037418297 0.995842411 -0.280286077 0.290846178 0.995842411 0.229131043 
NSMCE2 -0.512167482 0.031251449 0.996527617 -0.308959512 0.193492295 0.996527617 0.20320797 
INO80B -0.515890768 0.017820024 0.998019997 -0.53249095 0.02661184 0.998019997 -0.016600182 
CUL1 -0.519515423 0.001867307 0.99998777 -0.760790779 1.10066E-04 0.99998777 -0.241275356 
ACTR5 -0.521510069 0.003020597 0.999664378 -0.429203977 0.043490312 0.999664378 0.092306093 
RAD51C -0.524020216 0.021702105 0.997588655 -0.364352083 0.113616994 0.997588655 0.159668133 
UBC -0.53399397 0.17105301 0.98099411 -0.240221572 0.319689711 0.98099411 0.293772398 
SMARCA5 -0.539063506 0.001942941 0.999784118 -0.317331177 0.089334214 0.999784118 0.221732328 
SFPQ -0.539353578 0.035987943 0.99600134 -0.472652434 0.049026311 0.99600134 0.066701144 
MRE11 -0.552045358 1.88543E-04 0.999979051 -0.416697937 0.003387275 0.999979051 0.135347421 
WEE1 -0.553347577 0.051204483 0.994310613 -0.55979839 0.069213929 0.994310613 -0.006450813 
WRAP53 -0.555013619 0.002984207 0.999668421 -0.344633636 0.086903678 0.999668421 0.210379983 
PDS5B -0.556626107 0.021096573 0.997655936 -0.379042656 0.097722757 0.997655936 0.17758345 
KDM4A -0.55794361 0.00283 0.999685556 -0.42784437 0.032069603 0.999685556 0.13009924 
RAD17 -0.559543711 0.004165578 0.99993315 -0.901408686 6.03347E-04 0.99993315 -0.341864975 
RNF8 -0.559882093 0.034541288 0.996162079 -0.589318186 0.050428236 0.996162079 -0.029436093 
RMI1 -0.570967126 1.40335E-04 0.999979412 -0.641622427 1.40335E-04 0.999979412 -0.070655302 
SET -0.571000357 0.004028212 0.9998963 -0.918574764 9.33297E-04 0.9998963 -0.347574406 
WAPL -0.572820907 0.001391377 0.99976222 -0.674462372 0.001391377 0.99976222 -0.101641465 
POLR2G -0.584625034 0.079959761 0.997446221 -0.820139653 0.045334103 0.997446221 -0.235514619 
POLR2K -0.59571162 0.084374199 0.987262845 -0.629564716 0.084374199 0.987262845 -0.033853096 
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RAD51B -0.595792757 1.39498E-04 0.9999845 -0.631913209 0.001183107 0.9999845 -0.036120452 
SMC6 -0.596548189 0.003379865 0.999345574 -0.810964001 0.003379865 0.999345574 -0.214415812 
UVRAG -0.598472671 2.67008E-04 0.999970332 -0.67358317 5.31623E-04 0.999970332 -0.075110499 
MTOR -0.599883978 4.52729E-04 0.999949697 -0.519913795 0.004064661 0.999949697 0.079970184 
FANCI -0.605414404 0.043271177 0.995192091 -0.383691008 0.250591065 0.995192091 0.221723397 
UBE2N -0.605661129 0.001335053 0.999808198 -0.672414641 0.001335053 0.999808198 -0.066753512 
TIMELESS -0.605961603 0.002525248 0.999719417 -0.58850862 0.008488559 0.999719417 0.017452983 
DNMT1 -0.606238396 3.08331E-04 0.999965741 -0.347424933 0.055334608 0.999965741 0.258813463 
TERF1 -0.606902174 0.098687015 0.989034776 -0.380461603 0.149199926 0.989034776 0.226440571 
CHAF1A -0.607760097 0.009374157 0.998605523 -0.616528298 0.014738668 0.998605523 -0.008768202 
ERCC1 -0.608959397 7.17505E-04 0.999920277 -0.618593574 0.003684935 0.999920277 -0.009634178 
DDX11 -0.612202105 0.003677219 0.999667691 -0.867831673 0.00299078 0.999667691 -0.255629568 
RAD50 -0.619088614 9.78E-07 0.999999891 -0.525851959 0.002264283 0.999999891 0.093236655 
RNASEH2A -0.633098337 0.001455201 0.999838311 -0.315842774 0.074537796 0.999838311 0.317255563 
MMS22L -0.637095931 5.78971E-04 0.99993567 -0.544054541 0.022522814 0.99993567 0.09304139 
UBE2M -0.642867839 0.001539701 0.99993481 -0.942652837 5.86712E-04 0.99993481 -0.299784997 
RFC4 -0.643045643 0.001434892 0.999840568 -0.492300714 0.039813359 0.999840568 0.150744929 
FANCM -0.648945492 8.79891E-04 0.999902234 -0.472884958 0.020160665 0.999902234 0.176060534 
NAE1 -0.651524075 3.92E-06 0.999999565 -0.567564635 1.89E-05 0.999999565 0.08395944 
UBE2D3 -0.657876035 0.080523003 0.997770826 -0.840914225 0.068166793 0.997770826 -0.18303819 
SMC2 -0.659453252 0.011944405 0.998050525 -0.631655212 0.025619039 0.998050525 0.02779804 
H2AFX -0.661130878 0.010612095 0.998820878 -0.645226422 0.017080208 0.998820878 0.015904456 
SENP6 -0.6637173 6.05160E-04 0.99993276 -0.80674806 6.69474E-04 0.99993276 -0.14303076 
RAD1 -0.673110354 0.003659453 0.999593394 -0.76978318 0.008876769 0.999593394 -0.096672826 
SMC3 -0.689872104 9.32226E-04 0.999896419 -0.831304401 0.001562601 0.999896419 -0.141432297 
FANCG -0.69122434 0.001387593 0.999845823 -0.461730573 0.040873382 0.999845823 0.229493767 
DNA2 -0.701327248 0.034541048 0.997085571 -0.888864407 0.026229862 0.997085571 -0.187537159 
GAR1 -0.703137931 0.002365365 0.99968861 -0.869079322 0.001938396 0.99968861 -0.165941391 
FANCC -0.704821451 1.59E-05 0.999998236 -0.365285594 0.033990772 0.999998236 0.339535858 
RIF1 -0.706251531 1.69E-05 0.999998123 -0.595986728 5.08760E-04 0.999998123 0.110264803 
CHEK1 -0.707462919 0.030196048 0.9943534 -0.670544483 0.042520934 0.9943534 0.036918436 
NSMCE1 -0.709858081 7.47286E-04 0.99991118 -0.64069105 7.47286E-04 0.99991118 0.06916703 
BRD4 -0.711113154 7.10488E-04 0.999964741 -0.893007158 3.17332E-04 0.999964741 -0.181894004 
RPS27L -0.71657304 0.032752451 0.999927292 -1.466963551 6.53192E-04 0.999927292 -0.750390511 
DSCC1 -0.717425194 4.71E-05 0.999994766 -0.465510166 0.027457823 0.999994766 0.251915028 
PRMT1 -0.718984959 0.00147153 0.999836497 -0.549841624 0.028663352 0.999836497 0.169143334 
POLE4 -0.724956104 1.68468E-04 0.999981281 -0.665003351 0.003794188 0.999981281 0.059952752 
NSMCE4A -0.726873567 5.14719E-04 0.999942809 -0.785133146 0.001095579 0.999942809 -0.058259579 
RNF20 -0.728301274 4.33E-06 0.999999519 -0.526992805 0.002913086 0.999999519 0.201308468 
SIN3A -0.730538101 2.41E-05 0.999999614 -1.013703366 3.47E-06 0.999999614 -0.283165265 
RNF40 -0.73881293 1.22863E-04 0.999986349 -0.029221108 0.710868279 0.999986349 0.709591822 
BARD1 -0.738839984 0.001083637 0.99981174 -0.770984988 0.001083637 0.99981174 -0.032145004 
RUVBL1 -0.739972476 0.001637605 0.999640183 -0.815365688 0.001637605 0.999640183 -0.075393212 
UCHL5 -0.742440726 9.36E-07 0.999999896 -0.625684018 4.32089E-04 0.999999896 0.116756708 
CTCF -0.744663808 7.32478E-04 0.999918614 -0.661548381 0.004102201 0.999918614 0.083115427 
CSNK2B -0.745571525 5.51784E-04 0.999938691 -0.335199514 0.098440714 0.999938691 0.41037201 
SUPT6H -0.746657561 0.002192787 0.999391397 -0.861343914 0.002192787 0.999391397 -0.114686353 
POLR2B -0.752953743 0.015752097 0.998193741 -0.414558124 0.164797606 0.998193741 0.338395619 
RPA1 -0.759143778 0.00730068 0.99954152 -0.982863907 0.00412632 0.99954152 -0.223720129 
FEN1 -0.760073358 2.41264E-04 0.999973193 -0.740843131 0.005210954 0.999973193 0.019230227 
UHRF1 -0.771743133 8.46514E-04 0.99999626 -1.190513475 3.37E-05 0.99999626 -0.418770341 
USP37 -0.774675195 9.09908E-04 0.999898899 -0.882488746 0.001557334 0.999898899 -0.107813551 
BCCIP -0.775237049 0.010231943 0.998808704 -0.783068992 0.010231943 0.998808704 -0.007831943 
XAB2 -0.77755665 2.45249E-04 0.99997275 -0.537115832 0.04553182 0.99997275 0.240440817 
MAD2L2 -0.778527676 2.19E-05 0.999997565 -0.905986965 5.05308E-04 0.999997565 -0.127459289 
NCAPG -0.785677183 1.46863E-04 0.999983682 -0.878838743 5.21785E-04 0.999983682 -0.09316156 
GTF2H5 -0.786441457 9.59E-05 0.999989346 -0.519688318 0.018317109 0.999989346 0.266753138 
RAD9A -0.787602975 0.0069951 0.999222767 -0.529611682 0.067132826 0.999222767 0.257991293 
ACTR8 -0.811343162 5.22E-06 0.99999942 -0.70880241 7.62257E-04 0.99999942 0.102540752 
RAD51D -0.815465721 5.97E-08 0.999999993 -0.843700159 1.18E-06 0.999999993 -0.028234438 
BUB1B -0.815530539 1.14180E-04 0.999987313 -0.673143636 0.002955252 0.999987313 0.142386904 
FANCF -0.81909573 2.62E-05 0.999997085 -0.431643108 0.037613913 0.999997085 0.387452622 
CCNA2 -0.820320278 4.53595E-04 0.999949601 -0.74001539 0.003496758 0.999949601 0.080304889 
CEP57 -0.820384317 1.23E-06 0.999999863 -0.804457113 2.33039E-04 0.999999863 0.015927203 
PCNA -0.823563296 0.003476035 0.999618781 -0.950407408 0.002009772 0.999618781 -0.126844112 
POLE3 -0.825123736 1.15721E-04 0.999987142 -0.592634187 0.005320778 0.999987142 0.232489549 
RPA3 -0.836425466 4.26491E-04 0.999948141 -1.055987547 4.26491E-04 0.999948141 -0.219562081 
ERCC4 -0.841939163 1.24E-05 0.999998625 -0.458190294 0.027251309 0.999998625 0.383748869 
NONO -0.848853275 2.26E-07 0.999999975 -0.721935339 2.63559E-04 0.999999975 0.126917936 
MNAT1 -0.854794009 1.87358E-04 0.999979182 -1.059231572 2.63248E-04 0.999979182 -0.204437563 
CUL2 -0.857561838 1.21E-06 0.999999866 -0.772105909 1.21596E-04 0.999999866 0.085455929 
POLR2C -0.866047847 4.08E-06 0.999999547 -0.656255437 0.001678245 0.999999547 0.20979241 
TERF2 -0.871423011 0.030474781 0.996613913 -0.656041054 0.068957806 0.996613913 0.215381957 
USP5 -0.873813393 9.95063E-04 0.999889437 -0.921589222 0.001830971 0.999889437 -0.047775829 
RAD51 -0.879470827 0.00108351 0.99987961 -0.505067813 0.050711825 0.99987961 0.374403014 
TERT -0.890344915 5.12E-05 0.999994311 -0.776186557 0.011895478 0.999994311 0.114158358 
SKP1 -0.890751182 0.001789046 0.999801217 -0.838565608 0.003508149 0.999801217 0.052185574 
HDAC3 -0.890895992 0.002931244 0.999994236 -0.932773817 0.009628739 0.999994236 -0.041877825 
RFC2 -0.892677464 3.97E-05 0.999995591 -0.450196195 0.047321048 0.999995591 0.442481269 
RTEL1 -0.897650218 9.82E-06 0.999998909 -0.466794288 0.021191095 0.999998909 0.43085593 
POT1 -0.898140107 8.44E-05 0.999990622 -0.679050932 0.008759856 0.999990622 0.219089175 
HUS1 -0.902720807 2.22223E-04 0.999975309 -1.08362732 3.67523E-04 0.999975309 -0.180906513 
Chapter 8: Appendix 
 260 
NSMCE3 -0.905593203 7.92E-05 0.999991203 -1.106826843 1.47235E-04 0.999991203 -0.20123364 
GTF2H1 -0.919259143 1.35E-07 0.999999996 -1.303689509 3.59E-08 0.999999996 -0.384430366 
POLR2H -0.922983558 4.22E-05 0.999999145 -1.171365717 5.65E-06 0.999999145 -0.248382158 
NCAPD2 -0.923381072 1.63E-05 0.999998189 -0.98297521 2.92483E-04 0.999998189 -0.059594138 
TOPBP1 -0.925758858 3.98E-08 0.999999996 -0.767975488 1.49E-05 0.999999996 0.15778337 
PDS5A -0.926834728 3.87E-05 0.999995695 -0.773964263 0.005073667 0.999995695 0.152870465 
RUVBL2 -0.927458697 3.81E-06 0.999999577 -0.849480065 2.75882E-04 0.999999577 0.077978632 
CCNH -0.934723175 0.001494055 0.999833994 -0.95105308 0.005074572 0.999833994 -0.016329905 
BOD1L1 -0.943571931 6.34E-06 0.999999296 -0.745247096 4.45225E-04 0.999999296 0.198324835 
POLE2 -0.944057041 1.72725E-04 0.999980808 -0.752997217 0.010574456 0.999980808 0.191059823 
MMS19 -0.950005689 1.26E-06 0.99999986 -0.883233076 2.04447E-04 0.99999986 0.066772613 
PLK1 -0.951993708 0.001796867 0.999800348 -0.787926557 0.021661373 0.999800348 0.164067151 
PNKP -0.964557122 5.20E-07 0.999999942 -0.851711551 2.19999E-04 0.999999942 0.112845571 
MAU2 -0.96832087 8.70E-07 0.999999903 -0.70706527 8.99236E-04 0.999999903 0.2612556 
NCAPG2 -0.97170784 1.80149E-04 0.999979983 -0.971596494 7.17926E-04 0.999979983 1.11346E-04 
CTC1 -0.974149564 1.98191E-04 0.999977979 -0.590325184 0.016902436 0.999977979 0.38382438 
POLR2I -0.975017693 9.75E-05 0.999989168 -1.046959267 2.45639E-04 0.999989168 -0.071941575 
PCID2 -0.981880826 1.06E-06 0.999999883 -0.630060278 0.009347545 0.999999883 0.351820548 
PRPF19 -0.988881213 7.88992E-04 0.999912334 -0.90149646 0.003343997 0.999912334 0.087384752 
RRM2 -0.989679496 1.42E-05 0.999998419 -0.923249047 6.28091E-04 0.999998419 0.066430449 
COPS8 -0.990173499 5.21373E-04 0.99994207 -0.914636479 0.006818796 0.99994207 0.07553702 
MCPH1 -0.991052357 4.56E-06 0.999999494 -0.71936576 0.003862328 0.999999494 0.271686598 
HUWE1 -0.996059806 6.02E-06 0.999999817 -1.321807026 1.65E-06 0.999999817 -0.32574722 
POLR2E -1.010734931 2.03E-05 0.999997744 -1.106857688 9.49E-05 0.999997744 -0.096122757 
USP7 -1.012593368 1.42086E-04 0.999984213 -0.939610607 0.002888682 0.999984213 0.072982761 
UBA1 -1.02293677 2.61E-06 0.99999971 -1.089239714 9.92E-06 0.99999971 -0.066302944 
ACTL6A -1.024202976 1.12E-06 0.999999998 -1.484751078 2.18E-08 0.999999998 -0.460548103 
TINF2 -1.027020011 0.004600589 0.999488823 -0.854854318 0.060804359 0.999488823 0.172165692 
CDC5L -1.029656352 5.30E-08 0.999999994 -1.232466119 1.80E-07 0.999999994 -0.202809767 
TRAIP -1.033210521 3.16E-06 0.999999649 -1.16154149 1.37497E-04 0.999999649 -0.128330969 
CDK9 -1.055727381 1.18917E-04 0.999986787 -1.156210503 1.93697E-04 0.999986787 -0.100483122 
FANCL -1.070090152 1.21E-06 0.999999866 -0.778514536 6.44640E-04 0.999999866 0.291575616 
TAF1 -1.079666714 1.42E-07 0.999999984 -1.216174351 6.19E-07 0.999999984 -0.136507638 
RFC3 -1.085430692 3.39E-06 0.999999623 -0.819789301 0.002226218 0.999999623 0.265641392 
TELO2 -1.090506084 2.31E-08 0.999999997 -0.643763677 0.002380353 0.999999997 0.446742407 
BCAS2 -1.095781321 1.75E-06 0.999999806 -0.940137707 1.72958E-04 0.999999806 0.155643614 
SMARCB1 -1.123693211 1.23E-05 0.999998637 -0.912760447 4.14381E-04 0.999998637 0.210932764 
COPS6 -1.12380299 6.47E-07 0.999999928 -1.188384001 4.03E-05 0.999999928 -0.064581011 
TOP3A -1.129628629 1.15E-08 0.999999999 -0.873527182 7.97348E-04 0.999999999 0.256101448 
NOP10 -1.129730869 6.82E-06 0.999999242 -0.67370674 0.016102566 0.999999242 0.456024129 
FANCD2 -1.134188172 2.89E-07 0.999999968 -1.051699737 3.17E-05 0.999999968 0.082488435 
TICRR -1.13479981 2.90E-08 0.999999997 -1.035849042 7.46E-06 0.999999997 0.098950769 
THOC1 -1.146114008 2.32E-10 1 -1.160490799 2.51E-07 1 -0.014376792 
TONSL -1.157474749 2.83E-07 0.999999969 -0.984835513 3.49403E-04 0.999999969 0.172639236 
CDK7 -1.158117741 3.51E-05 0.999996104 -0.83226292 0.006740316 0.999996104 0.325854821 
DCLRE1B -1.159531775 6.48E-05 0.999992796 -0.859535013 0.003297575 0.999992796 0.299996762 
RRM1 -1.163855663 7.95E-05 0.999991166 -1.066559007 0.00122264 0.999991166 0.097296656 
PPM1D -1.17032895 2.33E-06 0.999999741 -1.086653491 5.19758E-04 0.999999741 0.083675459 
COPS5 -1.173461324 6.96E-08 0.999999992 -1.174918054 1.18E-06 0.999999992 -0.00145673 
KAT8 -1.192625092 2.28E-07 0.999999975 -1.309115872 4.62E-06 0.999999975 -0.11649078 
NCAPH2 -1.203770205 7.34E-06 0.999999184 -0.674458158 0.021290023 0.999999184 0.529312046 
GTF2H4 -1.209308858 3.39E-11 1 -0.995347295 9.85E-07 1 0.213961564 
FZR1 -1.211366218 1.19E-11 1 -0.6669526 3.85460E-04 1 0.544413617 
TRIP13 -1.212553425 1.70E-07 0.999999981 -0.98454926 3.85278E-04 0.999999981 0.228004165 
SUPT4H1 -1.226964967 4.36E-06 0.999999516 -1.184084867 9.36E-05 0.999999516 0.042880101 
HINFP -1.228375501 4.37E-08 0.999999995 -1.041099163 2.85187E-04 0.999999995 0.187276339 
CDK4 -1.229252468 1.08175E-04 0.999987981 -1.054519737 0.00223532 0.999987981 0.174732731 
RPA2 -1.247560967 1.89E-08 0.999999998 -1.010994076 6.29E-05 0.999999998 0.23656689 
UBE2I -1.268176607 1.31E-07 0.999999985 -0.977469343 7.06388E-04 0.999999985 0.290707264 
DDB1 -1.268930991 1.72E-09 1 -1.155184823 2.18E-06 1 0.113746168 
TTI2 -1.286990104 6.12E-11 1 -1.539749541 3.73E-09 1 -0.252759438 
ATR -1.291043485 1.41E-07 0.999999984 -1.210676503 2.43E-05 0.999999984 0.080366982 
STN1 -1.307813463 1.01E-09 1 -1.041584562 2.62E-05 1 0.266228901 
SMC5 -1.372502462 1.24E-08 0.999999999 -0.717572023 0.002850351 0.999999999 0.654930439 
NHP2 -1.37492816 1.73E-09 1 -1.376299318 3.26E-05 1 -0.001371158 
DDX1 -1.378347942 5.38E-13 1 -1.536340219 1.38E-10 1 -0.157992277 
BRAT1 -1.384128988 1.35E-09 1 -1.015259778 2.63E-05 1 0.36886921 
YBX1 -1.392920742 3.80E-05 0.999992389 -1.740350813 3.80E-05 0.999992389 -0.347430071 
GPS1 -1.397191665 8.90E-11 1 -1.668772551 3.87E-09 1 -0.271580886 
SMC1A -1.401416682 1.36E-09 1 -1.397096706 2.15E-06 1 0.004319976 
NELFB -1.410347624 1.07E-14 1 -1.347416491 4.09E-09 1 0.062931133 
TTI1 -1.429240394 4.07E-11 1 -1.377682204 3.90E-07 1 0.05155819 
GTF2H3 -1.441793994 1.14E-12 1 -1.270428534 2.15E-08 1 0.171365461 
XRCC3 -1.443889834 1.51E-13 1 -1.088064552 3.18E-07 1 0.355825282 
MYBBP1A -1.448519931 2.69E-13 1 -1.532077732 3.06E-10 1 -0.0835578 
ERCC3 -1.488842436 1.06E-07 0.999999988 -1.474146327 8.00E-07 0.999999988 0.014696109 
DKC1 -1.540157248 2.39E-09 1 -1.09704993 2.55E-05 1 0.443107317 
UBE2T -1.545201154 5.11E-10 1 -1.635110774 3.54E-08 1 -0.08990962 
PPP4C -1.5485548 3.11E-10 1 -1.818304254 2.77E-08 1 -0.269749454 
XRCC2 -1.552260107 1.04E-12 1 -0.739173379 8.75793E-04 1 0.813086728 
ERCC2 -1.571883538 3.46E-12 1 -1.550486756 5.20E-09 1 0.021396781 
APEX2 -1.610227732 9.31E-13 1 -1.58286698 1.17E-09 1 0.027360752 
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PPP6C -1.632962193 3.12E-19 1 -1.474868263 3.09E-11 1 0.158093931 
THOC2 -1.665220487 4.45E-11 1 -2.006963324 2.15E-10 1 -0.341742837 
UBA2 -1.766771251 2.37E-16 1 -1.523906595 5.57E-10 1 0.242864656 
TCEB1 -1.83403278 6.32E-11 1 -1.025927353 3.54E-05 1 0.808105427 
TEN1 -1.902750858 4.01E-14 1 -1.547284435 8.69E-08 1 0.355466423 
TCEB2 -2.008223442 3.54E-11 1 -1.656887611 3.14E-06 1 0.351335831 
RFC5 -2.101292684 1.35E-18 1 -1.703344812 7.02E-09 1 0.397947871 
NEDD8 -2.124387862 1.56E-13 1 -2.679174078 4.45E-12 1 -0.554786216 
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Appendix Table 9 List of genes showing greater enrichment in CPT treated samples than DMSO treated 
samples compared to the day 14 control (from related JACKS analysis).  
 
Genes showing greater enrichment in CPT treated compared to DMSO treated 
(difference>0.3, FDR<10%) 
WT 5nM CPT WT 2nM CPT E5 2nM CPT G7 2nM CPT Both 
knockouts 
2nM CPT 
TP53 TP53 TP53 MAPK14 TP53 
UBE2D3 RPS27L CDKN1A TP53 CDKN1A 
POLR2A CDKN1A CHEK2 ENDOV MAPK14 
UBC SOD1 SMARCC1 CDKN1A CHEK2 
CDKN1A POLR2A POLD3 CUL3 ZDHHC16 
APEX2 UBE2D3 EME2 DNTT POLD3 
PPP4C PPP4C MAPK14 SHFM1 SMARCC1 
FANCD2 THOC2  DCLRE1A PBRM1 
RPS27L MDM2  CDC25A CHFR 
PCNA GPS1  APEX1 EME2 
BRD7 TINF2  GADD45G SETD2 
THOC2 APEX2  MLH3  
TTI2 TTI2  PBRM1  
MDM2 FANCD2    
DNAJC2 PCNA    
PPM1D USP7    
SOD1 POLR2D    
RRM1 UBC    
RUVBL2 SMC5    
TINF2 PPM1D    
GPS1 TICRR    
NCAPD3 NCAPD3    
POLR2E CCND1    
MDM4 PLK1    
NEDD8 RRM1    
CCND1 NEDD8    
POLE2 USP37    
PLK1 RUVBL2    
RPAIN USP5    
MASTL SF3B1    
POLR2D MASTL    
USP5 RAD21    
CHEK2 CCNH    
DCLRE1B DKC1    
BRCA2 MMS22L    
POLR2G POLR2L    
SF3B1 DNAJC2    
TOP1 CDK4    
XAB2 DCLRE1B    
TICRR RPAIN    
RAD21 COPS6    
UPF1 RUVBL1    
USP7 POLR2G    
SMC5 XAB2    
UBE2I BRD7    
POLR2L CHEK2    
RUVBL1 POLD3    
 COPS4    
 UPF1    
 BRCA2    
 POLR2H    
 H2AFX    
 NHP2    
 HNRNPK    
 PNN    
 
Chapter 8: Appendix 
 263 
 
 
